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Abstract 
The cellular response to low oxygen tension (hypoxia) is orchestrated through an elegant 
pathway involving a number of molecular players and is well characterised in development, 
physiology and pathology. The hypoxia inducible factors (HIFs) comprise a family of 
transcription factors whose activity is responsible for mediating transcriptional responses 
to hypoxia and maintaining cellular oxygen homeostasis.  
Of particular interest, is the relationship between the HIFs and mitochondria. Mitochondria 
consume oxygen and generate chemical energy in the form of adenosine triphosphate 
(ATP). Mitochondrial function and the electron transport chain are necessary for the 
stabilisation of HIF-α protein in response to hypoxia and the transactivation of HIF target 
genes. Conversely, mitochondrial adaptation to hypoxia is controlled through a number of 
HIF target genes. However, the molecular relationship between the HIFs and mitochondria 
and vice versa is still emerging.  
Oxygen-dependent regulation of HIF-α protein stability is controlled by the prolyl 
hydroxylase domain (PHD) proteins. Using several approaches to stabilise and activate the 
HIFs, this thesis has explored the role of the oxygen-sensing machinery in regulating 
mitochondrial function. This work identifies altered subcellular localisation of the HIF-
complex and PHD proteins. Additionally, manipulation of the oxygen-sensing pathway 
results in gross mitochondrial morphological and ultrastructural differences in addition to 
alterations in a number of mitochondrial parameters, including DNA maintenance, electron 
transport chain (ETC) protein expression, bioenergetics and autophagy.   
Together these data identify a novel role for members of the oxygen-sensing machinery in 
mitochondrial function.  
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1.1 The importance of oxygen 
Understanding how cells sense and respond to changes in oxygen tension, particularly low 
oxygen (hypoxia), is important. This extends not only from the perspective of 
understanding physiology, development and adaptation to environmental change, but also 
pathophysiology of disease. Cancer, cardiovascular disease and stroke can all be 
characterised by an impairment of oxygen perfusion to tissue and cells. Without an 
adequate supply of oxygen, cells do not survive. Therefore it is essential that cells maintain 
an appropriate level of oxygenation to sustain viability. Cells have compensatory 
mechanisms by which they can adapt to changes in oxygen tension both rapidly and 
effectively. Atmospheric oxygen concentration varies depending on altitude and 
atmospheric pressure, however despite this and under ambient conditions, healthy cells in 
the same organ (e.g. kidney) in vivo may experience as little as 5% oxygen tension (Solaini 
et al., 2010).  
Cells respond and adapt to hypoxia through the activation of multiple signalling pathways, 
which cooperate to minimise cellular injury and maintain survival. The capacity of cells to 
react and adapt to variations in oxygen relies on a family of transcription factors known as 
the hypoxia inducible factors (HIFs). The involvement of HIFs in hypoxia signalling, cancer, 
ischaemia and cardiovascular disease is well established with the HIFs playing a crucial role 
particularly in regulating metabolism, maintaining vascular supply and promoting cell 
survival (Shohet and Garcia, 2007, Ziello et al., 2007). Notably, small molecule activation of 
the HIFs has been proposed as a novel strategy in treating ischaemic injury. Conversely, 
inhibition of the HIF pathway is used as adjunct to traditional therapy in treating solid 
tumours (Harten et al., 2010). Therefore, much interest is focused on understanding the 
cellular mechanisms that regulate the HIFs and components of the oxygen-sensing 
machinery as a basis for exploiting the HIF pathway therapeutically. 
 
1.2 The HIF pathway 
The major physiological mechanism by which cells respond to hypoxic stress is through 
activation of the HIFs, which regulate the cell’s transcriptional responses to hypoxia. The 
prototype of the family is hypoxia inducible factor-1 (HIF-1), which was first identified 
through analysis of a cis-acting sequence termed the hypoxic response element (HRE; 5’-
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RCGTG-3’) found within the 3’-enhancer of the erythropoietin (EPO) gene (Semenza and 
Wang, 1992). It was recognised that HIF-1 binding to this pentanucleotide HRE sequence 
increased EPO gene transcription and protein levels under hypoxic conditions (Semenza et 
al., 1991 , Semenza and Wang, 1992). These DNA sequences have since been found to be 
present in a broad range of genes in many cell types, thus providing a universal role in 
cellular oxygen-sensing (Maxwell et al., 1993, Webb et al., 2009). The identification of 
genes regulated either directly or indirectly by HIF-1 now extends to over one hundred and 
fifty (Mole et al., 2009), which are implicated in a plethora of physiological processes and 
regulatory networks. As such, the HIFs transcriptional activity maintains homeostatic 
responses to cellular variations in oxygen tension and permits the regulation of genes 
involved in cell survival, angiogenesis and metabolism (Wenger, 2002, Weidemann and 
Johnson, 2008).  
1.2.1 Structure and function of HIF-1 
HIF-1 is a heterodimeric DNA-binding protein complex, comprising of an oxygen-regulated 
HIF-1α subunit and constitutively expressed non-oxygen-regulated beta subunit (HIF-1β), a 
product of the ARNT gene (aryl hydrocarbon nuclear translocator; ARNT) (Wang and 
Semenza, 1995, Wang and Semenza, 1993). Both HIF-1α and HIF-1β messenger RNAs 
(mRNA) are constitutively transcribed and levels remain constant regardless of oxygen 
availability, as such HIF-1 is well placed to respond appropriately and rapidly to variations in 
oxygen concentration (Kallio et al., 1997). Both HIF-1 subunits are members of the basic 
helix-loop-helix (bHLH) PAS domain (Per/Arnt/Sim) containing family of transcription 
factors (Jiang et al., 1996a, Wang et al., 1995). The HIF-1α subunit translocates to the 
nucleus, where it dimerises with the HIF-1β/ARNT subunit via the bHLH and PAS domains 
(Figure 1.1) (Wang et al., 1995, Wang and Semenza, 1995, Semenza et al., 1997). 
Dimerisation of the alpha and beta subunits, instigates an alpha subunit conformational 
change (Kallio et al., 1997) and through the N- and C-terminal transactivation domains (N-
TAD and C-TAD), recruits and interacts with its co-activators including p300/CBP (CREB; 
cAMP-response element binding protein) (Jiang et al., 1996a, Arany et al., 1996). The HIF-1 
dimer along with its co-activators then binds via its basic region to DNA at the HRE 
consensus in either promoter or enhancer sites of target genes.  
In addition to HIF-1α, various other family members have since been identified; HIF-2α 
(also known as EPAS-1; endothelial PAS domain protein-1) (Tian et al., 1997, Ema et al., 
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1997) and HIF-3α (Gu et al., 1998), whose expression pattern is more restricted and 
function more enigmatic (Wenger, 2002). Among the several identified splice variants of 
HIF-3α, the inhibitory PAS domain protein (IPAS) has been identified as an endogenous HIF 
antagonist having a dominant-negative effect on gene expression under hypoxic conditions, 
through lack of a transactivational domain (Bardos and Ashcroft, 2005, Makino et al., 2001, 
Makino et al., 2002). Bioinformatic analysis reveals HIF-1α and HIF-2α share 48% structural 
homology and HIF-3α exhibits high similarity in the bHLH and PAS domains but lacks the C-
terminal transactivation domain (C-TAD) (Hara et al., 2001). HIF-2α is also stabilised in 
hypoxia and binds HIF-1β/ARNT to form the HIF-2 complex and regulates gene expression 
through the same mechanism as HIF-1 (Tian et al., 1997, Ema et al., 1997).  
 
 
 
Figure 1.1: Schematic representation of the HIF-1 protein.  
The bHLH and PAS domains of hypoxia-inducible factor 1α (HIF-1α) are involved in 
dimerisation and DNA binding; the oxygen dependent degradation (ODD) domain is 
required for degradation via the proteasome; and the transactivation domains (N-TAD 
and C-TAD) are involved in regulating gene expression. Hydroxylation of proline residues 
402 and 564 within the ODD domain mediates an interaction between HIF-1α and the 
von Hippel-Lindau tumour suppressor protein (pVHL). Hydroxylation of asparagine 803 in 
the C-TAD blocks the association between HIF-1α and transcriptional co-activator 
p300/CBP. bHLH = basic helix–loop-helix, PAS = Per-ARNT-Sim, ODD = oxygen dependent 
degradation, N-TAD = N-terminal transactivation, C-TAD = C-terminal transactivation. 
Adapted from (Poon et al., 2009). 
 
In response to hypoxia, the HIF-1 complex binds to genes involved in a number of distinct 
processes that each mediates cellular adaptation to the oxygen-limiting environment. 
Genes are activated that promote glycolysis (enolase), angiogenesis (vascular endothelial 
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growth factor; VEGF and Flt-1/VEGFR1), iron metabolism (transferrin and transferrin 
receptor), cellular proliferation and autophagy (insulin-like growth factor-1; IGF-1 and 
BCL2/adenovirus E1B 19kDa protein-interacting protein 3; BNIP3) among many others 
(Figure 1.2) (Semenza, 2003). The physiological role of HIF-2α will be discussed in chapter 6.  
 
 
 
Figure 1.2: Diagram showing processes regulated by HIF-1 transcriptional activity.  
Activation of HIF-1 induces expression of genes involved in processes such as 
maintenance of vascular tone and proliferation among many others. This allows the cell 
to adapt to changes in local oxygen tension.  TGF-α = transforming growth factor alpha, 
ADM = adrenomedullin, NOS2 = nitric oxide synthase 2, LDHA = lactate dehydrogenase A, 
COX4-2 = cytochrome c oxidase subunit 4-2, PDK = pyruvate dehydrogenase kinase. 
Adapted from (Semenza, 2003).  
 
Germline loss of Hif-1α and Hif-2α produce distinct phenotypes. Knock-out of Hif-1α in the 
mouse germline proves embryonically lethal in mid gestation at E9.5 and loss of Hif-2α can 
cause either embryonic or perinatal lethality, with some surviving to exhibit developmental 
abnormalities (Iyer et al., 1998, Tian et al., 1998, Peng et al., 2000, Scortegagna et al., 
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2003). These distinct phenotypes suggests that although there are common sets of target 
genes and some degree of redundancy, significant differences in their behaviour exist and 
hence functional overlap is avoided (Hu et al., 2003, Loor and Schumacker, 2008). 
Observations reveal HIF-2α to have a specific contribution to yolk sac vascularisation (Peng 
et al., 2000), while HIF-1α is important for mesenchymal cell survival and consequently Hif-
1α-/- mice die with cardiovascular malformations and open neural tube defects (Iyer et al., 
1998). Tissue specific loss of HIF-1α has been associated with distinct phenotypes (Helton 
et al., 2005, Cramer and Johnson, 2003). For instance, neurone and myeloid lineage specific 
knock-out of Hif-1α leads to neuroprotection and decreased inflammatory and 
antimicrobial responses respectively (Helton et al., 2005, Cramer and Johnson, 2003).  
1.2.2 Oxygen-dependent regulation of HIF-1 
In adequately oxygenated cells, HIF-1α has an extremely short half-life (t1/2~3-5 min). HIF-
1α and HIF-2α (from here on referred to as HIF-α) are not regulated by oxygen directly, 
instead their stabilisation and transactivational capacity is tightly regulated and 
coordinated by a number of post-translational modifications, including the hydroxylation of 
proline and asparagine residues respectively, described below (Brahimi-Horn et al., 2005, 
Lee et al., 2004). HIF-1α protein stabilisation occurs under hypoxia, an event which affects 
the subunit’s subcellular localisation and transcriptional potency (Lee et al., 2004). Contrary 
to this, protein levels of the HIF-1β subunit remain constant irrespective of oxygen 
availability, a phenomenon first demonstrated in HeLa and HepG2 cells and since found to 
be cell line independent (Kallio et al., 1997, Jiang et al., 1996a).  
1.2.3 Control of HIF-1α protein stabilisation by the PHD proteins and the ubiquitin-
proteasome pathway 
The HIF-1α protein remains at low levels under normoxia as it undergoes a tightly regulated 
process of continuous synthesis and degradation. HIF-1α protein stabilisation can be 
observed in culture and physiologically from approximately 5% oxygen, through 
immunoblotting and analysis of target gene expression (Jiang et al., 1996b, Tormos and 
Chandel, 2010). The targeting of HIF-1α for degradation, under ambient oxygen, is achieved 
through hydroxylation of conserved proline residues, Pro402 and Pro564, which contain a 
common core motif in the oxygen dependent degradation (ODD, residues 401-603) domain 
of HIF-1α (Masson et al., 2001). This rapid degradation is mediated through recognition of 
the hydroxylated residues and subsequent ubiquitination of HIF-1α by an E3-ubiquitin 
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ligase complex, which polyubiquitinates HIF-1α and ‘tags’ it for proteolytic degradation 
through the ubiquitin-proteasome pathway (Salceda and Caro, 1997, Maxwell et al., 1999, 
Ohh et al., 2000, Jaakkola et al., 2001) (Figure 1.3). 
 
      
 
Figure 1.3: Oxygen-dependent regulation of HIF-1α.  
Under conditions of ambient oxygen, HIF-1α is hydroxylated on specific proline residues 
by the PHD proteins and degraded in a pVHL-dependent manner. When oxygen becomes 
limiting, failure to hydroxylate HIF-1α allows protein stabilisation and translocation to 
the nucleus, where it dimerises with HIF-1β and binds hypoxic response elements in 
target gene DNA. OH = hydroxyl group, Ub = ubiquitin, HRE = hypoxic response element, 
PHD = prolyl hydroxylase domain enzyme, VHL = von Hippel Lindau protein. 
 
The proline hydroxylation reaction is catalysed by the oxygen-sensing prolyl hydroxylase 
domain (PHD) enzymes. The PHDs are Krebs-cycle (tri-carboxylic acid (TCA) cycle) 
intermediate α-ketoglutarate (2-oxoglutarate)-dependent dioxygenases, requiring non-
haem iron (Fe2+) and ascorbate as co-factors (Wenger, 2002). The reaction utilises 
molecular oxygen and proceeds through the conversion of α-ketoglutarate into succinate 
with subsequent carbon dioxide release (Webb et al., 2009, McNeill et al., 2002, Lando et 
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al., 2002). Ascorbate maintains iron in its ferrous (Fe2+) form, important for full enzymatic 
activity, therefore pharmacological chelators of iron, such as desferrioxamine (DFO) can be 
used to activate this pathway and stabilise HIF-α (Figure 1.4).  
 
 
Figure 1.4: PHD catalysed generation of 4-hydroxylproline.  
Molecular oxygen, Fe2+ and α-ketoglutarate are utilised to hydroxylate specific proline 
residues within the HIF-α ODD domain. Adapted from (Sen Banerjee et al., 2012). 
 
Three PHD isoforms have been described and well characterised; PHD1/HPH3/EGLN2, 
PHD2/HPH2/EGLN1 and PHD3/HPH1/EGLN3, of which PHD2 has the greatest affinity 
toward HIF-1α and is suggested to be the key rate-limiting enzyme relating to its 
stabilisation (Berra et al., 2003, Appelhoff et al., 2004). PHD2 has been shown to be the 
major oxygen-sensor responsible for the normoxic turnover of HIF-1α, as silencing alone 
through RNA interference is sufficient to mediate HIF-1α stabilisation (Berra et al., 2003). 
The recruitment of PHD2 is seemingly aided by Leu574 residing on HIF-1α which promotes 
the efficient hydroxylation of Pro564 (Kageyama et al., 2004). PHD3 primarily targets HIF-2α, 
while PHD1 demonstrates some selectivity for HIF-1α (Appelhoff et al., 2004). Recently a 
fourth hydroxylase, PHD4 has been identified in the membrane of the endoplasmic 
reticulum, with its catalytic site within the lumen (Oehme et al., 2002). PHD4 differs from 
those previously characterised, however it has also been shown to be capable of 
hydroxylating HIF-1α in vitro, yet questions remain over its role in vivo (Koivunen et al., 
2007b, Oehme et al., 2002).  
PHD2 and PHD3 are both HIF-1 target genes and mRNA expression is increased in response 
to hypoxia (Aprelikova et al., 2004). Increased PHD3 is thought to regulate the HIF response 
to prolonged hypoxia (Metzen et al., 2005, Pescador et al., 2005). The tissue expression 
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patterns of the enzyme family also differ (Lieb et al., 2002), as does their subcellular 
localisation (Metzen et al., 2003). PHD1 appears exclusively nuclear, PHD2 primarily 
cytosolic and PHD3 being localised to both nuclear and cytosolic compartments (Metzen et 
al., 2003). Studies in mice have demonstrated that knockout of Phd2 in vivo is 
embryonically lethal, with embryos displaying placental and cardiovascular defects (Takeda 
et al., 2006). However both Phd1 and Phd3 nulls are viable and appear normal (Takeda et 
al., 2006). In hypoxia, the Siah E3 ligase (Siah2) regulates the protein abundance of PHD1 
and PHD3 after targeting for proteasomal degradation, therefore positively regulating 
hypoxic HIF-α stabilisation (Nakayama et al., 2004).  
The PHD-dependent 4-hydroxyproline modification in ambient oxygen concentrations 
facilitates the recruitment and highly specific binding of the von Hippel-Lindau protein 
(pVHL) through its β-domain (Maxwell et al., 1999, Jaakkola et al., 2001, Ohh et al., 2000). 
pVHL encodes the protein product of the VHL gene and in co-operation with elongins B and 
C, cullin-2 and ring-box 1 (RBX-1) forms the ECV multi-protein E3-ligase complex. pVHL is 
analogous to an F-box protein and so is the principal component responsible for substrate 
recognition and recruitment to the ubiquitination machinery (Brahimi-Horn et al., 2005, 
Ohh et al., 2000). As a result the poly-ubiquitinated HIF-1α protein is then targeted for 
degradation by the 26S proteasome (Maxwell et al., 1999, Jaakkola et al., 2001). 
pVHL is expressed ubiquitously throughout different tissues and has the ability to shuttle 
between the nucleus and cytoplasm enabling it to target HIF-1α for degradation in both 
cellular compartments (Berra et al., 2001). Mutation of either or both proline residues on 
HIF-1α abrogates the association between HIF-1α and pVHL and consequently allows 
partial or full HIF-1α stabilisation respectively, despite normal oxygen levels (Masson et al., 
2001). The same holds true for loss of function VHL mutation, a phenotype associated with 
VHL disease and observed in clear cell renal cell carcinomas (CCRCC) (Maxwell et al., 1999, 
Kaelin, 2002).  
1.2.4 Control of HIF-1 transcription by FIH-1 
HIF-1α can be transactivationally controlled through the α-ketoglutarate and Fe2+ 
dependent dioxygenase - factor inhibiting HIF-1 (FIH-1) (Mahon et al., 2001, Lando et al., 
2002, McNeill et al., 2002). FIH-1 functions as a homodimer to inhibit the trans-acting co-
activator p300/CBP binding HIF-1α. FIH-1 splits molecular oxygen to enzymatically 
hydroxylate the beta-carbon of asparagine 803 in the C-TAD of HIF-1α (Asp851 in HIF-2α) 
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(Webb et al., 2009, Lancaster et al., 2004a, Lancaster et al., 2004b). Thus FIH-1 acts as a 
negative regulator of HIF-1 transcriptional activity (Mahon et al., 2001, Lando et al., 2002, 
McNeill et al., 2002). Expression of FIH-1 protein and mRNA are independent of oxygen 
concentration and the FIH-1 protein is primarily cytosolic as demonstrated by three 
dimensional 2-photon confocal fluorescence microscopy (Metzen et al., 2003). Asparagine 
hydroxylation disrupts hydrogen bonding between HIF-1α and its co-activators and 
prevents binding (Maxwell, 2005, Semenza, 2004). Hypoxia abrogates this interaction as 
oxygen, the major substrate for FIH-1 is decreased thereby allowing p300/CBP co-activator 
binding and transactivation of downstream HIF target genes (Mahon et al., 2001, Lando et 
al., 2002). The FIH-1-mediated hydroxylation reacts to variations in oxygen concentration 
over the physiological range. It is also worth noting that there are isoform and cell specific 
differences with regulatory control of the various HIF-α proteins by FIH-1. For example in 
mouse embryonic fibroblasts (MEFs), HIF-2α is not hydroxylated by FIH-1 (Park et al., 2003). 
Moreover, FIH-1 has been suggested to interact with pVHL, forming a ternary complex 
along with HIF-1α that will modulate protein stability and transcriptional activity (Mahon et 
al., 2001, Khan et al., 2011). Because of the inherent oxygen dependency of the 
hydroxylases, decreasing oxygen availability linearly reduces the enzymatic capacity of both 
the PHDs and FIH-1 and as substrate levels become limited enzymatic activity diminishes.  
1.2.5 Oxygen-independent regulation of HIF-α 
In addition to the oxygen dependency of HIF-α regulation, there are also oxygen-
independent mechanisms that can govern HIF-α protein synthesis, stabilisation and 
transactivation. HIF-1α can undergo various distinct regulatory post-translational 
modifications. Examples include phosphorylation at threonine 706 by casein kinase 2 which 
inhibits FIH-1 binding (Lancaster et al., 2004b) and also by mitogen activated protein 
kinases (MAPKs) at serine 641 and serine 643 which promotes nuclear translocation and 
transactivation (Mylonis et al., 2006). S-nitrosylation at cysteine 800 has also been shown 
to affect HIF-1α transcriptional activation. However, whether this modification promotes or 
inhibits the interaction of HIF-α with co-activators and how it affects transactivation 
remains a matter of debate (Cho et al., 2007, Yasinska and Sumbayev, 2003). Conflicting 
reports also relate to the SUMOylation of HIF-1α, as conjugation has been shown to 
increase stabilisation (Bae et al., 2004) and more recently to decrease transcriptional 
activity (Berta et al., 2007).  
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Transition metals also play a role in regulating HIF-1α. These include regulation by cobalt 
and nickel which stabilise HIF-1α under normoxia, as does nitric oxide (NO) produced 
through inducible nitric oxide synthase (iNOS) (Chun et al., 2002, Huang et al., 1999). 
Growth factor-mediated activation of phosphoinositol-3-kinase (PI3K) and MAPK pathways 
are involved in promoting synthesis of HIF-1α protein, through either receptor tyrosine 
kinase (RTK), non-RTK or G-protein coupled receptors (Poon et al., 2009, Fukuda et al., 
2002, Laughner et al., 2001). Under normoxic conditions HIF-1α can be induced by various 
growth factors including, insulin-like growth factor -1 and -2 (IGF-1 and IGF-2), epidermal 
growth factor (EGF), fibroblast growth factor-2 (FGF-2), transforming growth factor-β1 
(TGF-β1) and platelet derived growth factor-β (PDGF-β) (Feldser et al., 1999, Richard et al., 
2000, Wenger, 2002). An array of protein effectors have also been observed to be involved 
in regulating the stabilisation of HIF-1α, including the oxygen-independent degradation of 
HIF-α by hypoxia-associated factor (HAF) (Koh and Powis, 2009), positive regulation of HIF-
α through mammalian target of rapamycin (mTOR) (Hudson et al., 2002) and the protein 
chaperone heat shock protein 90 (HSP90) (Minet et al., 1999).  
Interestingly, a number of TCA cycle intermediates have been identified to inhibit the PHD 
proteins, thereby indirectly affecting HIF-1α stabilisation. Fumarate, succinate and 
oxaloacetate have been observed to inhibit all three of the PHD proteins and additionally 
citrate demonstrated to inhibit PHD3 and most effective at inhibiting FIH-1 (Koivunen et al., 
2007a). These observations highlight an exciting link between mitochondrial function and 
PHD-mediated regulation of HIF. Finally, recent observations suggest that mitochondria 
themselves, as the primary consumers of oxygen, play an important role in oxygen sensing. 
Mitochondria are hypothesised to be involved in the hypoxic stabilisation of HIF-α, via the 
PHDs and various paradigms exist as to the mechanism. The importance of mitochondria to 
the HIF/hypoxia response and vice versa therefore remains a subject of intense current 
interest within the field. 
 
1.3 Mitochondrial oxygen homeostasis in cells 
The control of metabolic homeostasis in cells involves tightly regulated dynamic pathways, 
able to respond rapidly to changes in the environment, energy demand and bioenergetic 
substrate supply (Shohet and Garcia, 2007). Central mediators in this process are 
mitochondria, whose primary function is the provision of sufficient energy requirements. 
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Amazingly mitochondrial respiration is only compromised at environmental oxygen 
concentrations of less than 0.1% due to the extremely high affinity that cytochrome c 
oxidase has for molecular oxygen (Tello et al., 2011). In the heart, a highly metabolically 
active aerobic organ, to cope with demand, mitochondrial composition extends to ~25-35% 
of total cardiomyocyte volume (Pi et al., 2007). This energy is provided in the form of the 
co-enzyme adenosine triphosphate (ATP), which acts as the physiological currency of 
energy transduction and releases intrinsic energy through the hydrolysis of two 
phosphoanhydride bonds (Jeremy M Berg, 2002). In vivo, oxidative phosphorylation 
(OxPhos) provides the majority of ATP necessary for cellular function. However, depending 
on the cell type there is a different reliance on ATP produced by glycolysis. Mitochondria 
are often referred to as being the ‘powerhouse of the cell’; that being said it is also 
extremely clear that the role of mitochondria extend beyond that of just vital ATP 
biosynthesis. Indeed mitochondria also participate in multiple regulatory signalling 
pathways stimulated in response to physiological stressors such as ischaemia, hypoxia and 
oxidative damage. Thus, they are considered integral in their role in processes such as, cell 
survival and apoptosis.  
1.3.1 Respiration, the electron transport chain and oxidative phosphorylation 
Oxidative metabolism (OxPhos) is a vital function of mitochondria under normal conditions, 
functioning to maintain adequate ATP to meet fluctuating cellular demand. Mitochondrial 
substrate utilisation for OxPhos is dependent on the cell type or tissue. Under normal 
physiological conditions, in the well oxygenated heart, beta-oxidation of fatty acids 
provides the primary carbon fuel source and undergoes a process of oxidation, hydration 
and cleavage to yield 90% of the acetyl coenzyme-A (acetyl co-A) to enter the TCA cycle 
(Jeremy M Berg, 2002, Neely and Morgan, 1974, Solaini and Harris, 2005, Jafri et al., 2001, 
Neely et al., 1972). In cells distinct from cardiomyocytes, it is the oxidation of glucose that 
produces the substrates which are delivered to the TCA cycle. Pyruvate is produced 
through enzyme-mediated, stepwise conversion from glucose and its ordered 
dehydrogenation. Pyruvate is then converted to the common precursor acetyl co-A by 
pyruvate dehydrogenase (PDH) in mitochondria, ultimately feeding the TCA cycle (Jafri et 
al., 2001).  
The TCA cycle occurs in the matrix of mitochondria and links the glycolysis and fatty acid 
oxidation to OxPhos. The TCA cycle provides the reducing equivalents required to feed into 
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the electron transport chain (ETC), while producing various intermediates such as α-
ketoglutarate, succinate, citrate and fumarate (Jafri et al., 2001), some of which regulate 
the HIF response as outlined above. 
OxPhos is the process through which cells produce the majority of ATP. ATP is synthesised 
through the generation and coupling of a proton gradient across the inner mitochondrial 
membrane to phosphorylation of adenosine diphosphate (ADP) at the F1FO-ATPase 
(complex V) (Jafri et al., 2001). ATP synthesis is achieved through an intricate system of 
electron transfer through a series of acceptor cytochromes (complexes I-IV) (Semenza, 
2007b). Reducing equivalents such as reduced nicotinamide adenine dinucleotide (NADH) 
and flavin adenine dinucleotide (FADH2), products of the TCA cycle donate electrons to ETC 
complexes I and II respectively. The sequential transfer of electrons through to complex III, 
cytochrome c and finally to complex IV is coupled to proton flux across the mitochondrial 
inner membrane from the matrix into the intermembrane space (IMS) (Figure 1.5). At 
complex IV, oxygen is utilised as the final electron acceptor to produce water. Serial 
electron transfer and proton flux creates an electrochemical gradient of protons (ΔμH+) of 
approximately 200 mV across the mitochondrial inner membrane (Solaini and Harris, 2005). 
The electrochemical gradient (proton motive force) consists of a pH gradient between the 
matrix and the IMS cytosol (of -1 pH unit; -60 mV) and electrical potential/voltage gradient 
(of 140 mV) (negative inside) (Wheaton and Chandel, 2011, Brand and Nicholls, 2011). The 
electrochemical potential is used to drive ATP biosynthesis from ADP and phosphate via 
proton flow back down their gradient, through the membrane bound F1FO-ATPase. 
Alternatively, a small proportion of protons may leak back across the inner membrane into 
the matrix (Heineman and Balaban, 1990, von Ballmoos et al., 2009, Bruce Alberts, 2002). 
The process of oxidative metabolism is not 100% efficient despite generating 38 molecules 
of ATP per molecule of glucose (Taylor and Pouyssegur, 2007) and is estimated that 0.2-2% 
of the total oxygen consumption will be incompletely reduced and yield reactive oxygen 
species (ROS) (Solaini and Harris, 2005, Addabbo et al., 2009). At low levels, ROS by-
products may play a physiological role in signal transduction and their detoxification via 
mitochondrial and cytosolic superoxide dismutases (SODs) is carefully balanced. Changes in 
levels of ROS or their neutralizing enzymes can have pathophysiological consequences, 
such as in ischaemia-reperfusion injury, a state during which cells and tissue experience 
lack of oxygen and nutrients as a result of infarct, while reperfusion results in a burst of 
ROS, causing further cellular damage. 
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Figure 1.5: Diagrammatic representation of proton and electron flow through the 
electron transport chain (ETC).  
Electrons are passed along the ETC and using the free energy generated, protons (H+) are 
moved against their concentration gradient from the matrix to the inter-membrane space 
(IMS) to generate an electrochemical gradient of protons (ΔμH+) across the inner 
mitochondrial membrane (IMM). Protons then flow back down their gradient through 
the F1FO-ATPase in a reaction coupled to the phosphorylation of ADP to ATP. OMM = 
outer mitochondrial membrane.  
 
1.3.2 Mitochondria and oxygen-sensing 
The PHD proteins are inhibited by oxygen deprivation and were initially thought of as the 
sole regulators of HIF-α (defined this now above) stabilisation under low oxygen. However 
recent data points to the fact that mitochondria act as additional oxygen sensors in vivo, 
although the cellular mechanism for this remains to be understood. Over the last decade 
several groups have shown mitochondrial involvement in the process of oxygen-sensing 
and demonstrated that the regulation of HIF-α stabilisation under hypoxia and HIF-
dependent gene transcription requires mitochondria (Agani et al., 2000, Chandel et al., 
1998, Chandel et al., 2000, Guzy et al., 2005, Hagen et al., 2003, Lin et al., 2008, Mansfield 
et al., 2005, Emerling et al., 2005, Brunelle et al., 2005). However, under anoxia (0% O2), 
oxygen deprivation and substrate limitation to the PHD proteins inhibits proline 
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hydroxylation of HIF-α and in this environment mitochondria are not required for the 
HIF/hypoxic response (Srinivas et al., 2001, Vaux et al., 2001). Currently two independent 
theories have been proposed through which mitochondria may participate in HIF-α 
stabilisation; (i) the generation of ROS from complex III mediates hypoxic HIF-α stabilisation 
and (ii) mitochondrial oxygen consumption and the redirection of oxygen away from the 
cytoplasm (and the PHD proteins) to mitochondria in hypoxia leads to HIF-1α stabilisation 
(Tormos and Chandel, 2010).  
1.3.2.1 HIF-α stabilisation in hypoxia requires a functional ETC 
Although debate continues as to the specific mechanism of mitochondrial involvement in 
HIF-α stabilisation, one observation is clear and has been re-produced across a number of 
laboratories; the stabilisation of HIF-α cannot occur in response to hypoxia without a 
functional ETC (Agani et al., 2000, Chua et al., 2010, Chandel et al., 2000, Chandel et al., 
1998, Chandel and Schumacker, 1999, DeHaan et al., 2004, Schroedl et al., 2002, Agani et 
al., 2002). Early observations identified the necessity of a functional ETC for the 
stabilisation of HIF-1α and HIF-2α in hypoxia (1% oxygen) using pharmacological inhibitors 
such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and rotenone (complex I 
inhibitors), myxothiazol and stigmatellin (complex III inhibitors). The use of genetic models 
and mitochondrial DNA deficient rho-zero cells (ρ0 cells) confirmed these initial 
observations (Chandel et al., 1998, Guzy et al., 2005, Mansfield et al., 2005, Bell et al., 
2007). ρ0 cells are engineered through culture of parental cells with a low concentration of 
ethidium bromide over a number of weeks. Although mitochondrial DNA (mtDNA) only 
encodes 13 protein encoding genes, genetic ablation of these genes leads to the absence of 
components of complexes I, III, IV and V. Consequently, these cells lack the capacity to 
respire and despite containing petit mitochondria and a membrane potential, they rely 
solely on ATP generated from glycolysis alone to survive (Chandel and Schumacker, 1999). 
There is additional evidence demonstrating that HIF-1α stabilisation in ρ0 cells in response 
to anoxia can occur despite the lack of a functional ETC (Srinivas et al., 2001, Vaux et al., 
2001). Collectively, these observations suggest that mitochondria are important for HIF-1α 
stabilisation in hypoxia but not anoxia due to the inherent oxygen dependence of the PHD 
proteins. Notably, there may be biochemical and technical considerations regarding ρ0 cell 
heterogeneity and generation that may affect how ρ0 cells respond differently to hypoxia 
versus anoxia (Bell et al., 2005).  
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One early observation by Agani et al (Agani et al., 2000), noted that the neurotoxin and 
complex I inhibitor MPTP blocked HIF-1α induction in hypoxia and abrogated HIF-1 DNA 
binding capacity. MPTP produced an approximate 56% inhibition of complex I activity by 5 
hours treatment in a neuroblastoma cell line. Additionally, MPTP intra-peritoneal injection 
in the striatum after hypoxic challenge produced a similar phenotype (Agani et al., 2000). 
Xenomitochondrial cybrids engineered using human ρ0 cells fused with primate 
mitochondrial DNA and harbouring a 40% reduction in complex I activity, also prevented 
the hypoxic accumulation of HIF-1α. Interestingly, HIF-1α stabilisation was restored when 
indirectly supplying complex II with the substrate succinate, re-establishing electron flux to 
complex III. This suggests that even a mild reduction in complex I activity and oxygen 
consumption results in failure to stabilise HIF-1α in hypoxia (Agani et al., 2000).  
Genetic approaches have been exploited to determine which elements of the ETC are 
necessary for the hypoxic stabilisation of HIF-1α (Guzy et al., 2005, Mansfield et al., 2005, 
Bell et al., 2007). These studies have identified that two components of the ETC are vital for 
the HIF/hypoxic response; complex III and cytochrome c. For example, using RNA 
interference (RNAi) toward the Rieske iron-sulphur protein and Q0 site of complex III (Guzy 
et al., 2005, Bell et al., 2007) or cytochrome c embryonic knockout mice (Mansfield et al., 
2005), studies have demonstrated failure of HIF-1α stabilisation in hypoxia. Notably 
however, neither perturbation to the ETC affected stabilisation of HIF-1α in anoxia, possibly 
due to oxygen limiting effects on the PHDs (Bell et al., 2005, Appelhoff et al., 2004). 
1.3.2.2 Mitochondrially derived ROS and their role in stabilisation of HIF-1α in response to 
hypoxia 
ROS have been recognised as signalling molecules as well as being cytotoxic. Paradoxically 
ROS levels have been observed to increase in hypoxia, through an unknown mechanism 
(Chandel et al., 1998, Guzy et al., 2005, Duranteau et al., 1998). Specifically, 
cardiomyocytes have been shown to increase ROS production in hypoxia, by oxidation of 
the redox-sensitive fluorescent probe 2, 7-dichlorofluorescein (DCF), which was attenuated 
by antioxidants (Duranteau et al., 1998). Upon tissue reperfusion complexes I and III appear 
to be the primary sites for ROS generation (Duranteau et al., 1998). The pathophysiological 
significance of reoxygenation/reperfusion injury is clear (Solaini and Harris, 2005) and ROS 
production during hypoxia/ischaemia and at the restoration phase is a principal mediator 
of the pathology associated with this injury. Hence, it is important to decipher the role of 
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ROS as signalling molecules and their potential for oxidative damage, as is delineating the 
mechanism behind their generation and behaviour in each situation. Mitochondrial 
manganese or cytosolic copper/zinc superoxide dismutase’s (Mn-SOD, Cu/Zn-SOD) catalyse 
the production of hydrogen peroxide (H2O2) from superoxide (O2
-), which will either be 
converted to oxygen and water by catalase or under certain circumstances, react with 
transition metals or nitric oxide to form the highly reactive hydroxyl radical (·OH) or distinct 
reactive nitrogen species (RNS) respectively (Li and Jackson, 2002, Goswami et al., 2007). 
The absence of oxygen creates an environment whereby ETC complexes become and 
remain in their reduced state and allows for further superoxide production, an event 
compounded through the highly oxidative environment at reperfusion (Li and Jackson, 
2002).  
The first theory regarding a mechanism underlying mitochondrial involvement in HIF-1α 
hypoxic stabilisation concerns the necessity of mitochondrial ROS produced under hypoxia 
for HIF-1α protein stability. A small percentage of the oxygen utilised by mitochondria is 
incompletely reduced, yielding ROS even in the resting/quiescent state (Tormos and 
Chandel, 2010, Addabbo et al., 2009, St-Pierre et al., 2002). ROS produced by the 
mitochondrial ETC complex III are generated through the Q-cycle, whereby ubiquinone is 
reduced to ubiquinol (Tormos and Chandel, 2010) and have the capacity to diffuse into the 
mitochondrial matrix or mitochondrial IMS as the ubiquinol oxidation site which generates 
the superoxide is located adjacent to the IMS (Sun and Trumpower, 2003). In contrast, 
superoxides formed at complexes I and II are released into the matrix only (Muller et al., 
2004, Tormos and Chandel, 2010). The increase in ROS in hypoxia has been proposed by a 
number of groups to mediate stabilisation and transcriptional activation of HIF-α (Brunelle 
et al., 2005, Agani et al., 2000, Chandel et al., 2000, Guzy et al., 2005, Mansfield et al., 
2005, Poyton et al., 2009, Chandel et al., 1998). A proposed mechanism is that ROS oxidise 
the PHD protein substrate Fe2+ to form Fe3+, via Fenton chemistry. Fe3+ cannot be utilised 
by the PHD proteins, decreasing their catalytic activity and enabling HIF-1α stabilisation 
(Guzy et al., 2005, Guzy and Schumacker, 2006, Gerald et al., 2004, Pan et al., 2007).  
Chandel et al in 1998 were first to correlate hypoxia-induced gene transcription with 
mitochondrial ROS production (Chandel et al., 1998). Chandel et al observed an increase in 
DCF oxidation and fluorescence at decreasing oxygen levels and the attenuation of this 
effect using the glutathione peroxidise mimetic ebselen, which catalyses the conversion of 
Chapter 1: Introduction 
Page | 35  
 
H2O2 to water. Chandel et al also demonstrated that mitochondria were required for the 
increase in ROS production during hypoxia using ρ0 cells which are devoid of mitochondrial 
DNA and produced no ROS and DCF fluorescence in hypoxia. Chandel et al proposed that 
the ROS generated at complex III were necessary for the activation of HIF-1α in hypoxia. 
Additionally Chandel et al suggested that hypoxic ROS, produced in hypoxia, promoted HIF-
1α DNA binding and HIF-1 target gene expression - an event abolished by the addition of 
the antioxidants ebselen and thiol reductive agent pyrrolidine dithiocarbamate (PDTC) 
(Chandel et al., 1998). The same group demonstrated two years later that ROS generated 
by the mitochondria were not just necessary but sufficient to stabilise HIF-1α protein 
through the observation that exogenous H2O2 stabilised HIF-1α in normoxia (Chandel et al., 
2000).  
Schroedl et al (Schroedl et al., 2002) confirmed using ρ0 cells, the necessity of a functional 
ETC for the hypoxic stabilisation of HIF-1α and demonstrated that anoxic stabilisation of 
HIF-1α occurs in a mitochondrially-independent manner. Schroedl et al proposed that 
prolyl hydroxylases are not the single primary oxygen sensor and suggested a role for 
activation of mitochondrial-dependent ROS-mediated intracellular signalling pathways. 
Using a ROS-sensitive dye, Schroedl et al demonstrated that hypoxia, but not anoxia, 
increases mitochondrial ROS generation and using a HRE-driven luciferase reporter showed 
that transcriptional activation of HIF-1 was inhibited in ρ0 cells. The same group also 
observed the abolition of hypoxic (1.5% O2) but not anoxic stabilisation of HIF-1α, using the 
complex I inhibitor rotenone, which proximally blocks electron transfer through to complex 
III. Using the complex II substrate methyl-succinate, bypassing complex I and restoring 
electron flow even in the presence of rotenone, reversed this complex I mediated block on 
HIF-1α stabilisation by rotenone (Schroedl et al., 2002). These data from ρ0 cells and 
rotenone mediated complex I inhibition were later replicated by Guzy et al in 2005 (Guzy et 
al., 2005). Furthermore, Guzy et al, used RNA interference (RNAi) methods and a novel 
redox-sensitive fluorescence resonance energy transfer (FRET) protein sensor and over-
expression of antioxidants to assess the contribution of mitochondrial-dependent oxidant 
signalling and determined that again a functional ETC and complex III ROS generation is 
necessary for hypoxic HIF-1α protein stabilisation (Guzy et al., 2005). Moreover Guzy et al 
observed involvement of the Rieske-iron sulphur protein, which regulates electron flux 
through complex III and effects free radical generation and demonstrated that lack of this 
component prevented hypoxic mitochondrial ROS generation and HIF-1α stabilisation. Guzy 
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et al deduced that H2O2, not superoxide, is the responsible ROS mediating HIF-1α 
stabilisation in hypoxia (Guzy et al., 2005).  
More recently, genetic approaches have been used to navigate around the contention 
surrounding pharmacological ETC disruption and variability in the production and 
prolonged culture of ρ0 cells (Mansfield et al., 2005, Brunelle et al., 2005). Mansfield et al 
(Mansfield et al., 2005) demonstrated the importance of cytochrome c for the HIF/hypoxic 
response, after targeted mutagenesis of the cytochrome c gene (Li et al., 2000) in murine 
embryonic cells. Mansfield et al observed that subsequent stable re-expression of mutant 
cytochrome c protein, which prevents oxidation of cytochrome c1 and maintains the Rieske 
iron-sulphur protein in a reduced state, prevented the HIF/hypoxic response but not anoxic 
HIF-1α stabilisation (Mansfield et al., 2005). Brunelle et al, used siRNA to knockdown the 
Rieske iron-sulphur protein resulting in loss of Q-cycle initiation, formation of 
ubisemiquinone radical and subsequent ROS generation. Brunelle et al confirmed that 
observed by Mansfield et al (Mansfield et al., 2005) and the resultant in failure of hypoxic, 
but not anoxic HIF-1α stabilisation (Brunelle et al., 2005). In the same study, Brunelle et al 
(Brunelle et al., 2005) used fibroblasts with SURF-1 mutation, derived from patients with 
Leigh’s syndrome. SURF-1 encodes a protein involved in the assembly of cytochrome c 
oxidase and produces a phenotype of impaired OxPhos but residual electron transport. 
SURF-1 null fibroblasts are still capable of stabilising HIF-1α in hypoxia. In addition to this 
the authors also provided evidence demonstrating that Chinese hamster ovary cells, with 
over 90% complex I deficiency are able to stabilise HIF-1α in hypoxia. Brunelle et al 
confirmed that hydrogen peroxide and not superoxide, is the species responsible for the 
effects on HIF-1α, by demonstrating that over-expression of catalase and glutathione 
peroxidise, but not superoxide dismutase 1 (SOD1) or SOD2 could prevent the hypoxia-
induced stabilisation of HIF-1α. Brunelle et al concluded that electron transport, but not 
the consumption of oxygen or OxPhos, is necessary for hypoxic stabilisation of HIF-1α, due 
to the production of ROS. Brunelle et al suggested that OxPhos and generation of 
intracellular oxygen gradients are dispensable and not responsible for the regulation of 
hypoxic stabilisation of HIF-1α (Brunelle et al., 2005).  
Cytochrome b is a subunit component of complex III. Bell et al (Bell et al., 2007) re-
expressed a mutant form of this protein into ρ0 cells to create mutant cybrids which are 
unable to consume oxygen and however generate ROS. Bell et al observed that these 
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cybrids were still able stabilise HIF-α in hypoxia, adding further evidence to the hypothesis 
that mitochondrial ROS, derived from complex III are required for the hypoxic stabilisation 
of HIF-1α (Bell et al., 2007).  
The studies described above link hypoxia signalling with mitochondrial ROS production and 
their cytosolic diffusion. These observations demonstrate a role for mitochondria in oxygen 
sensing in hypoxia, through as yet an unknown mechanism, but potentially one which is 
dependent on PHD proteins. Until anoxic (0% O2) conditions, when the PHDs are 
completely inactivated, HIF-α hydroxylation is completely inhibited, blocking subsequent 
degradation and thereby enabling a HIF-α response (Guzy et al., 2005). Because of the 
inherent difficulties in measuring ROS and the variable data in ROS measurements between 
laboratories, questions still remain as to their mitochondrial production in hypoxia, which 
species of ROS is responsible and the mechanism by which they act to stabilise HIF-1α. 
Nevertheless, enough evidence exists to suggest the ROS regulation of HIF-1α is most 
definitely evident.  
Finally, data also suggest an essential role for mitochondrial-derived ROS in the non-
hypoxic stabilisation of HIF-1α in response to the vasoactive hormone angiotensin II (Ang II) 
in vascular smooth muscle cells (Patten et al., 2010, Richard et al., 2000). Ang II has 
demonstrated effects on HIF-1α, such as increased stabilisation, activation and gene 
transcription, which all require mitochondrial ROS generated at complex III as an signalling 
intermediary (Patten et al., 2010). Interestingly these findings by Pattern et al (Patten et al., 
2010, Richard et al., 2000) link hormone-mediated signalling, ROS and HIF. Other growth 
factors, such as IGF-1 have also been linked to redox chemistry and ROS-dependent 
receptor activation (Vardatsikos et al., 2009) and it would be of interest to determine 
whether any inherent ROS-dependency is necessary for IGF-1 mediated HIF-α induction.  
1.3.2.3 Mitochondrial oxygen consumption and stabilisation of HIF-1α in hypoxia 
The mitochondrial ETC consumes the majority of cellular oxygen and therefore it is 
conceivable the ETC plays a critical role in oxygen sensing. An alternative ROS-independent 
model has been proposed to explain why a functional ETC is required for HIF-1α 
stabilisation in hypoxia (Hagen et al., 2003, Taylor, 2008). This model is based on the 
premise that actively respiring cells will consume oxygen and hence have a lower 
intracellular oxygen concentration than those treated with respiratory inhibitors. The 
“oxygen re-distribution model” hypothesises that mitochondria control intracellular oxygen 
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availability in hypoxia, through alterations in oxygen consumption at cytochrome c oxidase 
and this may be responsible for HIF-1α protein stabilisation, independent of ROS 
generation at complex III (Hagen et al., 2003, Chua et al., 2010, Doege et al., 2005) with a 
similar conclusion with HIF-2α (Brown and Nurse, 2008). Through the generation of an 
intracellular oxygen gradient in hypoxia, the oxygen concentration at mitochondria will be 
higher in order to maintain a degree of electron transport, while the oxygen concentration 
will be lower in the cytoplasm (Figure 1.6). The latter would inhibit the PHD proteins and 
promote stabilisation of HIF-1α. Therefore, at 1% oxygen, ETC inhibitor-treated cells would 
have an intracellular oxygen concentration at or around 1%, sufficient to allow the PHDs to 
functionally hydroxylate HIF-1α. In untreated cells the rate of hydroxylation will decrease 
as the ETC consumes oxygen and continue until oxygen is depleted. To summarise, a 
decrease in the rate of mitochondrial oxygen consumption and electron transport when 
the ETC is blocked by inhibitors results in an increase in cytoplasmic oxygen concentration 
and PHD re-activation, through a re-distribution of intracellular oxygen.  
Hagen et al championed the “oxygen re-distribution model” as an alternative idea to the 
ROS-dependent model for HIF-α stabilisation, based on the observation that antioxidants 
did not reverse the inhibition of hypoxia-dependent HIF-1α stabilisation by myxothiazol and 
antioxidants failed to prevent HIF-1α stabilisation in hypoxia (Hagen et al., 2003). Through 
this work and previous observations (Mateo et al., 2003), Hagen et al proposed that re-
distributed oxygen is a consequence of competitive binding of nitric oxide (NO). Hagen et al 
used nitric oxide donors to cytochrome c oxidase and ETC inhibition as a means to an 
increase non-respiratory oxygen and demonstrate inhibition of HIF-1α stabilisation at 3% 
oxygen as a result of PHD mediated prolyl hydroxylation and increased proteasomal 
degradation (Hagen et al., 2003).  
The use of the F1FO-ATPase inhibitor oligomycin has also been observed to decrease HIF-1α 
protein in hypoxia, however not in response to PHD inhibitors DFO or dimethyloxalylglycine 
(DMOG) or in cells treated under anoxic conditions (Gong and Agani, 2005). Oligomycin 
decreases mitochondrial oxygen consumption, increases mitochondrial membrane 
potential and increases mitochondrial ROS. However, despite an increase in ROS induced 
after oligomycin treatment, HIF-1α fails to be stabilised in hypoxia (Gong and Agani, 2005). 
Collectively, these findings suggest that the mitochondrial ETC is necessary for the hypoxic 
stabilisation of HIF-1α, independent of ROS generation and instead as a result of 
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mitochondrial oxygen consumption indirectly modulating PHD function (Gong and Agani, 
2005). 
Chua and colleagues contributed the most striking observation to date to confirm the ROS-
independent mechanism for mitochondrially mediated HIF-1α stabilisation in hypoxia. Chua 
et al demonstrated that by bypassing complex III, HIF-1α can still be stabilised in hypoxia 
(Chua et al., 2010). Chua et al observed no significant increase in ROS generation using 
dihydroethidium, after exposure of cells to hypoxia (1% O2) and no reduction in response to 
ETC inhibitors, indicating no role for mitochondrial ROS in HIF-1α stabilisation in hypoxia. 
Chua et al continued to demonstrate that, in spite of using myxothiazol to inhibit complex 
III and superoxide production, that the artificial electron donor to cytochrome c and 
complex IV, N,N,N′,N′-tetramethyl-p-phenylenediamine (TMPD) could rescue the 
myxothiazol-induced block on HIF-1α stabilisation. Hence, the restoration of oxygen 
consumption at complex IV is sufficient to stabilise HIF-1α in hypoxia and the inhibitory 
effects on HIF-α stabilisation after myxothiazol treatment alone, are potentially due to the 
consequential reduction in oxygen utilisation/consumption. Additionally, bypassing 
complex III and complex IV altogether using alternative oxidase (AOX) to accept electrons 
from co-enzyme Q and directly reduce oxygen to water, allowed maintenance of oxygen 
consumption and avoidance of complex III-dependent ROS production. Using AOX, HIF-1α 
was also observed to be stabilised under hypoxia, suggesting complex III and ROS are not 
involved. Finally, Chua et al demonstrated using an in vitro hydroxylation assay that 
exogenous hydrogen peroxide does not inhibit PHD protein activity directly (Chua et al., 
2010). 
The mechanism underlying both the ROS-dependent and oxygen re-distribution models is 
one involving the PHD proteins, although the precise role of the PHD proteins has yet to be 
demonstrated. It is likely that the role of mitochondria in the hypoxic stabilisation of HIF-α 
in hypoxia will involve elements of both these models. It is highly likely that in fact, 
mitochondrial ROS generation and oxygen re-distribution occurs during hypoxia and may 
allow for fine tuning of the HIF response. 
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Figure 1.6: Diagram showing alternative models for mitochondrial involvement in the 
hypoxic stabilisation of HIF-1α. 
The ROS-dependent (left) and oxygen re-distribution (right) are two alternate models 
described for the role of mitochondria in the stabilisation of HIF-α in hypoxia. 
Mitochondria, shown in green, in hypoxia provide a source of ROS from complex III (left) 
or alternatively as the primary consumers of oxygen, create an oxygen gradient within 
cell (right). Both models are proposed to mediate the inhibition of PHD activity, 
stabilising HIF-α protein in hypoxia.  
 
1.3.2.4 Regulation of HIF-1α through interaction with the mitochondrial import 
machinery 
Ultrastructural analysis of mitochondria reveals that they consist of two aqueous 
compartments, the matrix and the IMS, separated by an inner membrane. Recently, a 
conserved mechanism for mitochondrial IMS protein import and biogenesis has been 
discovered, central to which is the mitochondrial protein Mia40, identified in yeast as 
essential for viability and import of small translocase of the inner membrane (Tim) proteins 
(Naoe et al., 2004, Chacinska et al., 2004).  
The human homologue of Mia40 was described as being soluble in the IMS and not 
tethered through an N-terminal sequence as in lower eukaryotes (Hofmann et al., 2005) as 
well as being the principal mechanism of import for a wide range of mitochondrial IMS 
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proteins (Koehler and Tienson, 2009). Subsequently our group has identified the human 
coiled-coil helix coiled-coil helix domain 4 (CHCHD4) mitochondrial protein family (Yang et 
al., 2012). The human CHCHD4 gene encodes two alternatively spliced isoforms (CHCHD4.1 
and CHCHD4.2), which are differentially expressed across human tissues. CHCHD4.1 is 
identical to human MIA40 and contains structurally and functionally essential conserved 
cysteines, within the conserved CHCH domain. We have shown that CHCHD4 (MIA40) 
regulates cellular oxygen consumption rate and ATP synthesis and that CHCHD4 (MIA40) is 
essential for regulating HIF-1α stabilisation in response to hypoxia. CHCHD4 (MIA40) 
knockdown blocks HIF-1α induction and transcriptional activity, decreases oxygen 
consumption rate and ATP biosynthesis in normoxia and inhibits tumour growth and 
angiogenesis in vivo. The converse also holds true, where over-expression of CHCHD4 
(MIA40) can enhance HIF-1α stabilisation in hypoxia, correlates with increased tumour 
progression and decreased survival (Yang et al., 2012). 
Most proteins present in the IMS are small (<20 kDa) and contain conserved cysteine 
residues arranged in either twin C-X3-C or twin C-X9-C domains particularly important for 
the formation of disulphide bonds and ultimately their import and mitochondrial trapping 
through the disulphide relay system (DRS) and the CHCHD4 (MIA40) machinery. 
CHCHD4/MIA40 is ubiquitously expressed and contains six essential cysteine residues 
involved in disulphide bond formation, four structural (C-X9-C) and two (CPC motif) involved 
in electron shuttling after direct interaction and oxidation of mitochondrially imported 
proteins after translocation through the translocase of the outer mitochondrial membrane 
(TOMM) complex. IMS protein import does not require ATP or an inner membrane 
potential, unlike those targeted to the inner membrane or matrix (Tokatlidis, 2005). IMS 
proteins are imported in their reduced state through the TOMM complex and interact with 
Mia40 through a transient disulphide bond between the first cysteine residue in the 
substrate and the N-terminal cysteine in the CPC motif of Mia40 (Koehler and Tienson, 
2009). Mia40 is redox sensitive and can be present in two different oxidation states, 
capable only of forming transient disulphide bonds with its substrates in its fully oxidised 
form. It is the role of the FAD-linked sulfhydryl oxidase Erv1 to re-oxidise Mia40 through 
transfer of electrons (Mesecke et al., 2005, Bien et al., 2010), which are then passed to 
either oxygen or cytochrome c (Dabir et al., 2007). Electrons passed via a redox reaction 
through a physical interaction between Erv1 and cytochrome c continue down the 
Chapter 1: Introduction 
Page | 42  
 
respiratory chain, allowing re-oxidation of Erv1 and preventing the formation of toxic 
hydrogen peroxide (Figure 1.7) (Bihlmaier et al., 2007, Allen et al., 2005).  
 
 
 
 
Figure 1.7: Mitochondrial protein import through the disulphide relay system (DRS).  
Diagram depicting protein import into the mitochondrial intermembrane space (IMS). 
Import substrates enter the mitochondrial IMS through the translocase of the outer 
mitochondrial membrane (TOMM) where they interact with oxidised Mia40. The 
substrate then becomes oxidised, folded and trapped in the IMS. Reduced Mia40 is re-
oxidised through the donating an electron to Erv1 and subsequently to cytochrome c and 
the ETC. ox = oxidised, red = reduced. 
 
1.3.3 Mitochondria and the HIFs 
Mitochondria and the HIFs exist in a reciprocal relationship. It has not only been observed 
that mitochondrial respiration plays a role in regulating HIF-α stabilisation and activity but 
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HIF activation also regulates mitochondrial metabolism. HIF is well documented to play a 
major role in the cellular metabolic adaptation to hypoxia (Figure 1.8). This regulation is 
indirect and mediated through increased expression of HIF-specific target genes. For 
example, expressed on cell surface membranes, the glucose transporter GLUT-1 is up-
regulated in hypoxia through a HIF-dependent mechanism (Ebert et al., 1995). HIF-
dependent induction of GLUT-1 was initially observed in HepG2 cells, over 12 hours hypoxia 
and is responsible for facilitating and regulating the transport glucose across the plasma 
membranes, increasing glycolytic substrate supply and flux under low oxygen tension 
(Ebert et al., 1995). 
Substrate supply to the mitochondrial ETC is one of the limiting factors in respiratory rate. 
Acetyl co-A enters the Krebs cycle, after its conversion from pyruvate a reaction catalysed 
by pyruvate dehydrogenase (PDH). In hypoxia, the HIF targets pyruvate dehydrogenase 
kinase-1 (PDK-1) and PDK-3 in melanoma are up-regulated and drive pyruvate away from 
the mitochondria by phosphorylating and inactivating PDH, decreasing the supply of 
reducing equivalents to the ETC and suppressing respiration, ATP production and 
preventing hypoxia-induced oxidative damage (Kluza et al., 2012, Papandreou et al., 2006, 
Kim et al., 2006). Papandreou et al observed an increased sensitivity to the cytotoxin 
tirapazamine and cell death with loss of HIF-dependent PDK-1 expression. Papandreou et al 
therefore suggested, as a potential therapeutic strategy the combination of HIF-1 
inhibitors, in order to force tumour cells to become more hypoxic, by inhibition of negative 
regulation of mitochondrial metabolism and hypoxic cytotoxics agents  (Papandreou et al., 
2006).  
Hypoxic promotion of glycolysis functions in concert with the HIF-1α-dependent induction 
of lactate dehydrogenase A (LDHA), an enzyme that converts the pyruvate to lactate. 
Increased lactate contributes to a fall in intracellular pH, compensated for by HIF-
dependent expression of the sodium/hydrogen exchanger-1 (NHE-1) and monocarboxylate 
transporter-4 (MCT-4) (Shimoda et al., 2006, Ullah et al., 2006), and further decreases 
pyruvate available to enter the TCA cycle (Firth et al., 1995).  
HIF-dependent expression of PKM2 encoding pyruvate kinase-M2, an isoform of pyruvate 
kinase expressed in the embryo and in cancer cells further limits substrate supply to the 
mitochondria in hypoxia. PKM2 functions in the terminal phase of glycolysis to convert 
phosphoenolpyruvate (PEP) to pyruvate, which in turn enters the TCA cycle (Luo and 
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Semenza, 2011). Luo et al recently uncovered a HRE within the PKM2 gene and observed 
HIF-1α to up-regulate its expression in hypoxia, a trait observed in cancer cells as a 
mechanism to increase aerobic glycolysis or the Warburg effect. Interestingly, PKM2 was 
observed to physically bind HIF-1α and HIF-2α and function as a transcriptional co-activator 
and augment transactivation of target genes and the shift from oxidative to glycolytic 
metabolism, functioning to promote HIF-dependent aerobic glycolysis (Luo and Semenza, 
2011, Luo et al., 2011).  
HIF-dependent cellular adaptation to hypoxia also directly regulates the ETC and OxPhos 
machinery. Fukuda et al (Fukuda et al., 2007), observed that under ambient oxygen, the 
predominant isoform of subunit 4 of cytochrome c oxidase is COX4-1. However, hypoxia 
increases mRNA transcription and protein expression of the more efficient COX4-2 isoform, 
(i.e. higher affinity for oxygen) in the liver and lungs of mice, in a HIF-dependent fashion. 
This increased expression works in tandem with HIF-mediated COX4-1 isoform degradation 
through up-regulated mitochondrial protease LON. Fukuda et al hypothesised that the 
COX4 subunit switch, from COX4-1 in normoxia to COX4-2 in hypoxia is a homeostatic 
response to maintain flow of electrons to complex IV and the reduction of oxygen to water 
to limit premature electron reduction earlier in the ETC and the formation of superoxide 
radicals, protecting the hypoxic cells from oxidant stress (Fukuda et al., 2007).  
Tello et al (Tello et al., 2011), observed HIF-1α-dependent hypoxic induction of NADH 
dehydrogenase (ubiquinone) 1 alpha sub-complex, 4-like 2 (NDUFA4L2), a protein which 
down-regulates complex I activity, limiting mitochondrial oxygen consumption, 
mitochondrial membrane potential and ROS generation under hypoxia (Tello et al., 2011). 
Questions remain as to the precise role of NDUFA4L2 in hypoxic adaptation but it has been 
hypothesised to act in concert with PDK isoforms to limit substrate supply to the ETC 
through effects on complex I activity. Parallel decrease in NADH dehydrogenase 
(ubiquinone) 1 alpha sub-complex, 4 (NDUFA4) protein in hypoxia also may suggest that as 
observed with complex IV in hypoxia (Fukuda et al., 2007), there is the potential for a 
subunit switch (Tello et al., 2011). The role and position of NDUFA4L2 protein in complex I 
has not yet been fully elucidated. 
Stabilisation and activation of HIF-1α has been shown to induce the transcription of 
microRNA-210 (miR-210) (Kulshreshtha et al., 2007). MicroRNAs (miRNAs) are small non-
coding RNA oligonucleotides that bind to and facilitate cleavage of messenger RNA 
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preventing their respective translation and have surfaced as central regulators of gene 
expression (Bartel, 2004). miR-210 has been demonstrated to be up-regulated in hypoxia in 
a HIF-1 (but not HIF-2) dependent manner (Camps et al., 2008, Kulshreshtha et al., 2007) 
and negatively regulates mitochondrial metabolism in hypoxia through repression of iron-
sulphur cluster assembly proteins -1 and -2 (ISCU-1/2) translation in human pulmonary 
artery endothelial cells (Chan et al., 2009). ISCU proteins are involved in the biogenesis and 
assembly of iron-sulphur clusters, prosthetic groups involved in electron transport and 
redox reactions. Iron sulphur cluster incorporation into proteins allows participation in 
numerous cellular processes and importantly identified to affect complexes I and IV of the 
mitochondrial ETC and the TCA cycle enzyme aconitase (Chan et al., 2009). Here, miR-210 
directed translational repression of ISCU1/2 mediated a metabolic shift toward glycolysis, 
down-regulating mitochondrial function in hypoxia and promoting the Pasteur effect (Chan 
et al., 2009).  
Finally, on a more macro scale, HIFs have been observed to affect mitochondrial biogenesis 
and turnover as an adaptive mechanism to hypoxia. The HIF-1α dependent expression of 
MXI-1 negatively regulates c-MYC transcriptional activity in VHL-deficient renal cells by 
competing with c-MYC for binding to MAX. The c-MYC-MAX heterodimer is necessary for c-
MYC-dependent gene transcription. Therefore the c-MYC induced expression of 
peroxisome proliferator activated receptor gamma (PPARγ) co-activator-1β (PGC-1β) is 
reduced under hypoxia, affecting mitochondrial biogenesis and negatively regulating 
mitochondrial mass, mitochondrial DNA content and cellular oxygen consumption rates 
(Zhang, 2007). A similar phenotype is observed through the HIF-1α dependent up-
regulation of BNIP3. BNIP3 gene transcription in prolonged hypoxia (48 hours) results in 
increased protein levels and displacement of the BH3-only protein, B-cell lymphoma-2 
(BCL-2) binding beclin, freeing beclin and promoting autophagy and mitochondrial 
turnover, again preventing ROS-mediated damage and cell death in hypoxia (Zhang et al., 
2008).  
It is clear there is a central role for the HIFs in regulating mitochondrial metabolism and 
adaptation in response to hypoxia. Metabolic adaptations are not just observed 
physiologically, but also pathophysiologically, for example solid tumours have large hypoxic 
regions towards their core and consequent HIF-α activation in this location will promote 
adaptive tumour cell survival.  
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Figure 1.8: HIF-1 regulates metabolic responses to hypoxia. 
HIF-1 target genes, shown in red are involved in regulating glycolysis, mitochondrial 
biogenesis and oxidative metabolism through up-regulation of genes involved in glucose 
uptake, mitochondrial autophagy and the diversion of metabolic substrates. (For full 
description of proteins, see abbreviation list). 
 
1.4 Mitochondrial dysfunction in disease  
1.4.1 Mitochondria and cardiovascular disease 
The cardiovascular system is responsible for the delivery of oxygen and metabolic nutrients 
to tissues and principally mediates body and cell homeostasis. The heart is one of the most 
metabolically active organs and in most circumstances periods without oxygen and vital 
nutrients can be particularly detrimental and result in various pathologies (Shohet and 
Garcia, 2007). Ischaemic cardiovascular disease is characterised by disruption in the proper 
functioning and regulation of cardiac metabolism due to the body’s inability to meet the 
hearts substantial metabolic demand, through the oxygen supply to the cardiac tissue 
being compromised. The cause of this, stems from either coronary artery occlusion or 
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increased myocardial oxygen requirements both resulting in reduced myocardial perfusion, 
localised tissue injury and ultimately in a heterogeneous group of pathological conditions 
(Shohet and Garcia, 2007). The severity of the resulting injury will be dependent on 
duration, intensity of the insult, and myocardial tolerance (Jafri et al., 2001). 
In situations of myocardial ischaemia, diminished perfusion to the myocardium permits 
metabolic demand to outstrip supply and causes localised hypoxia. The interruption of the 
molecular oxygen supply causes OxPhos to slow, energy stores diminish and the quantity of 
reducing equivalents increase. The myocardium has a large bioenergetic demand, a high 
rate of ATP consumption and limited tolerance to perturbations in ATP supply (Heineman 
and Balaban, 1990). Cellular oxygen consumption falls when oxygen levels tend toward 
hypoxia (1-3% oxygen) and so in hypoxic or anoxic hearts as an adaptive response, 
metabolism switches from oxidation of fatty acids to a potentially 10-20% acceleration in 
glycolysis (Neely and Morgan, 1974). Under these situations electron flux through the 
respiratory chain decreases and consequently so does ATP biosynthesis, additionally in 
ischaemia this situation is accompanied by an build-up in lactate and cytosolic acidification 
(Solaini and Harris, 2005). Mitochondrial membrane potential will decrease during periods 
of ischaemia and the F1FO-ATPase reverses direction and instead of driving ATP synthesis 
will hydrolyse ATP and in an effort to maintain membrane potential (Leyssens et al., 1996). 
The outcome is a time-dependent loss of cellular integrity due to the amalgamation of ATP 
depletion, disruption of intracellular calcium signalling, mitochondrial permeability 
transition pore (mPTP) opening, ROS generation and failure of cellular repair mechanisms 
(Reviewed in (Cadenas et al., 2010, Levraut et al., 2003a)). 
Activation of the glycolytic pathway alone is insufficient to satisfy the requirements of the 
demanding heart. In cardiac tissue the build-up of adenosine monophosphate (AMP) and 
phosphate will in turn inhibit the hearts contractile machinery and lactic acid, the by-
product of anaerobic respiration, will in turn, cause extracellular pH to decrease (Halestrap 
et al., 2007, Jafri et al., 2001). Clinically, the first-line treatment for myocardial ischaemia is 
to re-establish blood flow, as irreversible necrotic ischaemic damage occurs within 20 
minutes of occlusion (Downey et al., 2007). However, this is associated with its own 
problems such as enzyme and free radical release, and morphological changes, indicative of 
reperfusion injury (Halestrap et al., 2007).  
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Re-supplying the ischaemic myocardium with oxygen paradoxically results in more damage 
and this triggers a sequence of events leading to activation of cell death pathways, a 
phenomenon known as ischaemia-reperfusion (I/R) injury (Braunwald and Kloner, 1985). 
I/R injury is evident in a variety of clinical settings including in those individuals undergoing 
coronary artery bypass graft (CABG) surgery, patients who have survived cardiac arrest and 
those receiving thrombolysis or percutaneous coronary intervention (PCI) for an acute 
myocardial infarction (Hausenloy and Yellon, 2007). 
In both mild and severe ischaemia, the heart is forced to adapt metabolically. As cells 
switch to aerobic respiration, the reperfusion post-ischaemia causes necrotic and apoptotic 
cell death, thought to be mediated by activation of FAS-ligand dependent cell death 
pathways, a rise in intracellular calcium and mitochondrial dysfunction (Taylor and 
Pouyssegur, 2007, Cadenas et al., 2010). Additionally, the cytotoxic ROS generated from 
mitochondria in combination with ROS generated elsewhere that is released during 
myocardial ischaemia and during reperfusion have detrimental consequences on the heart 
and particularly mitochondria (Levraut et al., 2003b, Di Lisa and Bernardi, 2006, Misra et al., 
2009, Cadenas et al., 2010). It has been shown that oxidative stress during simulated 
ischaemia primes cardiomyocytes for cell death during reperfusion (Robin et al., 2007) and 
highlights the physiological importance of ROS homeostasis in the heart (Shohet and 
Garcia, 2007). 
Increased oxidative stress is commonly associated with cardiovascular disease (CVD) risk 
and pathology, highlighting the importance of mitochondrially derived species. Oxidative 
stress correlates with a number of cardiovascular risk factors including 
hypercholesterolemia and oxidised low density lipoprotein, being observed in vitro to 
increase mitochondrial oxidant production and reduce membrane potential and free 
cholesterol to promote cytochrome c release and apoptosis (Ballinger, 2005). As mediators 
and targets of oxidative damage, mitochondria have also been implicated in the increased 
risk of diabetes associated with CVD (Ballinger, 2005). Interestingly, many disease causing 
mitochondrial DNA mutations have been associated with cardiac disease, particularly 
cardiomyopathy, which has been linked with mutations that affect mitochondrial protein 
synthesis (Ballinger, 2005).  
HIF-α in vivo has been shown to be stabilised and activated in oxygen-deprived 
myocardium and after myocardial infarction (Lee et al., 2000). HIF-α is up-regulated in 
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response to chronic ischaemia (Lee et al., 2000) and HIF-1α mRNA levels and expression of 
its target gene VEGF were both increased after coronary artery occlusion (Lee et al., 2000). 
1.4.2 Mitochondria and neurodegenerative disease 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder, associated with 
postural instability, rigidity, tremor and bradykinesia with approximately only 5-10% of 
affected individuals having identified genetic causes, known as familial PD with the rest 
classified as idiopathic (Deas et al., 2011b). Quality control mechanisms exist in the cell to 
eliminate aged, damaged or dysfunctional mitochondria. Quality control mechanisms also 
allow the cell to prevent build up toxic reactive species, avoid activation of cell death 
pathways and rid itself of unnecessary metabolic burden (Vives-Bauza and Przedborski, 
2011). Autophagy is an adaptive process by which the cell non-selectively degrades and 
recycles cytosolic components (He and Klionsky, 2009). The formation and elongation of an 
isolation membrane encapsulates and fuses, trapping cytosolic components forming a 
double membrane vesicle, known as  the autophagosome (Mizushima, 2007). Mitophagy is 
the process of selective mitochondrial autophagy, a term coined by Lemasters in 2005 and 
has been observed be dysregulated in neurones in the substantia nigra in familial PD 
(Lemasters, 2005). Mitophagy uses the autophagic machinery to degrade mitochondria, 
however relies on specialised machinery to ensure mitochondrial targeting and specificity 
(Vives-Bauza and Przedborski, 2011).  
Autophagy under basal conditions proceeds at a very low rate and is regulated by a large 
number of autophagy-related gene (ATG) proteins, which are recruited upon autophagic 
induction and are highly conserved between yeast and mammalian cells (He and Klionsky, 
2009). Autophagosomes fuse with endosomes to form an intermediate known as an 
amphisome before fusing with the lysosome and creating the autophagolysosome. The 
content of the autophagosome are then degraded by the acid proteases within the 
lysosomal compartment and amino acids are recycled (Ravikumar et al., 2010).  
Microtubule-associated protein 1 light chain 3 (LC3), is the only identified protein 
component of the inner autophagosome membrane. LC3 is synthesised as a pre-cursor and 
immediately cleaved in the cytoplasm at its C-terminus and forming LC3-I. It is then 
covalently bound to phosphatidylethanolamine by the concerted efforts of ATG7 and ATG3 
to form LC3-II, which allows its targeting to both sides of the autophagosome membrane 
and thought to be necessary for the expansion and final fusion of the autophagosome (He 
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and Klionsky, 2009, Ravikumar et al., 2010). Autophagosomes then fuse with endosomes 
and finally the lysosome, involving lysosomal-associated membrane protein-2 (LAMP-2) 
and RAB7. The contents of the autophagosome are degraded by the acid proteases and 
released back into the cytosol to be re-used in bio-synthetic pathways (He and Klionsky, 
2009). 
Although the vast majority of PD occurs spontaneously, in approximately 5-10% of affected 
individuals there is a genetic link (Deas et al., 2011b). Heritable mutations in the 6 
identified PARK genes are associated with dominant and recessive forms of the disease and 
result in loss of dopaminergic neurones in the substantia nigra and accumulation of 
cytoplasmic Lewy Bodies in the remaining neurones (Deas et al., 2011b). PARK6 encodes 
the PTEN (phosphatase and tensin homologue)-induced putative kinase-1 (PINK1), a 
mitochondrially localised serine/threonine kinase, with kinase activity necessary for the 
translocation of parkin (encoded by PARK2) to the mitochondrial outer membrane (Vives-
Bauza, 2010). 
Mutations in PARK2 and PARK6, encoding parkin and PINK1 respectively are associated 
with recessive early onset PD. PINK1 and parkin were hypothesised to cooperate in the 
same pathway through the phenotypes of the respective knockouts in Drosophila 
melanogaster resulting in a similar phenotype (Park, 2006, Clark, 2006). PINK1 knockout 
phenotype could be rescued by over-expression of parkin, however PINK1 over-expression 
failed to rescue parkin deficiency, suggesting parkin functions downstream of PINK1 (Clark, 
2006, Park, 2006). The physical interaction of these proteins is still a matter of debate and 
the mechanism by which PINK1 recruits parkin to depolarised mitochondria remains 
unknown (de Vries and Przedborski, 2013).  
Parkin is a cytosolic E3-ubiquitin ligase and associates with mitochondria that have 
stabilised PINK1 associated with their outer membrane. Parkin was first observed by 
Narendra et al in 2008 (Narendra et al., 2008) to translocate to mitochondria and promote 
their autophagic degradation after mitochondrial uncoupling and dissipation of the 
mitochondrial inner membrane potential using carbonyl cyanide m-chlorophenyl 
hydrazone (CCCP) (Narendra et al., 2008). Parkin translocation causes LC3B-II association of 
mitochondria and their turnover using the autophagic pathway (Narendra et al., 2008, 
Kawajiri, 2010).   
Chapter 1: Introduction 
Page | 51  
 
Parkin translocation after depolarisation of the mitochondrial inner membrane was 
demonstrated to be PINK-1 dependent. PINK1 accumulates rapidly in pharmacologically 
depolarised mitochondria, using CCCP or combination of antimycin A and oligomycin, full 
length PINK1 can be observed in the mitochondrial fraction and this promotes the PINK1-
parkin dependent peri-nuclear trafficking of mitochondria (Vives-Bauza, 2010). The voltage-
dependent cleavage of PINK1 is inhibited by loss of membrane potential and its 
mitochondrial accumulation is independent of parkin expression however sufficient and 
necessary for parkin recruitment and mitophagy (Narendra, 2010). Presenilin-associated 
rhomboid-like protein (PARL) is the membrane potential sensitive component that is 
localised to the mitochondrial inner membrane and processes PINK1 under conditions 
where the membrane remains polarised and the PINK1 fragment is degraded by the 
proteasome. Loss of the mitochondrial proton gradient inhibits PARL activity and allows 
full-length PINK1 to accumulate and recruit parkin (Imai, 2012). Interestingly NIX has also 
been observed to increase parkin recruitment to mitochondria and induce parkin-mediated 
mitochondrial autophagy (Ding, 2010). 
There are a number of mechanisms through which PINK1 and parkin may affect mitophagy. 
PINK1 and parkin have been observed to regulate mitochondrial size, through effects on 
fusion and fission machinery, promote peri-nuclear re-distribution of mitochondria toward 
the increased density of autophagosomes and lysosomes or directly recruit the autophagic 
machinery to the mitochondria. Disruption of these processes will lead to alteration in 
mitochondrial quality control and build-up of dysfunctional mitochondria and cellular 
damage and degeneration associated with neurones in the substantia nigra in PD (for 
review see (de Vries and Przedborski, 2013)). 
Disease causing mutations in the PARK2 gene are deficient in mitophagy, however mutants 
display distinct phenotypes determined by their capacity to ubiquitinate target proteins, 
which promotes final clearance, however dispensable for the peri-nuclear re-distribution of 
parkin-associated mitochondria (Lee et al., 2010b). E3-ligase activity deficient parkin 
mutants maintain their ability to associate with mitochondria and form peri-nuclear 
aggresomes however are defective in final clearance, unlike those with mutations in the 
ubiquitin-like domain, in which parkin fails to be recruited to mitochondria (Lee et al., 
2010b). 
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Parkin has been observed to ubiquitinate several mitochondrial proteins that are 
associated with the outer mitochondria membrane such as voltage dependent anion 
channel-1 (VDAC1) and mitofusins -1 and -2 (MFN-1 and MFN-2) (Geisler, 2010, Gegg, 
2010). The parkin-mediated degradation of MFNs promotes mitochondrial fragmentation 
prior to mitophagy, an event believed to inhibit the re-fusion of damaged mitochondria, 
ensure their removal and avoid their re-complementation with healthy mitochondria. 
Parkin-mediated ubiquitination of mitochondrial outer membrane proteins promotes the 
recruitment of key regulatory components of the mitophagic response. The 
polyubiquitinated proteins that line the outer mitochondrial membrane are recognised and 
bound by the adaptor molecules p62/sequestosome-1 and histone deacetylase-6 (HDAC6) 
(Figure 1.9) (Lee et al., 2010b, Pankiv, 2007, Lee et al., 2010a).    
The protein p62 facilitates the association of the ubiquitinated mitochondria with the 
autophagosome membrane through direct binding to LC3 (Pankiv, 2007) and HDAC6 
controls the fusion of the autophagosome and lysosome (Lee et al., 2010a). Narendra et al 
demonstrated that p62 is required for parkin-induced mitochondrial clustering but not 
necessary for mitophagy to occur (Narendra et al., 2010). In contrast to earlier 
observations, Narendra et al also demonstrated VDAC1, is dispensable for both the 
clustering of mitochondria and mitophagic turnover (Narendra et al., 2010, Geisler, 2010). 
Recently Sarraf et al have published a large proteomic study on the depolarisation-
dependent parkin ubiquitylome (Sarraf et al., 2013). Investigations into mitochondrial 
depolarisation-dependent parkin ubiquitination has paved the way to better understand 
the diverse range of parkin substrates, its role in mitophagy and undoubtedly other cellular 
processes. 
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Figure 1.9: Mechanism of PINK1 and parkin mediated mitophagy. 
Mitochondrial depolarisation stabilises PINK1 and recruits parkin to the outer 
mitochondrial membrane. Parkin ubiquitinates target proteins and facilitates 
mitochondrial recognition by adaptor proteins HDAC6 and p62. Adaptor proteins then 
bind LC3B on the autophagosomal membrane and mitochondria are subsequently 
degraded through the classical autophagic pathway. Adapted from (Vives-Bauza and 
Przedborski, 2011). 
 
Interestingly, parkin has been identified not only to promote mitophagy in vivo, but also to 
induce the selective turnover of mitochondrial respiratory chain proteins in Drosophila 
melanogaster (Vincow et al., 2013). Using parkin knockout flies, Vincow et al demonstrated 
that loss of parkin in vivo prolongs mitochondrial protein half-life. Surprisingly 40 proteins 
demonstrated greater dependence on parkin for their turnover than on ATG7, which acts 
downstream, of parkin in the mitophagic pathway. This suggests a parkin-dependent ATG7-
independent process mediating mitochondrial protein turnover. Within these 40 proteins, 
subunits of the ETC where over-represented and components of all five complexes 
identified, with most being membrane bound. Identification of parkin sensitive proteins 
suggests a wider role for parkin in the selective turnover of respiratory chain proteins 
which, for example in PARK2 mutants could contribute to the mis-folding of ETC complexes 
observed in parkin mutant flies and perhaps in PD (Vincow et al., 2013). 
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1.4.3 Mitochondria and cancer 
In 1956 Otto Warburg described the metabolic profile of cancer cells, that despite the 
abundance of oxygen, cancer cells will utilise glucose and glycolysis as their predominant 
source of energy (Warburg, 1956). Aerobic glycolysis became known as the Warburg effect. 
Despite Warburg’s observation and contrary to what one might think, mitochondrial 
function is essential for the survival of cancer cells and depletion of their mitochondrial 
DNA reduces tumourigenicity and proliferation (Cavalli et al., 1997), highlighting the 
importance of mitochondrial function, outside their role of generating ATP.  
As discussed, the HIFs have a well-recognised involvement in regulating mitochondrial 
metabolism and function in cancer. Through target gene transactivation, HIF stabilisation 
increases glucose uptake, up-regulates a number of glycolytic proteins and promotes 
lactate production. HIF additionally down-regulates mitochondrial oxidative metabolism 
and HIF is therefore well placed to promote tumour cell adaptation and survival and to 
support the classical Warburg effect (Semenza, 2007a). Mutations in mitochondrial 
enzymes fumarate hydratase (FH) and succinate dehydrogenase (SDH) also contribute to 
HIF-α stabilisation and to the tumourigenic profile of the HIFs. Mutations in these TCA cycle 
genes, causes excess fumarate and succinate respectively, which have been demonstrated 
to inhibit the PHD proteins and promote the stabilisation of HIF-α (Cardaci and Ciriolo, 
2012, Koivunen et al., 2007a). These mutations support the expression of classical HIF 
target genes such as VEGF, involved in promoting angiogenesis, IGF-1 which promotes cell 
survival and plasminogen activator inhibitor-1 (PAI-1), which promotes metastasis (Poon et 
al., 2009). Thus targeting  HIF, although challenging, is an alternative therapeutic strategy in 
cancer (Poon et al., 2009). 
An interesting and distinct area of cancer biology is the role of mitochondria in determining 
the metastatic potential of cancer cells, which accounts for approximately 90% of cancer 
associated deaths. Through the production of trans-mitochondrial cybrids, whereby 
endogenous mitochondria DNA from a poorly metastatic cell line was replaced with that of 
a highly metastatic one and vice versa, Ishikawa et al demonstrated that the recipient cell 
acquired the metastatic potential of the donor (Ishikawa et al., 2008). Mitochondrial DNA 
from the highly metastatic cells contained a mutation in the ND6 gene, encoding NADH 
dehydrogenase subunit 6, leading to complex I dysfunction and ROS generation. Increases 
in HIF-1α and VEGF protein expression were also demonstrated (Ishikawa et al., 2008). 
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Treatment of cells containing mitochondrial DNA from highly metastatic cells with ROS-
scavengers repressed their metastatic potential, identifying a role of oxidant stress in the 
promotion of the metastatic phenotype (Ishikawa et al., 2008). In line with the anti-oxidant 
evidence, mice that expressed a mitochondrially targeted catalase were crossed those that 
developed metastatic breast cancer and demonstrated reduced metastatic burden 
compared to mice without mitochondrial catalase. This catalase-mediated metastatic 
suppression again suggested a role for mitochondrial ROS in promoting cancer metastasis 
(Goh et al., 2011). Mitochondrial DNA mutations in cancer cells have also been 
demonstrated to promote resistance to autophagy as a mechanism to increase metastatic 
potential (Kulawiec et al., 2009). 
Loss of caveolin-1 in stromal fibroblasts, has led to a new paradigm of a two-compartment 
tumour metabolism model, termed “the reverse Warburg effect” or stromal-epithelial 
metabolic coupling (Wallace, 2012, Martinez-Outschoorn et al., 2010a, Martinez-
Outschoorn et al., 2010b, Sotgia et al., 2012). H2O2 has been observed to be secreted from 
cancer cells into the adjacent heterogeneous mass of cells. H2O2-dependent loss of 
caveolin-1 from the stromal fibroblasts promotes their mitophagy. This reduces 
mitochondrial mass of these cells and promotes glycolysis. In stromal cells, mitochondrial 
dysfunction and promotion of the ‘Warburg effect’ or aerobic glycolysis leads to the 
excretion of lactate and ketones and their subsequent uptake by epithelial tumour cells. 
Lactate and ketones fuel cancer cell mitochondrial energy production and mitochondrial 
generation of precursors of cellular biogenesis and anabolic growth (Wallace, 2012, 
Martinez-Outschoorn et al., 2010a, Martinez-Outschoorn et al., 2010b, Sotgia et al., 2012). 
Interestingly, secondary tumours from metastatic breast cancer in the brain have 
dramatically increased oxidative metabolism compared to the tumour from which they 
originated. Cells from secondary tumours also exhibit up-regulation of genes involved in 
the pentose phosphate pathway and glutathione system, which reduces ROS. This increase 
in oxidative metabolism provides the metastatic cancer cell with resistance towards 
therapy as well as a proliferative and survival advantage (Chen et al., 2007). Metastatic 
breast cancer cells display oxidative metabolism and stain positively for TOMM20 and COX-
IV. Conversely tumour adjacent fibroblasts stain positively for MCT-4 (glycolytic marker), 
demonstrating that two-compartments exist side-by-side in a primary tumour and its 
metastases (Sotgia et al., 2012).  
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Mitochondrial dynamics have also been shown to regulate cancer cell metabolism. Up-
regulation and activation of the mitochondrial fission protein dynamin related protein -1 
(DRP-1) and fragmented mitochondria have been observed in an invasive breast carcinoma 
cell line and their lymph node metastases. Silencing of DRP-1 and over-expression of MFN-
1 reduces mitochondrial fission, promotes elongation and leads to reduced cancer cell 
invasion (Zhao et al., 2012). Lamellipodia are necessary for chemo-attractant-induced 
breast cancer invasion and metastasis. Increases in mitochondrial fusion or decreases in 
fission inhibits lamellipodia formation, whereas increases in mitochondrial fragmentation 
promotes the  formation of lamellipodia (Zhao et al., 2012).  
A number of mitochondrially metabolically targeted treatments are currently under 
investigation, including small molecule BH3-domain mimetics, which promote apoptosis in 
cancer cells, mitochondrially targeted heat shock protein 90 (HSP90) inhibitors, use  of 
lipophilic molecules to take advantage of the hyperpolarised mitochondrial inner 
membrane potential of cancer cells as well as mitochondrially targeted catalase as 
discussed (Bhandary et al., 2012). 
 
1.5 Conclusions 
The relationship between HIF and mitochondria is clearly a well explored aspect of HIF 
biology. Important and intimate links exist between mitochondria, key organelles which 
consume oxygen and the cellular pathways through which low oxygen is sensed and 
relayed.  
Drug discovery approaches aimed toward manipulating the HIF pathway hold the promise 
of clinical benefit and much interest exists in targeting the pathway for the purpose of 
treating defined pathologies. Activation of the HIF pathway may provide cardioprotection 
for those at risk of cardiovascular and ischaemic disease and conversely inhibition of HIF 
activity in solid cancers would reduce tumour cell survival and disease progression in 
response to conventional treatment.  
How mitochondria interface with the HIF oxygen-sensing machinery is of great interest. The 
possibility that HIF and/or other components of the oxygen-sensing pathway perform yet 
unidentified novel mitochondrial functions that may result in cell survival/homeostasis are 
being explored in our lab and in other labs across the field.            
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2.1 Tissue culture and protein analysis  
2.1.1 Antibodies and Reagents 
For all antibodies and reagents used please see table 1 and table 2. 
2.1.2 Cell culture 
Murine atrial HL-1 cardiomyocytes, described previously (Claycomb et al., 1998, White et 
al., 2004) were maintained in Claycomb medium (Sigma/SAFC biosciences) and 
supplemented with 2mM L-glutamine, 100U/ml penicillin, 100μg/ml streptomycin (all 
purchased from Gibco/Life Technologies), 100μM norepinephrine in 30mM L-ascorbic acid 
(both Sigma) and 10% fetal calf serum (FCS; Harian). Cells were subcultured at confluence 
in a split ratio of 1:3. Culture flasks (Falcon) were pre-coated with a solution of 0.02% (w/v) 
gelatin (Sigma) containing 1μg/ml fibronectin (Sigma).  
HCT116 containing wild type p53 (designated HCT116 +/+) described previously (Bunz et al., 
1998), HeLa (Health Protection Agency) and pVHL positive and negative 786O cells, 
described previously (Iliopoulos et al., 1995) were maintained in Dulbecco Modified Eagle 
Medium (DMEM; Invitrogen), supplemented with 10% FCS, 2mM L-glutamine, 100U/ml 
penicillin and 100μg/ml streptomycin. Stable pools of RCC10 cells described previously 
(Bond et al., 2011), were maintained in DMEM selection media containing 0.5μM G418 
(Sigma) in addition to supplements listed above. At confluence, cells were split in ratios 
between 1:10 – 1:20. All cells were maintained at standard cell culture conditions (37 °C, 
5% CO2 and 95% relative humidity). 
Normoxia (Nx) or ambient oxygen refers to incubation at 37°C in (21%) oxygen and 5% 
carbon dioxide. For hypoxic (Hx) treatment, cells were placed in a Ruskinn in vivo 1000 
hypoxic workstation at 1% O2, 5% CO2, and 94% N2 at 37°C for the desired time, as stated.  
2.1.3 Cell Lysis 
Following treatment, samples were washed in ice-cold phosphate buffered saline (PBS) and 
harvested in 1% NP40 lysis buffer (100mM Tris pH 8, 100mM NaCl, 1% (v/v) NP40, 10% 
(v/v) glycerol, 0.5mM EDTA, supplemented with 10mM glycerophosphate, 1mM sodium 
fluoride, 1mM sodium orthovanadate and 100x EDTA-free protease inhibitor cocktail 
(Thermo Scientific). 
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2.1.4 SDS-PAGE and western blotting 
Protein concentration in the cell lysate was measured using the Biorad DC protein assay  
(Biorad) according to manufacturer’s instructions and 30-60µg of protein was made to 
volume with 2x sample buffer (125mM Tris pH 6.8, 4% sodium dodecyl sulphate (SDS), 
0.01% (v/v) bromophenol blue, 10% (v/v) β-mercaptoethanol, 10% (v/v) glycerol). Proteins 
were separated using 7.5%, 10% or 12.5% SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and subsequently transferred electrophoretically to a polyvinylidene fluoride (PVDF) 
membrane (Millipore) over night at 4°C at 30V or for 5 hours at 0.5A at 4°C. Membranes 
were then blocked for one hour at room temperature in 5% (w/v)-skimmed milk-Tris-
buffered saline (140mM NaCl, 200mM Tris base, pH 7.4) - 0.1% (v/v) tween-20 (TBS-T). 
Membranes were incubated in primary antibody overnight at 4°C, before being washed for 
5x 5 minutes in TBS-T and incubated with HRP-conjugated secondary antibody (Amersham 
or Dako) for one hour at room temperature. Membranes were washed again in TBS-T for 5x 
5 minutes and bands were visualised using enhanced chemiluminescence solution (ECL) or 
ECL plus solution and hyperfilm-ECL (Amersham).  
2.1.5 Growth factor-mediated induction of HIF-1α protein 
HL-1 cardiomyocytes were plated at a density of 2.5x106 in 6 well plates and incubated for 
24 hours in Claycomb media at 37 °C and 5% CO2. The media was aspirated and then was 
replaced with serum-free DMEM and returned to the incubator for 40 hours. Serum free 
media was replenished and IGF-1 (100ng/ml) was added to each well. Cells were harvested 
in ice cold 1% NP40 lysis buffer at specific time points.  
 
2.2 Cell manipulation 
2.2.1 Plasmid preparation 
Enhanced green-fluorescent protein (EGFP) plasmids in pcDNA-3 for each of the PHD 
protein were provided by Prof. Patrick Maxwell (University of Cambridge, UK) and 
described previously (Metzen et al., 2003). Targeted ATP Luciferase constructs in pcDNAI, 
described previously (Jouaville et al., 1999), were provided by Dr. Gyuri Szabadkai 
(University College London, UK). Constructs were transformed into competent cells (BL21-
GOLD (DE3), Agilent technologies) using a heat shock method described in the 
manufacturer’s instructions. Purified DNA was prepared by Maxi-prep (Qiagen) as 
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manufacturer’s instructions. Plasmid DNA was quantified using a Nanodrop 8000 UV-Vis 
spectrophotometer (Thermo Scientific).  
2.2.2 Transient transfection of plasmid DNA 
Cells at 70-80% confluence in 10cm tissue culture plates were transfected either using 
Lipofectamine 2000 (Invitrogen) as per manufacturer’s instructions (2μg DNA:4μl 
Lipofectamine in one chamber of 6-well plate) or using the calcium phosphate method. 
Briefly, calcium phosphate-DNA complexes were prepared as follows for a 10cm plate: 
10µg DNA was diluted in water to a total volume of 440µl. 500ul of 2x Hanks Balanced Salt 
Solution (HBSS; 280mM NaCl, 10mM KCl, 1.5mM Na2HPO4-7H2O, 12mM dextrose, 50mM 
HEPES pH 6.8) was added to the DNA solution. 60 µL of 2M CaCl2 was added drop wise to a 
final volume of 1ml. The mix was incubated at room temperature for 10-20 minutes to 
allow the complexes to form. The precipitate was re-suspended by gentle pipetting and 
added drop wise over the cell monolayer and returned to the incubator overnight for 16 
hours. The precipitate was washed and replaced with fresh complete media and cells were 
allowed to recover for 24 hours at 37 °C. 
2.2.3 siRNA duplexes and transient transfection 
Custom made siRNA to human HIF-1α (5’-TACGTTGTGAGTGGTATTATT-3’) and HIF-2α (5’-
CCCGGATAGACTTATTGCCAA-3’) were purchased from Dharmacon and used at a final 
concentration of 20nM. A non-silencing control siRNA duplex (5’-
AATTCTCCGAACGTGTCACGT-3’) was obtained from Qiagen and published previously 
(Carroll and Ashcroft, 2006, Carroll and Ashcroft, 2008). Transient transfection with siRNA 
duplexes were performed using HiPerfectTM (Qiagen) or Lipofectamine 2000 transfection 
reagent according to manufacturer’s instructions. Protein knockdown was confirmed by 
western blotting and mRNA by real-time quantitative polymerase chain reaction (RT-qPCR).  
2.2.4 RNA isolation and complementary DNA synthesis 
Total RNA was extracted from cells using RNeasy mini kit with DNase digestion (Qiagen) as 
manufacturer’s instructions and quantified using the Nanodrop 8000 spectrophotometer. 
1μg of total RNA was used for first strand synthesis using the qScript First-Strand cDNA 
synthesis system (Quanta Biosciences) in a total volume of 20μl. Complementary DNA 
(cDNA) was synthesised using the G-Storm thermocycler with the following cycling 
parameters: 
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1) 25°C for 5 minutes 
2) 42°C for 30 minutes 
3) 85°C for 5 minutes 
4) Hold at 4°C 
cDNA was diluted to 600μl with RNase and DNase free ddH2O and used for RT-qPCR 
analysis.  
2.2.5 Real-time quantitative polymerase chain reaction (RT-qPCR) 
Forward and reverse primers were diluted to 2.5μM and used at a final concentration of 
0.5μM in 25μl volume. 7.5μl diluted complementary DNA (cDNA) and 12.5μl 2x Mesa Blue 
SYBR green mix (Eurogentec) was used per reaction. Duplicate reactions were performed 
and average values obtained and used in analysis. Primer sequences can be found in table 
3. 
The PCR reaction was performed using a DNA Engine Opticon 2 (MJ Research) with the 
following cycling parameters: 
1) 95°C for 5 minutes 
2) 94°C for 20 seconds 
3) 60°C for 25 seconds 
4)  72°C for 50 seconds 
5)  Steps 2-4 were repeated 39 times 
Data was analysed using the comparative cycle threshold (Ct) method. The Ct values were 
obtained during the exponential phase of the fluorescence logarithmic curve. Values from 
technical replicates were averaged and analysed using the equation below and as 
published (Schmittgen and Livak, 2008): 
 
                                         
 
       [                                                 
                                                    
 
Chapter 2: Materials and methods 
Page | 62  
 
2.2.6 Agarose gel electrophoresis 
PCR products were run on a 1.5% agarose gel in TAE buffer (40mM Tris-acetate, 1mM 
EDTA) plus ethidium bromide at 90V until completion and visualised using a BioDoc-It 
imaging system (UVP). 
 
2.3 Mitochondrial and metabolic assays 
2.3.1 Mitochondrial isolation from cells 
After treatment, cells from confluent 15 cm plates were trypsinised and washed once in 
PBS before fractionation. Mitochondria were isolated using a mitochondrial isolation kit for 
cultured cells (Thermo Scientific). The non-mechanical, reagent-based method was used 
according to the manufacturer’s instructions. Mitochondria were lysed in 1% NP40 lysis 
buffer and stored at -20°C until processing. Fractionated proteins were assessed by SDS-
PAGE and western blotting.  
Alternatively, mitochondria were isolated by differential centrifugation. Briefly, after 
treatment, cells from confluent 15 cm plates were trypsinised and washed once in PBS. 
Cells were re-suspended in homogenisation buffer A (250mM mannitol, 0.5mM 2-[4-(2-
hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) pH 7.4 and 0.5mM ethylene glycol-
bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA); all obtained from Sigma, plus 
100x EDTA-free protease inhibitor cocktail). Cells were homogenised with a glass-on-glass 
Dounce homogeniser using 100 strokes of a tight fitting pestle. A small volume of the total 
cell homogenate was removed and stored (load fraction). The homogenate was centrifuged 
at 900g for 10 minutes to pellet nuclei and intact cells, the supernatant containing 
mitochondria was removed and this step was repeated and supernatant again removed. 
Mitochondria were sedimented after centrifugation at 9000g for 10 minutes. The 
supernatant was removed and stored (cytosolic fraction). The crude mitochondrial pellet 
was washed in homogenisation buffer A and centrifuged at 9000g for 10 minutes. The 
pellet was lysed in 1% NP40 lysis (mitochondria fraction). All steps were performed on ice 
and centrifugation was performed at 4°C. 
2.3.2 Mitochondrial isolation from tissue 
Mitochondria were isolated from mouse livers, using differential centrifugation. Livers were 
collected from healthy mice, minced and washed in mitochondrial isolation buffer A 
Chapter 2: Materials and methods 
Page | 63  
 
(250mM mannitol, 0.5mM HEPES pH 7.4 and 0.5mM EGTA, plus 100x EDTA-free protease 
inhibitor cocktail). Tissue was then homogenised using a Dounce homogeniser using 2ml of 
buffer A per gram of tissue (20 strokes loose, 20 strokes tight). A small sample of the 
resulting homogenate was removed and stored (homogenate). The remaining homogenate 
was centrifuged at 800g for 10 minutes to pellet nuclei and the supernatant was removed. 
This step was repeated on the supernatant. The post nuclear supernatant was then spun at 
10,300g for 10 minutes to pellet mitochondria and a small volume of supernatant removed 
(post mitochondrial supernatant). The pellet was re-suspended and spin repeated to wash 
the pellet. Mitochondria were re-suspended in 1ml of buffer A and a small volume removed 
(crude mitochondria). Purified mitochondrial fraction was obtained after layering crude 
mitochondrial samples on a 30% (v/v) Percoll™ gradient in solution B (225mM mannitol, 
5mM EGTA, 25mM HEPES pH 7.4 plus 100x protease inhibitor cocktail) and spinning at 
95,000g for 40 minutes. Fractions were collected, washed in solution A and spun at 6,300g 
for 10 minutes, re-suspended in a solution A and stored at -20°C. 
2.3.3 Total cellular ATP assay 
Cells were either seeded in 96 wells plates in either DMEM containing glucose or galactose 
(both at 4.5g/l) for 24 hours prior to drug treatment or re-suspended to a constant cell 
concentration before addition of the reagent. Cell-Titre Glo reagent (Promega) was added 
and assay performed as outlined in the manufacturer’s instructions. Samples were 
quantified using a Tropix TR717 microplate luminometer. 
2.3.4 Measurement of oxygen consumption and of extracellular acidification rate 
The oxygen consumption rate (OCR) and extracellular acidification (ECAR) rate was 
measured using the XF24 Bioanalyser (Seahorse Bioscience). Briefly, cells were seeded in 
complete media at densities between 15,000-20,000 for HL-1 and 45,000 for HCT116 cells 
in the Seahorse V7 cell culture plate the night before the assay using a 2 step seeding 
protocol. Prior to the assay, cells were washed twice and media changed to un-buffered 
basal DMEM, without sodium bicarbonate and phenol red (Sigma). This was supplemented 
with 4.5 g/l glucose or galactose, 4mM L-glutamine and 1mM pyruvate at pH 7.4 and 
placed into a non-CO2 incubator. The dissolved oxygen in the media was measured and OCR 
and extracellular acidification rate calculated. Mix-wait-measure cycles were optimised to 
3, 0.5, 3 minutes for HL-1 cells and 3, 2, 2 minutes respectively for HCT116 cells. Drug 
concentrations optimised to 0.5 µg/ml oligomycin, 1µM FCCP and 2µg/ml antimycin A for 
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HL-1 cells and 0.5 µg/ml oligomycin, 1.5µM FCCP and 2µg/ml antimycin A for HCT116 cells. 
Measurements were normalised to protein using the sulforhodamine B (SRB) assay. 
The Seahorse XF24 extracellular flux analyser allows measurement of cellular oxygen 
consumption over time, in a multiwall plate based format. The XF24 analyser utilises 
fluorescent sensors to measure extracellular fluxes of oxygen. The fluorescent sensors form 
part of a bio-cartridge that during the assay lowers to approximately 200μm above the cell 
monolayer and creates a 7μl microchamber in which the change in oxygen concentration is 
measured over time (measure cycle). The bio-cartridge is then elevated and media allowed 
to equilibrate (mix and wait cycles), before the next reading (Ferrick et al., 2008).  
2.3.5 Sulforhodamine B (SRB) assay for analysis of cellular protein content 
Cells were fixed by removing media and adding ice cold 10% trichloroacetic acid for 30 
minutes at 4°C before being washed 5 times with tap water and left to dry. To each well 
100µL of 0.4% SRB/1% acetic acid solution was added and left for 10 minutes. Wells were 
then washed 5 time with 1% acetic acid and again left to dry as before. SRB was solubilised 
by adding 100µl of 10mM Tris buffer followed by gentle shaking for 10 minutes. The 
absorbance was read at 570nm using a Magellan plate reader.  
2.3.6 Polarography 
Cellular oxygen consumption rates were obtained using the Oxygraph 2K (O2K; Oroboros 
Instruments). Cells were trypsinised and re-suspended in 3-6ml of HEPES-buffered DMEM 
or for analysis of permeabilised cells re-suspended in mitochondrial respiration media 
(0.5mM EGTA, 3mM MgCl2.6H2O, 60mM k-lactobionate, 20mM taurine, 10mM KH2PO4, 
20mM HEPES, 110mM sucrose, 1g/l (w/v) essentially fatty acid free bovine serum albumin 
(BSA) (all obtained from Sigma) and counted twice. Cells were added (2.2ml) to each 
chamber, plungers were replaced and cells incubated at 37°C under constant stirring. Cells 
were allowed to reach routine baseline respiration before the addition of the first 
compound. 2μg/ml oligomycin, 0.5μM increments FCCP, 0.5μM rotenone and 2.5μM 
antimycin A were injected in sequence and the OCR calculated.  
2.3.7 Real-time compartmental ATP Luciferase Assay 
HCT116 cells were plated at 400,000 per chamber of a 6-well plate and transfected with 
each plasmid encoding luciferase targeted to the mitochondria or a non-targeted plasmid 
(cytosolic) using Lipofectamine 2000 as described above. Cells were transfected for 6-8 
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hours; the complexes were then washed off, replaced with fresh complete media and 
incubated overnight at 37 °C. Cells were then trypsinised and re-plated in DMEM containing 
either glucose or galactose (both at 4.5g/l)  at a density of 60,000 cells per well in white 96 
well plates coated with 0.1% gelatine (Gibco) to aid adherence and left overnight. 
Immediately before the assay, the media was replaced with 200μl HEPES buffered phenol 
red free DMEM plus 10uM D-luciferin sodium salt (Sigma). Cells were placed in a 
temperature controlled Fluostar plate reader (BMG Labtech) at 37 °C and luminescence 
was read at one to two minutes intervals. Drugs were diluted in PBS plus 10μM D-luciferin 
and added in a 20μl volume at points indicated through an automated injection system. 
2.3.8 Metabolomics 
Cells were plated and treated in T175 flasks. Media was removed and stored at -80°C. Cells 
were washed in ice cold 0.9% saline and 6ml of ice cold methanol was added. Cells were 
incubated on ice for 10 minutes, after which they were scraped into a 50ml falcon tube and 
6ml ice cold chloroform added. Tubes were vortexed vigorously for 30 seconds before 6ml 
of ice cold de-ionised water was added to each tube and again vortexed vigorously for 30 
sec. Samples were centrifuged at ~10000rpm for 20 minutes for phase separation. The final 
chlorform: methanol: water ratio was 1:1:1 (v/v/v). The upper methanol-water phase 
contained the water-soluble cellular metabolites, the middle phase contained the protein 
pellet and the bottom chloroform phase contained the cellular lipids. After separation of 
the phases, the protein pellets were kept for protein concentration determination. The 
upper methanol-water phase was treated with Chelex 100 (~1mg/1ml) to remove divalent 
ions and centrifuged to remove Chelex, retaining the clear supernatants. The clear 
supernatents were lyophilized and dried samples stored at -20oC. The bottom chloroform 
phase was transferred into glass tubes and left in a fume hood overnight.  The dried 
samples were again stored at -20oC minimum. Metabolite analysis was performed by Dr. 
Yuen-Li Chung (The Institute of Cancer Research, Sutton, UK). 
2.3.9 Flow cytometric analysis of mitochondrial membrane potential 
Following treatment or 24hrs after plating, cells were collected by trypsinisation and 
pelleted by centrifugation (1500rpm for 3 minutes), approximately 1x106 cells/ml were re-
suspended in HEPES buffered DMEM plus 0.2nM 3,3'-Dihexyloxacarbocyanine Iodide 
(DIOC6(3); Sigma) and allowed to equilibrate for at least 30 minutes before analysis. Cells 
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were analysed using a CyAn ADP analyser (Beckman Coulter) and data analysed using the 
SUMMIT 4.3 software.   
2.3.10 Flow cytometric analysis of mitochondrial mass 
Cells were collected as above (2.3.9) and approximately 1x106 cells/ml were re-suspended 
in HEPES buffered DMEM plus 100nM mitoview green (Biotium) for 30 minutes. The 
mitochondrial uptake of mitoview green is independent of mitochondrial inner membrane 
potential and fluoresces only after partitioning into the mitochondria. Cells were then 
pelleted and re-suspended in HEPES buffered DMEM. Cells were processed using a CyAn 
ADP analyser (Beckman Coulter) and data analysed using the SUMMIT 4.3 software.    
2.3.11 Determination of mitochondrial DNA copy number 
Total DNA was isolated from cell pellets using QIAamp DNA blood mini kit (Qiagen). The 
amount of mitochondrial DNA relative to nuclear genomic DNA was determined by 
quantitative real-time PCR using primers for ND1 (mitochondrial) and beta-2-microglobulin 
(β2M; nuclear). Primer sequences used are listed in table 3. Estimation of the number of 
copies of the mitochondrial genome relative to nuclear genome was based on the 
threshold cycle (Ct) using the following equation and as described previously (Venegas and 
Halberg, 2012):  
                              [                 
The PCR reaction was performed with the same cycling parameters as described in 2.2.5.  
 
2.4 Microscopy 
2.4.1 Principles of fluorescence and fluorescence microscopy 
Fluorescence is a property of molecules, characterised by the rapid emission of light after 
the absorption of shorter wavelength light, with the difference between these two 
wavelengths known as ‘Stokes shift’. Molecules that exhibit fluorescent properties are 
known as fluorophores and through filtering out only the wavelength of light used to excite 
the fluorophore, it is possible to observe molecules that are fluorescent.  
After a fluorophore in its ‘ground’ or ‘resting’ state absorbs light energy, it becomes 
energetically ‘excited’, due to changes it the molecule’s electronic, vibrational and 
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rotational state. The release of this energy through fluorescence emission is the principal 
mechanism by which these molecules return to their ‘ground’ state (Lichtman and 
Conchello, 2005). The fluorescent properties of chemicals, genetically encoded probes and 
the intrinsic fluorescence of organic substances have been widely exploited in the field of 
cell biology to study numerous parameters, including protein localisation, cell function and 
ion signalling.  
2.4.2 The epi-fluorescent microscope 
Mercury or xenon arc lamps are traditionally used to illuminate fluorescent samples, and 
differ in their wavelength coverage and intensity. A dichroic mirror is required to separate 
the light use to excite the fluorophore from the light which is emitted.  A dichroic mirror is 
designed to reflect the shorter wavelength of light originating from the light source 
towards the sample, while light of a longer wavelength emitted from the sample passes 
through the dichroic mirror, and ultimately reaches a detector. The microscope’s objective 
lens images, magnifies and also acts as a condenser to illuminate the specimen. Dichroic 
mirrors are used in combination with an excitation filter, to ensure only light of a specific 
wavelength reached the sample, and an emission long pass filter, to ensure only 
transmitted light above a certain wavelength reaches the detector. The excitation filter, 
dichroic mirror and emission filter are held in a structure known as the filter cube which 
can be easily changed depending on the properties of the fluorophore to be imaged (Figure 
2.1). Alternatively a filter wheel can be used to rapidly switch between different excitation 
and emission filter; this approach uses the same more sophisticated dichroic mirror 
(Paddock, 2005, Lichtman and Conchello, 2005). 
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Figure 2.1: Diagrammatic representation of an epi-fluorescent microscope system. 
White light (A) emitted from the arc lamp is filtered by the excitation filter (B) such that 
only light of a specific wavelength reaches the dichroic mirror (D). Specific wavelength 
light is reflected toward the objective and focussed onto the sample. Emitted light from 
the sample collected by the objective, transmitted through the dichroic mirror and 
travels through the emission filter (C) and directed towards the camera or eye piece. 
Arrows indicate direction of light wave. Adapted from (Lichtman and Conchello, 2005). 
 
2.4.3 Optical sectioning microscopy: Confocal imaging 
Confocal microscopy is a technique capable of optical sectioning, such that light from 
outside the focal plane is removed, and the user is able to acquire images of thin sections 
of specimens. Optical sectioning allows for improved contrast, resolution and the 
generation of three-dimensional reconstructions. Confocal microscopy produces optical 
sections through point by point laser scanning and illumination of the specimen in 
sequence until all regions in a field are sampled. A laser beam is focussed in the sample and 
at the same time a spatial pin hole, present in front of the detector removes unwanted 
fluorescence emission from above and below the focal plane, allowing imaging of discrete 
structures within an intact biological specimen. The objective lens is used to focus light to a 
single point and also return light from the sample collected after it has passed through the 
spatial pinhole, present at a optically conjugate plane to the in-focus plane (Paddock, 2005, 
Conchello and Lichtman, 2005) (Figure 2.2).  
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Figure 2.2: Diagrammatic representation of the path of fluorescent light in optical 
sectioning microscopy. 
(A) Light from the laser reflects off the dichroic mirror and is focussed onto the sample, 
illuminating the fluorophore. (B) Light of higher wavelength emitted from the sample is 
transmitted through the dichroic mirror. Only light originating from the in-focus plane is 
focussed on to the image plane where the spatial pinhole is located, such that light from 
the out-of-focus plane fails to reach the detector. Arrows indicate direction of light wave. 
Adapted from http://www.bioimaging.dk/index.php?id=71 (last accessed Nov 2013). 
 
2.4.4 Immunofluorescence microscopy 
Cells were plated on glass coverslips (ø 13 mm, VWR) and allowed to adhere overnight. 
After treatment, cells were washed twice with PBS and fixed using 4% paraformaldehyde in 
PBS for 15 minutes. Cells were then washed twice with PBS and permeabilised for 10 
minutes using 0.5% Triton X in PBS before being blocked with IFF (1% BSA, 1% FCS in PBS) 
for 1 hour. Coverslips were incubated with primary antibody for 1 hour at room 
temperature or overnight at 4°C before being washed and incubated with fluorophore 
conjugated secondary (Alexa Fluor 564 and 488; Invitrogen) antibody for 1 hour. Coverslips 
were again washed twice with PBS and incubated in 1μg/ml DAPI solution (Biotium) for 10 
minutes, washed and then mounted using Fluoromount G (Southern Biotech). Images were 
acquired using a Nikon Eclipse E600 Upright microscope with a 40x objective and captured 
using a QIClick digital CCD camera (QImaging) and Image Pro Plus software (Media 
Cybernetics).  
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2.4.5 Fluorescent live-cell imaging of mitochondrial membrane potential 
For 24-48 hours prior to assay, cells were seeded into 12 or 24 wells plates in complete 
DMEM. Before the assay cells were loaded with 50nM tetramethylrhodamine methyl ester 
(TMRM; Sigma) in imaging buffer (basal DMEM supplemented with 4.5 g/l glucose, 4mM L-
glutamine, 1mM pyruvate, 10% FCS, 5mM HEPES) and allowed to equilibrate for 45-60 
minutes. Baseline measurements were taken over 30 minutes, after which compounds 
were added. Three fields of view were selected from each well and each condition imaged 
in duplicate using an Optiscan II motorised stage system (Prior Scientific). Samples were 
illuminated using a Lumen 200 Pro metal halide lamp (Prior Scientific) and imaged using an 
IX71 inverted microscope (Olympus) equipped with an Orca R2 C10600 digital CDD camera 
(Hamamatsu Photonics).  
Image sequences were analysed using Image Pro Plus (Media Cybernetics), using 3 
independent areas of interest per field of view and calculating the change in fluorescence 
intensity over time, with background subtraction.  
2.4.6 Confocal live-cell imaging 
Cells were seeded on to glass coverslips (ø 22mm, VWR) and stained with 1nM Hoechst and 
50nM TMRM to visualise the nucleus and mitochondria respectively. Hoechst was excited 
at 405nm and emitted fluorescence (peak 465nm) collected using 435-485 band pass filter. 
TMRM was excited at 543nm and emitted fluorescence (peak 573nm) collected using a 
560nm long pass filter. Mitoview green (Biotium) was used for mitochondrial imaging at a 
concentration of 100nM. EGFP and mitoview green were excited at 488nm and emitted 
fluorescence captured using a 505-530 band pass filter. Images were acquired with a Zeiss 
510 META confocal laser scanning microscope using a 63× oil objective.  
2.4.7 Electron microscopy 
Cells were seeded on to glass coverslips (ø 13 mm, VWR), and fixed with 2% 
paraformaldehyde and 1.5% glutaraldehyde in 0.1M cacodylate buffer. Samples were post 
fixed with 1% osmium tetraoxide and 1.5% potassium ferrocyanine in 0.1M cacodylate 
buffer. Samples were dehydrated in a graded ethanol-water series, cleared in propylene 
oxide and infiltrated with agar-100 resin. Ultra-thin sections were cut and collected on 300-
mesh grids and stained with lead citrate. Samples were viewed in a Joel 1010 transition 
electron microscope and images were recorded using a Gatan Orius CDD camera. 
Preparation and imaging of cells was undertaken by Mark Turmaine, UCL. Mitochondrial 
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length was analysed using ImageJ measure feature, calibrated to the scale bar of each 
image. Analysis of up to 15-20 mitochondria from 10 cells was performed. Statistical 
significance was calculated using an unpaired t-test. 
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Table 1: Antibodies, protein apparent molecular weight (kDa), source and supplier. 
Antibody 
Apparent Molecular 
Weight  
Clone Company 
AKT1 60 
Mouse 
monoclonal 
Cell Signalling (#2967) 
Anti-GFP 27(+) 
Mouse 
monoclonal 
Clontech or Roche 
ATG3 40 
Rabbit 
polyclonal 
Cell signalling (#3415) 
ATG5 55 
Rabbit 
polyclonal 
Cell Signalling (#8540) 
ATG7 78 
Rabbit 
polyclonal 
Cell Signalling (#8558) 
ATP5B 52 
Mouse 
monoclonal 
Abcam (ab14730) 
Beclin 60 
Rabbit 
polyclonal 
Cell Signalling #3495 
COX-IV 17 
Mouse 
monoclonal 
Abcam (ab14744) 
DRP-1 78-82 
Rabbit 
polyclonal 
Cell Signalling (#5391S) 
FIS-1 15 
Rabbit 
polyclonal 
Sigma (HP017430) 
GLUT-1 45-55 
Rabbit 
polyclonal 
Alpha Diagnostics 
(GT12-A) 
HIF-1α (OH-Pro564) 120 
Rabbit 
polyclonal 
Cell Signalling 
(#D43B5) 
HIF-1β/ARNT1 95 
Mouse 
monoclonal 
BD Pharmagen 
(611079) 
HIF-2α 96 
Mouse 
monoclonal 
Abcam (Ab199) 
HSP60 60 
Rabbit 
polyclonal 
Cell Signalling (#4870) 
HIF-1α (human) 120 
Mouse 
monoclonal 
BD Biosciences 
(610959) 
HIF-1α (Mouse) 120 
Rabbit 
polyclonal 
Novus (100-449) 
Lamin B 67 Goat Polyclonal Santa Cruz (sc-6216) 
LC3B 14, 16 
Rabbit 
polyclonal 
Cell signalling (#3868) 
MFN-1 84 
Rabbit 
polyclonal 
Abcam (ab104274) 
MFN-2 86 
Rabbit 
polyclonal 
Sigma (HPA030554) 
mtCO-2 19 
Mouse 
monoclonal 
Abcam (ab110258) 
OPA-1 86-92 
Rabbit 
polyclonal 
Sigma (HPA036926) 
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Table continued: 
   
p62 62 
Rabbit 
polyclonal 
Cell Signalling (#8025S) 
p-AKT (Ser473) 60 
Rabbit 
polyclonal 
Cell Signalling (#2971) 
Parkin 52 
Mouse 
monoclonal 
Abcam (ab77924) 
p-DRP-1 (Ser616) 78-82 
Rabbit 
polyclonal 
Cell Signalling (#3455S) 
p-DRP-1 (Ser637) 78-82 
Rabbit 
polyclonal 
Cell Signalling (#4867S) 
PHB1 32 
Rabbit 
polyclonal 
Cell Signalling (#2426) 
PHD1 40-45 
Rabbit 
polyclonal 
Novus (100-310) 
PHD2 43-46 
Rabbit 
polyclonal 
Novus (100-137) 
PHD3 27 
Rabbit 
polyclonal 
Novus (100-303) 
pVHL 19, 30 
Mouse 
monoclonal 
BD Pharmagen (Ig32; 
556347) 
SDHA 70 
Rabbit 
polyclonal 
Cell Signalling (#5839) 
VDAC1 31 
Rabbit 
polyclonal 
Abcam (ab15895) 
α-tubulin 50 
Mouse 
monoclonal 
Sigma (T6199) 
β-actin 42 
Mouse 
monoclonal 
Abcam (Ab6276) 
Secondary anti-goat HRP 
conjugate 
- Sheep Dako 
Secondary anti-mouse 
HRP conjugate 
- Sheep Amersham 
Secondary anti-rabbit 
HRP conjugate 
- Donkey Amersham 
Alexa Fluor 488 goat anti-
rabbit IgG 
- Goat Invitrogen (A-11034) 
Alexa Fluor 568 goat anti-
mouse IgG 
- Goat Invitrogen (A-11031) 
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Table 2: Reagents, working concentrations and supplier. A.D = assay dependent 
Reagent Supplier Assay Conc. 
Antimycin A Sigma 2μM 
Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone 
(FCCP) 
Sigma A.D 
Chloroquine Sigma 10μM 
Dimethyloxalylglycine (DMOG) Frontier Scientific 1mM 
DMSO Sigma A.D 
Insulin-like growth factor-1 (IGF-1) Sigma 100ng/ml 
Iodoacetic acid (IAA) Sigma 1mM 
MG132 Calbiochem 10μM 
Oligomycin Sigma A.D 
PHD-I (400084) (C21H16ClN3O) EMD Millipore 5μM 
Rotenone Sigma 1mM 
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Table 3: Forward and reverse primer sequences used for RT-qPCR and mitochondrial DNA 
copy number analysis. 
Gene Forward Primer Reverse Primer 
β-actin CCCAGAGCAAGAGAGG GTCCAGACGCAGGATG 
COX-IV GAGCAATTTCCACCTCTGT CAGGAGGCCTTCTCCTTCTC 
Cytochrome b TATCCGCCATCCCATACATT GGTGATTCCTAGGGGGTTGT 
EGLN3 GATGCTGAAGAAAGGGC CTGGCAAAGAGAGTATCTG 
GFM1 TCACAGACAAAGCCAACAGC TGGTCTCTCGAAAGGCAACT 
GLUT-1 TGGCATGGCGGGTTGT CCAGGGTAGCTGCTCCAGC 
HIF-1α CCAGTTACGTTCCTTCGATCAGT TTTGAGGACTTGCGCTTTCA 
HIF-2α/EPAS AAGCCTTGGAGGGTTTCATTG TGCTGATGTTTTCTGACAGAAA 
LC3B AGCAGCATCCAACCAAAATG CTGGGAGGCATAGACCATGT 
MRPL15 GATCCTGCCAAATTTCCTGA ATCTGCCTTGGATCCTTCCT 
MRPL20 GAACATGAGGACCCTCTGGA CCGCTAGGACTTTCCTGTTG 
MRPL3 CCAAGGATGGTCAAAAGCAT CAGACAGGGTTGCCATTTTT 
MRPL30 CAAGGACTTCCAGCAGAGGA TCATGTGCTTTCTGCTCCAC 
MRPL32 GATGGCAGCTCCCAAAAATA CCCCTTCTTGCTTCCCTATC 
MRPS16 GAGAGACTGCGAAGGAAACG GGGCAACTCAGGATACTCCA 
MRPS35 ACCCCAGAGCACGAGTAGTA CCTCCTTAAAGGGCACCTATCTG 
MRRF1 CCAGGGGAACACTCAGACAT GTCCCTTGGCAACATCAAGT 
mtCO-2 TTCATGATCACGCCCTCATA TAAAGGATGCGTAGGGATGG 
TIF2 AATGTTGGGCAAAAGTACGC ACTTCTCACGGGCTTTCTGA 
ND6 AGGTAGGATTGGTGCTGTGG CCAATAGGATCCTCCCGAAT 
NRF-1 GCAGCCGCTCTGAGAACTTCA TCGTAAGAGGTGTCCTCGGG 
NRF-2 (GABPa) CACACTTCTAGTCGCGGGAG CAAAGGATCAGTCCCACTC 
p62 GTGGTAGGAACCCGCTACAA GAGAAGCCCTCAGACAGGTG 
Parkin AACCGGTACCAGCAGTATGC TTCGCAGGTGACTTTCCTCT 
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Table continued: 
  
PEO-1 ACAGGATCGCAGCTCAAGAC CTGCTTCCTGGCTTGCTTTG 
PGC-1α TGATGACAGCGAAGATGA AGAAGAACAAGAAGGAGACA 
PGC-1β ACACTGACTACGATTCCAA TCTGAGGTATTGAGGTATTCC 
POLG GGAGGAGTTCCTGCTCACTG GAGGCAGCTTGAAAAACCA 
SDHA GGACAACTGGAGGTGGCATT TTTTCTAGCTCGACCACGGC 
TFAM CCGAGGTGGTTTTTCATCTGT ACGCTGGGCAATTCTTCTAA 
TUFM ATTGGCACCGGTCTAGTCAC CTTAAACGCAAGGGAAGCTG 
UCP2 TGCTGAGCTGGTGACCTATG GGGCATGAACCCTTTGTAGA 
UCP3 AGCCTCACTACCCGGATTTT CGTCCATAGTCCCGCTGTAT 
β2M (copy number) TCCTCTCCCGCTCTGCACCC GGCGGGCCACCAAGGAGAAC 
ND1 (copy number) GCCCCAACGTTGTAGGCCCC AGCTAAGGTCGGGGCGGTGA 
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3.1 Introduction 
In light of the ever increasing wealth of literature referencing the complex and intimate 
regulatory relationship between mitochondria and HIF-1α, it is clear that much is still to be 
delineated (Briston et al., 2011, Yang et al., 2012, Fukuda et al., 2007, Zhang et al., 2008, 
Rane et al., 2009). The most recent link lies in the control of HIF-1α hypoxic stabilisation by 
the mitochondrial DRS protein CHCHD4/MIA40, connecting mitochondrial IMS protein 
import, redox state and electron transfer to the HIF/hypoxic response (Yang et al., 2012). 
Furthermore unpublished data from our group, suggests that HIF-1α protein interacts with 
CHCHD4/MIA40 and the HIF-1α:CHCHD4/MIA40 complex associates with mitochondria.  
Indeed we have shown that HIF-1α is associated with mitochondria isolated from cells and 
tissues (Briston et al., 2011). Therefore, HIF-1α joins the list of well-characterised 
transcription factors that have recently been observed to localise to and perform non-
transcriptional roles within mitochondria. For example, Gough et al, observed that the 
promotion of cellular transformation by the H-RAS oncogene by signal transducer and 
activator of transcription 3 (STAT3) is dependent on serine phosphorylation taking place in 
mitochondria (Gough et al., 2009). In addition to STAT3, other transcription factors have 
been observed to be associated with/localise to mitochondria, including, the glucocorticoid 
receptor (and other members of the nuclear hormone superfamily; peroxisome proliferator 
activated receptor γ (PPARγ), thyroid, retinoid X (RXR) and oestrogen receptors), p53, 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), cyclic-AMP response 
element binding protein (CREB) and activator protein-1 (AP-1) (Marchenko et al., 2000, 
Psarra et al., 2005, Leigh-Brown et al., 2010, Psarra and Sekeris, 2009). 
Questions remain unanswered as to the mitochondrial role of many of these transcription 
factors. Given their defined function in regulating the transcription of nuclear genes, the 
binding of these proteins to distinct regions of the mitochondrial genome is of prime 
interest. Regions have been identified in mitochondrial DNA that correspond to consensus 
sites of nuclear binding elements and the idea of mitochondrially localised nuclear 
transcription factors regulating mitochondrial gene expression have been proposed (Leigh-
Brown et al., 2010).  
In addition to our previous work in tumour cells (Briston et al., 2011), validation of the HIF-
1α-mitochondria association in a non-tumour cell line is important, as is linking this novel 
relationship to a second disease phenotype. HIF has a well-defined role in cardiovascular 
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biology, demonstrating involvement in development, physiology, cardioprotection and 
pathology. As such, there has been much interest and investment in targeting and 
inhibiting the PHD proteins to promote HIF-α stabilisation and transcriptional activity for 
the treatment of cardiovascular disease. In cardiovascular disease, this extends to the 
treatment of atherosclerosis, ventricular remodelling, ischaemia/reperfusion injury and 
myocardial infarction (Sen Banerjee et al., 2012). Whether both short-term and/or acute 
induction of HIF-1α through inhibition of the PHD proteins can mediate cellular protection 
is yet to be established. The possibility that HIF-1α protein induced during brief periods of 
PHD inhibition or hypoxia, or in response to immediate exposure to PHD inhibition or 
hypoxia may provide a non-transcriptional role for HIF-1α is particularly interesting. With 
knowledge that HIF-1α co-localises with mitochondrial CHCHD4/MIA40, confirmation of 
HIF-1α mitochondrial localisation and investigation into the role of mitochondrial HIF-1α 
protein may provide novel insights into the regulation of mitochondrial function and 
metabolism.  
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3.2 Hypothesis 
Activation of the oxygen-sensing pathway alters mitochondrial function and cellular 
metabolism. 
 
 
3.3 Aims 
1. To explore how inhibition of the PHD proteins affect HIF-1α subcellular localisation. 
 
2. To determine the effects of PHD protein inhibition on mitochondrial function. 
 
3. To correlate whether any effects on mitochondrial function are dependent on the 
stabilisation of HIF-1α and its subcellular localisation. 
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3.4 Characterisation of the HIF response in HL-1 cardiomyocytes 
3.4.1 HIF-1α protein is stabilised in response to hypoxia 
HL-1 cardiomyocytes are an immortalised cardiac atrial muscle cell line derived from the 
AT-1 mouse (Delcarpio et al., 1991), in which expression of simian virus 40 (SV40) large T-
antigen is expressed under the control of the atrial natriuretic factor (ANF) promoter 
(Claycomb et al., 1998). These cells are currently the only published cardiomyocyte cell line 
that can spontaneously contract, maintain a differentiated phenotype and can be passaged 
serially in culture (White et al., 2004). Thus HL-1 cells provide a useful tissue culture model 
for assessing cardiac cell biology. 
Previous studies have observed that HL-1 cells exhibit stabilisation of HIF-1α and increased 
transcription and expression of downstream HIF-1 target genes in response to hypoxia 
(Nguyen and Claycomb, 1999, Cormier-Regard et al., 1998). To confirm previous studies, 
HL-1 cells were exposed to periods of normoxia and hypoxia and HIF-α protein observed. 
Figure 3.1 demonstrates HIF-1α protein induction in response to hypoxia (1% O2) over 24 
hours. Glucose transporter-1 (GLUT-1) is a well-recognised HIF-1α transcriptional target 
(Zelzer et al., 1998, Ebert et al., 1995). As anticipated, GLUT-1 protein, as anticipated was 
found to be up-regulated at 24 hours in response to hypoxia, confirming a HIF-1 
transcriptional effect (Figure 3.1). By 24 hours a decrease in HIF-1α protein levels was 
observed; a characterised behaviour of the HIF-1α protein described previously (Holmquist-
Mengelbier, 2006).  
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Figure 3.1: HIF-1α protein is induced in response to hypoxia in HL-1 cardiomyocytes.  
Western blot shows HIF-1α protein induction in response to normoxia (Nx) or hypoxia 
(1% oxygen) over a 24 hour time course (minutes (m) and hours (h)). GLUT-1 protein 
induction is shown as a HIF-1 transcriptional target and α-tubulin was used as a load 
control. 
 
3.4.2 HIF-1α protein is stabilised in response to DMOG treatment 
Dimethyloxalylglycine (DMOG) is a well-characterised competitive inhibitor of α-
ketoglutarate dependent dioxygenases, such as the PHD proteins and has been shown to 
induce proteins which correlate well with those whose expression changes in hypoxia 
(Elvidge et al., 2006). In order to determine the HIF-1α response in normoxia after PHD 
inhibition, 1mM DMOG was added to the culture media and cells harvested over a time 
course of 24 hours. SDS-PAGE and western blot analysis illustrates HIF-1α protein 
stabilisation can be observed after 1 hour and is fully stabilised at 4 hours of DMOG 
treatment (Figure 3.2). PHD3 is a HIF-1 target gene and induced in hypoxia (Aprelikova et 
al., 2004). A correlative increase in PHD3 protein expression is observed by 4 hours (Figure 
3.2), indicating that HIF-1 is transcriptionally active by 4 hours DMOG treatment in HL-1 
cells.  
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Figure 3.2: HIF-1α protein is induced in response to DMOG treatment of HL-1 
cardiomyocytes. 
Western blot shows HIF-1α protein induction in response to 1mM DMOG over a 24 hour 
time course (hrs). PHD3 protein induction is shown as a HIF-1 transcriptional target and 
β-actin was used as a load control. n.s = non-specific band.  
 
3.4.3 HIF-1α protein is induced in response to growth factor-mediated stimulation 
Growth factors have been previously demonstrated to induce HIF-α protein synthesis 
through phosphoinositide 3-kinase (PI3K) - protein kinase B (PKB/AKT) and mitogen 
activated protein kinase (MAPK) - dependent mechanisms in multiple cell types (Fukuda et 
al., 2002, Alam et al., 2009, Carroll and Ashcroft, 2006, Laughner et al., 2001). To explore 
whether growth factors can mediate an increase in HIF-1α protein in HL-1 cardiomyocytes, 
cells were serum starved for 40 hours before the addition of 100ng/ml insulin-like growth 
factor-1 (IGF-1). Samples were harvested over time and HIF-1α protein expression detected 
using SDS-PAGE and western blotting. Analysis revealed that HIF-1α protein was induced by 
2 hours of IGF-1 stimulation (Figure 3.3). An increase in the ratio of phosphorylated AKT (p-
AKT) at Ser473 to total AKT demonstrates that the PI3K pathway was active under these 
conditions. 
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Figure 3.3: HIF-1α protein is induced in response to IGF-1 treatment of HL-1 
cardiomyocytes. 
Western blot shows HIF-1α protein induction in response to of IGF-1 (100ng/ml) over 
time (0-32 hours). Phosphorylated AKT protein (p-AKT Ser473) is shown as a positive 
control for activation of PI3K/AKT signalling. Total AKT (t-AKT) protein and α-tubulin 
were used as load controls.  
 
3.5 HIF-1α protein association with mitochondria 
3.5.1 HIF-1α protein associates with mitochondria in response to hypoxia and DMOG 
As discussed, there is a well-established, complex relationship between the HIF-1 pathway 
and mitochondria; whereby HIF-1, via transcriptional responses has been observed to 
modulate mitochondrial function. Conversely, mitochondrial function and electron 
transport is necessary for the hypoxic stabilisation of HIF-1α (Fukuda et al., 2007, Zhang et 
al., 2008, Chandel et al., 1998, Agani et al., 2000, Chua et al., 2010). Recent work from our 
laboratory has demonstrated that HIF-1α associates with mitochondria rapidly after 
stabilisation in response to PHD inhibition or hypoxia in tumour cell lines (Briston et al., 
2011). These findings suggest a transcriptional-independent role for HIF-1α protein. To 
extend these studies and investigate whether HIF-1α also associates with mitochondria in 
HL-1 cardiomyocytes, cells were exposed to normoxia or hypoxia (1% O2) to stabilise HIF-α 
over time. Subcellular fractionation was performed and samples were subject to SDS-PAGE 
and analysed by western blot. HIF-1α protein induction was observed in both cytosolic and 
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mitochondrial fractions in response to hypoxia (Figure 3.4). These data are consistent with 
our previous studies in tumour cells (Briston et al., 2011) and a previous report using 
cardiomyocytes (Rane et al., 2009). Lamin B, α-tubulin and cytochrome c oxidase subunit IV 
(COX-IV) proteins were used as markers for nuclear, cytosolic and mitochondrial 
compartments respectively, to show appropriate fractionation.   
 
 
  
Figure 3.4: HIF-1α protein associates with mitochondria in response to hypoxia in HL-1 
cardiomyocytes. 
Subcellular fractionation analysis of HL-1 cells after exposure to normoxia (Nx, 21% O2) 
or hypoxia (Hx, 1% O2) for 4 hours. Western blot shows HIF-1α protein induction in 
response to hypoxia (Hx) in total (Load), cytosolic (Cyto) and mitochondrial fractions 
(Mito). Lamin B, α-tubulin and COX-IV proteins were used as specific markers for the 
nuclear, cytosolic and mitochondrial fractions respectively.  
 
To confirm the effects on HIF-1α mitochondrial association observed in hypoxia, and 
investigate the time course and kinetics of the association, DMOG was used to inhibit the 
PHD proteins and stabilise HIF-1α protein in normoxia. Cells were treated with 1mM DMOG 
to stabilise HIF-α protein over a time course of 4 hours. Subcellular fractionation was 
performed and samples subject to SDS-PAGE and western blot analysis. HIF-1α protein 
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induction was observed by 2 hours of DMOG treatment (Load) and correlates with an 
increase in HIF-1α protein present in the mitochondrial fraction (Mito) (Figure 3.5). These 
data are consistent with observations in hypoxia (Figure 3.4) and our previous findings in 
tumour cells (Briston et al., 2011). Interestingly, HIF-1β protein was also detected in 
mitochondrial fractions. Lamin B, α-tubulin and voltage dependent anion channel-1 
(VDAC1) were used as markers for nuclear, cytosolic and mitochondrial fractions 
respectively, to assess the efficiency of subcellular fractionation.   
 
 
 
Figure 3.5: HIF-1α associates with mitochondria in response to DMOG. 
Subcellular fractionation analysis of HL-1 cells after DMOG (1mM) treatment over a time 
course of 0 to 4 hours. Western blot shows HIF-1α protein induction in response to 
DMOG in total (Load), cytosol (Cyto) and mitochondrial fractions (Mito). HIF-1β protein is 
detected in both cytosolic and mitochondrial fractions. Lamin B, α-tubulin and VDAC1 
proteins were used as specific markers for the nuclear, cytosolic and mitochondrial 
fractions respectively.  
 
3.5.2 HIF-1α protein is detected in purified mouse liver mitochondrial fractions 
HIF-1α protein appears to associate with mitochondria when oxygen is low or the PHD 
proteins are inhibited (Figure 3.4 and Figure 3.5). In order to elucidate whether the 
association of HIF-1α protein with mitochondria was evident in vivo and under normal 
physiological conditions, mitochondria were isolated from mouse liver tissue and subject to 
Chapter 3: Inhibition of PHD-mediated oxygen-sensing and its effects on HIF-α localisation and mitochondrial function 
Page | 87  
 
Percoll™ gradient separation. Fractions were collected corresponding to the tissue 
homogenate (H), purified mitochondria (PM), crude mitochondria (CM) and post-
mitochondrial supernatant (PMSN; including cytosolic components, microsomes and 
lysosomes). Samples were subject to SDS-PAGE and western blotting. Crude mitochondria 
(CM) were those pelleted and collected after differential centrifugation and purified 
mitochondria (PM) those mitochondria isolated after ultracentrifugation and separation on 
a Percoll™ gradient. Mouse HL-1 cells were used as a positive control for HIF-1α protein 
stabilisation having been incubated in hypoxia for 20 hours. Figure 3.6A demonstrates the 
presence of an enriched diffuse band in the PM fraction, that may potentially correspond 
to modified forms of HIF-1α protein. As discussed, HIF-1α is highly post-translationally 
modified and although the banding pattern in the PM fraction does not match the control 
HL-1 cells, these results raise the possibility that a distinct species of the HIF-1α protein is 
associated with mitochondria in vivo. There is enrichment of the mitochondrial protein 
COX-IV in the PM fraction, and absence of both nuclear and cytosolic markers lamin B and 
α-tubulin respectively, suggesting efficient subcellular fractionation.  
In addition to HIF-1α protein, constitutively expressed HIF-1β protein can also be observed 
in mitochondrial fractions from HL-1 cells treated with DMOG (Figure 3.5). Interestingly, in 
cells treated with DMOG, after 2 hours incubation there appears to be a decrease in 
cytosolic localisation of HIF-1β protein (Figure 3.5). To confirm that HIF-1β is associated 
with mitochondria, the localisation of HIF-1β protein was assessed in mitochondria isolated 
from mouse liver and purified using Percoll™ gradient separation. Tissue homogenate (H), 
pure mitochondria (PM), crude mitochondria (CM) and post-mitochondrial supernatant 
(PMSN) were run in parallel as described previously. Figure 3.6B demonstrates HIF-1β 
protein was readily detected in the total tissue homogenate (H) and also in the PM fraction. 
Both the 87kDa and 84kDa protein isoforms of HIF-1β were observed in the PM fraction 
(Figure 3.6B). These findings pave the way for further investigation into the role of the HIF-
1 complex with mitochondria and elucidation of its physiological relevance/importance in 
this context. 
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Figure 3.6: HIF-1α and HIF-1β proteins are detected in mitochondrial fractions isolated 
from mouse liver. 
(A) Western blot shows HIF-1α protein in mouse liver subcellular fractions (H = 
homogenate, PM = purified mitochondria, CM = crude mitochondria, PMSN = post 
mitochondrial supernatant). Normoxic (Nx) and hypoxic (Hx) HL-1 cell lysates were used 
as controls for HIF-1α protein. (B) Western blot shows HIF-1β protein in mouse liver 
subcellular fractions as indicated in A. Lamin B, α-tubulin and COX-IV proteins were used 
as markers for the nucleus, cytosol and mitochondria respectively.  
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3.5.3 Hydroxylated HIF-1α protein is detected in mitochondrial fractions 
As discussed in the introduction, HIF-1α is highly post-translationally modified. Proline 
hydroxylation by the PHD proteins is the best characterised modification of HIF-1α to date 
(Jaakkola et al., 2001). Hydroxylation of HIF-1α maintains the protein at low levels under 
normal oxygen conditions and provides a mechanism for the cell to react quickly to 
changes in oxygen tension. The turnover of the alpha subunit is mediated through 
proteolytic degradation by the proteasome (Maxwell et al., 1999). In humans, HIF-1α is 
hydroxylated on two proline residues, at positions 402 and 564 by the PHD proteins and it 
is this hydroxylation which serves as the targeting signal for ubiquitination and proteasomal 
degradation (Jaakkola et al., 2001). Using MG132, a selective inhibitor of the proteolytic 
activity of the proteasome, HIF-1α degradation is blocked, while PHD-mediated 
hydroxylation is unaffected (Figure 3.7). Thus MG132 causes accumulation of hydroxylated 
HIF-α protein that can be detected by western blot using a HIF-1α-hydroxyproline specific 
antibody, targeted toward Pro564 (Figure 3.7; lane 2). The simultaneous addition of the PHD 
inhibitor DMOG causes a reduction of the band corresponding to the HIF-1α hydroxylated 
species (Figure 3.7; lane 3) confirming the specificity of the antibody and the expected 
effect of DMOG on inhibiting PHD activity. 
Having previously observed a diffuse protein banding pattern for the mitochondrially 
associated HIF-1α protein in cells (Figure 3.5) and an interesting protein banding pattern in 
liver (Figure 3.6A), the possibility that mitochondrial associated HIF-1α protein is 
hydroxylated, was tested. After subcellular fractionation and mitochondrial isolation, 
samples were exposed to SDS-PAGE and western blotting. Analysis revealed the presence 
of the hydroxylated species at position 564 (Pro564) on HIF-1α in mitochondrial fractions, in 
those samples treated with MG132 (Figure 3.7). Lamin B, α-tubulin and VDAC1 proteins 
were used as markers for nuclear, cytosolic and mitochondrial compartments respectively 
to demonstrate appropriate fractionation. These data suggest that hydroxylated HIF-1α 
protein is recruited to mitochondria, or most intriguingly, that HIF-1α protein is modified at 
the mitochondrial interface and/or within mitochondria. The possibility that HIF-1α protein 
is modified at the mitochondrial interface and/or within mitochondria would presumably 
rely on the PHD proteins sharing its mitochondrial association.  
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Figure 3.7: Hydroxylated HIF-1α is detected in mitochondrial fractions after proteasomal 
inhibition. 
Subcellular fractionation of HL-1 cells after treatment for 4 hours with MG132 (10μM), 
either alone or in combination with DMOG (1mM). Western blot shows the accumulation 
of hydroxylated HIF-1α (Pro564) in response to MG132 treatment and clear reduction after 
PHD inhibition by DMOG. A band corresponding to the hydroxylated species of HIF-1α 
protein is present in the mitochondrial fraction. Lamin B, α-tubulin and VDAC1 were used 
organelle controls for the nucleus, cytosol and mitochondria respectively. Load = total 
cell homogenate, Cyto = cytosolic fraction, Mito = mitochondrial fraction. 
 
3.6 Prolyl hydroxylase domain (PHD) protein association with 
mitochondria 
3.6.1 PHD protein over-expression and analysis of subcellular localisation using EGFP-
tagged constructs 
Having established that hydroxylated HIF-1α protein is detected in mitochondrial fractions, 
the subcellular localisation of the PHD proteins was investigated. The subcellular 
localisation of the exogenously expressed PHD proteins has previously been established 
using EGFP (enhanced green fluorescent protein)-tagged constructs (Metzen et al., 2003). 
Metzen et al demonstrated nuclear localisation of PHD1, cytoplasmic localisation for PHD2 
and PHD3 was observed in both nuclear and cytoplasmic compartments (Metzen et al., 
2003). Additionally and independently, it has been observed that the PHD3 orthologue in 
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rat, SM-20 is mitochondrial and contains a mitochondrial targeting sequence, that is absent 
in human PHD3 (Lipscomb et al., 2001). PHD2 has been described to co-localise with the 
adapter protein FKBP38 in mitochondria and ER (Barth et al., 2009), and PHD2 and PHD3 
have been observed to localise to mitochondria in rat hepatocytes (Khan et al., 2006). 
The subcellular localisation of PHD proteins was assessed after transient over-expression of 
EGFP-tagged PHD constructs in HeLa cells (Figure 3.8). Co-staining with Hoechst 33342 and 
TMRM was used to identify nuclei and mitochondria respectively (Figure 3.8A-C). 
Tetramethylrhodamine methyl ester (TMRM) accumulates in areas of negative potential 
based on its charge and is a well characterised tool to study mitochondrial membrane 
potential (Brand and Nicholls, 2011). The results obtained are in agreement with those 
described by Metzen et al in that PHD1 protein was predominantly nuclear, PHD2 protein 
was cytoplasmic and PHD3 protein was both nuclear and cytoplasmic (Figure 3.8A-C) 
(Metzen et al., 2003). There was little or no enrichment of any EGFP-PHD protein 
associated with mitochondria, however a small amount of EGFP-PHD2 and EGFP-PHD3 
protein co-localised with the TMRM signal. Cells imaged were then harvested in lysis buffer 
and samples assessed by western blotting to confirm respective PHD protein expression 
(Figure 3.8D).  
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Figure 3.8: Subcellular localisation and expression of EGFP-tagged PHD proteins. 
(A-C) Confocal live-cell imaging of HeLa cells transiently transfected with EGFP-tagged 
PHD proteins. Cells were transfected on coverslips and localisation of the EGFP constructs 
analysed. (A) EGFP-PHD1 localises exclusively to the nucleus. (B) EGFP-PHD2 is diffusely 
localised throughout the cytoplasm. (C) EGFP-PHD3 is localised in aggregates and 
diffusely expressed throughout the cytoplasm. TMRM (50nM) was used to identify 
mitochondria (red) and Hoechst 33342 (1nM) used to stain the nucleus (blue). Images 
were acquired with a Zeiss 510 META confocal laser scanning microscope using a 63× oil 
objective. (D) Western blot analysis of samples from A-C, probed with an anti-GFP 
antibody to confirm molecular weights of over-expressed EGFP-PHD proteins. The protein 
band running at 43-45kDa is non-specific (n.s).  
 
3.6.2 Localisation of PHD proteins in mouse liver mitochondria  
To further investigate the subcellular localisation of the PHD proteins, mitochondrial 
fractions were collected from mouse liver tissue and purified using a Percoll™ gradient as 
described above (Figure 3.6). Proteins were separated by SDS-PAGE and analysed by 
western blot. Tissue homogenate (H), pure mitochondria (PM), crude mitochondria (CM) 
and post-mitochondrial supernatant (PMSN) were run in parallel. Both PHD2 and PHD3 
proteins are HIF-1α targets and are robustly induced in hypoxia (Figure 3.9; lanes 1 vs. 2) 
and given that the localisation of PHD1 protein is clearly nuclear (Figure 3.8), only PHD2 
and PHD3 were assessed in the liver mitochondrial fractions. HL-1 normoxic (Nx) and 
hypoxic (Hx) samples were analysed to provide a positive control for PHD2 and PHD3 
protein bands (Figure 3.9). PHD3 in mouse has an approximate molecular weight of 
approximately 27kDa (UniProt; Q91UZ4). Unfortunately, the PHD3 antibody used here 
detected several bands, however a hypoxia inducible protein band was observed that 
appeared distinct from the non-specific (n.s) bands and was also detected in the 
mitochondria enriched fractions (Figure 3.9; PM and CM; lanes 4 and 5). Additionally, there 
was an increase in protein expression of PHD2 observed in the HL-1 cardiomyocytes after 
20 hours of exposure to hypoxia (Figure 3.9; Nx vs. Hx; lanes 1 vs. lane 2). PHD2 protein 
corresponding to an identical molecular weight was also detected in mitochondrial 
fractions of the mouse liver tissue (Figure 3.9; PM and CM; lanes 4 and 5). These results 
suggest the exciting possibility that the association of PHD2 and PHD3 proteins with 
mitochondria may be linked to the presence of the hydroxylated HIF-1α species observed 
in mitochondrial fractions described above (Figure 3.7). 
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Figure 3.9: PHD2 and PHD3 proteins are detected in mitochondrial fractions isolated from 
mouse liver tissue. 
Western blot analysis of fractions obtained after subcellular fractionation of mouse liver. 
Tissue was homogenised and subject to differential centrifugation and subsequent 
Percoll™ gradient separation. Fractions obtained were separated by SDS-PAGE with 
protein equally loaded across lanes. PHD2 and PHD3 proteins induced in HL-1 cells in 
response to hypoxia, were also detected in purified mitochondria samples (indicated by 
the arrows). H = homogenate, PM = purified mitochondria, CM = crude mitochondria, 
PMSN = post mitochondrial supernatant. n.s = non-specific. 
 
3.7 Characterisation of DMOG-mediated HIF-1α dependent and 
independent regulation of mitochondrial processes 
3.7.1 Effects of DMOG treatment on cellular oxygen consumption rate 
There is interest around the potential use and development of PHD inhibitors as 
therapeutics, particularly in cardiovascular disease (Harten et al., 2010). Investigations into 
the activation of the HIF pathway through PHD protein inhibition generally extends to 
between 8-24 hours treatment (Sridharan et al., 2007, Sridharan et al., 2008, Elvidge et al., 
2006). Previous studies have not investigated the effects of HIF-1α stabilisation after PHD 
protein inhibition on mitochondrial function within the first minutes to hours of exposure 
to treatment. Classically enzymes will catalyse their respective reactions at a rate 
dependent on the relative amounts of substrate, co-factors and catalysts, hence in the 
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presence of adequate ascorbate, α-ketoglutarate and oxygen, the PHD proteins will rapidly 
hydroxylate HIF-α. Substrate or co-factor limitation will have immediate consequences on 
the rate of the reaction and the result of this inhibition will immediately be paralleled by an 
increase in HIF-α protein abundance as a function of the regulatory system.  
HIF-1α protein stabilisation was detected in mitochondrial fractions by 2 hours in culture 
after DMOG treatment (Figure 3.5). To determine the effect of the acute activation (0-4 
hours) of the oxygen-sensing machinery on mitochondrial function it was first necessary to 
validate the concentration of DMOG necessary to fully inhibit the PHD proteins in HCT116 
colon carcinoma cells. The hydroxylation of the HIF-α subunits by the PHD proteins is 
necessary for the subsequent degradation by the proteasome (Jaakkola et al., 2001). As 
described, MG132 is a selective inhibitor of the proteolytic activity of the proteasome. 
MG132 treatment therefore causes accumulation of the hydroxylated species of HIF-α 
subunit as shown above (Figure 3.7). To validate the concentration at which DMOG fully 
inhibits these enzymes, cells were incubated overnight for 20 hours with the inhibitor and 
for the final 4 hours in the presence or absence of 10μM MG132 (Figure 3.10A). The 
disappearance of the hydroxylated species of HIF-1α at 1mM DMOG in the presence of 
MG132 confirmed the inhibition of the PHD proteins (Figure 3.10A). A concentration of 
1mM DMOG gave maximal HIF-1α stabilisation and is consistent with previous studies (Jin 
et al., 2012). Therefore 1mM was the concentration of DMOG used in functional studies.  
In order to understand the consequences of activation of the oxygen-sensing pathway on 
mitochondrial function, it is necessary to evaluate the kinetics of the HIF-1α response to 
PHD inhibition using DMOG. Importantly, exposure of HCT116 cells to increasing durations 
of 1mM DMOG showed that HIF-1α protein stabilisation could be observed by 30 minutes 
treatment, suggesting rapid inhibition of the PHD proteins with DMOG (Figure 3.10B). Of 
particular interest, is the possibility that HIF-1α protein stabilisation within minutes of PHD 
inhibition has effects on mitochondrial function. To date, no other study has evaluated the 
immediate effects of the HIF response on mitochondrial parameters.  
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Figure 3.10: Concentration and time-dependent inhibition of PHD proteins by DMOG. 
(A) Western blot analysis of HCT116 cells treated over a concentration titration of DMOG 
(20 hours) in the presence and absence of the proteasome inhibitor MG132 (10μM) for 
the final 4 hours. Inhibition of the proteasome by MG132 prevents the degradation of the 
hydroxylated species of HIF-1α, and DMOG blocks the hydroxylation of HIF-1α. (B) 
Western blot analysis of HCT116 cells treated over a time course of 1 hour with 1mM 
DMOG. DMOG treatment induces HIF-1α protein expression between 20 and 30 minutes. 
β-actin is used as a load control for both experiments.  
 
To investigate the consequences of PHD protein inhibition, HIF-1α stabilisation and 
mitochondrial association on mitochondrial function, cellular oxygen consumption rate 
(OCR) was measured. DMOG was used to inhibit the PHD proteins and stabilise HIF-1α 
protein, and cellular OCR was measured using the Seahorse XF24 bio-analyser. OCR is 
primarily a measure of mitochondrial respiration and can be used as a measure of 
mitochondrial functionality. The Seahorse XF24 bioanalyser, uses fluorescent optics to 
measure dissolved oxygen present in the buffer and has been used to probe various 
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aspects of mitochondrial respiration, metabolism and dysfunction in response to chemicals, 
drugs and genotypes (Gohil et al., 2010, Beeson et al., 2010, Nadanaciva et al., 2012). The 
Seahorse platform has also been utilised for more novel and inventive approaches (Guo et 
al., 2012). Through protocol manipulation, exploitation of the mechanism of measurement 
and control of gas, it has been possible to induce cell ischaemia and use the Seahorse 
platform as a high-throughput means by which cardioprotective agents can be screened 
and investigated (Guo et al., 2012).  
Basal OCR in HCT116 cells was measured for at least 4 cycles (of approximately 7 minutes) 
before the injection of 1mM DMOG or vehicle (DMSO, 1:2000). After addition, OCR was 
monitored for approximately 30 minutes and the average change in OCR, as a percentage 
of baseline compared between control and treated wells. HIF-1α has previously been 
observed as stabilised within this time period (Figure 3.10). The addition of DMOG 
significantly reduced OCR by approximately 30% compared to vehicle after 30 minutes of 
treatment (Figure 3.11). The addition of DMOG also had significant effects on maximal 
respiratory capacity, measured after the addition of the mitochondrial inner membrane 
protonophore, FCCP (Figure 3.11B), although using the Seahorse XF24 bioanalyser this 
effect was quite variable. There was no significant effect observed on the amount of 
oxygen consumed that was coupled to ATP synthesis between vehicle and DMOG treated 
cells (Leak respiration; OCR after the addition of F1FO-ATPase inhibitor, oligomycin). A 
representative trace is shown in figure 3.11B. These data suggest that DMOG is having 
effects on mitochondrial respiration within 30 minutes of treatment. 
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Figure 3.11: DMOG reduces cellular OCR in HCT116 cells. 
(A) HCT116 cells were either treated with vehicle (blue) or DMOG (1mM, red) and OCR 
was analysed over time using the Seahorse XF24 bioanalyser. Values are mean +/- S.E.M 
(n=4). Data was analysed using paired, two-tailed t-test (*** p<0.001). (B) Representative 
trace from the Seahorse XF24 bioanalyser demonstrating the addition of DMOG (1mM, 
red) or vehicle (blue) after four mix-wait-measure cycles. OCR reduced immediately upon 
treatment, decreasing further with time. Oligomycin (0.5μg/ml), FCCP (1.5μM) and 
antimycin A (2μM) were injected as indicated. Data was collected using a mix-wait-
measure cycle of 3-2-2 after optimisation experiments. All changed from here on to n= 
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3.7.2 Effects of prolyl hydroxylase inhibition on cellular ATP  
There are a number of mechanisms through which the cell can synthesise energy in the 
form of ATP. The two main pathways for cellular ATP generation are OxPhos and glycolysis. 
A proportion of the cells consumed oxygen is coupled to ADP phosphorylation and ATP 
synthesis at the F1FO-ATPase. ATP coupled respiration can be experimentally measured by 
following oxygen consumption in the presence and absence of the F1FO-ATPase inhibitor 
oligomycin. Cancer cells are highly glycolytic (Warburg effect; (Warburg, 1956)), generating 
the majority of their ATP through glycolysis alone. In tissue culture, cells also generate 
much of their ATP from glycolysis due to the excess of glucose in the media and the 
negligible consequences of lactate production and acidification in vitro (Figure 3.12A). 
However cells can be forced to undergo oxidative metabolism by substituting glucose for 
galactose in the culture media. Under these conditions cells utilise pyruvate and glutamine 
to generate ATP through OxPhos (Figure 3.12B). This is known as the Leloir pathway, the 
metabolic pathway for the catabolism of galactose. D-galactose is modified to a series of 
intermediates through sequential enzyme catalysed reactions, involving galactokinase, 
galactose-1-phosphate uridylyltransferase and UDP-galactose-4-epimerase to produce 
glucose-1-phosphate and subsequently glucose-6-phosphate (G-6-P) that feeds the 
canonical glycolytic pathway (Frey, 1996). The rates of these reaction are slower than the 
conversion of glucose to G-6-P, forcing cells to compensate by promoting mitochondrial 
respiration (Weinberg et al., 2010).  
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Figure 3.12: Diagrammatic representation of the metabolism of glucose and galactose in 
culture. 
(A) Cells in culture mostly utilise glucose through glycolysis to generate ATP and lactate 
as a by-product. (B) Cells utilise glutamine and pyruvate in the media, which after initial 
metabolism enters the TCA cycle, generates reducing equivalents, such as NADH and 
FADH2 that transport electrons to the ETC and generate ATP through OxPhos. Figure 
adapted from (Gohil et al., 2010). 
 
Through metabolomic analysis of intracellular metabolites, the cellular uptake of respective 
energy substrates was confirmed. HCT116 cells were cultured under high glucose-DMEM 
(here on referred to as glucose) or glucose free, galactose-substituted DMEM (here on 
referred to as galactose) for at least 24 hours prior to measurements. HCT116 cells were 
cultured in glucose or galactose, harvested and subject to dual-phase extraction and a 
broad panel of intracellular metabolites were analysed using magnetic resonance 
spectroscopy (MRS), at the Institute of Cancer Research (ICR), Sutton, UK by Dr Yuen-Li 
Chung. 
Figure 3.13 shows the intracellular metabolite profile of HCT116 cells under the two culture 
conditions (glucose or galactose). A significantly increased concentration of intracellular 
glucose was observed in cells cultured in glucose compared with galactose (Figure 3.13A). 
Conversely, in cells cultured in galactose there was a significantly increased level of 
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intracellular galactose observed, as anticipated (Figure 3.13B). Together, these data suggest 
that cells are taking up their respective carbon source (glucose or galactose), and the 
culture conditions promotes a more oxidative phenotype in the presence of galactose 
compared with glucose. 
To evaluate cellular metabolic change under glucose and galactose culture conditions, total 
cellular ATP was measured in HCT116 cells after the addition of metabolic inhibitors using a 
bioluminescent assay. HCT116 cells were cultured in the presence and absence of the F1FO-
ATPase inhibitor, oligomycin to inhibit OxPhos and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) inhibitor, iodoacetic acid (IAA), to inhibit glycolysis. Oligomycin 
and IAA were added in combination to inhibit both OxPhos and glycolysis. This assay 
allowed assessment of the relative contributions of OxPhos and glycolysis to total cellular 
ATP levels. Figure 3.13C shows that in glucose the addition of oligomycin had no significant 
effect on cellular ATP levels (red bar) compared to non-inhibitor treated control cells (blue 
bar). However, IAA significantly reduced ATP levels (green bar), indicating that HCT116 cells 
are highly glycolytic under high glucose culture conditions. Cells cultured in galactose for 24 
hours were significantly more sensitive to oligomycin, suggesting a greater contribution of 
OxPhos to total cellular ATP levels (Figure 3.13C). These data confirm the distinct culture 
conditions are promoting their respective metabolic phenotype.  
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Figure 3.13: Effects of manipulating cellular culture conditions on intracellular 
metabolites and ATP synthetic pathways. 
Metabolomic analysis of HCT116 cells cultured in high glucose (glucose-DMEM, blue) or 
glucose free-galactose substituted media (galactose-DMEM, red) for 24 hours. Graphs 
show the concentration of intracellular glucose (A) and galactose (B) in cells 
(concentration, nM/mg protein). Values are mean +/- S.E.M (n=4). (*** p<0.001; 
**p<0.01) and data analysed using paired, two-tailed t-test). (C) Graph shows the fold 
change in luminescence (relative to untreated) as a measure of total cellular ATP levels 
for cells incubated in glucose-DMEM (left) and galactose-DMEM (right). Cells were 
untreated (blue), or treated with either oligomycin (5µM, red) or IAA (1mM, green). 
Values are mean +/- S.E.M (n=3). Data analysed using paired, two-tailed t-test (*** 
p<0.01, ns p>0.05). 
 
To determine the metabolic/energetic consequence of the change in OCR precipitated by 
acute treatment of cells with DMOG, cellular ATP was measured using a bioluminescent 
assay. Under the glucose and galactose culture conditions detailed above, compartmental 
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ATP production was measured over time in HCT116 cells. Compartmental ATP was 
measured using a transiently transfected firefly luciferase ATP reporter construct, targeted 
either to the mitochondria, using a mitochondrial targeted sequence derived from 
cytochrome c oxidase subunit VIII (COX-VIII) (mitochondrial probe), or using an untargeted 
cytosolic probe (Jouaville et al., 1999). With the addition of D-luciferin in the presence of 
oxygen, cells expressing the luciferase protein in their respective cellular compartments 
generate light that is proportional to the amount of ATP present in the transfected cell. 
HCT116 cells were maintained at 37°C during the assay and luminescence was measured 
over time using an automated kinetic luminometer. After a 15 minute baseline stabilisation 
period, 1mM DMOG was injected into respective wells and luminescence measured every 
60 seconds. After 60 minutes incubation there was a small but significant increase in both 
cytosolic and mitochondrial luminescence in glucose, suggesting an increase in ATP over 
this period (Figure 3.14A). This result was replicated in those cells cultured in galactose for 
24 hours prior to the assay (Figure 3.14B), suggesting that the increase in ATP observed in 
figure 3.14A was generated independently of glycolysis. An experiment with vehicle only 
was run separately and had no effect on luminescence (data not shown). Collectively, these 
data indicate that despite a decrease in OCR, DMOG is able to maintain cellular ATP levels, 
either by promoting its synthesis or reducing hydrolysis of ATP. Data was corrected for 
background luminescence, obtained through combined injection of oligomycin and IAA and 
normalised to luminescent values prior to DMOG injection to account for variations in 
luciferase expression and luminescent signal between repeats.  
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Figure 3.14: Effect of DMOG on mitochondrial and cytosolic ATP levels. 
HCT116 cells were transfected with luciferase constructs targeted to the mitochondria or 
cytosol (untargeted) in either (A) glucose or (B) galactose culture conditions. Reaction 
substrates were added and luminescence measured at 60 second intervals. Data is 
presented as fold change in luminescence after 60 minutes DMOG incubation relative to 
baseline immediately before addition. Graphs show a significant increase in ATP 
luminescence by 60 minutes DMOG (1mM, red) treatment compared to untreated (blue) 
in both cytosolic and mitochondrial compartments in glucose and galactose culture 
conditions. Values are mean +/- S.E.M (n=4). Data was analysed using paired, two-tailed 
t-test (*p<0.05, ** p<0.01, *** p<0.001). 
 
3.7.3 The maintenance of cellular ATP levels in response to DMOG treatment is 
independent of HIF-1α  
To assess the contribution of HIF-1α to DMOG-induced maintenance of ATP, mitochondrial 
and cytosolic ATP was measured using the targeted luciferase construct as described above 
(Figure 3.14). Cells were transfected with either siRNA targeted towards HIF-1α or a non-
silencing control (NSC) siRNA, and luminescence was measured over time. DMOG was 
injected after 15 minutes and the change in luminescence was followed for 60 minutes at 2 
minute intervals. Despite effective silencing of HIF-1α (Figure 3.15C), treatment with DMOG 
continued to result in a significant increase in luminescence in both compartments under 
glucose and galactose conditions (Figure 3.15A and B). These data suggest the increase or 
maintenance of ATP observed in figure 3.14 is independent of HIF-1α. Data was corrected 
for background luminescence, obtained through combined injection of oligomycin and IAA 
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and normalised to luminescent values prior to DMOG injection to account for variations in 
luciferase expression and luminescent signal between repeats.        
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Figure 3.15: Maintenance of cellular ATP levels in response to DMOG are independent of 
HIF-1α. 
HIF-1α was silenced in HCT116 cells and then cells were subsequently transfected with 
luciferase constructs targeted to mitochondria or cytosol (untargeted) in either (A) 
glucose or (B) galactose culture conditions. Reaction substrates were added and 
luminescence measured at 2 minutes intervals. Data is presented as fold change in 
luminescence after 60 minutes DMOG treatment relative to baseline immediately before 
addition. Graphs show increases in ATP luminescence after 60 minutes DMOG (1mM, 
red) compared to untreated (blue) in both cytosolic and mitochondrial compartments in 
the presence of non-silencing control (NSC) siRNA or HIF-1α siRNA in glucose and 
galactose culture conditions. Values are mean +/- S.E.M (n=4). Data was analysed using 
paired, two-tailed t-test (** p<0.01, * p<0.05, ns p>0.05). (C) Western blot shows 
confirming knockdown of HIF-1α protein. In parallel with experiments in A-B, HCT116 
cells were treated with DMOG for 1 hour (+, 1mM). The absence of HIF-1α protein after 
DMOG treatment in the presence of the siRNA suggests effective silencing. β-actin was 
used as a load control.  
 
3.7.4 Effects of DMOG treatment on mitochondrial inner membrane potential 
Mitochondrial inner membrane potential (Δψm), together with a small pH gradient, forms 
the proton electrochemical potential, generated across the mitochondrial inner membrane. 
The serial transfer of electrons through membrane associated complexes along the ETC is 
coupled to the pumping of protons against their concentration gradient into the IMS. 
Mitochondrial membrane potential is an important indicator of cell viability and ultimately 
dictates the cellular capacity to generate ATP by OxPhos (Acton et al., 2004). Mitochondrial 
inner membrane potential can be measured by fluorescent microscopy using the cationic 
lipophilic dye, TMRM. TMRM accumulates in areas of negative potential based on its 
charge and is a well characterised tool to study mitochondrial membrane potential (Brand 
and Nicholls, 2011). Figure 3.16A shows the effect of addition of 1mM DMOG on 
mitochondrial inner membrane potential using TMRM and fluorescent time-lapse 
microscopy. HCT116 cells were equilibrated in TMRM for 45 minutes after which the assay 
was commenced with a 30 minute baseline imaging period. The addition of 1mM DMOG to 
cells cultured in glucose caused no significant difference observed in fluorescence over a 
period of 90 minutes (Figure 3.16A). 
To further explore the effects on DMOG treatment on mitochondrial membrane potential, 
an alternative approach to TMRM measurement was also undertaken, which allowed 
membrane potential to be measured over longer periods of DMOG treatment. DIOC6(3) is 
also a well characterised membrane potential-sensitive dye and suitable for flow 
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cytometric analysis. HCT116 cells were treated for 1, 4 or 24 hours with DMOG, before 
trypsinisation and equilibration with the DIOC6(3). Median fluorescence was then 
measured by flow cytometric analysis. Figure 3.16B shows no change in fluorescence up to 
24 hours DMOG treatment, confirming the data obtained using TMRM and suggesting no 
likely relationship between the changes observed in OCR and membrane potential. 
Together these data suggest that despite a decrease in OCR, DMOG is maintaining cellular 
ATP levels and mitochondrial membrane potential.  
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Figure 3.16: Effect of DMOG on mitochondrial inner membrane potential. 
(A) HCT116 cells were incubated with TMRM (50nM) and equilibrated for 45 minutes and 
measurements were then taken at 10 minute intervals. Values were normalised to 
fluorescence change from the first frame (DF/F). DMOG (1mM, red) or vehicle (blue) was 
added after 30 minutes and cells imaged for a total duration of 2 hours. Cells in each 
condition were imaged from two parallel wells using 3 fields of view per well, with 
average intensity calculated from three regions of interest, with background correction. 
Analysis was performed using Image Pro Plus software (Media Cybernetics, Rockville, 
USA). Values are mean +/- S.E.M (n=3). (B) HCT116 cells were incubated with DIOC6(3) 
(0.2nM) equilibrated for 30-45 minutes before analysis by flow cytometry using a 
Beckman Coulter CyAn™ ADP Analyser. Graph shows the fold change in median 
fluorescence with DMOG compared to vehicle alone for the times indicated (ns. p>0.05). 
Values are mean +/- S.E.M (n=3). Data was analysed using paired, two-tailed t-test.  
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3.8 Evaluation of the effects of a second PHD inhibitor on mitochondrial 
parameters 
3.8.1 Evaluation of a second PHD inhibitor on HIF-1α protein stabilisation 
DMOG is a well-characterised inhibitor of the PHD proteins/α-ketoglutarate-dependent 
dioxygenases enzymes that activate the hypoxic response. As such, DMOG is widely used to 
investigate HIF-1α stabilisation and downstream effectors of the oxygen-sensing pathway 
(Elvidge et al., 2006). However, to determine that the mitochondrial effects observed in 
response to DMOG treatment are due to PHD inhibition (Figure 3.11, Figure 3.14 and Figure 
3.16), we tested a second inhibitor of the PHD proteins (designated PHD-I). The structure of 
PHD-I is unrelated to that of DMOG (Figure 3.17A-B). Chemically, PHD-I is a 
hydroxyquinolone and has previously been demonstrated to inhibit the PHD proteins with 
an IC50 = 2µM in a cell-based assay (Smirnova et al., 2010) (reference compound: D2 #8), 
that utilised a stably transfected reporter comprising the HIF-1α ODD domain fused to 
luciferase and assessed for intracellular proline hydroxylation (Smirnova et al., 2010). PHD-I 
works through chelation of Fe2+ at the PHD active site, a mechanism distinct from non-
specific iron chelation (Smirnova et al., 2010). DMOG is an analogue of α-ketoglutarate and 
a competitive inhibitor for the α-ketoglutarate binding site on the PHD proteins (Mole et 
al., 2003). DMOG is also an inhibitor of distinct α-ketoglutarate-dependent dioxygenases 
(Rose et al., 2011), thus lacks specificity for the PHDs. 
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Figure 3.17: Structural comparison of PHD inhibitors, DMOG and PHD-I. 
(A) The structure of DMOG and (B) PHD-I. The two structures are unrelated, PHD-I being a 
hydroxyquinolone and DMOG an analogue of α-ketoglutarate. Structures sourced from 
www.calbiochem.com. 
 
First, it was important to determine that PHD-I was behaving as expected. In order to 
determine a working concentration of PHD-I and confirm inhibitory activity, as previously 
described for DMOG (Figure 3.10), HCT116 cells were incubated for 20 hours with PHD-I, in 
the presence and absence of 10μM MG132 (which was added for the final four hours of 
PHD-I treatment to inhibit the proteasome). HIF-1α protein was robustly induced by PHD-I 
at a concentration of 2.5-5μM and the disappearance of the hydroxylated species of HIF-1α 
at 5μM PHD-I confirmed the effective inhibition of the PHD proteins (Figure 3.18A). 
Therefore a dose of 5μM PHD-I was used in further experiments. 
To investigate the kinetics of the HIF-1α response to PHD-I, HCT116 cells were incubated 
with 5μM PHD-I over time and western blot analysis was performed to assess HIF-1α 
stabilisation (Figure 3.18B). PHD-I rapidly and robustly stabilised HIF-1α protein by 60 
minutes with the kinetics of the stabilisation being similar to that observed for DMOG 
(Figure 3.10B and Figure 3.18B). The effects of PHD-I on mitochondrial function were then 
assessed in order to compare these with effects observed with DMOG treatment.   
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Figure 3.18: Dose and time-dependent effects of PHD-I on HIF-1α protein. 
Western blot analysis of HCT116 cells treated over a concentration titration of PHD-I (20 
hours) in the presence and absence of the proteasome inhibitor MG132 (10μM), for the 
final 4 hours. (A) Western blot shows inhibition of the proteasome by MG132 prevents 
the degradation of the hydroxylated species of HIF-1α, and PHD-I blocks the 
hydroxylation of HIF-1α protein. Hydroxylated HIF-1α species fully disappeared at 5μM 
suggesting effective inhibition of the PHD proteins. (B) Western blot shows time course 
comparison of HIF-1α protein induction for DMOG (1mM) and PHD-I (5μM) treatment 
over a period of 60 minutes. Western blot analysis demonstrating HIF-1α protein is 
significantly induced at 45 minutes for both compounds. β-actin is used as a load control 
for both experiments.  
 
3.8.2 Investigation into the role of PHD-I on mitochondrial function 
In addition to the Seahorse XF24 bioanalyser, the Oroboros Oxygraph 2K (O2K) was used to 
measure oxygen consumption rate in intact cells. The advantage of the O2K is the capacity 
to add sequential volumes of compound to cells in suspension, so one can carefully titrate 
the concentration of agents in order to define the maximum respiratory capacity. The 
Oroboros O2K is a modular system for high-resolution respirometry, combining a two-
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parallel chamber, closed-system into which cells are added and dissolved oxygen in the 
buffer measured by polarographic oxygen sensors and rate calculated. Effect of PHD-I on 
OCR was measured over time. PHD-I was injected after an initial baseline stabilisation 
period and the OCR of HCT116 cells was followed over time. Figure 3.19A shows no change 
in baseline OCR in HCT116 cells cultured in glucose after injection of 5μM PHD-I over a 
period of 30 minutes. There was also no change in leak respiration (after the addition of 
oligomycin) or maximum respiratory capacity (after the addition of FCCP) (Figure 3.19). Re-
oxygenation was necessary to replenish consumed oxygen in the respiration buffer. To do 
this the chamber was opened for a few minutes while oxygen concentration returned to 
starting concentrations. These data raise the possibility that the change in OCR observed 
with DMOG (Figure 3.11) was not due to inhibition of the PHD proteins but due to some off 
target affect not recapitulated by PHD-I, which is a relatively more specific PHD inhibitor.  
 
 
Figure 3.19: Effect of PHD-I on OCR in HCT116 cells. 
Graph shows OCR (pmol.s-1.106 cells) measured over time in minutes (mins) using the 
Oroboros O2K in HCT116 cells. OCR was allowed to stabilise for approximately 10 
minutes before the addition of PHD-I (5μM; red) or vehicle (blue) for 30 minutes. 
Oligomycin (2μg/ml) was added to determine the oxygen consumed that is coupled to 
ATP synthesis, FCCP titration (0.5μM increments) allowed estimation of maximum 
respiratory rate and rotenone (0.5μM) and antimycin A (2.5μM) allowed correction for 
non-mitochondrial respiration. There is no change in basal OCR in cells cultured in 
glucose conditions.  
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DMOG also caused a small but significant increase in ATP levels when measured using 
targeted ATP-sensitive luciferase constructs (Figure 3.14). This experiment was repeated 
using PHD-I. After an initial baseline period for stabilisation of the signal, 5μM PHD-I was 
injected and the luminescence followed over time. There was no significant difference 
observed by 60 minutes of PHD-I treatment compared to control in either cytosolic or 
mitochondrial compartments in glucose conditions (Figure 3.20A). Similar findings were 
also observed in the cytosolic compartment in those cells cultured in galactose. However, 
there was a very small but significant decrease in luminescence in the cytosolic signal in 
cells cultured in galactose (Figure 3.20B). Oligomycin and IAA were injected at the end of 
the experiment to determine background luminescence. Data was collated from four 
independent experiments and presented as fold change in luminescence after background 
correction, normalised to values immediately prior to drug injection, to account for 
variations in transfection efficiency between conditions and experiments. 
These data suggest that the small but significant increase in luminescence observed after 
DMOG treatment is not mimicked by PHD-I. This result, when combined with the absence 
of an effect of PHD-I on OCR is suggestive of distinct mechanisms through which these 
inhibitors are affecting mitochondrial function, one which is unlikely to be through a 
common mechanism of action, since they do not produce identical results.  
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Figure 3.20: Effect of PHD-I on compartmental ATP levels. 
HCT116 cells were transfected with luciferase constructs targeted to mitochondria or 
cytosol (untargeted) in either (A) glucose or (B) galactose conditions. Reaction substrates 
were added and luminescence measured at 60 second intervals. Data is presented as fold 
change in luminescence after 60 minutes PHD-I incubation relative to baseline 
immediately before addition. (A) Graph shows there was no significant increase in 
luminescence by 60 minutes PHD-I treatment (5μM, red) compared to untreated (blue) in 
both cytosolic and mitochondrial compartments (ns p>0.05). (B) Graph shows there was a 
small significant decrease in luminescence in the cytosol after PHD-I treatment only in 
galactose conditions (cytosolic probe * p<0.05, mitochondrial probe ns p>0.05). Values 
are mean +/- S.E.M (n=4). Data was analysed using paired, two-tailed t-test.  
 
The data presented above led us to conclude that DMOG was affecting metabolism through 
functions independent of its established role as a PHD protein inhibitor. As DMOG is 
structurally related to α-ketoglutarate, it was possible that DMOG was acting through the 
TCA cycle (Figure 3.21).  
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Figure 3.21: Catabolism of amino acid skeletons and their entry into the TCA cycle. 
The structural similarities between DMOG and α-ketoglutarate make the TCA cycle a 
potential target for DMOG-mediated metabolic effects.  
 
To understand the mechanism through which DMOG was producing a bioenergetic 
phenotype, potentially independent of the PHD proteins, metabolomic analysis was 
undertaken. HCT116 cells were cultured either in the presence or absence of 1mM DMOG 
for 2 hours, under either glucose or galactose culture conditions. Media was replaced prior 
to the addition of DMOG to allow analysis of cellular uptake and excretion of metabolites in 
the 2 hour treatment window. After 2 hours, media was removed and frozen. The cells 
were repeatedly washed before being subjecting to dual phase extraction to separate 
water-soluble, protein and lipid-soluble metabolites. Metabolomic profiling was 
undertaken using magnetic resonance spectroscopy (MRS) at the Institute of Cancer 
Research (ICR), Sutton, UK by Dr Yuen-Li Chung. Aqueous and lipid phases were analysed 
and designated “cellular metabolites”. Analysis of media samples were designated “media 
metabolites”, with negative values denoting the excretion while positive values denoted 
the uptake of named metabolites. Total protein was quantified from the cell samples to 
allow normalisation of metabolite concentration to cellular protein content. The full 
metabolic analysis is included in the appendix. The analyses showed significant changes in 
cellular (Figure 3.22) and media (Figure 3.23) metabolites. Figure 3.22A shows that the 
addition of DMOG significantly reduced the cellular fumarate concentration in both glucose 
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and galactose culture conditions. Fumarate is a TCA cycle intermediate, formed by the 
oxidation of succinate by succinate dehydrogenase and contributes to maintaining the 
supply of reducing equivalents to the ETC. Reduction of fumarate would affect electrons 
entering the ETC at complex I and as a result potentially reduce oxygen consumption rate. 
The reduction of fumarate upon DMOG treatment raises the possibility that since the 
structure of DMOG is analogous to that of α-ketoglutarate, another TCA cycle intermediate; 
DMOG may be affecting the TCA pathway through competitive inhibition. When cells are 
cultured in galactose, they will be more reliant on the TCA cycle, since pyruvate and 
glutamine will be the primary metabolic substrates.  A reduction in flux through the TCA 
cycle would be expected to decrease the supply of electrons to the ETC and potentially be 
the underlying mechanism for the decreased OCR observed in DMOG treated cells.  
Levels of intracellular glucose were also reduced after DMOG treatment, in those cells 
cultured in glucose (Figure 3.22B). This is possibly a compensatory mechanism due to a 
block in TCA cycle, and a mechanism through which cells can produce ATP by glycolysis and 
maintain membrane potential through the reverse mode of the F1FO-ATPase and ATP 
hydrolysis. Interestingly, significant differences were also observed in aspartate levels 
(Figure 3.22E). HCT116 cells cultured in glucose exhibited an increase in cellular aspartate 
by 2 hours DMOG treatment. Conversely, cells cultured in galactose demonstrated a 
significant decrease in aspartate by 2 hours DMOG treatment. The initial levels of aspartate 
were also different between the culture conditions in the absence of the DMOG. Figure 
3.23 shows the extracellular metabolic changes that occurred in the media of HCT116 cells, 
as a result of increased uptake or excretion of metabolites in response to DMOG 
treatment. Valine, threonine, iso-leucine and phenylalanine all increase in response to 
DMOG treatment in those cells cultured in galactose. Collectively, there are clear 
differences in cell metabolism when HCT116 cells are treated with DMOG which occur 
within minutes to hours of treatment, suggestive of a non-transcriptional response and one 
mediated through perhaps a combination of the PHD proteins and non-specific off target 
effects of DMOG. 
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Figure 3.22: Metabolomic analysis of intracellular metabolites. 
HCT116 cells were cultured under either glucose or galactose conditions for 24 hours. 
DMOG (1mM) or vehicle was added to freshly replaced media for 2 hours. Media was 
removed and immediately frozen for analysis. Cells were washed and protein and 
metabolites separated through dual phase extraction. Metabolites were quantified by 
MRS (performed at the ICR, Sutton, UK) and presented as a concentration per mg of 
protein (nM/mg). Values are mean +/- S.E.M (n=3) (* p<0.05, ns p>0.05). 
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Figure 3.23: Metabolomic analysis of metabolites found in the media. 
HCT116 cells were cultured under either glucose or galactose conditions for 24 hours. 
DMOG or vehicle was added to freshly replaced media for 2 hours. Media was removed 
and immediately frozen for analysis. Media metabolites were quantified by MRS 
(performed at the ICR, Sutton, UK) and presented as a concentration per mg (μM/mg) of 
protein over 2 hours. Values are mean +/- S.E.M (n=3) (* p<0.05, ns p>0.05). 
 
3.9 Discussion 
The role of HIF-1 has been extremely well characterised since its discovery as a central 
mediator of the cellular response to hypoxia in 1992 (Semenza and Wang, 1992). Since 
then, HIF-1 has been observed to play an essential role in cardiovascular biology. The 
cardiovascular role of HIF-1 has been examined in many systems, including cell and tissue 
culture, ex vivo models, such as the Langendorff isolated perfused heart and in vivo (Date 
et al., 2005, Cai et al., 2008, Kido et al., 2005). Using each of these approaches HIF has been 
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identified to have a role in development, normal healthy physiology as well as under 
pathophysiological conditions. 
3.9.1 HIF-1 in maintaining cardiovascular physiology and function 
Despite its title as an ‘inducible factor’, basal HIF transcription has been identified as 
important and necessary for correct functioning of the heart. HIF-1 is required for basal 
gene transcription under physiological conditions in normoxia, for the maintenance of ion 
signalling, vascularity and energy metabolism (Huang et al., 2004). Additionally, basal HIF-
1α transcription has been observed as being crucial in the acute phase of ischaemic pre-
conditioning (Loor and Schumacker, 2008, Cai et al., 2008). A transgenic mouse model of 
HIF-1α constitutive over-expression in the myocardium demonstrated increased VEGF-
mediated angiogenesis, a reduction in infarct size and improved cardiac mechanics and 
function 4-weeks post coronary artery occlusion (Kido et al., 2005). Improvement in cardiac 
function was also observed using intramyocardial injection of small hairpin RNA (shRNA) 
toward PHD2, demonstrating enhanced neoangiogenesis and improved ventricular function 
in a mouse model of myocardial infarction (Huang et al., 2008). Taken together, this 
suggests that the control of HIF levels and maintenance of appropriate basal transcription 
is vital in cardiac dynamics and function. These observations are important as this chapter 
has aimed to explore the acute/short term consequences of activation of the oxygen-
sensing pathway, through inhibition of the PHD proteins on metabolism and mitochondrial 
function. HIFs role in cardiac pathology has also been characterised (Lee et al., 2000). HIF-
1α is up regulated in response to chronic ischaemia, its mRNA levels and expression of the 
HIF target gene VEGF are both increased after coronary artery occlusion (Lee et al., 2000).  
3.9.2 HIF-1 in cardioprotection 
Activation of HIF/hypoxia pathway in several studies has been demonstrated to exhibit a 
cardioprotective role, attributed to HIF-dependent downstream target genes, such as haem 
oxygenase-1 (HO-1), VEGF and inducible nitric oxide synthase (iNOS) (Loor and Schumacker, 
2008, Hyvarinen et al., 2010, Eckle et al., 2008, Dawn and Bolli, 2005).  
Cardioprotection has been demonstrated in Phd2 hypomorphic mice. Phd2 hypomorphs 
have decreased activity of PHD2 through a gene trap insertion cassette and expresses 
tissue-dependent amounts of Phd2 mRNA, with only 8% of control expression in the heart 
(Hyvarinen et al., 2010). These mice show chronic HIF-1α stabilisation in the heart and 
improved mechanical recovery after 20 minutes global ischaemia and 45 minutes 
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reperfusion. A reduction in infarct size was evidenced by decreased lactate dehydrogenase 
release. Hyvarinen et al suggested that the congestive heart failure observed in the broad 
spectrum conditional Phd2 knockout mouse model (Minamishima et al., 2008), was due to 
indirect polycythemic pathology and enhanced angiogenesis as consequence of systemic 
factors - as neither were evident in the heart of the hypomorphic mice (Hyvarinen et al., 
2010).  
Intriguingly, non-lethal rounds of ischaemia-reperfusion, pre-ischaemic insult or rounds of 
reperfusion/reoxygenation immediately post ischaemia, have been shown to be protective 
- processes known a pre- and post-conditioning respectively (IPC and IPost) (Taylor and 
Pouyssegur, 2007, Murry et al., 1986). IPC has both an immediate/early and delayed 
component leading to protection (Arstall et al., 1998). Early phase protection occurs in 
minutes and lasts up to a few hours post stimulus. Early phase protective events are 
mediated by ion channels and other signalling molecules with a delayed transcriptional 
response occurring within 12-24 hours and lasting as long as 3-4 days (Date et al., 2005). 
HIF-1 has been shown to be involved in both these situations; predictably the 
transcriptional response (Date et al., 2005), mediated through the up-regulation of HIF-
specific gene expression. However HIF-1 is thought to be involved in an immediate/early 
phase non-transcriptional response (Cai et al., 2008). 
In 2005, Date et al observed HIF-1α to be protective and also play a role in late phase 
response to ischaemic pre-conditioning (Date et al., 2005). HIF-mediated protection was 
observed in vitro using a hypoxia-reoxygenation approach, examining constitutively stable 
hybrid forms of HIF-1α and after determination of the influence on myocardial viability and 
gene expression (Date et al., 2005). In 2008, Cai at al reached the same conclusion (Cai et 
al., 2008). Cai et al identified relief of protection from hypoxic preconditioning using mice 
heterozygous for Hif-1α in a model of ischaemic injury. Cai et al identified that this HIF-
dependent protection was dependent on Hif-1α gene dosage and HIF-1α induced 
mitochondrial ROS production. Cai et al also demonstrated a role of HIF-1 in the early 
phase of cardiac protection, after observing an increased infarct size after IPC and 
ischaemic injury in the Hif-1α+/- (Cai et al., 2008). The HIF-dependent early phase protection 
was concluded not to be the acute activation of HIF-1 target genes, but the HIF-dependent 
basal expression of genes required for the mechanism behind the preconditioning stimulus. 
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Therefore loss of HIF-1 would interrupt the signalling pathway that in the presence of HIF-
1α would mediate protection (Cai et al., 2008).  
Studies showing that HIF-1 elicits protection in ischaemic preconditioning and 
cardioprotection were performed using intraventricular infusion of siRNA, targeted 
towards Hif-1α and Phd2 and pharmacological HIF-1 activation using DMOG. Eckle et al 
highlighted the increased purigenic signalling through the A2B adenosine receptor (A2BAR) 
under conditions of HIF-1α stabilisation and loss of protection in A2BAR-/- mice (Eckle et al., 
2008).  
Numerous problems can be identified with respect to targeting PHD2 and the suggestion 
that resultant HIF-1α stabilisation is responsible for the observed protective effect. Firstly 
PHD3, not PHD2 is the prominent isoforms in the heart, and there is increasing expression 
with age (Rohrbach et al., 2005). Secondly, a body of evidence suggests that the PHD 
proteins have functions outside their regulation of HIF-α (Table 4; below) and it may be 
interruptions to these distinct pathways which is responsible for the phenotypic changes 
associated with the cellular resistance to ischaemic injury.  
HIF-1 and HIF-2 have distinct roles in cardioprotection. HIF-1 regulates the transition in 
metabolism from aerobic respiration to glycolysis in the early phase of ischaemic 
preconditioning through up-regulating genes such as PDK-1 and mediating the cytochrome 
oxidase subunit switch. In the late phase, HIF-1 functions to up-regulate genes dictating 
vascular changes and cell survival such as VEGF, HO-1 (Dawn and Bolli, 2005, Ockaili et al., 
2005), cyclooxygenase-2 (Bolli et al., 2002), iNOS (Guo et al., 1999) and the A2B receptor 
(Synnestvedt et al., 2002). HIF-2 appears comparatively understudied and believed to be 
involved in maintaining mitochondrial and antioxidant homeostasis and regulating more 
adaptive responses (Shohet and Garcia, 2007). A delicate balance exists between glycolytic 
and aerobic metabolism and HIF-1 is central in directing these transitions. In the heart, 
these metabolic processes have been linked to cardioprotection against ischaemic injury 
and the involvement in ischaemic preconditioning. It therefore remains possible that the 
HIFs are having more of a direct role on metabolism, although precisely how, is yet to be 
elucidated.  
Although the involvement of HIF in cardioprotection is evident and effects multi-factorial, it 
has yet to be identified as the common pathway. Additionally, the concept of ischaemic 
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preconditioning still remains a complex subject and one that needs to be delineated if 
there is to be any therapeutic significance to this cytoprotection.  
3.9.3 Characterisation of HL-1 cardiomyocytes 
The first part of this chapter aimed to utilise the HL-1 cell line as a model system and tool to 
study fully differentiated adult cardiomyocytes and to further probe the HIF-mitochondria 
interface. HL-1 cells were developed by William Claycomb and established from atrial 
tumour cells derived from the AT-1 mouse in which the SV40 large T antigen has been 
targeted to atrial myocytes using the ANF promoter (Claycomb et al., 1998). HL-1 cells were 
isolated from an AT-1 subcutaneous tumour and display characteristics of a fully 
differentiated cardiomyocyte with respect to morphology, biochemistry and 
electrophysiology (Claycomb et al., 1998). HL-1 cardiomyocytes possess the ability to 
spontaneously contract and can be serially passaged in culture, making them a useful 
model to initially characterise HIF responses as a prerequisite to the isolation and 
characterisation of primary cells.  
Under hypoxia, oxygen, the essential substrate for the generation the hydroxyproline in the 
ODD domain of HIF-α becomes limiting and hydroxylation is inhibited. Inhibition of 
hydroxylation allows HIF-1α to escape pVHL-mediated targeting and proteasomal 
degradation, stabilising the HIF-α protein. The response of HIF-1α to hypoxia was 
successfully validated in the HL-1 cells, shown by a robust increase in HIF-1α protein 
observed over time in 1% oxygen. Additionally, we confirmed HIF-1α protein stabilisation 
after inhibition of the PHD proteins. The α-ketoglutarate analogue, DMOG, prevents 
hydroxyproline formation by competing with the α-ketoglutarate and at the co-factor 
binding site. HL-1 cells therefore demonstrate a characteristic response to both hypoxia 
and PHD inhibition; demonstrate reproducible HIF-1α induction and HIF-1-dependent 
target gene expression after 24 hours, making this a useful model system in which to study 
the potential role of HIF-1α in a cardiomyocyte background.  
IGF-1 is produced in every tissue, constitutively expressed and mediates autocrine-
paracrine-endocrine actions on cell survival, differentiation and proliferation (Suleiman et 
al., 2007). The IGF-system consists of two ligands (IGF-1 and -2), two receptors (IGF-1R and 
-2R) and IGF-binding proteins, which function in tandem to allow receptor-mediated 
responses under tight regulation (Suleiman et al., 2007). IGF-1 is a survival factor and a HIF-
1 target gene, encoding a functional HRE present in intron 1 (Tazuke et al., 1998). IGF-1 
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stimulation can equally induce HIF-1α protein synthesis in tumour cells (Feldser et al., 
1999). Circulating, non-bound IGF-1 binds its cognate receptor on the cell membrane and 
activates either the MAPK or the PI3K-AKT/PKB signalling pathways. To confirm growth 
factor signalling to HIF-1α as we have previously described (Bardos et al., 2004), IGF-1 was 
successfully demonstrated to induce HIF-1α protein synthesis after 2 hours treatment, 
increasing over time in HL-1 cells. The importance of this lies in ensuring well characterised 
pathways leading to effects on HIF exist and are operating as expected in this cell line.  
The HL-1 cell line provided a good model for characterisation of the mitochondrial 
association of the HIFs. However, these cells do not behave exactly like primary 
cardiomyocyte. HL-1 cells rely heavily on glycolysis and less on OxPhos for their energy 
production (Monge et al., 2009). They have decreased cytochrome content, decreased 
respiratory chain complex activities, particularly complex I (Monge et al., 2009, Eimre et al., 
2008). For further analysis of the functional consequence of HIF-1α association with 
mitochondria and its potential effects on mitochondrial function with respect to cardiac 
biology, it would be necessary to use primary cardiomyocytes derived from rat or mouse, 
which would provide a more physiological context with respect to the  balance between 
glycolytic and OxPhos metabolism.  
3.9.4 Mitochondrial association of the HIFs 
The second part of this chapter aimed to illustrate alternative, non-transcriptional roles of 
the HIF-1α protein outside of its traditional nuclear role. There is a significant amount of 
evidence to suggest extensive cross-talk between the HIF pathway and mitochondria 
(Briston et al., 2011, Yang et al., 2012, Fukuda et al., 2007, Zhang et al., 2008, Rane et al., 
2009). It is not only evident that mitochondrial respiration plays a role in regulating HIF 
activity, but HIF activation also controls mitochondrial metabolism and cellular metabolic 
adaptation to hypoxia (Ebert et al., 1995, Papandreou et al., 2006, Kim et al., 2006, Fukuda 
et al., 2007). This indirect response is mediated through HIF-dependent expression of 
target genes, such as GLUT-1, PDK1, LON and COX4-2 (Ebert et al., 1995, Papandreou et al., 
2006, Kim et al., 2006, Fukuda et al., 2007). The question of whether there is more 
immediate and/or role for the HIFs within minutes to hours of hypoxia or pharmacological 
activation is an area still yet to be fully explored, particularly in relation to mitochondria.  
In addition to work from our own lab (Briston et al., 2011), to date only one other group 
has suggested the possibility that HIF-1α protein associates with mitochondria (Rane et al., 
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2009). In this work, Rane et al demonstrated that in rat primary cardiomyocytes HIF-1α can 
be co-purified with mitochondria after a period of hypoxic preconditioning, however not 
after 24 hours hypoxia alone (Rane et al., 2009). Our observations extend these studies and 
indicate that after activation of this pathway, there is rapid accumulation of the stabilised 
HIF-1α protein observed in mitochondrial fractions. The kinetics for stabilisation of HIF-1α 
protein in vivo in response to hypoxic preconditioning may provide an explanation as to 
why Rane and colleagues did not observe mitochondrial HIF-1α at 24 hours hypoxia. It is 
perhaps that the direct molecular association of HIF-1α protein with mitochondria is 
transient, and forms part of the early immediate response to hypoxia, prior to the 
activation of gene transcription.  
In a number of experiments and conditions we have observed HIF-1α to be present in 
mitochondrial fractions. It is clear that HIF is central in mediating transcriptional adaptive 
responses to hypoxia, however it is plausible that in line with other transcription factors 
and distinct from its nuclear role that HIF-1α may associate with mitochondria. This 
mitochondrial association may directly affect mitochondrial metabolism in a more acute 
setting (Rane et al., 2009).  
HIF-1α is constitutively transcribed and regulated on the level of protein stability. In 
normoxia, despite a short protein half-life and low abundance, HIF-1α is transcriptionally 
active, as we found that HIF-1α knockdown in normal, ambient oxygen concentrations 
reduced the expression of validated HIF-1 target genes (data not shown). Western blot 
analysis has limited sensitivity and in the results obtained from cells in culture, HIF-1α 
protein can only be observed in mitochondrial fractions after inhibition of the PHD protein-
mediated hydroxylation. There remains the possibility that HIF-1α is associated with 
mitochondria in normal, ambient oxygen concentrations and is below the limit of detection 
by western blotting. The isolation and purification of mitochondria from liver tissue allowed 
for analysis of the HIF-1α/mitochondrial association in a more physiological environment. 
The liver is a highly aerobic organ (Lemasters et al., 1992) and in spite of this, in the purified 
mitochondrial fractions HIF-1α protein can be readily detected, suggestive of enrichment in 
this fraction. Careful examination of the western blot from liver tissue (Figure 3.6), 
demonstrated distinct differences in the banding pattern of HIF-1α compared to that from 
hypoxia in HL-1 cells (compare lanes 1 and 2) and that found in the purified mitochondrial 
fraction (lane 4). The diffuse HIF-1α band in hypoxic HL-1 cells is likely a result of heavy 
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post-translational modification. The different banding patterns observed in enriched 
mitochondria isolated in these experiments from cells exposed to hypoxia versus tissue 
may arise from distinct alterations in these post-translational modifications between 
tissues and/or cellular compartments.  
It must be noted and is important to consider, that there are clear limitations associated 
with fractionation protocols and methods for purifying mitochondria. Results from these 
experiments must be carefully interpreted; there resides the inherent probability of 
fraction contamination, a limitation which can be overcome to some degree through 
sucrose gradient separation, but remains present nonetheless. Therefore to confirm the 
subcellular fractionation data, further work and analysis would be necessary. Biochemical 
fractionation after ultracentrifugation and immunoblotting would be appropriate to 
confirm the organelle fractions in which the HIF-1α protein can be observed. Analysis of 
HIF-1α by immunogold labelling and electron microscopy would allow in situ analysis of 
cellular localisation. Additionally, protease protection assays of mitochondrial fractions, 
would allow determination of intra-mitochondrial localisation. This would entail proteinase 
K digestion of mitochondrial outer membrane tethered proteins and sodium carbonate 
extraction of matrix components to delineate HIF-1α protein mitochondrial topology. 
Immunoprecipitation of HIF-1α from purified mitochondrial fractions and mass 
spectrometry of the proteins would allow identification of the protein in addition to 
analysis of any post-translational modifications. This approach would allow determination 
of whether a specifically modified form of HIF-1α resides in or with mitochondria. These 
analyses would also allow determination of whether HIF-1α protein exists as a complex 
within mitochondria with its beta subunit or other mitochondrial protein(s). Finally, 
mitochondrial import assays could be utilised to assess uptake of radiolabelled in vitro 
translated HIF-1α protein into isolated intact mitochondria. 
A second interesting observation is the identification of HIF-1β in mitochondrial fractions 
obtained from both cells and tissue. HIF-1β identification, raises the possibility of the alpha 
and beta isoforms complexing on the outer mitochondrial membrane or intra-
mitochondrially and functioning in partnership. RNA interference experiments or using null 
cells to investigate loss of HIF-1β may reveal more information with respect to this 
localisation. Further examination would allow determination of whether the paralleled 
association HIF-1β with HIF-1α is firstly necessary for mitochondrial association of HIF-1α 
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and secondly whether this has any immediate consequence on mitochondrial function after 
hypoxic insult or pharmacological inhibition of the PHD proteins. Interestingly in HL-1 cells, 
after 2 hours DMOG treatment, mitochondrially-associated HIF-1β protein decreases. This 
mitochondrially-associated decrease in HIF-1β protein may reflect that HIF-1β localisation 
at this time point is most likely to be nuclear, where it will dimerise with HIF-1α and form 
the transcriptional complex. Previous studies have shown that HIF-1β is nuclear, due to the 
presence of a putative nuclear localisation sequence in the N-terminal domain (Holmes and 
Pollenz, 1997, Pollenz et al., 1994); however, as yet, there are no published reports 
describing mitochondrial association of HIF-1β protein. 
Identification of a hydroxylated species of HIF-1α protein in mitochondrial fractions raises a 
number of intriguing questions and possibilities. Firstly, it is perhaps plausible that HIF-1α is 
functionally hydroxylated within or immediately surrounding the mitochondria. The 
mitochondria are the primary consumers of oxygen within the cell and as such under non-
pathological conditions are well supplied with oxygen. It is therefore not surprising, if HIF-
1α is present at the mitochondrial interface for it to be hydroxylated due to the abundance 
of available substrate for the PHD proteins. Secondly, if future work proves the localisation 
of HIF-1α protein to be intra-mitochondrial, it would be interesting to investigate whether 
the hydroxylation of HIF-1α is a pre-requisite for import or exclusion from the organelle.  
The next challenge would be the functional assessment of HIF-1α protein-mitochondria 
association. For future work, HIF-1α protein could be fused with a mitochondrial targeting 
sequence (MTS). Albeit an over-expression system, though these experiments it would be 
possible to identify if and how HIF-1α affects mitochondrial function directly. An extremely 
interesting possibility is that in keeping with HIF-1α’s role as a transcription factor, it may 
be regulating mitochondrial gene transcription under specific conditions. Assessing 
mitochondrial gene expression in combination with the over-expressed MTS-tagged protein 
would allow delineation of alterations in mitochondrial gene expression by RT-qPCR. 
Finally, using techniques such as electrophoretic mobility shift assay (EMSA) or chromatin 
immunoprecipitation (ChIP) assays, identification of the HIF-1α protein binding 
mitochondrial DNA could be established.  
A second proposed model as to the function of the HIF-mitochondria association is one of 
direct protein binding. A model could be proposed whereby HIF-1α is binding directly to 
mitochondrial outer-membrane or intra-mitochondrial proteins and by some undefined 
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mechanism affecting or maintaining mitochondrial function. Work from our lab has 
described the human CHCHD4/MIA40 mitochondrial protein family, a novel regulator of 
HIF-1α (Yang et al., 2012). CHCHD4.1 is identical to human MIA40, which is an IMS protein 
and contains structurally and functionally essential conserved cysteine domains necessary 
to participate in IMS protein import. As discussed, we have shown that CHCHD4/MIA40 
regulates cellular oxygen consumption rate and ATP synthesis and that CHCHD4/MIA40 is 
essential for regulating HIF-1α stabilisation in response to hypoxia (Yang et al., 2012). 
CHCHD4/MIA40 knockdown prevents HIF-1α induction and transcriptional activity, 
decreases oxygen consumption rate in normoxia, ATP biosynthesis and inhibits tumour 
growth and angiogenesis in vivo (Yang et al., 2012). Unpublished observations from our lab, 
show HIF-1α to be present in a complex with CHCHD4 and this is hypothesised to limit 
electron flow through the disulphide relay system, affecting flux through to cytochrome c 
and indirectly affecting oxygen consumption. Questions however still remain as to the 
relationship between HIF-1α and mitochondria. The endeavour to provide solutions to the 
proposed questions will uncover novel molecular and mechanistic insights into the role of 
HIF-α in regulation of metabolism and mitochondrial function. Despite the limitations of 
the techniques described in this work, collectively these observations pave the way to 
better understand the functional and physiological significance of the HIF-mitochondria 
association.  
3.9.5 HIF-independent roles and mitochondrial association of the PHD proteins  
EGFP-tagged PHD protein constructs have previously determined cellular topology of the 
exogenous PHD proteins (Metzen et al., 2003). Metzen et al demonstrated nuclear 
localisation of PHD1, PHD2 distributed throughout the cytosol and PHD3 was observed in 
both nuclear and cytosolic compartments (Metzen et al., 2003).  Using the same constructs, 
our data confirm the data published by Metzen and colleagues (Metzen et al., 2003). The 
rat orthologue of PHD3, SM-20 has been observed in mitochondria, however unlike human 
PHD3, SM-20 encodes an additional mitochondrial targeting sequence (Lipscomb et al., 
2001). PHD2 has been described to co-localise with the adapter protein FKBP38 in 
mitochondria and ER (Barth et al., 2009) and PHD2 and PHD3 have been observed to 
demonstrate mitochondrial localisation in rat hepatocytes (Khan et al., 2006). The protein 
aggregation observed after EGFP-PHD3 expression is consistent with that reported by 
Metzen et al where it was concluded to be a consequence of over-expression (Metzen et 
al., 2003). PHD protein aggregation however, has recently been observed with endogenous 
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PHD3 and mediated through SQSTM1/p62 (p62) which promotes cytosolic aggregation of 
proteins, an effect lost in hypoxia (Rantanen et al., 2013).   
In addition to the studies on HIF-1α, we have also presented that both PHD2 and PHD3 are 
present in mitochondrial fractions under physiological conditions. Our data confirms 
published observations for PHD2 (Barth et al., 2009) but is novel for human PHD3. Further 
experiments are however necessary to characterise their exact sub-mitochondrial 
localisation, determine mitochondrial topology and eliminate outer-mitochondrial 
membrane association, using the same approach as discussed for HIF-1α. Our data on PHD 
subcellular localisation remain subject to the same limitations as outlined above, such that 
more detailed investigation would be necessary to confirm intra-mitochondrial localisation. 
Collectively, our observations are however most intriguing and raise questions regarding 
PHD-mediated HIF-1α modifications within mitochondria or potential HIF-independent 
roles of the PHD proteins.  
The HIF-independent roles of the PHDs are still under investigation and to date a growing 
number of distinct substrates have been identified (Cummins et al., 2006, Mikhaylova et al., 
2008, Kuznetsova et al., 2003, Koditz et al., 2007, Xie et al., 2009). To date, PHD3 has the 
most interacting partners outside of the HIFs. It has been observed to hydroxylate the β2-
adrenergic receptor to mediate pVHL-dependent ubiquitination and subsequent 
degradation (Xie et al., 2009). PHD3 has also been observed to be pro-apoptotic under 
certain circumstances (Lee et al., 2005) as well as binding to and regulating activity of 
activating transcription factor-4 (ATF-4) in a pVHL-independent manner (Koditz et al., 
2007). PHD3 interacts with mitogen activated protein kinase organiser-1 (MORG-1) (Hopfer 
et al., 2006), human homologue of the Caenorhabditis elegans biological clock protein CLK-
2 (HCLK2) (Xie et al., 2012) and p62 (Rantanen et al., 2013).   
Additionally, the large subunit of RNA polymerase II (RPB1) has been demonstrated to be 
regulated by pVHL, after both PHD1 and PHD2 were co-immunoprecipitated with RPB1 in 
response to oxidative stress. Interplay has also been demonstrated between PHD1 and NF-
κB signalling through PHD1-mediated inhibition of inhibitor of nuclear factor kappa-B 
kinase (IKKβ) and linking hypoxia to NF-κB signalling (Cummins et al., 2006). Table 4 
summarises these investigations and additional HIF-independent roles of the PHD proteins. 
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Partner Model  Function Reference 
PHD1 
 
 
RPB1 Human 
Hydroxylation of RPB1 is necessary for oxidative stress induced 
phosphorylation of RPB1 
 (Mikhaylova et 
al., 2008) 
  
 
 
IKKβ Human Hydroxylation of IKKβ promotes activation of NF-κB signalling 
 (Cummins et al., 
2006) 
  
 
 
SPRY2 Human Hydroxylation necessary for pVHL mediated degradation 
(Anderson et al., 
2011)  
  
 
 
ATF-4 Human 
Stabilisation of ATF-4, through hydroxylation independent binding 
and control of transactivation activity 
 (Hiwatashi et al., 
2011) 
    
  
  
PHD2 
 
 
RPB1 Human 
Loss of PHD2 stimulates hydroxylation necessary for oxidative 
stress induced phosphorylation of RPB1 
 (Mikhaylova et 
al., 2008) 
  
 
ING-4 Human 
 
Direct interaction involved in the regulation of HIF-1α activity in 
hypoxia  (Colla et al., 2007) 
    
  
  
PHD3 
 
 
MORG-1 Human 
MORG-1 interacts with PHD3 proposed to act as molecular scaffold 
providing a  framework between HIF regulation and potentially 
other signalling pathways 
 (Hopfer et al., 
2006) 
  
 
 
BCL-2 Rat 
Interacts with BCL-2, inhibits the formation of BCL-2-BAX complex 
and inhibits the anti-apoptotic effect of BCL-2  (Liu et al., 2010) 
  
 
 
β2-AR Human 
Hydroxylation necessary for pVHL recognition and proteasomal 
degradation  (Xie et al., 2009) 
  
 
 
ATF-4 Human 
Binding to ATF-4, hydroxylation independent control of 
transactivation activity through ATF-4 destabilisation 
 (Koditz et al., 
2007) 
  
 
 
p62 Human 
p62 required for normoxic aggregation of PHD3 which is lost in 
hypoxia. Regulates expression, localisation and activity of PHD3 
 (Rantanen et al., 
2013) 
  
 
 
PKM2 Human 
PKM2-PHD3 interaction enhances binding of PK-M2 to HIF-1α 
facilitating role as potential co-activator  (Luo et al., 2011) 
  
 
 
PAX-2 Human 
Binds PAX-2 and hydroxylation activity necessary for PAX-2 
degradation  (Yan et al., 2011) 
  
 
 
PRP19 Human 
Complexes and inhibits PHD3 mediated apoptotic cell death under 
prolonged hypoxia  (Sato et al., 2010) 
  
 
 
HCLK2 Human 
 
Hydroxylation necessary for HCLK2 interaction with ATR allowing 
activation of ATR/CHK1/p53 and apoptotic cell death in response to 
DNA damage  (Xie et al., 2012) 
          
 
Table 4: HIF-independent regulatory roles of the PHD proteins.  
Table detailing the model system in which the interaction was elucidated, the function of 
the relationship and the reference from which the information was derived. BCL-2 = B-
cell lymphoma 2, PAX-2 = Paired box gene-2, SPRY2 = Sprouty-2. 
 
Interestingly, from a metabolic perspective, knockout of PHD1 has been shown to re-
programme basal metabolism in skeletal muscle, reducing oxygen consumption through 
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controlling the switch from glucose oxidation to a more glycolytic phenotype in generating 
ATP (Aragones et al., 2008). Mice null for Phd1 are better adapted to survive acute 
ischaemic/hypoxic insults as they consume less oxygen (Aragones et al., 2008). 
Consequentially Phd1-null mice generate less oxidative stress, preventing damage to 
mitochondria and continue to maintain OxPhos, albeit at a low residual level. This effect is 
mediated through PPARα, HIF-2α and increased expression of multiple isoforms of 
pyruvate dehydrogenase kinase (Aragones et al., 2009, Aragones et al., 2008). 
Due to the relatively low affinity of the PHDs toward oxygen, many of the cellular responses 
to low oxygen occur at concentrations well above those that limit oxidative mitochondrial 
ATP production and prevent the cell from metabolic crisis. In this situation PHD activation 
could be seen as a more anticipatory response or early warning system (Sridharan et al., 
2008). What is interesting about the PHDs is their presence in many other organisms 
including those which either do not have a HIF orthologue or in oxygen generating (photo-
synthetic) organisms, which may suggest an important physiological role independent of 
HIF (Boulahbel et al., 2009). In addition to this and also interesting to note is their seeming 
unnecessary redundancy in terms of HIF regulatory activity, with PHD2 being the principle 
negative regulator and PHD1 and PHD3 only playing a small role (Boulahbel et al., 2009).  
3.9.6 Effects of DMOG treatment and PHD protein inhibition on mitochondrial function 
The final part of this chapter aimed to investigate the short-term or acute effects (within 
minutes to hours) of activation of the oxygen-sensing pathway and determine if any 
phenotype could be attributed to the mitochondrial localisation of HIF-1α. To begin to 
explore the functional effects of HIF-1α stabilisation and activation of the oxygen-sensing 
pathway on mitochondria, several mitochondrial parameters were assessed. Most notably, 
oxygen consumption immediately decreased upon addition of the PHD inhibitor DMOG. 
This effect increased over time and a large significant effect on the maximum respiratory 
rate was also recognised.  
HCT116 cells are highly glycolytic, a phenotypic characteristic of tumour cells. This 
observation was validated with the ATP data presented here. HCT116 cells appear to 
generate most, if not all their ATP through glycolysis (Warburg effect; (Warburg, 1956)). 
Predominantly glycolytic ATP production was confirmed by the negligible decrease in total 
cell ATP levels after the addition of oligomycin and the significant decrease after the 
addition of the glycolysis inhibitor IAA. In response to DMOG treatment over a period 60 
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minutes, total cellular ATP appeared to be maintained. There was a small but significant 
increase in cytosolic and mitochondrial ATP over the first hour of DMOG treatment, 
notwithstanding the significant decrease in OCR. Together these data suggest that cells are 
able to maintain their ATP levels while utilising less oxygen. 
DMOG treatment caused no change in mitochondrial membrane potential. We have also 
demonstrated that the reduction in OCR with DMOG treatment cannot be reversed with 
pre-treatment with a HIF-1α inhibitor (data not shown). The maintenance of ATP after 
DMOG treatment was also found to be HIF-1α-independent. DMOG produced a small but 
significant increase in mitochondrial and cytosolic ATP in the presence of HIF-1α silencing. 
To date there are two papers from Gary Wright’s group detailing the metabolic HIF-1α-
dependent and -independent effects of over 20 hours PHD inhibition (Sridharan et al., 
2007, Sridharan et al., 2008). Initially Sridharan et al observed that inhibition of the PHD 
pathway is cytoprotective. Treatment of cardiomyocytes with PHD inhibitors allows 
maintenance of mitochondrial membrane potential during metabolic inhibition (MI), 
induced after cardiomyocyte culture in glucose-free media containing potassium cyanide 
(KCN) with or without 2-deoxyglucose (2-DG). There was significantly less toxicity in the 
presence of the PHD inhibitors DMOG and ethyl 3,4-dihydroxybenzoate (EDHB). Post 
metabolic insult and 2 hours recovery, PHD inhibitor treatment afforded maintenance of 
ATP levels and increased 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) reducing capacity, compared to pre-MI values, suggestive of a mechanism other than 
an increase in anaerobic glycolysis. Mitochondrial membrane potential decrease after 
cardiomyocyte culture in MI medium reduces less after the activation of the PHD pathways 
and also increases to a greater degree after 2 hours recovery. Membrane potential 
maintenance was not affected by oligomycin, eliminating the reverse mode of the F1FO-
ATPase and ATP hydrolysis for mechanism of maintenance. The major observation is that in 
the absence of PHD inhibition, KCN is sufficient to depolarise the membrane, however the 
addition of rotenone is necessary in the PHD treated cells, suggesting that complex I is still 
active during and after MI. OCR was also reduced to 15% of controls and extracellular 
acidification rate (ECAR) increased after 22 hours DMOG treatment (Sridharan et al., 2007).    
In their second paper (Sridharan et al., 2008), Sridharan et al observed that treatment with 
DMOG causes a decrease in cardiomyocyte ATP turnover by reducing contractility and a 
reduced oxygen consumption rate. After the addition of the uncoupler, dinitrophenol 
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(DNP) to cardiomyocytes treated with DMOG, Sridharen et al observed a significant 
decrease in maximum respiratory rate, an effect which interestingly was reversed when 
HIF-1α was knocked down (Sridharan et al., 2008). This suggests that the reduction in basal 
OCR was not just a consequence of the reduced ATP turnover, but is actively “clamped” 
under conditions of PHD inhibition. Intriguingly, the initial reduction in basal ATP turnover 
and reduced basal OCR in PHD inhibitor treated cells is HIF-1α-independent. HIF-1α-
independence suggests differential and distinct roles for the PHDs in controlling the direct 
suppression of OxPhos and the down-regulation of ATP turnover (by a reduction in 
contractile activity of cardiomyocytes) through HIF-1α-independent and -dependent roles 
respectively (Sridharan et al., 2008). To summarise, PHD inhibitor-mediated; 
 ↓ basal OCR and ↓ ATP turnover   →   HIF-1α-independent 
 ↓ max respiratory rate   →   HIF-1α-dependent  
Therefore, flux through the ETC in the presence of PHD inhibition is independent of the 
stabilisation and activity of HIF-1α. The PHD-mediated decrease in OCR and ATP 
maintenance correlates with what was observed in our system, whereby the acute 
treatment with DMOG resulted in an immediate and significant decrease in OCR, which 
continued to fall over a 30 minute period. This may suggest we are observing the 
immediate effects that ultimately mediated the final 85% reduction in the basal OCR 
observed by Sridharan et al (Sridharan et al., 2007, Sridharan et al., 2008). Sridharen et al 
propose a mechanism, through inhibition of the PHD proteins increasing flux through the 
purine nucleotide cycle, which re-generates adenosine monophosphate (AMP) from inosine 
monophosphate (IMP), consumes aspartate and produces fumarate and ammonium as by 
products (Sridharan et al., 2008). Fumarate then is reduced at complex II to succinate. This 
PHD-mediated adaptation would allow cells under periods of metabolic inhibition to utilise 
fumarate as the terminal electron acceptor when complex IV is inhibited. This also makes 
sense of their observation in that in PHD inhibitor-treated cells, rotenone is also required in 
addition to KCN to depolarise the mitochondrial membrane, as complex I retains activity 
and complex II provides an outlet for electrons. These findings correlate with our data. 
Here, we observe a reduction in aspartate levels in galactose culture conditions and 
reduced fumarate in both glucose and galactose conditions, possibly suggesting the 
involvement of complex II and fumarate being used as a terminal electron acceptor. We 
would have to measure succinate levels to be confident of this. However, under high 
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glucose conditions the increase in aspartate does not correlate with that observed by 
Sridharen et al and what we observe in galactose. These are however two separate 
systems, one being a highly oxidative cardiomyocyte and other a highly glycolytic tumour 
derived cell line and perhaps the comparison of HCT116 culture in galactose is more 
reflective of the oxidative cardiomyocyte.  
The maintenance in ATP, despite the DMOG-induced decrease in OCR, may be dependent 
on decreased ATP utilisation, in contrast to increased ATP biosynthesis. ATP turnover was 
demonstrate to be reduced in cardiomyocytes by reducing contraction in a HIF-1α-
independent fashion (Sridharan et al., 2008). There is no parallel process in the HCT116 
colon cancer cell line, so an alternative explanation is necessary. The major cellular 
consuming processes of ATP are translation (protein synthesis) and the Na+/K+-ATPase. 
There are no reports suggesting that inhibition of the PHD proteins for 2 hours affects 
translation, however in one study DMOG was observed to inhibit the Na+/K+-ATPase after 
24 hours treatment, without altering expression or membrane localisation (Ward et al., 
2011) – this effect could account for the maintenance of ATP in the HCT116 cells.  
Although there are strong correlations with the data presented here and that presented by 
Sridharan et al (Sridharan et al., 2008), one could also hypothesise that the PHD proteins 
are not responsible for the DMOG induced changes in metabolism. Treatment of cells with 
second PHD inhibitor (PHD-I), failed to reproduce those effects observed by DMOG with 
respect to OCR and ATP. Other dioxygenases which are potentially inhibited by DMOG 
include FIH, JmjC domain containing protein 2A (JMJD2A), PHD finger protein 8 (PHF8) and 
γ-butyrobetaine hydroxylase (BBOX1) (Rose et al., 2011). BBOX1 is involved in carnitine 
biosynthesis and is localised to mitochondria. Inhibition of BBOX1 would result in 
decreased fatty acid metabolism (Rose et al., 2011). Possibly reducing OCR, however the 
extent to which these cells rely on fatty acid metabolism is unknown. Performing the total 
cellular ATP assay in the presence of additional fatty acid metabolism inhibitor would allow 
clarification of this. Additionally, simultaneous knockdown of each of the PHD proteins 
would be necessary to elucidate their precise role and determine the exact mechanism. 
Chemically, DMOG is an α-ketoglutarate analogue, which raises the possibility that 
interference with the TCA cycle directly may be responsible for the decrease in oxygen 
consumption rate observed in response to DMOG. To test this, we employed a second, 
none chemically related PHD inhibitor, PHD-I. Unfortunately the same phenotype was not 
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observed with this inhibitor. PHD-I did not reduced OCR, had no effect on ATP or affect 
mitochondrial membrane potential. This may suggest that DMOG is having off-target 
effects and influencing metabolism independent of the PHD proteins or HIF-1α. 
Metabolomic analysis suggests large significant decreases in cellular fumarate after 2 hours 
DMOG treatment. Decreased fumarate may be indicative of a block in the TCA cycle, 
preventing the re-synthesis of fumarate through competitive inhibition of α-ketoglutarate 
dehydrogenase. However fumarate depletion, does not affect the maintenance of ATP and 
possibly co-incidental or compensatory mechanisms are in play. However, based on the 
observations outlined above (Sridharan et al., 2007, Sridharan et al., 2008), the potential 
still exists that fumarate is being reduced at complex II and oxygen is not being consumed 
at complex IV, causing a decrease in OCR. Fumarate respiration is only likely to be used 
when respiration clamped and glycolysis is insufficient to maintain ATP levels, for example 
when DMOG treated HCT116 cells were cultured in galactose. However, in our system we 
also see a decrease in fumarate levels in glucose conditions, perhaps suggesting an 
alternative cause.  
A number of questions remain; 
(i) Why does DMOG reduce OCR in our system? 
(ii) Where is the ATP coming from to allow maintenance of levels despite 
decreased OCR? 
(iii) PHD inhibition ensures ATP is maintained by reducing turnover by inhibiting 
cardiomyocyte contraction. What is the parallel process in non-
cardiomyocytes? 
(iv) Why does PHD-I not produce the same phenotype as DMOG? 
Interestingly, significant differences were also observed in aspartate levels after DMOG 
treatment. HCT116 cells cultured in glucose-DMEM exhibited an increase in cellular 
aspartate and conversely, cells cultured in galactose demonstrated a significant decrease. 
Aspartate can be metabolised to oxaloacetate, raising the possibility that to overcome the 
block in the TCA cycle, cells are increasing their consumption of this amino acid as a 
compensatory mechanism. Valine, threonine, iso-leucine and phenylalanine all increase in 
response to DMOG treatment in those cells cultured in galactose. A hypothesis may be that 
as a consequence of a non-functional TCA cycle, metabolites that would otherwise feed the 
pathway are not necessary, present in excess and excreted. Without profiling of the 
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complete set of metabolites and understanding of the unique properties and metabolism, 
the data is hard to interpret. Additionally, the metabolomic profile of PHD-I would be 
useful to interpret these findings with DMOG to allow validation and separation of those 
metabolites which are changing as a result of PHD protein inhibition and those which 
change with DMOG alone, to delineate the PHD protein-independent effects of the 
compound. 
Future work would involve metabolomic analysis of the second PHD inhibitor to confirm 
which of the metabolite changes are common between inhibitors and to investigate the 
underlying mechanisms behind those pathways and metabolite changes. To confirm the 
predicted effect of DMOG on the TCA cycle, the transfer of reducing equivalents to the ETC 
could be measured. The intrinsic auto-fluorescent properties of the TCA cycle product, 
NADH can be exploited for this purpose. This may demonstrate that in the presence of 
DMOG, output from the TCA cycle appears to change, characterised by a decrease in 
fluorescence. This would however also be the situation if DMOG and PHD inhibition was 
directing fumarate to be used as a substrate for complex II.  
Is important to note that DMOG is the prototypical PHD inhibitor and routinely the ‘go to’ 
compound to activate the oxygen-sensing pathway. It has been used to probe the effect of 
HIF-1α on cellular function and therefore data gained using this inhibitor must be carefully 
evaluated in light of its HIF-independent effect on metabolism.  
 
3.10 Summary 
How mitochondria interface with the HIF oxygen-sensing machinery is of great interest. The 
possibility that HIF or other components of the oxygen-sensing pathway perform yet 
unidentified novel mitochondrial functions that may result in cell survival/homeostasis will 
be key to investigate and a number of important questions remain: 
(i) Is HIF-1α present within mitochondria; does it associate with any mitochondrial 
proteins what is its function? 
(ii) Would the presence of HIF-1α and HIF-1β in mitochondria affect mitochondrial 
gene expression? 
(iii) Do the PHD proteins have HIF-α-independent mitochondrial functions? 
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(iv) Should DMOG continue to be used as a tool to study the HIF/hypoxic response 
given the absence of a common metabolic phenotype with a second inhibitor 
of the PHD proteins? 
The observation that a number of key regulators of the hypoxic response associate with 
mitochondria, hopefully will ignite work and open people’s eyes toward investigating an 
alternative paradigm as to the role of HIF in hypoxia. Key details are still unknown; however 
exploration of a more direct relationship between the oxygen-sensing pathway and 
mitochondria, functioning either in the acute phase or in parallel to the traditional hypoxic 
response, would allow us to build on our initial findings. 
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4.1 Introduction 
Normoxic regulation of the HIF-α subunits (HIF-1α and HIF-2α) is under the control of the 
von Hippel-Lindau (pVHL) tumour suppressor, the protein product of the VHL gene 
(Maxwell et al., 1999). Inactivating germline mutations of the VHL gene are responsible for 
the development of visceral cysts, particularly in the kidney giving rise to VHL disease (Shen 
and Kaelin Jr, 2013). Tumours arise in VHL patients after somatic inactivation of the second 
wild type VHL allele in the susceptible cell. The aetiology of many sporadic clear cell renal 
carcinomas is also due to biallelic inactivation of the VHL tumour suppressor gene and has 
been estimated to be present in a large percentage of patients with disease (Lai et al., 
2011, Kaelin, 2008, Shen and Kaelin Jr, 2013).  
VHL is transcribed as two isoforms, derived from two in-frame initiation codons within the 
VHL gene, VHL19 and VHL30. VHL19 lacks the N-terminal acidic domain present in VHL30, 
however still serves as the recognition component of the E3-ligase machinery (Lai et al., 
2011). pVHL forms the substrate recognition and catalytic component of an E3-ligase 
complex, along with elongins B and C, RBX1 and cullin 2 functions to poly-ubiquitinate the 
HIF-α subunits targeting them for destruction by the 26S proteasome (Stebbins et al., 1999, 
Iwai et al., 1999, Maxwell et al., 1999). Studies of the VHL gene and the gene product have 
gone a long way to help understand the signalling pathways that allow cells to sense and 
respond to changes in oxygen tension (Kaelin, 2002).  
There has been much interest in uncovering protein targets of pVHL other than HIF-α and 
to date, this search has uncovered a number of candidates (Pal et al., 1997, Lai et al., 2011, 
Mukhopadhyay et al., 1997). Analysis of gene expression has identified a number of 
putative pVHL targets and an overlapping but also distinct number of genes regulated by 
pVHL and/or hypoxia (or HIF) (Kaelin, 2002, Harten et al., 2009, Jiang et al., 2003). pVHL has 
been observed to interact and suppress the SP1 transcription factor (Mukhopadhyay et al., 
1997) and bind to isoforms of atypical protein kinase C (Pal et al., 1997), fibronectin and the 
ARF tumour suppressor (Lai et al., 2011). It has also been observed to have HIF-
independent roles in the maintenance of primary cilia, control of extracellular matrix 
formation and regulation of apoptosis (Kaelin, 2008).  
pVHL has previously been described to affect mitochondrial function. pVHL-dependent 
mitochondrial effects have been demonstrated using renal carcinoma cell lines devoid of 
functional pVHL and direct comparison with stable functional wild type pVHL re-expression 
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(Hervouet et al., 2005, Hervouet et al., 2008). Hervouet et al observed that re-expression of 
pVHL increases protein expression of a number of ETC subunits, increases oxygen 
consumption and ETC enzyme activity. Re-expression of pVHL also increases mitochondrial 
DNA copy number, proposed to be via a TFAM-mediated mechanism (Hervouet et al., 
2005). A follow up study demonstrated the effects of pVHL loss could be rescued through 
simultaneous knockdown of HIF-2α in pVHL-deficient cells (Hervouet et al., 2008).  
pVHL has been demonstrated to localise to mitochondria when over-expressed (Shiao et 
al., 2000). Shiao et al observed enlarged mitochondria in the presence of wild type over-
expressed pVHL, detected using immunogold labelling and electron microscopy (Shiao et 
al., 2000). However, the immunogold signal was exclusive to the mitochondria, making the 
observations speculative, as pVHL has been shown to be mainly cytosolic, but capable of 
trafficking to the nucleus in vitro at low cell density (Lee et al., 1996). 
In order to explore the role of pVHL in the regulation of mitochondrial homeostasis, renal 
adenocarcinoma derived cell lines, devoid of functional pVHL have been widely used 
(Hervouet et al., 2005, Hervouet et al., 2008). The 786O clear cell renal cell carcinoma 
(CCRCC) cell line has a single VHL allele with a single nucleotide deletion, resulting in a 
frameshift mutation (Gnarra et al., 1994). Transfection of pVHL into these cells was 
originally demonstrated to suppress tumour formation in nude mice (Iliopoulos et al., 
1995), the first observation as to the role of pVHL in tumourigenesis. Patient derived 786O 
cells have constitutively stabilised HIF-2α and do not express HIF-1α (Maxwell et al., 1999), 
allowing elimination of confounding effects of both HIF-1α and HIF-2α stabilisation on 
interpretation of the data. pVHL re-expressing 786O cells have been vital in understanding 
the role of pVHL in oxygen-sensing and in the delineation of HIF-dependent function. In this 
work, these cells were used as a model to investigate how re-expression of functional pVHL 
(786O-VHL); with parallel control of empty pCMV vector (786O-EV), in a pVHL defective 
background affects the mitochondrial phenotype.  
Figure 4.1 demonstrates that in the 786O cells, HIF-2α protein levels are reduced to basal 
levels upon stable re-expression of functional pVHL. The 786O cell model allows 
mitochondrial function of pVHL to be assessed in the absence of the well described 
mitochondrial and metabolic actions of HIF-1α (Zhang et al., 2008, Fukuda et al., 2007, 
Papandreou et al., 2006). The 786O cells therefore provide a model by which the role of 
pVHL protein expression can be easily delineated, providing rationale for their use.  
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Figure 4.1: Re-expression of functional pVHL protein in 786O renal carcinoma cells 
reduces HIF-2α protein to basal levels. 
Western blot analysis shows 786O (786O-VHL (VHL, stably re-expressing pVHL) and 786O-
EV (EV, vector control)) cells and demonstrates the presence of stably transfected pVHL 
and the effect on the constitutive stabilisation of HIF-2α observed in the 786O-EV cells. β-
actin was used as a load control. 
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4.2 Hypothesis 
pVHL status regulates mitochondrial function.  
 
 
4.3 Aims 
1. To use matched pVHL positive and negative 786O cell lines to assess the effects of 
pVHL on mitochondrial function.  
 
2. To evaluate the effects of pVHL mutation on mitochondrial function.  
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4.4 The effect of pVHL status on the expression of nuclear and 
mitochondrially encoded electron transport chain proteins 
With respect to the relationship between pVHL and mitochondria, the most striking 
observation to date is the selective loss of mitochondrial ETC proteins in cells devoid of 
functional pVHL (Hervouet et al., 2005). Hervouet et al have observed that re-expression of 
pVHL in a pVHL defective background increases the protein expression of select ETC 
subunits (Hervouet et al., 2005).  
To confirm the role of pVHL status in regulating mitochondrial ETC protein expression, 
protein levels of key ETC subunits were assessed using SDS-PAGE and western blot analysis 
on protein samples harvested from 786O cells. Analysis demonstrated clear differences in 
protein expression of both mitochondrial and nuclear encoded subunits of complex IV 
(mtCO-2 and COX-IV) after pVHL re-expression in the 786O-VHL cells compared to the 
786O-EV cells (Figure 4.2). The protein expression of VDAC1, heat shock protein-60 (HSP60) 
and ATPB were similar in both 786O cell lines (Figure 4.2).  
Observations from figure 4.2 extend published literature (Hervouet et al., 2005, Craven et 
al., 2006, Sarto et al., 1997), which previously demonstrated decreases in the complex I 
protein, NADH-ubiquinone oxidoreductase, complex III proteins (core II, iron sulphur 
protein (ISP), ubiquinol-cytochrome c reductase complex core protein 2 and 13kDa protein) 
and ATP6, a mitochondrially encoded subunit of the FO channel of the F1FO-ATPase in cells 
devoid of pVHL when compared to cells with pVHL stable re-expression. Notably, protein 
changes in the alpha subunit of the F1-ATPase and adenine nucleotide translocase-1 (ANT1) 
were not observed (Figure 4.2)(Hervouet et al., 2005, Craven et al., 2006, Sarto et al., 
1997). Interestingly, pVHL stable re-expression appeared to increase the expression of ETC 
proteins of both nuclear and mitochondrial genetic origin, while the expression of a 
number distinct non-electron transporting mitochondrial proteins were unaffected by VHL 
status (Figure 4.2).  
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Figure 4.2: Expression of mitochondrial proteins is differentially affected by pVHL status.  
Western blot analysis of 786O-EV (EV, vector control) cells and 786O-VHL (VHL, stably re-
expressing pVHL) cells demonstrating changes in the expression of multiple complex IV 
ETC proteins (mtCO-2 and COX-IV) and absence of changes in distinct non-electron 
transporting mitochondrial proteins (VDAC, ATPB and HSP60). α-tubulin and β-actin were 
used as load controls.  
 
4.5 The effect of pVHL status on cellular bioenergetics and energy 
homeostasis 
Mitochondrial respiration is highly regulated and controls a large number of cellular 
processes, such as ion regulation and membrane potential and hence is a key controller of 
cellular homeostasis (for review see (Pesta and Gnaiger, 2012). A previous study into the 
bioenergetic role of pVHL was unable to show statistical significance when investigating the 
effect of pVHL re-expression on cellular oxygen consumption rate (OCR) in a pVHL defective 
background, however there was a trend toward an increase in OCR after wild type pVHL re-
expression in matched cells (Hervouet et al., 2005). To determine the functional effects of 
the pVHL-dependent ETC protein expression (Figure 4.2) and to further characterise any 
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mitochondrial phenotype associated with stable re-expression of pVHL in 786O cells, OCR 
was measured. 
To assess mitochondrial respiration the Oroboros O2K was used. This equipment facilitates 
closed chamber, high resolution respirometry and was used previously to characterise the 
effects of PHD inhibition on mitochondrial respiration (see chapter 3; Figure 3.19). 
Respirometry allows the measurement of oxygen dissolved in the respiration medium by 
polarographic oxygen sensors and calculation the oxygen consumed as a function of time, 
producing a rate. The O2K design allows for sequential titrations of compound to 
determine their effects on respiration and better understand ETC function (Pesta and 
Gnaiger, 2012). Careful titration of compound allows the dissection of metabolic fluxes 
with respect to in situ mitochondria and whole cellular physiology.  
To assess the role of pVHL status on cell respiration, 786O cells were trypsinised, washed, 
counted twice and re-suspended in HEPES-buffered DMEM. Using intact cells, multiple 
aspects on mitochondrial respiration were investigated. Routine respiration is supported by 
the metabolites in the cell culture media (glucose-DMEM). In 786O cells stably re-
expressing pVHL (786O-VHL) basal oxygen consumption rate was significantly higher 
compared to 786O-EV control cells (Figure 4.3A). The addition of oligomycin and inhibition 
of the F1FO-ATPase allows calculation of the leak respiration. Significant increases in leak 
respiration (non-phosphorylating respiration, mainly controlled by and compensating for 
the proton leak across the inner membrane) were observed in the 786O-VHL cells 
compared to the 786O-EV cells (Figure 4.3B). Increased leak respiration reflects that in cells 
with stable pVHL re-expression, a greater volume of total oxygen consumed is not coupled 
to ADP phosphorylation at the F1FO-ATPase. Increased leak respiration in the presence of 
pVHL is perhaps to be expected as routine respiration also increases (Figure 4.3A-B). 
Maximum respiratory capacity (after titration of FCCP) is also observed to increase in the 
presence of function pVHL protein (Figure 4.3C). Non-mitochondrial respiration was 
determined through the combined administration of rotenone and antimycin A to inhibit 
complexes I and III respectively (Figure 4.3).  
From the described parameters the respiratory flux ratios were calculated. Flux ratios are 
ratios of oxygen flux under different respiratory states, normalised for a maximum flux in a 
common reference state (normally maximum respiratory capacity). Ratios are therefore 
independent of mitochondrial content and cell size, with each experiment serving as its 
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own internal control (Pesta and Gnaiger, 2012). Routine control ratio (R/E) is defined as the 
ratio of routine respiration to maximum respiratory capacity in the non-coupled state. The 
routine control ratio is a measure of how close routine respiration operates to maximum 
respiratory capacity under the specific condition of the assay (Pesta and Gnaiger, 2012). 
There is no significant different between 786O-EV and 786O-VHL cells, suggesting they are 
both respiring at approximately 30-35% of maximum capacity (Figure 4.3D) and indicates 
no limitation in substrate oxidation in 786O-EV cells compared to 786O-VHL cells. 
The leak control ratio (L/E) is defined as the ratio of leak respiration to maximum 
respiratory capacity. It is an index of uncoupling at constant ETC capacity. L/E increases 
with uncoupling from a theoretical minimum of 0.0 for a fully coupled system, to 1.0 for a 
fully uncoupled system (Pesta and Gnaiger, 2012). In the 786O-VHL cells, the ETC functions 
as a more coupled system compared to the 786O-EV cells (Figure 4.3D).  
Net-routine control ratio (R-L)/E calculates the proportion of routine respiration that is 
being used to drive ATP synthesis corrected for maximum flux. The net-routine control 
ratio remains constant, if uncoupling is fully compensated by an increase of routine 
respiration and a constant rate of oxidative phosphorylation (OxPhos) is maintained (Pesta 
and Gnaiger, 2012). Net-routine control ratio is less in cells devoid of functional pVHL 
(786O-EV), compared to 786O cells stably re-expressing pVHL (786O-VHL), hence a smaller 
proportion of the maximum capacity was being used to drive ATP synthesis, possibly 
because of increased leak/uncoupling or less ATP demand (Figure 4.3D). A representative 
trace for the 786O cells, from the Oroboros O2K is shown in figure 4.3E.  
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Figure 4.3: pVHL status affects routine OCR and associated bioenergetic parameters.  
786O (786O-EV (EV, red) and 786O-VHL (VHL, blue)) cells were analysed using the 
Oroboros O2K, and OCR (pmol.s-1.106 cells) corrected for cell number and non-
mitochondrial respiration. (A) Graph shows stable re-expression of pVHL significantly 
increases basal OCR (** p<0.01). (B-C) Graph shows leak respiration and maximum 
respiratory capacity are significantly increased in the presence of pVHL (** p<0.01). (D) 
Graph shows bioenergetic ratios affected by pVHL status (*** p<0.01, ** p<0.01 and ns 
p>0.05). Values are mean +/- S.E.M (n=4). Data analysed using paired, two-tailed t-test. 
(E) Graph shows a representative trace of OCR using the Oroboros O2K comparing 786O-
EV (EV, red) and 786O-VHL (VHL, blue) cells. R/E = routine control ratio, L/E = leak control 
ratio and R-L/E = net-routine control ratio.  
 
In search of a potential explanation for the difference in the degree of ETC coupling in the 
presence and absence of functional pVHL, the expression levels of the uncoupling proteins 
(UCPs) were examined. UCP1 is specifically expressed in adipocytes of brown adipose tissue 
(Brand and Esteves, 2005), therefore mRNA expression of UCP2 and UCP3 was analysed 
using real time-quantitative polymerase chain reaction (RT-qPCR). A small but significant 
increase in UCP3 mRNA expression was observed in 786O-EV cells compared to 786O-VHL 
cells, which may contribute to the changes in the degree of uncoupling observed (Figure 
4.4). 
 
 
 
Figure 4.4: pVHL status affects the mRNA expression of UCP3 in 786O cells.  
Graphs show transcript analysis of (A) UCP2 and (B) UCP3 using RT-qPCR in 786O-EV (EV, 
red) and 786O-VHL (VHL, blue) cells. UCP3 expression is up-regulated in 786O-EV cells 
compared to 786O-VHL cells (* p<0.05 and ns p>0.05). Data was analysed using the 
comparative Ct method after normalisation to a single experimental repeat. Values are 
mean +/- S.E.M (n=4) and data analysed using paired, two-tailed t-test.  
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The degree to which cells rely on glycolysis for ATP production relative to their need for 
mitochondrially-generated ATP influences the extent to which cells respire and consume 
oxygen. Therefore the experiments described above (Figure 4.3) were performed in cells 
that had been cultured in glucose-free galactose media for 24 hours, as described 
previously (chapter 3). As anticipated, under galactose conditions, routine respiration 
increased due to the increased reliance on OxPhos (Figure 4.3A and Figure 4.5A; compare 
axis).  
After culture in galactose, significant increases were also observed in leak respiration and 
maximal respiratory capacity in 786O cells (Figure 4.5A-C). The trend between 786O cell 
lines was the same for flux ratios obtained in both glucose and galactose culture conditions 
(Figure 4.3D and 4.5D), however in galactose conditions a significant difference between 
786O-EV and 786O-VHL cells for leak and net-routine controls ratios was not observed 
(Figure 4.5D). pVHL status did not affect the routine control ratio in galactose, suggesting 
that both cell lines are respiring at the same fraction of their maximum capacity, correlating 
with the observation in glucose. Forcing these cells to become more oxidative does 
however decrease the difference between routine respiration and maximal respiratory 
capacity, from approximately 30-35% of maximum capacity in the glycolytic environment 
(glucose conditions) compared to 40-45% in the galactose-induced oxidative conditions 
(R/E; Figure 4.5D). This is predictable as cells are relying more heavily on their mitochondria 
for ATP production. A representative trace is shown in figure 4.5E. 
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Figure 4.5: pVHL status affects routine OCR and associated bioenergetic parameters after 
culture in galactose for 24 hours. 
786O (786O-EV (EV, red) and 786O-VHL (VHL, blue)) cells were analysed using the 
Oroboros O2K, and OCR (pmol.s-1.106 cells) corrected for cell number and non-
mitochondrial respiration. (A) Graph shows stable re-expression of pVHL significantly 
increases basal OCR (** p<0.01). (B-C) Graph shows leak respiration and maximum 
respiratory capacity are significantly increased in the presence of pVHL (* p<0.05). (D) 
Graph shows effect of pVHL status on bioenergetic ratios (ns p>0.05). Values are mean 
+/- S.E.M (n=4). Data analysed using paired, two-tailed t-test. (E) Graph shows a 
representative trace of OCR using the Oroboros O2K comparing 786O-EV (EV, red) and 
786O-VHL (VHL, blue) cells having been cultured in galactose for 24 hours. R/E = routine 
control ratio, L/E = leak control ratio and R-L/E = net-routine control ratio.  
 
To assess the consequences of pVHL status on total cellular ATP and to correlate the 
significant differences in OCR to a functional end point, cellular ATP was measured using a 
luminescent assay described previously (chapter 3). Cells were counted and suspended to 
equal concentration across lines. Assay reagent was then added and the luminescence 
measured. In the presence of functional pVHL protein there was a significant increase in 
luminescence, suggesting higher cellular ATP concentration of per cell compared to those 
cells devoid of functional pVHL (Figure 4.6A). This is potentially a consequence of the 
increase in OCR and increased expression of a number of key mitochondrial ETC complex 
proteins.   
Having observed an increase in cellular ATP levels in 786O-VHL cells compared to 786O-EV 
cell, the mechanism through which pVHL status affects the pathways of cellular ATP 
maintenance was investigated. Utilising the same luminescent assay as above, inhibitors of 
glycolysis (IAA) and OxPhos (oligomycin) were added for 30 minutes and the change in 
luminescence interpreted. As described previously (chapter 3), IAA was used to inhibit 
glycolytic and oligomycin to inhibit mitochondrial ATP synthesis. Interestingly the cells 
without functional pVHL (786O-EV) were more sensitive to oligomycin and significant 
differences were observed in luminescence after 30 minutes treatment (Figure 4.6B). 
Unlike HIF-1α, HIF-2α does not up-regulate glycolytic target genes, such as PDK and LDH 
(Hu et al., 2003). These observations reflect that, despite stabilisation and activation of HIF-
2α after loss of pVHL, the 786O-EV cells are more reliant on mitochondrially generated ATP. 
An oxidative phenotype associated 786O cells over-expressing HIF-2α has previously been 
observed (Biwas et al, 2010), where 786O cells over-expressing HIF-2α were grown as 
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xenographs and displayed a metabolic profile associated with lower glycolytic and greater 
mitochondrial metabolism (Biswas et al., 2010).  
 
 
 
Figure 4.6: pVHL status affects total cellular ATP levels and the pathways of ATP 
synthesis. 
(A) Graph shows total cell ATP content in significantly increases in 786O-VHL (VHL, blue) 
compared to 786O-EV (EV, red) (*** p<0.001). 500,000 cells/ml were counted for each 
cell line before lysis is assay reagent. Luminescence was measured after 10 minutes 
stabilisation period. Data presented is raw luminescence values of the mean of 3 well 
replicates over 3 independent experiments (n=3) +/- S.E.M and analysed using a paired, 
two-tailed t-test. (B) Graph shows pVHL status affects the contribution of the ATP 
synthetic pathways to total cell ATP. Total cell ATP assay was performed in 786O (786O-
VHL (VHL, blue) and 786O-EV (EV, red)) cells in the presence and absence of inhibitors of 
glycolysis (IAA; 1mM) and OxPhos (oligomycin; 5μg/ml) for 30 minutes. A combination of 
both inhibitors was used to determine background luminescence. Graph shows there is a 
significant difference between 786O-VHL and 786O-EV cells in the presence of oligomycin 
(*** p<0.001 and ns p>0.05). Values are mean of 3 well replicates over 3 independent 
experiments, relative to untreated control (n=3) +/- S.E.M and data analysed using a 
paired, two-tailed t-test. 
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4.6 The effect of pVHL status on mitochondrial DNA maintenance 
Each mitochondrion contains multiple copies of mitochondrial DNA, which unlike nuclear 
DNA, is continually replicated independent of cell division (Smits et al., 2010). The 
mitochondrial genome contains approximately 16,600 base pairs and in humans encodes 
proteins from four of the five respiratory complexes, a number of transfer RNAs and two 
ribosomal RNAs. Altered mitochondrial DNA copy number (the number of mitochondrial 
DNA copies per cell), can occur either through variations in biosynthesis or DNA 
maintenance. The depletion of mitochondrial DNA can produce a dysfunctional in ETC, 
involving complex I, III and IV dysfunction and has been associated with a variety of 
diseases (Venegas and Halberg, 2012, Clay Montier et al., 2009).  
Mitochondrial DNA copy number can be estimated through calculation of the ratio 
between a single copy nuclear gene, such as beta-2-microglobulin (β2M) and a region of 
the mitochondrial genome by RT-qPCR as previously described (Venegas and Halberg, 
2012). A significant increase in mitochondrial DNA copy number was observed in 786O-VHL 
cells compared to 786O-EV cells (Figure 4.7). These data suggest that there are significantly 
fewer copies of the mitochondrial genome in cells devoid of functional pVHL, a phenotype 
which could cause the reduced mitochondrial protein expression observed in these cells 
(Figure 4.2). Mitochondrial DNA copy number has previously been demonstrated to be 
reduced in the absence of functional pVHL and a reduction in the protein expression of the 
mitochondrial transcription factor A (TFAM) proposed as the mechanism (Hervouet et al., 
2005). Mitochondrial DNA content has also been demonstrated to decrease in clear cell 
renal carcinoma in tissue from patients (Simonnet et al., 2002, Selvanayagam and 
Rajaraman, 1996).  
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Figure 4.7: pVHL status affects mitochondrial DNA copy number. 
The graph shows mitochondrial DNA copy number calculated through analysis of 
expression of the single copy nuclear gene, β2M and mitochondrial ND1 by RT-qPCR. Ct 
values were obtained for gene and the ratio calculated as described (Venegas and 
Halberg, 2012). There is a significant increase in mitochondrial DNA copy number in the 
786O-VHL (VHL, blue) cells compared to the 786O-EV (EV, red) cells (** p<0.01). Values 
are mean +/- S.E.M (n=5) and data analysed using paired, two-tailed t-test.  
 
A large number of proteins are implicated in the replication, integrity and maintenance of 
the mitochondrial genome (Smits et al., 2010). The protein machinery is unique to 
mitochondria and disruptions to which are well documented through mutation analysis of 
patients with mitochondrial disease (Venegas and Halberg, 2012). Regulators of 
mitochondrial DNA maintenance include, TFAM (Ekstrand et al., 2004), the mitochondrial 
DNA helicase TWINKLE, encoded by the PEO-1 gene and the mitochondrial DNA 
polymerase gamma (POLG). Other proteins include the single stranded DNA binding protein 
(mtSSB) and a number of accessory proteins (Venegas and Halberg, 2012, Falkenberg et al., 
2007). 
To determine whether known mitochondrial regulators, such as TFAM, POLG and TWINKLE 
are altered in 786O cells, gene expression was analysed using RT-qPCR. A small but 
significant increase in TFAM expression was observed in 786O-VHL cells compared to 786O-
EV cells (Figure 4.8A), consistent with a previously reported increase in TFAM protein 
expression associated with pVHL (Hervouet et al., 2005). No differences were identified in 
the expression of PEO-1 and POLG was slightly but non-significantly increased after pVHL 
re-expression (Figure 4.8B and C). These results indicate that pVHL status affects TFAM 
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expression and highlight a mechanism through which pVHL regulates mitochondrial DNA 
copy number in the 786O cells.  
 
 
 
Figure 4.8: Effect of pVHL status on the expression of factors involved in mitochondrial 
DNA replication and maintenance. 
Graphs show relative expression of mRNA transcripts (TFAM, POLG and PEO-1) involved 
in the regulation mitochondrial DNA replication analysed using RT-qPCR. Graphs show (A) 
small significant increase in TFAM expression (** p<0.01) and (B and C) no change in PEO-
1 or POLG expression between 786O-EV (red) and 786O-VHL (blue) cells (ns p>0.05). Data 
analysed using the comparative Ct method after normalisation to a single experimental 
repeat. Values are mean +/- S.E.M (n=4-8). Data analysed using paired, two-tailed t-test.  
 
4.7 The effect of pVHL status on the control of mitochondrial biogenesis 
To further investigate how pVHL status affects mitochondria, mitochondrial mass was 
analysed in 786O cells. Mitochondrial mass can be measured using fluorescent probes and 
flow cytometric analysis, where notably, the uptake of probe is independent of 
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mitochondrial membrane potential. To analyse mitochondrial mass in 786O cells, mitoview 
green was used. Mitoview is a membrane permeable dye that binds to mitochondrial 
phospholipids and insensitive to changes in membrane potential. The major mitochondrial 
lipid is cardiolipin (CL) which composes approximately 12-20% of a mitochondrial inner 
membrane total phospholipid content (Chicco and Sparagna, 2007, Hatch, 2004). OxPhos 
complex integration and assembly is dependent on CL and as such, mitochondrial lipids are 
vital for the efficient coupling of respiration and mitochondrial function. CL is synthesised in 
and exclusive to mitochondria (Ventura-Clapier et al., 2008).  
786O cells were trypsinised, re-suspended and incubated in mitoview green for 30 minutes 
at 37°C before analysis by flow cytometry. A small shift in mitoview green fluorescence was 
observed in 786O-VHL cells compared to 786O-EV cells (Figure 4.9), suggesting an increase 
in mitochondrial mass or CL content.  
 
 
 
Figure 4.9: pVHL status affects mitochondrial mass. 
Graph shows flow cytometric analysis of mitochondrial mass analysed using mitoview 
green fluorescence. A small increase in median cell fluorescence was observed in 786O-
VHL cells (blue) compared to 786O-EV cells (red). Data presented is representative of 3 
independent experiments. Over 5000 cells were analysed per experimental repeat (n=3). 
 
Mitochondrial biogenesis is regulated by a number of transcription factors and their co-
activators, most notably the peroxisome proliferator activated receptor co-activator (PGC) 
family of proteins. These include PGC-1α and PGC-1β co-activators, which interact with a 
number of transcription factors to regulate the expression of a large number of 
mitochondrial genes (Ventura-Clapier et al., 2008). The TFAM promoter contains binding 
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sites for both the nuclear respiratory factors -1 and -2 (NRF-1 and NRF-2), which are nuclear 
encoded transcriptional factors and are among a number of proteins which are involved in 
orchestrating nuclear control of mitochondrial biogenesis. The co-activation of these 
factors by PGC-1α results in the up-regulation of mitochondrial biogenesis, a circuit highly 
active in oxidative tissue or rapidly induced in response to exercise and increased energy 
demand (Ventura-Clapier et al., 2008).  
To explore the possibility that transcriptional regulation of nuclear encoded mitochondrial 
genes is affected by pVHL status, mRNA expression of PGC-1α, PGC-1β, NRF-1 and NRF-2 
was analysed by RT-qPCR. There were no significant differences observed in either PGC-1α 
or PGC-1β expression (Figure 4.10A-B) in the presence or absence of functional pVHL 
protein in the 786O cells. Likewise, there was also no significant difference in NRF-1 or NRF-
2 expression between the 786O cell lines (Figure 4.10C-D). These data suggest that the 
changes observed in mitochondrial mass are likely not due to altered expression of 
mitochondrial transcriptional controllers.  
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Figure 4.10: pVHL status does not affect transcript expression of major regulators of 
mitochondrial biogenesis. 
(A-D) Graphs show relative expression of mRNA transcripts (PGC-1α, PGC-1α, NRF-1 and 
NRF-2) involved in mitochondrial biogenesis analysed using RT-qPCR. No significant 
difference was observed between 786O-EV (EV, red) and 786O-VHL (VHL, blue) cells. Data 
analysed using the comparative Ct method after normalisation to a single experimental 
repeat. Values are mean +/- S.E.M (n=4) and data analysed using paired, two-tailed t-test 
(p>0.05).  
 
4.8 The effect of pVHL status on mRNA expression of mitochondrially 
localised proteins 
In light of the increase in mitochondrial ETC protein expression and increased 
mitochondrial DNA copy number in the 786O-VHL cells compared to the 786O-EV cells, it is 
likely that there could also be a parallel increase in mitochondrial gene transcription. 
Although the major controllers of mitochondrial gene transcription have been assessed, 
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there are distinct mechanisms through which mitochondrial genes can be induced and 
PGC-1α is highly regulated through post-translational modifications. 
A panel of genes were selected that comprise both nuclear encoded (SDHA and COX-IV) 
and transcripts encoded by the mitochondrial genome (ND6, cytochrome b and mtCO-2). At 
least one subunit of each of the electron transporting complexes was selected for analysis. 
RT-qPCR was performed and demonstrated no significant effect of pVHL status on the 
expression of all genes analysed (Figure 4.11). Only a sample of the ETC subunits were 
analysed, however a number of the genes analysed (Figure 4.11) correlated with proteins 
previously demonstrated to be altered by pVHL status on the protein level (Figure 4.2) and 
elsewhere (Hervouet et al., 2005). Interestingly, the 786O-EV cells express mitochondrially-
derived mRNA transcripts at a similar level as the 786O-VHL cells, despite their being fewer 
copies of the genome per cell in the 786O-EV cells. Together these data suggest that a 
decrease in mRNA expression is not the causal factor for the observed difference in 
mitochondrial ETC protein expression in the 786O cells (Figure 4.2).  
 
 
 
Figure 4.11: pVHL status does not affect the transcript expression of nuclear and 
mitochondrially encoded genes. 
Graph shows relative expression of mRNA transcripts (ND6, SDHA, cytochrome b, mtCO-2 
and COX-IV) analysed using RT-qPCR. No significant difference was observed between 
786O-EV (EV, red) and 786O-VHL (VHL, blue) cells. Data analysed using the comparative 
Ct method after normalisation to a single experimental repeat. Values are mean +/- 
S.E.M (n=4-8) and data analysed using paired, two-tailed t-test (ns p>0.05).  
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4.9 The effect of pVHL status on the expression of genes involved in 
mitochondrial protein translation 
The process of ribosomal translation sits between gene transcription and protein folding 
and mitochondria contain their own machinery for the translation of mitochondrial 
genome derived transcripts. As a potential mechanism for the discrepancy between protein 
and mRNA expression of ETC complexes observed in the 786O cells (Figure 4.2 and  
Figure 4.11), the mitochondrial translational machinery was investigated. Notably, both 
proteins of mitochondrial and nuclear origin are affected by pVHL status, raising the 
possibility that synthesis of mitochondrially encoded proteins is impaired and as a 
consequence affecting the protein expression and/or turnover of those nuclear encoded. 
The pVHL-dependent change in mitochondrially encoded ETC subunits may cause 
incomplete assembly of ETC complexes and possibly increase degradation of those 
incompletely assembled. 
To investigate whether pVHL status mediates effects on the mitochondrial translational 
machinery, RT-qPCR was performed to examine the expression of key genes involved in this 
pathway. Translation initiation, involves mitochondrial initiation factors-2 (TIF2), elongation 
requires mitochondrial elongation factor-Tu (TUFM) and elongation factor G1 (GFM1). The 
final stages of termination and mitochondrial ribosomal recycling require mitochondrial 
ribosomal release factor (MRRF1) (Christian and Spremulli, 2012).  
No significant differences observed in the mRNA expression of any of the translational 
machinery analysed in the 786O cells (Figure 4.12). These data suggest that the transcript 
levels of the mitochondrial translational machinery are likely unaffected by pVHL status, 
however until the process of translation is measured, the precise effect of pVHL status on 
mitochondrial translation cannot be fully determined. 
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Figure 4.12: Effect of pVHL status on the transcript expression of major regulators of 
mitochondrial translational. 
Graphs shows relative expression of mRNA transcripts (TIF2, GFM1, TUFM and MRRF1) 
analysed using RT-qPCR. No significant difference was observed between 786O-EV (EV, 
red) and 786O-VHL (VHL, blue) cells. Data analysed using the comparative Ct method 
after normalisation to a single experimental repeat. Values are mean +/- S.E.M (n=4-8) 
and data analysed using paired, two-tailed t-test (ns p>0.05).  
 
A number of gene arrays have been generated comparing the presence and absence of 
pVHL in various renal cell backgrounds (Hervouet et al., 2008, Harten et al., 2009). Analysis 
of these micorarrays reveals an abundance of mitochondrial ribosomal protein (MRP) large 
(L) and small (S) subunits to be significantly up-regulated after re-expression of pVHL. 
Changes in mitochondrial ribosomal protein expression are subtle but remain significant at 
between a 1.2 and 2 fold induction. In 786O cells, MRPS35 (p<0.01), MRPS18C, MRPL30 
isoform A and MRPL30 isoform B (p<0.05) are all up-regulated when pVHL is re-expressed 
(Hervouet et al., 2008). In RCC10 cells with re-expression of wild type pVHL, MRPL17, 
MRPL35, MRPL42, MRPL46, MRPL50, MRPL21 and MRPS33 are all up-regulated at a 
significance of p<0.01 and an additional 19 distinct subunits at a significance of p<0.05 
(Harten et al., 2009). Therefore it was thought appropriate to validate microarray data with 
respect to the role of pVHL status in the expression of mitochondrial ribosomal subunits. 
Mitochondrial ribosomes are distinct from cytoplasmic ribosomes, they are nuclear 
encoded, imported and specific to the translation of the 13 mitochondrially encoded 
protein transcripts (O'Brien, 2003). The ribosomal genes MRPS35 and MRPL30 were 
selected for analysis on the basis of their appearance in a gene array performed in 786O 
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cells (Hervouet et al., 2008) and the remaining genes were arbitrarily selected as they were 
absent from significance in either array. Interestingly, the expression of three from seven 
mRNA transcripts were significantly decreased in the 786O-EV cells compared to the 786O-
VHL cells (Figure 4.13), two of which have been identified previously through microarray 
analyses ((Hervouet et al., 2008); Figure 4.13). These data suggests that pVHL status affects 
the expression of ribosomal subunits, an observation that correlates which the pVHL-
dependent changes in mitochondrial ETC protein expression.   
 
 
 
Figure 4.13: Effect of pVHL status on the expression of mitochondrial ribosomal subunits.  
Graph shows relative expression of mRNA transcripts (MRPS16, MRPS35, MRPL3, 
MRPL15, MRPL20, MRPL30 and MRPL32 analysed using RT-qPCR in 786O (786O-EV (EV, 
red) and 786O-VHL (VHL, blue)) cells. Data analysed using the comparative Ct method 
after normalisation to a single experimental repeat. Values are mean +/- S.E.M (n=4-8) 
and data analysed using paired, two-tailed t-test (ns p>0.05). ADDED LEGEND 
  
4.10 The effect of silencing HIF-2α on pVHL-dependent changes in 
mitochondrial ETC protein expression 
A previous report suggests silencing HIF-2α in 786O-EV cells, increases mitochondrial ETC 
protein expression (Hervouet et al., 2008). To explore the role of HIF-2α on mitochondrial 
protein expression, HIF-2α was silenced using RNA interference (RNAi) as described 
previously (Carroll and Ashcroft, 2008) and the expression of ETC proteins was examined. 
There were no observed changes in the expression level of pVHL-affected ETC proteins, 
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COX-IV and mtCO-2 in the 786O-EV cells despite effective knockdown of HIF-2α protein for 
48 hours (Figure 4.14). These data indicate that the pVHL-dependent changes in ETC 
protein expression in 786O cells are likely independent of the stabilisation and 
transcriptional activity of HIF-2α and dependent on a role of pVHL outside that of its 
negative regulation of HIF-α.  
 
 
 
Figure 4.14: Effect of HIF-2α knockdown on mitochondrial protein expression. 
Western blot analysis of ETC proteins (mtCO-2 and COX-IV) in 786O (786O-EV (EV) and 
786O-VHL (VHL) cells, in the presence of non-silencing control (NSC) siRNA or HIF-2α 
siRNA (+). α-tubulin was used as a load control. 
 
4.11 Analysis of mitochondrial parameters in pVHL positive and negative 
RCC10 cells 
To determine if the pVHL-dependent mitochondrial effects described above could be 
observed in a distinct cell line, further investigation was undertaken using RCC10 cells. 
RCC10 cells, like 786O cells are human renal carcinoma derived cells, which lack functional 
pVHL (Harten et al., 2009, Maxwell et al., 1999). In contrast to the 786O cells, RCC10 cells 
express both HIF-1α and HIF-2α subunits.  
Pooled RCC10 cell lines were previously generated that stably express wild type and mutant 
forms for the pVHL protein (Bond et al., 2011). The R200W mutation in VHL is associated 
with polycythemia and homozygotes for the mutation present with stabilised HIF-1α and 
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HIF-2α protein, elevated blood haematocrit and increases in HIF downstream targets such 
as EPO and VEGF (Hickey et al., 2007), a phenotype known as Chuvash polycythemia. There 
is a single substitution at base pair 598 which results in tryptophan to arginine change in 
the carboxyl-terminus of pVHL at codon 200 (Hickey et al., 2007). Mutations in the extreme 
C-terminal of pVHL decreases, but does not eliminate the ability of pVHL to bind and 
negatively regulate HIF-1α (Lewis and Roberts, 2003). The D126N and S183L mutations 
were identified in a single patient after sequencing of the VHL gene in a young boy (Bond et 
al., 2011). When these mutants are over-expressed in a pVHL null background they display 
an intermediate phenotype with relation to HIF-1α stabilisation and role in regulating 
metabolic function/glycolysis (Bond et al., 2011). The N78S mutation is an inactivating pVHL 
mutation; it lacks the capacity to negatively regulate HIF-1α and behaves similarly to the 
R200W mutant with respect to HIF-α induction. Unlike the 786O cells, the RCC10 express 
HIF-1α and as such distinct differences will exist between the cell lines due to the 
contribution of HIF-1α.  
Figure 4.15A demonstrates the effect of expression of pVHL mutants on the stabilisation of 
HIF-α protein subunits and downstream target (GLUT-1). Parallel analysis of the expression 
of the HIF target gene PHD3, was used as confirmation of the genotype (Figure 4.15B). 
From these four pVHL mutants, the R200W and N78S were taken forward for further study.  
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Figure 4.15: Introduction of wild type pVHL or pVHL mutants differentially affects the 
stabilisation of HIF-1α, HIF-2α protein and target gene expression. 
(A) Western blot analysis demonstrating the effect of wild type pVHL (VHL) and mutant 
pVHL (R200W, D126N, N78S, S183L) protein expression in RCC10 cells on the constitutive 
stabilisation of HIF-α (HIF-1α and HIF-2α) protein, compared to control (pCMV). α-tubulin 
was used as a load control. (B) Graph shows relative expression of HIF target gene PHD3 
analysed using RT-qPCR in cells described in A. Data analysed using the comparative Ct 
method after normalisation to a single experimental repeat. Values are mean +/- S.E.M 
(n=4) and data analysed by paired two-tailed t-test. 
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pVHL status in the 786O cells had significant effects on mitochondrial DNA content. Similar 
observations were found in the RCC10 cells (Figure 4.16). There was a significant increase in 
mitochondrial DNA copy number in RCC10-VHL cells compared with RCC10-pCMV. Despite 
stabilisation of HIF-1α and HIF-2α (Figure 4.15), expression of the R200W mutant also 
produced a significant increase in mitochondrial DNA copy number to a value comparable 
with that of wild type pVHL expression in the RCC10 cells (Figure 4.16). Stable re-expression 
of the N78S mutant in RCC10 cells produced a small and non-significant increase in 
mitochondrial DNA copy number compared to RCC10-pCMV, producing an intermediate 
phenotype (Figure 4.16). These data suggest that the pVHL-induced increase in 
mitochondrial DNA copy number is independent of HIF-1α or HIF-2α stabilisation and the 
ability of pVHL to bind and negatively regulate HIF-α.  
 
 
 
 
Figure 4.16: pVHL status affects mitochondrial DNA copy number in RCC10 cells. 
Graph shows mitochondrial DNA copy number calculated through analysis of expression 
of the single copy nuclear gene β2M and mitochondrial ND1 by RT-qPCR in control 
(pCMV), wild type pVHL (VHL) and mutant pVHL (R200W, N78S) RCC10 cells. Ct values 
were calculated for each and the difference calculated as described (Venegas and 
Halberg, 2012). There is a significant difference between the wild type pVHL and pCMV-
empty vector (** p<0.01). There are differential effects on mitochondrial DNA copy 
number dependent on the mutation in pVHL (** p<0.01, ns p>0.05). Values are mean +/- 
S.E.M (n=5). Data analysed by paired, two-tailed t-test. 
 
 
Chapter 4: The role of pVHL in the maintenance of mitochondrial homeostasis 
Page | 167  
 
Next, total cellular ATP was measured using a luminescent assay, described previously. In 
the RCC10-pCMV cells there was a significant reduction in luminescence compared to the 
RCC10-VHL cells, as observed previously in the 786O cells (Figure 4.6A), suggesting lower 
total cellular ATP concentration per cell (Figure 4.17). Correlating with the previous data, 
the RCC10-R200W mutant demonstrated a phenotype similar to re-expression of wild type 
pVHL and the RCC10-N78S mutant was more intermediate (Figure 4.17).  
 
 
 
Figure 4.17: pVHL status affects total cellular ATP levels in RCC10 cells. 
Graph shows total cellular ATP content in control (pCMV), wild type pVHL (VHL) and 
mutant pVHL (R200W, N78S) RCC10 cells. There is a significant difference between the 
luminescence generated in wild type pVHL and mutant pVHL cells (R200W and N78S) and 
that generated in the pCMV-empty vector cells (*** p<0.001). Values are mean +/- S.E.M 
(n=3). Data analysed by paired, two-tailed t-test. 
 
pVHL status was previously observed to affect protein expression of a select number of ETC 
proteins of both of nuclear and mitochondrial origin (Figure 4.2). To investigate whether 
mitochondrial ETC protein expression was also affected in RCC10 cells, protein samples 
were subject to SDS-PAGE and western blotting. In the absence of wild type pVHL, a 
reduction in both mt-CO2 and COX-IV expression was observed in the RCC10-pCMV cells 
compared to RCC10-VHL cells, correlating well with that in the 786O cells (Figure 4.18; 
lanes 1 and 2).  Additionally no differences in other mitochondrial proteins, including those 
involved in OxPhos, such as ATPB, SDHA, VDAC1 and prohibitin-1 (PHB1) were observed.  
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Intriguingly, mutant pVHL in RCC10 cells had differential effects. Analysis of the RCC10-
R200W and RCC10-D126N mutants revealed a phenotype similar to that of wild type pVHL 
expression. An increase in mtCO-2 and COX-IV expression was observed in the RCC10-
R200W and RCC10-D126N mutants compared to RCC10-pCMV cells (Figure 4.18; lanes 3 
and 4). Analysis of RCC10-N78S and RCC10-S183L demonstrate an intermediate phenotype 
between observed changes in the RCC10-pCMV and after wild type pVHL expression 
(RCC10-VHL) (Figure 4.18; lane 5).  
Together these data suggest that the changes in mitochondrial protein expression are 
independent of the stabilisation or abundance of either HIF-α subunit and that the changes 
are dependent on pVHL but not on its ability to recognise the HIF-α subunits. Consistent 
with the 786O data, re-expression of pVHL in RCC10 cells increases mitochondrial ETC 
protein expression, cellular ATP and mitochondrial DNA copy number.  
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Figure 4.18: pVHL status affects mitochondrial ETC protein expression in RCC10 cells.  
Western blot analysis of RCC10 cells expressing empty vector control (pCMV), wild type 
pVHL (VHL) or pVHL mutants (R200W, D126N, N78S and S183L) and their effect on the 
expression of mitochondrial proteins (SDHA, ATPB, VDAC1, PHB1, mtCO-2 and COX-IV). β-
actin and α-tubulin were used as load controls. 
 
4.12 Discussion 
VHL disease is an autosomal dominantly inherited, multi-system hereditary cancer 
syndrome, where affected individuals are predisposed to the development of a spectrum of 
vascularised tumours. Tumours can affect both the central nervous system in addition to 
visceral organs. The disease is the leading cause of inherited renal cell carcinoma and VHL 
mutation has been associated sporadic renal cell carcinoma, originating from the proximal 
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tubule, which are highly aggressive (Lai et al., 2011, Kaelin, 2008, Shen and Kaelin Jr, 2013, 
Simonnet et al., 2002).  
Details regarding the role of pVHL status and influence on mitochondrial homeostasis are 
still in their infancy. To date, there have been a small number of studies detailing the role 
of pVHL in mitochondrial function, all of which have focussed on renal carcinoma derived 
cells (Hervouet et al., 2005, Hervouet et al., 2008). The negative regulation of the HIF-α 
subunits by pVHL has understandably been the focus of most attention and study, however 
novel HIF-independent functions of pVHL are emerging (Li and Kim, 2011). The emerging 
evidence suggests an apparent a role for pVHL in the regulation of mitochondrial function 
(Hervouet et al., 2005, Hervouet et al., 2008, Li and Kim, 2011). However, the importance 
and biological significance of this less characterised function of pVHL remains a mystery. 
Exploring this novel aspect of pVHL function, may ultimately provide some further insight 
into the pathophysiology of renal disease.  
Loss of pVHL in CCRCC has been shown to specifically reduce the expression of a number of 
OxPhos proteins, decrease ETC complex in vitro activity and affect OCR without influencing 
membrane potential or F1-ATPase activity (Hervouet et al., 2005). A significant decrease in 
mitochondrial DNA copy number in cells and tissue has also been documented to be 
influenced by pVHL status, as has an effect on oxidative stress in vitro (Hervouet et al., 
2005, Hervouet et al., 2008). 
An interesting comparison has been made between these CCRCC and oncocytomas 
(Simonnet et al., 2002). In CCRCC, observations suggest that OxPhos and mitochondrial 
impairments are increased in parallel with the tumour aggressiveness; however 
oncocytomas, which originate in the renal collecting duct, rarely cause metastatic disease 
and interestingly have increased mitochondrial density and DNA content. This has led to 
the hypothesis that a down-regulation of OxPhos enables a growth advantage and 
increased ability to metastasise (Simonnet et al., 2002). It would be interesting to explore 
the role of proliferating versus metastatic cancer cell phenotype in terms of mitochondrial 
characteristics and function, whether manipulation of epithelial to mesenchymal transition 
(EMT) state would affect mitochondrial function, morphology or bioenergetics. 
Alternatively, it would be interesting to assess whether modulation of mitochondrial 
function can promote or inhibit the metastatic potential or the proliferative capacity of 
cancer cells.  
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In this work we aimed to link previous observations relating to the role of pVHL (Hervouet 
et al., 2005, Hervouet et al., 2008, Craven et al., 2006) and to further explore a potential 
mechanism behind the effects on mitochondrial ETC protein expression, bioenergetics and 
mitochondrial DNA maintenance. Through expression of wild type pVHL and pVHL mutants 
and detailed investigation into a broad range of parameters that relate to mitochondrial 
function, in this chapter we have observed a number of novel functions relating to the role 
of pVHL in modulating mitochondrial homeostasis.  
4.12.1 pVHL re-expression affects the expression of mitochondrially and nuclear encoded 
ETC proteins 
Here, we observed a decrease in the expression of number of integral mitochondrial 
proteins in renal carcinoma cell lines devoid of pVHL function compared with cells stably re-
expressing pVHL. Most notably was reduced protein expression of mtCO-2 and COX-IV. This 
is in addition to published observations that ISP, core II and 13kDa protein of complex III 
and ATP6 are also decreased in cells devoid of pVHL function. F1-ATPase-α and F1-ATPase-β 
however, were not affected and expressed at similar levels irrespective of pVHL status 
(Hervouet et al., 2005). A second proteomic study, in UMRC2 cells with stable pVHL re-
expression, also identified increases in ubiquinol-cytochrome c reductase complex core 
protein 2 of complex III and identified effects on complex I (Craven et al., 2006). A full list of 
mitochondrial ETC proteins identified as changing in a pVHL-dependent manner identified 
in cell culture is included in the table below (Table 5).   
Alterations in protein expression appeared to be limited to those proteins involved in 
electron transport, while the expression of proteins with functions outside the ETC 
appeared not to change in the 786O cells. HSP60, VDAC1 and PHB1 proteins are all 
expressed at comparable levels and not affected by pVHL status. Published observations 
also suggest that adenine nucleotide translocase (ANT) expression is also maintained in the 
presence and absence of pVHL (Hervouet et al., 2005). Collectively these observations raise 
the question as to why a select number of ETC proteins are decreased in the absence of 
functional pVHL compared to its re-expression. A more substantial proteomic approach of 
mitochondrial proteins would be beneficial in determining the full complement of affected 
proteins and ETC complexes to aid in the elucidation of a potential mechanism. 
Interestingly, the alterations in protein expression comprise elements which are both 
mitochondrially and nuclear encoded, and all ETC complexes identified with alterations in 
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protein expression contain elements that are mitochondrially encoded. Complex II, of 
which all four subunits are nuclear encoded, was interestingly not measured in all 
published analyses (Hervouet et al., 2005, Hervouet et al., 2008, Craven et al., 2006, Sarto 
et al., 1997) and does not change in the RCC10 cells (Figure 4.18). The data presented here 
with respect to the effect of pVHL status on ETC protein expression correlates well with 
previous observations (Hervouet et al., 2005), and indicating the data is robust and 
reproducible.  
Complex Protein 
Genetic 
origin 
Change in expression after 
stable pVHL re-
introduction 
Ref. 
I 
NADH-ubiquinone oxidoreductase 24 kDa 
(NDUFV2) 
Nuc Increased 
(Sarto et 
al., 1997) 
 
I 
NADH-ubiquinone oxidoreductase 39 kDa 
(NDUFA9) 
Nuc 
No change (cells) 
increased (tissue) 
(Craven et 
al., 2006) 
     
III 
Ubiquinol cytochrome c reductase core protein 2 
(UQCRC2) 
Nuc Increased 
(Craven et 
al., 2006) 
 
III 
Ubiquinol cytochrome c reductase core protein 1 
(UQCRC1) 
Nuc Increased 
(Craven et 
al., 2006) 
 
III 13kDa protein Nuc Increased 
(Hervouet 
et al., 2005) 
 
III Core II Nuc Increased 
(Hervouet 
et al., 2005) 
 
III Iron sulphur protein (ISP) Nuc Increased 
(Hervouet 
et al., 2005) 
     
IV Cytochrome c oxidase subunit 2 (mtCO-2) Mito Increased 
(Hervouet 
et al., 2005) 
 
IV Cytochrome c oxidase subunit 4 (COX-IV) Nuc Increased 
(Hervouet 
et al., 2005) 
     
V ATP synthase, FO subunit 6 (ATP6) Mito Increased 
(Hervouet 
et al., 2005) 
 
V 
ATP synthase, mitochondrial F1 complex, alpha 
(ATP5A) 
Nuc No change 
(Hervouet 
et al., 2005) 
 
V 
ATP synthase, mitochondrial F1 complex, beta 
(ATP5B) 
Nuc No change 
(Hervouet 
et al., 2005) 
     
 
Table 5: Effects of pVHL re-expression on mitochondrial protein expression in renal 
carcinoma cells. 
Table detailing the protein, genetic origin and change in response to pVHL re-expression. 
The re-expression of pVHL has been identified in a number of proteomic and biochemical 
analyses to affect mitochondrially localised proteins of both nuclear (Nuc) and 
mitochondrial (Mito) origin. References are indicated. 
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Analysis of ETC complex assembly would be necessary to determine if the pVHL-dependent 
change in mitochondrial protein abundance is paralleled by a reduction in OxPhos protein 
assembly. Blue-native poly acrylamide gel electrophoresis (BN-PAGE) is a tool that allows 
protein complexes to be separated in their native conformation. This also allows separation 
of respiratory super-complexes and identifies failures in complex synthesis and/or 
assembly. BN-PAGE would be beneficial not only to determine if the decreased expression 
of the ETC proteins correlates with reduced complex assembly, but also using this same 
approach, in-gel activity assays could be undertaken investigate the specific activities of 
each complex. As a comparable and/or complementary approach, spectrophotometric 
assays could be performed to measure the activity of each ETC complex, using a 
combination of substrates and inhibitors of each complex.  
Being the principal negative regulator of HIF-α subunits, pVHL governs the cellular 
abundance of stabilised HIF-1α and activity of the HIF complex, thus indirectly controls 
target gene expression. 786O cells express HIF-2α only and loss of pVHL in these cells leads 
to constitutively stabilised and active HIF-2α. Differences observed after pVHL re-
expression need first to be interpreted in relation to their HIF-α status in order to 
determine the potential involvement of stabilised HIF-α (HIF-1α and/or HIF-2α). Thus for 
the 786O cell system differences in mitochondrial parameters described in this chapter are 
independent of any role of HIF-1α and only consideration of stabilised and transcriptionally 
active HIF-2α is necessary. A previous report suggests that silencing of HIF-2α in 786O-EV 
cells increases ETC protein expression in 786O cells, but not to the same degree of 
expression as observed after pVHL re-expression (Hervouet et al., 2008). Data from 
Hervouet et al, suggests the increase in ROS observed in 786O-EV cells and the HIF-2α-
dependent expression of manganese superoxide dismutase (Mn-SOD), increases 
mitochondrial H2O2 and propose this increase in oxidative stress is responsible for the 
reduction in complex protein expression (Hervouet et al., 2008). Our studies failed to 
confirm the observations by Hervouet et al. After silencing of HIF-2α in 786O-EV cells, we 
observed no change in mitochondrial protein expression, indicating that the effects on 
mitochondrial ETC protein expression are mediated through pVHL-dependent, HIF-2α-
independent processes. Additionally, the incubation of these cells over night with the 
antioxidant N-acetyl cysteine fails to rescue the decrease in ETC proteins in the 786O-EV 
cells (data not shown), suggesting that increased oxidative stress (ROS) produced in the 
786O-EV cells is likely not responsible for the effects of pVHL on mitochondrial ETC protein 
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expression observed. Finally, data obtained in pVHL mutant expressing cells, particularly 
RCC10-R200W cells, suggest that despite the presence of constitutively stabilised HIF-2α in 
these cells compared to cells re-expressing wild type pVHL (RCC10-VHL) there was no 
difference on their respective ability to effect mitochondrial protein expression. 
A striking observation from the changes in protein abundance between the pVHL positive 
and negative cell lines is that ETC proteins of both nuclear and mitochondrial origin were 
affected by pVHL status. Since the control of mitochondrial genome transcription is distinct 
from cellular control of nuclear transcription, it is likely that the change of protein 
expression is happening post-transcriptionally or from alterations in mitochondrial 
DNA/RNA processing. Approaches were first used to fully characterise the mitochondrial 
phenotype, understand how the alterations in protein expression affected function and 
attempts made to correlate these with pVHL status.  
4.12.2 pVHL re-expression affects mitochondrial bioenergetics and cellular energy 
processing 
The reduced mitochondrial respiration in the 786O-EV cells compared to the 786O-VHL 
cells is likely a function of reduced ETC protein expression. In this chapter we have 
demonstrated a significant increase in OCR when pVHL is re-expressed in 786O cells. This 
correlates with significant increases in leak respiration and maximum respiratory capacity 
in the 786O-VHL cells. The increased OCR in 786O-VHL cells is maintained under galactose-
induced oxidative conditions. Determination of the flux ratios allows interpretation of more 
subtle effects on bioenergetics. Under both glucose and galactose conditions, independent 
of pVHL status, cells were respiring at a similar proportion of their theoretical maximum 
rate, as ascertained by the routine control ratio. In galactose, as predicted respiration was 
slightly closer to the maximum capacity. The coupling of the ETC appears to significantly 
increase in the presence of pVHL determined by the leak control ratio. The biological 
significance of this however is less clear.  
Analysis of mRNA transcripts of the UCPs demonstrates a significant up-regulation of UCP3 
expression in the 786O-EV cells compared to the 786O-VHL cells, possibly promoting an 
uncoupling effect. However, evidence suggests that these channels only promote proton 
conductance in the presence of specific activators (Brand and Esteves, 2005). Hence UCPs 
catalyse only an inducible proton conductance and notably fatty acids and products of ROS 
metabolism have been observed to activate the channels (Brand and Esteves, 2005). We 
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and others (Hervouet et al., 2008) have observed mitochondrial oxidative stress to be 
increased in the absence of pVHL in 786O cells (data not shown) and activation of UCPs 
could potentially be a mechanism to promote uncoupling and function to reduce 
superoxide production. Increased uncoupling would attenuate mitochondrial ROS and 
protect cells from reactive species induced damage (Brand and Esteves, 2005). The net-
routine control ratio estimates the proportion of the maximum capacity coupled to ATP 
synthesis. The net-routine control ratio is reduced in the absence of pVHL function and may 
be suggestive of a number of cellular characteristics, potentially less ATP demand or as a 
consequence of uncoupling. The differences in ratios are small and biological significance 
needs to be carefully interpreted and more data necessary to draw solid conclusions.  
A biological consequence of the significant increase in OCR and ETC protein expression in 
the 786O-VHL cells compared to the 786O-EV cells is an augmentation in cellular ATP levels. 
786O-VHL cells have a greater cellular concentration of ATP, a phenotype mimicked in the 
RCC10-VHL cells. The energetic profile of the RCC10 cells demonstrates a parallel 
relationship with respect to the role of pVHL status on cellular ATP levels and as observed 
in the 786O cells, re-expression of pVHL increases total cellular ATP. Initial characterisation 
of the bioenergetics in the RCC10 cells also reveals parallel observations and increased OCR 
after wild type pVHL re-expression. This confirms a pVHL-dependent, HIF-1α-independent 
mechanism controlling the OCR phenotype. Interestingly, the RCC10-R200W mutant has an 
equivalent cellular concentration of ATP as wild type RCC10-VHL and preliminary 
investigation of bioenergetics reveals comparable rates of respiration. The RCC10-N78S 
mutant has a total cellular ATP intermediate between RCC10-pCMV and wild type pVHL 
expression. The pathway through which this ATP is produced is to date unknown. However 
with the constitutively stabilised HIF-1α in these two mutant lines, and high levels of 
glycolysis would be predicted to be a contributory factor.  
Interestingly, despite 786O-VHL cells consuming more oxygen, as a proportion of their 
basal ATP concentration, these cells are slightly, but significantly less reliant of OxPhos for 
ATP synthesis compared to the 786O-EV cells. Conversely, 786O-EV cells are slightly but 
significantly more reliant on OxPhos for biosynthesis of ATP, demonstrated by their 
increased sensitivity to oligomycin. This has been observed elsewhere in tumour 
xenographs using the same cell line devoid of functional pVHL and with constitutively 
stabilised HIF-2α (Biswas et al., 2010). HIF-2α over-expressing xenographs displayed a 
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metabolic profile associated with lower glycolytic and greater mitochondrial metabolism 
and perhaps greater tolerance to mitochondrial ROS-dependent damage (Biswas et al., 
2010).  
Further experiments using the Oroboros O2K would be worthwhile. Permeabilisation of the 
cells and treatment with exogenous respiratory substrates would allow further analysis of 
respiration. Using a combination of glutamate, malate, pyruvate and succinate and 
inhibitors of complexes I and II (rotenone and malonate) it would be possible to determine 
the contribution of complexes I and II to ADP-stimulated respiration. Inhibition at complex 
III and addition of ascorbate and N,N,N',N'-tetramethyl-p-phenylenediamine 
dihydrochloride (TMPD) would allow complex IV activity to be analysed in isolation. The 
experimental protocol could also be extended to using isolated mitochondria, whereby the 
metabolism of saturating exogenous substrates could be assessed in the absence of extra-
mitochondrial control and regulation. This would allow the precise mitochondrial 
bioenergetic phenotype to be assessed in detail. Spectrophotometric assays have been 
performed in the presence and absence of pVHL with reference to citrate synthase and 
succinate cytochrome c reductase. Interestingly, there was no change in citrate synthase 
activity after the re-expression of pVHL; this is normally used as an indicator of 
mitochondrial number, however a significant reduction in succinate cytochrome c 
reductase activity, a measure of combined activity of complexes II and III was observed. 
The ATP hydrolysis of the F1-ATPase does not change after pVHL re-expression (Hervouet et 
al., 2005). These data suggest that minimal/absent deficit in TCA cycle function and down-
regulation of OxPhos in cells devoid of functional pVHL.  
4.12.3 pVHL re-expression affects mitochondrial DNA maintenance  
Mitochondrial DNA copy number is a measure of mitochondrial DNA content. 
Mitochondrial DNA content has been quantified in a number of tumours and decreases 
have been observed in breast, prostate, hepatocellular and gastric tumours (Chandra and 
Singh, 2011). Decreased mitochondrial DNA copy number in tumours has been associated 
with increased invasiveness and high-grade aggressive disease in a number of situations 
(Chandra and Singh, 2011, Simonnet et al., 2002). Conversely, increased mitochondrial DNA 
copy number and bioenergetic function have been associated with increased invasiveness 
of oesophageal squamous cell carcinoma cells (Lin et al., 2012, Mambo et al., 2005). Hence 
the story of mitochondrial function and relation to tumour progression is complex. 
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A previous study along with observations from our own laboratory (Figure 4.7 and  
Figure 4.16) suggest that mitochondrial DNA copy number is reduced in the absence of 
functional pVHL in renal carcinoma cell lines (Hervouet et al., 2005). A reduced 
mitochondrial DNA copy number implies there is a lower number of copies of the 
mitochondrial genome per cell, however usually does not provide any information on the 
number of the copies of the mitochondrial genome per mitochondria, i.e. no relationship 
with mitochondrial mass. Additionally, the organisation of DNA molecules remains 
unknown and analysis of nucleoid DNA content and cellular distribution may reveal 
additional insight into pVHL-dependent effects on mitochondrial DNA maintenance.  
The RCC10 cells again display parallel characteristics with respect to the 786O cells and 
mitochondrial DNA copy number. Re-expression of wild type pVHL (RCC10-VHL) 
significantly increases mitochondrial DNA copy number compared to RCC10-pCMV. RCC10-
R200W mutation retains a mitochondrial DNA copy number similar to that of wild type 
pVHL, consistent with the results for ATP, ETC protein expression and preliminary 
respirometry. The RCC10-N78S mutant reproducibly displays an intermediate phenotype, 
again consistent with results for ATP and early respirometry data. 
Further investigation into the role of pVHL in the maintenance of mitochondrial DNA may 
be informative. In addition to studies on mitochondrial DNA organisation and localisation, 
depletion of mitochondrial DNA using ethidium bromide and tracking rate of re-population 
could reveal insights into the role of pVHL in mitochondrial DNA replication.  
Despite this change in mitochondrial DNA copy number, observations suggest that 
mitochondrially encoded transcripts can be maintained in the 786O-EV cells.  The mRNA 
expression of the mitochondrial transcription factor TFAM is significantly reduced in 786O-
EV cells compared with 786O-VHL cells. Transcript expression of neither POLG nor PEO-1 
was affected by VHL status. TFAM has been linked to mitochondrial genome maintenance 
and levels of TFAM protein have been observed to be proportional to the quantity of 
mitochondrial DNA present (Ekstrand et al., 2004, Campbell et al., 2012). Therefore, the 
lower mitochondrial DNA copy number observed in the 786O-EV cells compared with the 
786O-VHL cells could be a result of a correlative lower level of the TFAM transcript 
(Hervouet et al., 2005). However, the mechanism underlying how pVHL affects TFAM 
expression remains to be investigated. It has been observed that TFAM over-expression in 
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mice results in an increase in mitochondrial DNA copy number, but changes to 
mitochondrial mass and respiratory chain are not observed. This suggests a separable role 
for TFAM in regulation of biogenesis/transcript expression versus mitochondrial DNA copy 
number/mitochondrial DNA replication, and highlights that mitochondrial DNA copy 
number changes do not always directly relate to  changes in mitochondrial activity 
(Falkenberg et al., 2007, Ekstrand et al., 2004). 
TFAM mRNA expression is regulated via PGC-1α. PGC-1α lacks DNA binding capacity but 
interacts and co-activates a number of transcription factors, including the nuclear 
respiratory factors (NRFs) (Ventura-Clapier et al., 2008). The NRFs are a family of 
transcription factors, linked to the transcriptional control of many mitochondrial genes 
(Scarpulla, 2008). However there are no changes in the expression of these factors 
observed after transcript analysis in the 786O cells. 
PGC-1α has been explored in a number of situations relating to its role in renal carcinoma 
and to date, through microarray, serial analysis of gene expression (SAGE) and direct RT-
qPCR, changes in its expression have failed to be identified (Hervouet et al., 2005). 
However, PGC-1α is heavily post-translationally modified by number of proteins including 
p38MAPK, AMPK and SIRT1 (Ventura-Clapier et al., 2008, Fernandez-Marcos and Auwerx, 
2011), giving rise to the possibility that since activity is not necessary regulated on the level 
of mRNA or protein expression, that changes in PGC-1α post-translational modification 
could potentially be playing a role. TFAM is among a number of PGC-1α targets that change 
with loss of pVHL. MFN1, MRPS35 and OPA-1 are also targets which we have observed 
change either on the transcript or protein level in pVHL positive and negative cells. 
However, our analysis of the expression of other PGC-1α genes, such as PEO-1 and SDHA 
showed they were not affected by pVHL status change, making a conclusion as to the role 
of co-activation difficult.  
To understand the role of PGC-1α and its activation status, a larger number of target genes 
would need to be analysed (Yao et al., 2013). The Mitocarte database (Broad Institute; 
(Pagliarini et al., 2008)) holds information on the degree of PGC-1α-dependent induction of 
mitochondrial proteins, after PGC-1α over-expression. The Mitocarte database can be used 
to cross reference changes observed in a number of analysed transcripts with the degree of 
induction by PGC-1α, to possibly delineate any relationship. 
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The expression of PGC-1β was also not significantly affected by VHL status. PGC-1β 
expression is under the control of c-MYC, and loss of PGC-1β has been observed to reduce 
respiration in pVHL-deficient renal cells that express HIF-1α (Zhang, 2007). However 
despite HIF-2α having been shown to activate c-MYC (Gordan et al., 2007), there is no 
difference in the expression of this co-activator across the 786O cells.  Collectively, these 
observations suggest that in the absence of pVHL, constitutively stabilised HIF-2α is not 
affecting c-MYC-dependent PGC-1β activity.  
4.12.4 pVHL re-expression affects nuclear and mitochondrial transcription and 
translation  
As discussed above, regulation of the PGC family of co-activators occurs mainly on the post-
translational level, therefore we explored the possibility that the observed pVHL-
dependent changes in ETC protein levels was occurring upstream of protein expression. To 
determine that the decreased mitochondrial protein expression observed in the 786O-EV 
cells compared to the 786O-VHL cells was potentially a result of reduced gene 
transcription, RT-qPCR was performed. Genes encoding at least one protein of each ETC 
complex was analysed in addition to genes transcribed from both mitochondrial and 
nuclear genomes. There were no significant differences observed, suggesting a post-
transcriptional mechanism. Despite the decreases in protein abundance of mtCO-2 and 
COX-IV, their mRNA was expressed at similar levels between cell lines.  
Since there was no significant alteration in ETC gene transcription between cell lines and in 
search of a mechanism responsible for the observed deficiencies in ETC protein expression 
in the absence of pVHL protein in 786O cells, the mitochondrial translational machinery 
was investigated. As mitochondria contain their own distinct equipment for translation, 
including a discrete set of ribosomes (Christian and Spremulli, 2012) and a large spectrum 
of clinical presentations and cellular phenotype have been documented relating to 
dysfunction in these processes (Rötig, 2011), investigation seemed appropriate. 
Deficiencies in the synthesis of mitochondrially encoded proteins may lead to mis-assembly 
and/or deficiency in assembly of ETC holoenzymes and increased turnover of other 
subunits, as observed elsewhere (Fernández-Vizarra et al., 2009), hence why changes in 
nuclear encoded proteins may also be observed. There are distinct phases to mitochondrial 
translation and genes encoding the auxiliary factors involved in each process were selected 
to study. Translation begins with initiation, whereby the start site on the mRNA is selected 
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and the initiator methionine-tRNA occupies the p-site of the ribosome. Translation 
initiation involves mitochondrial initiation factors-2 and -3 (TIF2 and TIF3). Elongation 
involves mitochondrial elongation factor-Tu (TUFM), elongation factor-Ts (TSFM) and 
elongation factors G1 and G2 (GFM1 and GFM2) which are responsible for directing the 
sequential additions of amino acids to the growing polypeptide, corresponding to the 
specific codons in the mRNA transcript. The final stages are translational termination and 
mitochondrial ribosomal recycling. It is during these phases, the full-length polypeptide is 
released and ribosomes are disassembled, mitochondrial ribosomal release factor (MRRF1) 
is involved at this stage (Christian and Spremulli, 2012). Analysis of transcript expression of 
these auxiliary factors revealed no significant difference between the 786O-VHL and 786O-
EV cells, indicating that pVHL status has no effect on the expression of the mitochondrial 
translational machinery. However this analysis is limited to those transcripts analysed and 
is not evidence of the translational process being functional.  
In this chapter we have also investigated the effects on the transcript levels of 
mitochondrial ribosomes. Mitochondria contain a discrete set of ribosomes, distinct from 
that in the cytoplasm. These are responsible for the translation of mRNA transcripts 
derived from mitochondrial DNA and could potentially be a factor in the discrepancy 
between protein and transcript expression observed in mitochondrial ETC subunits in the 
presence and absence of pVHL. Ribosomal proteins are themselves nuclear encoded and 
differ in their RNA content and physical properties to cytoplasmic ribosomes (O'Brien, 
2003). In this chapter, we have observed significant alterations the expression of a number 
of mitochondrial ribosomal protein subunits, including MRPS35, MRPL3 and MRPL30. These 
findings are consistent with data obtained from SAGE analyses and micro-arrays detailing 
the effects of pVHL re-expression in renal carcinoma cells (Harten et al., 2009, Jiang et al., 
2003, Hervouet et al., 2008). There are at least 78 proteins that compose the mitochondrial 
ribosomes, organised in to small (28S) and large (39S) subunits and clearly analysis of them 
all would require a high through-put method.  
Analysis of mitochondrial ribosome assembly may however reveal the global and cellular 
effects of alterations in expression and clearly confirmation of corresponding changes in 
protein expression need to be determined. Interestingly, a number of mitochondrial 
ribosomal proteins also have a distinct moonlighting roles and involvement in cellular 
processes distinct from structural regulation of mitochondrial translation. MRPS29, also 
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known as death associated protein-3 (DAP3) has been observed to be involved in apoptosis 
and (Koc et al., 2001). Mutations have also been documented in a number of these 
proteins, including MRPL3, which presented as mitochondrial cardiomyopathy, associated 
with decreased ETC activity, ETC protein expression and complex assembly (Galmiche et al., 
2011).  
In vitro mitochondrial translation assays would be necessary to determine the exact effects 
of loss of pVHL on mitochondrial translation. At this stage, this analysis is outside the scope 
of this thesis. However, using chloramphenicol to inhibit mitochondrial protein translation 
would be a preliminary experiment to determine if the effects of pVHL re-expression could 
be related to mitochondrial protein translation. 
4.12.5 pVHL re-expression affects mitochondrial biogenesis 
4.12.5.1 pVHL status affects mitochondrial mass 
In this chapter we have also observed mitochondrial mass to be altered in a manner 
dependent on pVHL status; the significance of this difference is however difficult to 
interpret, as the assay is limited by the absence of an independent positive control. 
However, it can be concluded that the re-expression of pVHL increased median cell 
fluorescence as detected by mitoview green staining and flow cytometric analysis. The 
uptake of mitoview green is independent of mitochondrial membrane potential as it binds 
lipids in the mitochondrial membrane. This observation is intriguing as a decrease in 
mitochondrial mass would likely explain the decrease in OCR, simply because there is a 
smaller mitochondrial density, but cannot explain the difference between mitochondrial 
protein and mRNA expression or the fact that some mitochondrial proteins are significantly 
affected by pVHL status while others are not. Additionally, there are similar levels of VDAC1 
and other integral mitochondrial proteins across the cell lines, which are often and 
justifiably used as markers for mitochondrial load in a number of assays. Finally, there is a 
documented maintenance of citrate synthase activity between the cell lines, often used as 
a measure and control for mitochondrial abundance (Hervouet et al., 2005).  
Mitoview green, however does not directly measure mitochondrial number or amount and 
hence mitochondrial mass per se, but mitochondrial lipid content. It would be appropriate 
to repeat the mitochondrial mass experiments using the well characterised generic nonyl 
acridine orange (NAO). When a single molecule of CL is excited at 488nm it emits a green 
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fluorescence which is typically measured and reported as a measure of mitochondrial mass. 
However, it has been observed that two molecules of NAO can bind one molecule of CL 
which results in a red fluorescence, when excited under the same conditions. This red 
fluorescence has been demonstrated to be a more accurate indicator of the true CL 
content of a cell as it is a function of the unusual diacidic nature of CL compared to other 
lipids. Menadione could be used as a positive control as it has been shown to decrease CL 
content through the production of ROS (Davis, 2002, Garcia Fernandez et al., 2004). There 
is however still confusion over whether the uptake and distribution of NAO is truly 
membrane potential independent (Jacobson et al., 2002) and therefore results must be 
carefully considered and if differences are present, full lipid analysis by mass 
spectrophotometry (MS) or radio-labelled phosphorous may be appropriate. Even analysis 
using NAO in fixed cells by flow cytometry would perhaps be worthwhile to pursue in 
future experiments.  
The number and characteristics of the mitochondrial proteins affected raises the question 
of whether the lipid composition of the inner membrane is affected by pVHL status. The 
expression of proteins that comprise the F1-ATPase complex do not change in the absence 
of pVHL, yet this is a component of the OxPhos machinery and the ATP6 subunit protein 
expression does change. The F1-ATPase can however exist as a separate entity, detached 
from the channel and has even been shown to be present outside the mitochondria and 
potentially moonlights as a cell surface receptor for apolipoprotein A1 and angiostatin 
among other ligands (Champagne et al., 2006).  
Other proteins investigated are not inner membrane associated, such as VDAC1, which is 
outer membrane, PHB1 and HSP60. To explore the possibility that the changes in protein 
expression in the OxPhos subunits are related to inner membrane integrity or composition, 
distinct proteins of the mitochondrial inner membrane need to be explored, TIMM10, a 
translocase of the mitochondrial inner membrane for example. Published data also 
suggests that ANT1, the inner membrane translocase is unaffected through pVHL re-
expression (Hervouet et al., 2005). It may however be the role of CL in the organisation and 
assembly of higher order oligomeric complexes and super complexes, that is responsible 
for the ETC protein differences between pVHL positive and pVHL negative cell lines (Wittig 
and Schägger, 2009). 
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4.12.5.2 Potential role of cardiolipin in the expression of ETC protein expression 
CL is an interesting and unique tetra-acyl phospholipid that is unique to mitochondria 
composing approximately 12-20% of a mitochondrial inner membrane total lipid content 
(Chicco and Sparagna, 2007, Hatch, 2004). To date there is no data directly linking pVHL 
with the synthesis or maintenance of CL and initial characterisation of the role of pVHL on 
transcript expression of enzymes involved in the synthesis of CL gave no significant results 
(data not shown). There are however striking similarities between defects in the CL 
synthetic pathway in yeast and the phenotype we observe with loss of pVHL in the 786O 
cells. Genetic loss of phosphatidylglycerophosphate synthase (PGS1) in yeast, which gives 
rise to loss of phospatidylglycerol and CL causes translational defects whereby proteins of 
nuclear and mitochondrially encoded subunits of complex IV fail to be translated. This was 
associated with changes in mitochondrial morphology, failure to grow on non-fermentable 
carbon sources and eventually loss of mitochondrial DNA (Ostrander et al., 2001). A later 
study using mitochondrially targeted GFP fused to the COX4 promoter and re-introduction 
of PGS1 led to translation of the COX4-mt GFP suggesting that restoration of mitochondrial 
lipid restores translation (Su and Dowhan, 2006). There are also similarities with Chinese 
hamster ovary (CHO) mutant cells deficient for CL. Intracellular ATP was reduced, as was 
oxygen consumption and complex I activity (Ohtsuka et al., 1993). Other complex activities 
were however not significantly modified.  
CL is required for proper assembly of respiratory super-complexes and their insertion into 
the membrane. Defects in cardiolipin synthesis or remodelling, as in the case of Barth 
syndrome and tafazzin mutation, levels of individual complexes are affected as well as 
super-complexes, affecting the efficient coupling between complexes of the ETC (Gonzalvez 
et al., 2013).  Native page would again be useful here to determine if complex and higher-
order super-complex assembly of the ETC proteins is affected in addition to their individual 
protein subunits in the 786O cells.  
4.12.6 pVHL and the ECV E3-ligase complex: Mechanism behind the differential effects of 
pVHL mutants on mitochondria? 
Data obtained in RCC10 cells expressing wild type pVHL and a panel of pVHL mutants 
revealed a number of interesting insights into the potential mechanism behind the role of 
pVHL in mediating the mitochondrial ETC protein expression phenotype described in this 
chapter. Reassuringly there was a direct correlation between the observations in 786O cells 
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and those in the RCC10 cells. In both lines, the expression of COX-IV and mtCO-2 proteins 
were higher in pVHL positive compared to pVHL negative cells while expression of VDAC1 
and ATPB proteins were unaffected by pVHL status. Additionally, in the RCC10 cells there 
was no difference observed in the expression of either SDHA or PHB1 proteins across wild 
type and mutant pVHL cell lines.  
Stabilised HIF-2α and downstream target expression has been proposed as the mechanism 
behind the selective loss of mitochondrial ETC proteins (Hervouet et al., 2008). Intriguingly 
however, here we found that despite constitutively stabilised HIF-2α in the RCC10-R200W 
mutant, the phenotype is highly representative of that observed after wild type pVHL 
expression in both the 786O and RCC10 cell lines (Figure 4.18). The RCC10-R200W mutant 
is deficient with respect to HIF-α binding capacity (Hickey et al., 2007), however we still 
observed ETC protein expression at levels equivalent to that of wild type pVHL. The RCC10-
N78S mutation gave rise to an intermediate phenotype. COX-IV and mtCO-2 protein levels 
were between that that of RCC10-pCMV and RCC10-VHL cells, while the levels of ATPB and 
VDAC1 proteins were unaffected. There are also intriguing distinctions after the 
introduction of RCC10-D126N and RCC10-S183L mutants, with the former behaving as 
RCC10-R200W and wild type pVHL and the latter giving rise to a phenotype similar to 
RCC10-N78S and RCC10-pCMV.  
pVHL is a component of the ECV E3-ligase complex, responsible for maintaining substrate 
specificity and interactions with target proteins. The E3-ligase complex contains RBX1, 
cullin 2 (Cul2) and elongins B and C (Stebbins et al., 1999, Iwai et al., 1999, Kibel et al., 
1995). pVHL directly links to elongin C and this heterodimer interacts with cullin 2-RBX 
through the scaffold elongin B. This arrangement serves as the mechanism through which 
the E2-ubiquitin conjugating enzyme is brought into proximity of the pVHL bound substrate 
(Hacker et al., 2008).  
The crystal structure of pVHL was solved in 1999 by Stebbins et al (Stebbins et al., 1999), 
who observed two domains within pVHL, an N-terminal domain, rich in β-sheets and 
smaller α-helical domain, separated by small polypeptide linking regions. Interactions 
between pVHL and elongin C were observed within a large portion of the α-domain and 
small number of amino acids in the β-domain being also necessary for the interaction. The 
β-domain extends between residues 63-154. The α-domain of pVHL, residues 155-192, 
contains three α-helices and a fourth helix from elongin C fits in to this arrangement. pVHL 
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residues 154-156 and 189-194 are linker regions of the protein that separate the α and β 
domains (Stebbins et al., 1999). 
The H1 Helix within the α-domains of pVHL has been observed to make interactions 
necessary for the stable association of pVHL with elongin C, the most significant being 
between Leu158, Arg161 and Cys162  (Figure 4.19). These residues are necessary for van der 
Waals bonding; contacts which are further augmented by Lys159, Val165, Val166, and Leu169 
(Stebbins et al., 1999).  
Contacts between the α-domains and elongin C are also made by Leu178, Ile180 and Leu184, 
being the most extensive (Stebbins et al., 1999). These residues again sit in the α-domain of 
pVHL within the other two helices.  Ser183 sits immediately adjacent to this region and has 
been predicted to interact with elongin C. Using the Crescendo software programme, 
Forman et al, have predicted that the Ser183 residue to interact with elongin C (Forman et 
al., 2009). Additionally with the proximity of the residue to Leu184, mutation at the 
neighbouring site may alter the orientation of this serine residue and further affect binding. 
This suggests that the RCC10-S183L mutation may affect ECV complex assembly through 
interference with the pVHL-elongin C binding interface.  
N78S mutation maintains a protein structure similar to that of wild type pVHL (Shmueli et 
al., 2013), however gives a mitochondrial phenotype that is intermediate and perhaps 
more reflective of loss of pVHL. This mutation effects the binding of pVHL to HIF-1α 
(Forman et al., 2009) and additionally predicted to have proximal atom pairs directed 
toward elongin C (Rechsteiner et al., 2011), suggesting a possible role in the binding and 
complex assembly. The N78S mutation has also been observed as unstable, hypothesised 
to be consequence of the lack of complex formation with elongins B and C (Bangiyeva et 
al., 2009). Inability to bind and complex leads to rapid turnover of pVHL protein by the 
proteasome (Schoenfeld et al., 2000a). 
As predicated for N78S, the R200W mutation has minimal structural perturbations on pVHL 
protein. However the R200W mutation can maintain interaction with the whole ECV 
complex as when it is over-expressed its interaction with elongin C, elongin B, cullin 2 and 
RBX1 has been observed (Hacker et al., 2008). This would suggest that it is the E3-ligase 
activity of the complex and pVHL-elongin C interaction that is important for the observed 
mitochondrial phenotype, or at least the stability of the pVHL protein and potentially the 
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pVHL-mediated turnover and/or binding of an as yet unknown protein is responsible for 
the mitochondrial phenotype described in this chapter.  
As D126N is a novel mutation, there is limited information of how it affects the structure of 
pVHL and its interaction with elongins B and C. Its position on the protein however is not 
adjacent to any interacting residues (Stebbins et al., 1999) and prediction suggest that the 
adjacent amino residues 123, 124, 125, 128 do not share proximal atoms pairs with elongin 
C (Rechsteiner et al., 2011). This adds weight to the hypothesis that the observed 
phenotype with loss of pVHL and pVHL mutations is independent of its capacity to 
recognise HIF-but instead maintain its ability to complex with elongin C and form the ECV 
E3-ligase machinery. 
Interactions that have been observed as necessary for the HIF-α interaction are found in 
the β-domain of pVHL and extend to residues, Tyr98, Ser111 and Trp117 all of which have been 
observed to abolish the pVHL recognition of pVHL-HIF-α binding. Ubiquitination however 
requires an intact α-domain (Ohh et al., 2000).  
 
 
 
Figure 4.19: Schematic representation of the pVHL protein.  
Representation of the pVHL protein highlighting the alpha and beta domains and residues 
which are responsible for HIF-1α and elongin C binding. H = helix.  
 
Potentially the pVHL mutants in which we observed a mitochondrial phenotype distinct 
from wild type pVHL are more representative of an intermediate or pVHL deficient 
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phenotype, therefore those mutated residues may be less important in maintaining the 
interaction between pVHL and elongin C, but still playing a role. The mutations that behave 
similarly to wild type pVHL (R200W and D126N) are predicted not to be involved in this 
binding. To determine if the binding of pVHL to elongin C is important for the pVHL-
mediated increase in mitochondrial protein expression and the observed mitochondrial 
phenotype, knockdown of elongin C or other component of the ECV E3-ligase complex, in 
the presence of wild type pVHL could be performed. Knockdown of a distinct ECV E3-ligase 
component, would allow determination of whether the effects of pVHL loss can be 
recapitulated. Helix one from the pVHL α-domain contains the most interactions with 
elongin C, the most significant contacts being Leu158, Cys162 and Arg161 (Stebbins et al., 
1999). Mutation of these residues in pVHL and/or the generation of alpha domain mutants 
and their subsequent expression in a pVHL null background would allow determination of 
whether the contact with elongin C is necessary for the observed effects on mitochondrial 
function and protein expression. Additionally, expression of these constructs, used above in 
a 786O background would be a useful comparator of phenotype where the role of pVHL 
could be assessed in the context of HIF-2α only and would be more representative, as many 
renal cell carcinomas have lost HIF-1α expression.  
Co-immunoprecipitation or MS of the pVHL-elongin C complex would facilitate the 
identification of any relationship between disruptions of this interface with respect to the 
role of pVHL status on mitochondrial function. Determination of the effect of the mutant 
constructs on E3-ligase complex formation will reveal the extent to which the mutation 
affects the complex and assessment made as to its relationship between the mitochondrial 
phenotype observed. Over-expression of pVHL in a cell line already expressing wild type 
pVHL would prove a useful control as to the role of pVHL protein dose on any 
mitochondrial phenotype observed. High over-expression of the pVHL protein may be 
having effects beyond that which would be expected with physiological levels of pVHL. 
4.12.7 Potential model of pVHL-mediated effects on mitochondrial function 
It must be considered that pVHL is an extremely well-characterised component of an E3-
ligase complex and therefore traditionally will affect processes post-translationally, by 
directing substrate recognition and turnover by proteasomal degradation. Interestingly 
inhibition of the 26S proteasome does not rescue this phenotype (data not shown), 
however pVHL has been observed to bind, sequester and inhibit proteins, including SP1 and 
Chapter 4: The role of pVHL in the maintenance of mitochondrial homeostasis 
Page | 188  
 
aPKC (Mukhopadhyay et al., 1997, Pal et al., 1997). Additionally, inhibition of the 
proteasome is likely to have a diverse range of effects on global protein turnover, so 
specificity toward the pathway of interest may be lost.  
Having observed that there is lower expression of a number of ETC subunits in 786O-EV 
cells compared to 786O-VHL cells, a likely explanation, considering the function of pVHL 
function in negative regulation, is that pVHL is directing the turnover of distinct protein(s) 
also involved in negative regulation, perhaps a protease. This would create the phenotype 
in pVHL defective cells of increased expression of a negative regulator of proteins, 
therefore promoting turnover and degradation (Figure 4.20). A potential family of protease 
are the AAA-proteases found in the mitochondria. These are found bound to the inner 
mitochondrial membrane and participate in quality control of mitochondrial inner 
membrane proteins, such as those which are found in the ETC. Interestingly pVHL has been 
observed to interact with p97 (Barry, 2004), a AAA-protease involved in directing 
proteolytic turnover of MFN1 and MFN2 during parkin-mediated mitophagy (Tanaka et al., 
2010).  
A second hypothesis would be that pVHL works in concert with a binding partner to 
regulate the efficient turnover and replacement of damaged/dysfunctional proteins. This 
scenario could give rise to at least two possibilities: (i) pVHL binding is necessary for the 
activity of the protein complex, as observed in the ECV-E3 ligase complex, or (ii) the 
expression of pVHL suppresses the activity of the bound protein, as is observed for SP-1 
(Mukhopadhyay et al., 1997). Interestingly, the m-AAA protease, composed of AFG3L2 and 
paraplegin in humans has been observed as necessary for MRPL32 processing and required 
for mitochondrial protein translation and ultimately respiratory capacity (Nolden et al., 
2005). Protein synthesis is also necessary for the maintenance of mitochondrial DNA. 
Additionally loss of m-AAA protease in yeast, reduced mitochondrial protein expression and 
protein synthesis, yeast are respiratory deficient and there are defects in the proteolysis of 
non-assembled inner membrane proteins and the assembly of respiratory chain complexes, 
potentially linking a number of observed phenotypes (Arlt et al., 1998).  
Intriguingly, selective turnover of mitochondrial ETC proteins has recently been described 
to be carried out by parkin E3-ligase (Vincow et al., 2013). The role of pVHL in 
mitochondrial dynamics and autophagy will be discussed in the next chapter (chapter 5); 
however change in parkin expression may clarify the discrepancy in mitochondrial protein 
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expression and explain the absence of changes in transcript expression. Finally, the loss of 
pVHL has been observed, through a number of microarrays and SAGE analysis to affect the 
expression of many genes, hence the pVHL dependent phenotype could be transcriptional.  
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Figure 4.20: Simplified hypothesis of the role of pVHL protein in the turnover of 
mitochondrial proteins.  
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Future experiments in addition to those detailed above would include bioenergetic analysis 
of the pVHL mutant RCC10 lines. Preliminary data suggests that the R200W mutation 
behaves as wild type pVHL and the N78S mutant behaves like pCMV. These observations 
are in alignment with the data obtained for ETC protein expression, ATP levels and 
mitochondrial DNA content across the pVHL and mutant cell lines.  
Using siRNA to silence elongins B or C, cullin 2 or RBX1 and investigation into whether the 
pVHL-dependent effects observed can be phenocopied. In line with this, co-
immunoprecipitation and/or mass spectrometric analysis of the ECV complex with the 
relevant mutants would underscore the point of appropriate complex assembly as 
necessary for the mitochondrial phenotype. Re-expression of the same mutant constructs 
in to 786O background would eliminate the confounding effects of HIF-1α. Through the use 
of VHL-/- MEFs, interpretation of the effects of pVHL loss in a distinct cell line could be 
investigated while avoiding an over-expression system.  
 
4.13 Summary  
There is still much to consider with respect to the role of pVHL in the regulation of 
mitochondrial function. In this chapter we have observed changes in several mitochondrial 
parameters and a single causal link is yet to be established, however the data presented 
here provides the basis for further investigation of a number of potential mechanisms.  
It is evident that the pVHL-dependent mitochondrial ETC protein phenotype is post-
transcriptional, independent of HIF-1α and HIF-2α and likely independent of ROS. When 
considering data in this chapter, it is important to consider the true “wild type” cell line. 
The cells devoid of pVHL are patient derived and pVHL has been re-expressed. In the latter 
system, the pVHL protein will therefore most likely be present in excess. Further studies are 
therefore necessary. Using targeted siRNA toward pVHL and other distinct cell lines to 
determine effects on mitochondrial function are essential. These experiments will require 
additional consideration of the HIF-1α status. In much of this chapter we have avoided the 
confounding factor of stabilised HIF-1α and this has aided the delineation of the true, direct 
role of pVHL. The role of HIF-2α in regulating mitochondrial function will be considered in 
more detail the final chapter. There is clearly plenty to be resolved in terms of the signalling 
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pathway in which pVHL appears a major player and how this is affecting many different 
aspects of mitochondrial biology. 
A number of important questions remain: 
(i) Is the E3-ligase activity of the ECV E3-ligase complex necessary for the 
observed mitochondrial phenotype upon pVHL re-expression and can this 
phenotype be observed in pVHL positive cells lacking another component of 
the ECV complex?  
(ii) Can we recapitulate this phenotype when we knockout or knockdown pVHL in 
a different cell line/context? 
(iii) Is it the pVHL directed turnover of an as yet elusive protein that is responsible 
for the increase in ETC protein expression and relief of the negative pressure 
and regulation on mitochondrial proteases or complex assembly proteins? 
(iv) Is the mechanism for the observed phenotype at the level of translation 
(mitoribosome), protein, ETC complex assembly (cardiolipin, assembly factors) 
or protein turnover? 
Answering these questions will provide insight not only into a novel role for pVHL in 
mitochondrial homeostasis, but applicable to understand further the pathophysiology of 
CCRCC and VHL disease.   
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5.1 Introduction 
Mitochondria are dynamic organelles, capable of trafficking throughout the cell and able to 
undergo frequent cycles of fusion and fission that regulate their mass, bioenergetic 
capacity and turnover. Mitochondrial dynamics are intimately linked with cellular health 
and coordination of cellular processes. A number of pathologies are associated with 
disrupted mitochondrial dynamics, which have been extensively reviewed (Liesa et al., 
2009). The morphological plasticity of mitochondria is mediated through the regulated 
expression, localisation and modification of a number of proteins. Specialised proteins such 
as dynamin-related protein 1 (DRP-1), fission-1 (FIS-1) and mitochondrial fission factor 
(MFF), mediate mitochondrial fission events and fusion is facilitated through mitofusins -1 
and -2 (MFN-1 and MFN-2) and optic atrophy -1 (OPA-1).  
Mitochondrial fusion antagonises fission and the balance of these two processes dictates 
mitochondrial morphology and function. DRP-1 is the master regulator of mitochondrial 
fission (Smirnova et al., 2001). DRP-1 localises mainly as distinct punctate structures of 
homo-oligomers in the cytoplasm, with a small proportion of protein associated with the 
mitochondrial outer membrane. Multimeric DRP-1 has been proposed to wrap around 
constriction points of the mitochondrion to promote division (Smirnova et al., 2001). 
Importantly, not all mitochondrially associated DRP-1 occupied sites undergo fission 
(Hoppins et al., 2007).  
The GTPase activity of DRP-1 is essential for mitochondrial membrane constriction and 
tubulation, as addition of a non-hydrolysable GTP or mutation of the GTPase activity 
inhibits this function (Yoon et al., 2001). Therefore, DRP-1 mutations that inhibit GTP 
binding or alternatively the absence of GTP, reduce membrane association of DRP-1 and 
prevent self-assembly into spirals. In contrast, mutations that inhibit DRP-1 GTPase activity 
and hydrolysis result in tight and prolonged periods of mitochondrial membrane 
attachment, without scission. These malfunctions in DRP-1, function to inhibit 
mitochondrial division in vitro (Hoppins et al., 2007, Yoon et al., 2001).  
In addition to a number of other proteins, FIS-1 serves as a receptor for DRP-1 and is 
localised uniformly on the mitochondrial outer membrane (Losón et al., 2013, Chen and 
Chan, 2004). In the absence of FIS-1, the targeting and association of DRP-1 with 
mitochondria is compromised and results in an elongated mitochondrial morphology 
(Hoppins et al., 2007). However, the best characterised receptor for DRP-1 on the 
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mitochondrial outer membrane is MFF. The expression of MFF is necessary and essential 
for DRP-1 recruitment to the mitochondrial membrane, in contrast to FIS-1 where DRP-1 
can be recruited in its absence (Losón et al., 2013, Otera et al., 2010). The molecular 
regulators of mitochondrial inner membrane fission are as yet unknown.  There are also a 
number of proteins that have non-essential regulatory roles in mitochondrial division, 
including endophilin B1, ganglioside induced differentiation associated protein-1 (GDAP-1) 
and the mitochondrial ubiquitin ligase, MARCH5/MITOL (Hoppins et al., 2007). 
Mitochondrial fusion is mediated through the combined efforts of the mitofusins (MFN-1 
and MFN-2) and OPA-1. MFN-1 and MFN-2 are large transmembrane GTPases and although 
both function in mitochondrial fusion through the same mechanism, their relative activities 
differ, as does their tissue expression, with MFN-1 present at higher levels in the brain and 
MFN-2 in the heart and testes (Hoppins et al., 2007). Loss of a single mitofusin can be 
compensated for through expression of the other, however double knockout causes 
mitochondrial fragmentation (Chen et al., 2005). Mitofusins form homo- and hetero-
dimeric complexes and are required on both adjacent mitochondrial membranes to 
mediate tethering, which promotes proximity and mitochondrial fusion (Chan, 2012).  
OPA-1, also a transmembrane GTPase and related to dynamin, resides on the 
mitochondrial inner membrane. OPA-1 is responsible for the fusion of mitochondrial inner 
membrane and loss or mutation of OPA-1 results in mitochondrial fragmentation. 
Additionally, OPA-1 has been observed to play an important role in mitochondrial cristae 
maintenance (Chan, 2012, Meeusen et al., 2006).  
Mitochondrial content exchange has emerged as an important consequence of 
mitochondrial fusion and fission events. Mitochondrial DNA is shared between 
mitochondria upon fusion and disruptions to this process result in respiratory deficits and 
mitochondrial genome instability (Parone et al., 2008, Vidoni et al., 2013, Chen et al., 
2010). Fusion of mitochondria is hypothesised to allow complementation of mitochondrial 
DNA and protect mitochondria form consequences of accumulation of mitochondrial DNA 
mutations (Chan, 2012). Mitochondrial fusion and fission events have also been linked to 
apoptosis and adaptation to cellular stress (Frank et al., 2001). Mitochondria have been 
observed to elongate in response to nutrient deprivation (Rambold et al., 2011, Gomes et 
al., 2011), ultra violet radiation and after general inhibition of RNA translation or protein 
translation (Chan, 2012).     
Chapter 5: The role of pVHL on mitochondrial dynamics and cellular degradative pathways 
Page | 196  
 
A dynamic relationship exists between mitochondrial bioenergetics and morphology. 
Inhibition of the ETC and OxPhos machinery has been observed to alter mitochondrial 
morphology and inhibition of fusion decreases mitochondrial oxygen consumption (Legros 
et al., 2002, Galloway et al., 2012, Chen et al., 2005). Conversely, inhibition of 
mitochondrial fission, through DRP-1 targeting, collapses mitochondrial membrane 
potential, reduces ATP and decreases oxygen consumption (Parone et al., 2008). These 
observations demonstrate the importance of maintaining a balance between fission and 
fusion, and the coordinated regulation of these opposing processes maintains cellular 
homeostasis.   
In the last chapter (chapter 4), re-expression of pVHL in renal carcinoma cells was observed 
to increase cellular oxygen consumption rate, cellular ATP levels, mitochondrial mass and 
increase expression of a select number of mitochondrial proteins, namely components of 
the ETC. pVHL has also been observed to have differential effects on mitochondrial 
ribosomal protein mRNA expression and have significant effects on mitochondrial DNA 
content, through as yet an unknown mechanism (Hervouet et al., 2008). As yet, an 
unexplored question is how the loss of pVHL affects mitochondrial morphology. 
Mitochondrial morphology has been shown to affect bioenergetic capacity, mitochondrial 
DNA content and conversely cellular stress has been observed to mediate changes in 
mitochondrial morphology. The extent to which pVHL may govern these processes in renal 
cells however remains to be elucidated.  
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5.2 Hypothesis 
pVHL status affects mitochondrial dynamics and morphology. 
 
 
5.3 Aims 
1. To explore the effects of pVHL on mitochondrial morphology.  
 
2. To investigate the extent to which pVHL-mediated changes in morphology are 
paralleled across cell lines. 
 
3. To determine the mechanism behind morphological changes mediated by pVHL 
and link these to cellular physiology. 
  
Chapter 5: The role of pVHL on mitochondrial dynamics and cellular degradative pathways 
Page | 198  
 
5.4 The effect of pVHL status on mitochondrial morphology 
Mitochondria are dynamic organelles, undergoing frequent fusion and fission cycles, which 
govern function and mitochondrial number. Equally mitochondrial function or dysfunction 
can affect the network and morphology, as such mitochondrial homeostasis relies on the 
appropriate communication between cell and organelle, disruption of which had been 
linked to dysfunction and disease.   
In order to further explore the relationship between the pVHL and the mitochondrial 
phenotype described in chapter 4, 786O-VHL and 786O-EV cells were stained with 
mitoview green and imaged using confocal microscopy to assess mitochondrial 
morphology. Clear differences in mitochondrial morphology were observed across both 
786O cell lines (Figure 5.1). 786O-EV cells exhibited a more fused and elongated 
mitochondrial phenotype compared to 786O-VHL which appeared to have smaller and 
more fragmented mitochondria (Figure 5.1). Interestingly, mitochondrial distribution 
appeared unaffected by pVHL status and mitochondria appeared equally dispersed 
throughout the cell in both 786O-EV and 786O-VHL cells (Figure 5.1). These data suggest 
that stable re-expression of functional pVHL in 786O cells increases mitochondrial 
fragmentation and alters the mitochondrial phenotype from an interconnected fused 
reticular network to a more ubiquitous distribution of smaller tubules (Figure 5.1). 
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Figure 5.1: pVHL status affects mitochondrial morphology in 786O cells. 
786O-EV and 786O-VHL cells were stained with 100nM mitoview green for 30 minutes 
washed and imaged by confocal microscopy. 786O-VHL cells exhibit a network of small 
mitochondrial units and limited tubular phenotype compared to 786O-EV cells which 
exhibit fused and elongated mitochondria. Images were acquired with a Zeiss 510 META 
confocal laser scanning microscope using a 63× oil objective and represent independent 
fields of view. Right panel shows higher magnified images. 
 
To further investigate the mitochondrial morphological changes in the 786O cells, electron 
microscopy (EM; carried out by Mark Turmaine, UCL, UK) was used to image cells and their 
mitochondria. In agreement with the images obtained by mitoview staining and live-cell 
imaging (Figure 5.1), ultrastructural analysis revealed that after pVHL re-expression in 786O 
cells (786O-VHL), mitochondria appeared smaller and more rounded (Figure 5.2A). This is in 
direct contrast to 786O-EV cells which are devoid of functional pVHL, in which 
mitochondria appear more elongated, thinner and more tubular (Figure 5.2B). 
Quantification of mitochondrial length, using Image J software (National Institute of Health, 
Maryland) measure tool, revealed a statistical difference between the two 786O cell lines 
(Figure 5.2C). Consistent with the imaging data (Figure 5.2A-B), the average mitochondrial 
length was significantly smaller in 786O-VHL cells (1.15μm) compared to 786O-EV cells 
(1.54μm) (Figure 5.2C). This analysis revealed that the length of mitochondria in 786O-VHL 
cells was approximately 25% smaller than those mitochondria in 786O-EV cells; collectively 
indicating that re-expression of functional VHL in 786O cells regulates mitochondrial 
morphology and length.  
Overall assessment reveals that mitochondrial cristae appeared normal with equal density 
between the 786O cell lines. There are no other obvious mitochondrial abnormalities, 
beyond the difference in overall morphology between the cell lines. Nor are there any 
obvious changes in membrane contacts or mitochondrial distribution. Images were 
magnified to allow closer inspection of mitochondria (Figure 5.2A and B, lower panels). 
Taken together, these data suggest that the changes in morphology and size of 
mitochondria in pVHL re-expressing 786O cells may in part be responsible for the alteration 
in mitochondrial function observed previously in chapter 4.  
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Figure 5.2: pVHL status affects mitochondrial morphology and length. 
786O (786O-EV and 786O-VHL) cells were fixed, sectioned and imaged by electron 
microscopy (EM). Preparation for imaging and microscopy was performed by Mark 
Turmaine at UCL. (A) EM images of 786O-VHL cells show small and round mitochondrial 
morphology. (B) EM images of 786O-EV cells show an elongated tubular mitochondrial 
network. N = nucleus (C) Graph shows mitochondrial length measured from EM images of 
786O-EV (red) and 786O-VHL (blue) cells. Mitochondrial length was measured from the 
most highly curved membrane through the central axis to the periphery (as indicated, 
black bar). Measurements were calculated using Image J software (National Institute of 
Health, Maryland) after calibration of scale using the scale bar. Over 200 mitochondria 
were scored from single images of 9-10 cells. Data analysed using unpaired, two-tailed t-
test (*** p<0.001). 
 
5.5 The effect of pVHL status on the protein expression, phosphorylation 
and sub-cellular localisation of controllers of mitochondrial fusion and 
fission 
Mitochondrial and cellular homeostasis relies on the appropriate balance between fission 
and fusion. As discussed above, a number of key proteins, including DRP-1, MFN-1, MFN-2 
and OPA-1 dictate mitochondrial morphology, governing the processes of mitochondrial 
fission and fusion respectively. DRP-1 protein is important in mediating outer membrane 
fission where FIS-1 protein serves in its recruitment to the outer mitochondrial membrane 
(Losón et al., 2013). Working in opposition, MFN-1 and MFN-2 are outer mitochondrial 
membrane proteins that in partnership with OPA-1 to regulate the fusion of outer and 
inner mitochondrial membranes respectively. The regulation of fission and fusion protein 
expression, their post-translational modification and turnover, coordinates the role that 
each protein plays in maintaining mitochondrial architecture, size and morphology. 
To determine the contribution of the mitochondrial fusion and fission machinery to the 
morphological phenotype observed in pVHL re-expressing 786O cells, expression of fission 
and fusion proteins was investigated. Interestingly, in the 786O-EV cells a global reduction 
in all fusion and fission proteins assessed was observed, compared to 786O-VHL cells 
(Figure 5.3A-E). Reduction in isoforms of DRP-1 (Figure 5.3A), MFN-1 (Figure 5.3C), MFN-2 
(Figure 5.3D) and OPA-1 (Figure 5.3E) were detected in 786O-EV cells compared to 786O-
VHL cells. Interestingly, FIS-1 protein (Figure 5.3C) appears similar between pVHL positive 
and negative cells. A second interesting observation is that despite the lower levels of total 
DRP-1 protein in the 786O-EV cells compared to the 786O-VHL cells (Figure 5.3A), an 
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increase in the phosphorylation at Ser637 of DRP-1 was observed (Figure 5.3A). This post-
translational modification is a DRP-1 inactivating modification (Chang and Blackstone, 
2007) and in the 786O-EV cells, an increase in the ratio of p-DRP-1 (Ser637): DRP-1 (total) 
was detected (Figure 5.3A). DRP-1 Ser616 phosphorylation is an activating modification, and 
was also found to be reduced in the 786O-EV cells compared to the 786O-VHL cells, 
reflective of protein abundance of total DRP-1 (Figure 5.3). Collectively, these data may 
suggest that the observed morphological phenotype in the 786O-EV cells compared with 
the 786O-VHL cells is a consequence of reduced fission, mediated through DRP-1 inhibition 
and not increased fusion. 
There may also be differences in the expression of OPA-1 isoforms and differences in its 
processing. There are eight isoforms of OPA-1, which each undergoing differential 
processing due to the presence of cleavage sites in differentially spliced mRNA, giving rise 
to five bands on western blot (van der Bliek et al., 2013) (Figure 5.3E). The top two protein 
bands in figure 5.3E constitute the long form of OPA-1 and the lower three protein bands 
are the short form of OPA-1 (Figure 5.3E). All five OPA-1 protein forms were detected in the 
786O cells (Figure 5.3E, labelled 1-5). Forms 2 and 4 of OPA-1 are expected to be present in 
a 50:50 ratio based on constitutive proteolytic cleavage; however in 786O-EV cells there 
appeared to be relative reduction in form 4, possibly suggesting differential mRNA splicing 
or altered proteolytic processing.  
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Figure 5.3: pVHL status affects expression and the post-translational modification of 
mitochondrial regulators of fusion and fission. 
(A-E) Western blot analysis of the 786O (786O-VHL (VHL) and 786O-EV (EV)) cells 
demonstrating the differential effect on mitochondrial dynamic protein expression (DRP-
1, MFN-1, MFN-2, FIS-1 and OPA-1) and post-translational modifications (p-DRP-1 (Ser637), 
p-DRP-1 (Ser616)). β-actin was used as a control for protein load and pVHL was assessed to 
confirm appropriate cellular expression.  
 
Typically DRP-1 resides in the cytosol and mediates mitochondrial fission, through a GTP 
dependent mechanism after binding to receptors located on the mitochondrial outer 
membrane (Smirnova et al., 2001). Therefore an alteration in total DRP-1 protein does not 
reflect that which is involved in mediating fission, as mitochondrially associated DRP-1 
protein is not estimated.  
To determine the influence of mitochondrially associated DRP-1, the subcellular localisation 
of endogenous DRP-1 protein was assessed in the 786O cells, in the presence and absence 
of re-expressed pVHL. As observed above (Figure 5.3C), there was increased total DRP-1 
protein expression in the 786O-VHL cells compared to the 786O-EV cells (Figure 5.4; Load - 
lanes 1 and 2). Because of the clear difference in total DRP-1 protein expression between 
the 786O-VHL and 786O-EV cell lines, there was also a relative difference observed in the in 
DRP-1 protein in the cytosolic and mitochondrial fractions. Indeed, there was reduced DRP-
1 protein in total, cytosolic and mitochondrial fractions in 786O-EV compared with 786O-
VHL cells.  
Interestingly, when comparing total DRP-1 protein levels with respect to total VDAC1, an 
outer membrane protein and mitochondrial marker, the ratio of total DRP-1 to VDAC1 
present in the mitochondrial fraction was also increased in the 786O-VHL cells compared to 
the 786O-EV cells (Figure 5.4; Mito - lanes 5 and 6). Taken together, these data suggest that 
in the 786O-VHL cells there is more mitochondrially associated DRP-1 protein and 
highlights a potential mechanism through which pVHL may influence fission. Increased 
mitochondrially associated DRP-1 protein correlates with an increase in fragmented 
mitochondria observed in 786O-VHL cells, however how pVHL does this is yet to be 
determined.  
Additionally, compared to the DRP-1 protein load for 786O-EV cells, there was an 
unexpected absence of DRP-1 protein observed in both cytosolic and mitochondrial 
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fractions, suggesting that DRP-1 protein may be localised in another compartment (e.g. 
nucleus). Indeed, DRP-1 protein has been observed to localise to the nucleus under hypoxia 
(Chiang et al., 2009). Additionally, in contrast to a previous study (Shiao et al., 2000), no 
pVHL protein was detected in the mitochondrial fraction, despite high pVHL expression in 
the 786O-VHL cells.  
 
 
Figure 5.4: pVHL status affects the subcellular distribution of DRP-1. 
Subcellular fractionation of 786O (786O-EV (EV) and 786O-VHL (VHL)) cells and western 
blot analysis demonstrating increased ratio of DRP-1: VDAC1 in 786O-VHL cells compared 
to 786O-EV cells. α-tubulin and VDAC1 were used markers for the cytosol and 
mitochondria respectively, and pVHL was assessed to confirm appropriate cellular 
expression. Load = total cell homogenate, Cyto = cytosolic fraction, Mito = mitochondrial 
fraction.  
 
5.6 The effect of wild type and mutant pVHL re-expression on 
mitochondrial morphology in RCC10 cells 
Since there were striking differences in the morphology of mitochondria in the presence 
and absence of functional pVHL protein in the 786O cells (Figure 5.1), it was important to 
assess other renal carcinoma cell lines and investigate the influence of pVHL mutations on 
the phenotype. As described previously, RCC10 cells are devoid of functional pVHL and 
after re-expression of wild type pVHL share a mitochondrial phenotype similar to that of 
786O-VHL cells (chapter 4). After introduction of mutant pVHL protein, described 
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previously in chapter 4, the RCC10-R200W mutation appears to behave as wild type pVHL 
and RCC10-N78S mutant promoted a more intermediate phenotype (between wild type 
pVHL and empty vector) with respect to mitochondrial biology and the parameters 
assessed (chapter 4; Figure 4.16, Figure 4.17 and Figure 4.18). 
In order to further assess mitochondrial morphology, RCC10 cells were fixed and the 
mitochondrial network examined using indirect immunofluorescence toward the ATPB 
subunit of the F1FO-ATPase. ATPB protein expression has previously been observed to be 
unaffected by pVHL status (chapter 4; Figure 4.2 and Figure 4.18). Confocal imaging 
demonstrated a similar morphological phenotype to that observed in the presence and 
absence of pVHL in the 786O cells. Like 786O-EV cells, RCC10-pCMV cells are devoid of 
functional pVHL and had more elongated and tubular mitochondria compared to the 
smaller more fragmented mitochondria observed in cells with wild type pVHL re-expressed 
(Figure 5.5 and Figure 5.1).  
Interestingly, RCC10 cells expressing the R200W pVHL mutant appeared to exhibit a similar 
mitochondrial morphology to cells expressing wild type pVHL (Figure 5.5). Notably, 
mitochondria in both mutant RCC10-R200W and wild type RCC10-VHL cell lines appeared 
fragmented and less tubular to a similar degree, compared to the RCC10-pCMV cells. These 
data are consistent with the previously described similarities observed in mitochondrial 
DNA content, ATP levels and mitochondrial ETC protein expression between the pVHL 
R200W mutation and wild type pVHL (chapter 4; Figure 4.16, Figure 4.17 and Figure 4.18). 
In contrast, the RCC10-N78S cells exhibited a mitochondrial morphology similar to the 
RCC10-pCMV cells (Figure 5.5). RCC10 cells expressing the N78S pVHL mutant, displayed a 
more elongated mitochondrial appearance compared to those expressing wild type pVHL, 
an observation suggesting an intermediate phenotype between RCC10-VHL and RCC10-
pCMV.  
Interestingly, cell shape is also affected by pVHL status. Loss of pVHL promotes a shift from 
an epithelial-like morphology to a more elongated cellular morphological phenotype, an 
observation that has been previously described and reflected in both the 786O and the 
RCC10 cell lines (Davidowitz et al., 2001). The possibility that the mitochondrial 
morphological changes observed in these cells are linked to cell shape is of particular 
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interest, given that mitochondrial dysfunction is associated with metastatic and aggressive 
disease.   
Taken together, these data suggest that pVHL status affects mitochondrial morphology and 
this is evident across a number of renal carcinoma cell lines. Additionally, given that both 
wild type and R200W mutant pVHL protein have similar effects on mitochondrial 
morphology, it is possible that the role of pVHL in regulating mitochondrial morphology is 
distinct from its role in recognition of HIF-1α.   
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Figure 5.5: pVHL status affects mitochondrial morphology in RCC10 cells. 
RCC10 cells expressing empty vector control (pCMV), wild type pVHL (VHL) or pVHL 
mutants (R200W and N78S) were stained using primary antibody towards ATPB and 
visualised using secondary antibody conjugated to Alexa Fluor 568 (red), nuclei were 
stained with DAPI (blue) and imaged using confocal microscopy. Images were acquired 
with a Zeiss 510 META confocal laser scanning microscope using a 63× oil objective and 
represent independent fields of view. Right panel shows higher magnified images.  
 
5.7 The effect of pVHL status in the regulation of autophagy 
The mechanisms of mitochondrial fusion and fission have been characterised in great 
detail. However the mechanism of their regulation and the relationship between 
morphology, dynamics and cell physiology is only recently coming to light and remains 
comparatively less well understood.  
DRP-1 has been implicated in mitochondrial fission necessary for promotion of apoptosis 
(Frank et al., 2001) and conversely the fusion machinery has been observed to delay or 
inhibit the process (Neuspiel et al., 2005). The cellular inheritance and intracellular 
distribution of mitochondrial nucleoids and DNA is also influence by mitochondrial fusion 
and fission events (Parone et al., 2008, Chen et al., 2010). Mitochondrial fusion has 
additionally been demonstrated to promote resistance to mitochondrial clearance by 
starvation-induced autophagy (Gomes et al., 2011, Rambold et al., 2011).  
Interestingly, analysis of EM images of 786O cells revealed the presence of 
autophagosomes in 786O-EV cells and comparative lack of membrane vesicles in those cells 
expressing wild type pVHL (Figure 5.6A and B). These data suggest that pVHL status may 
affect autophagy. The magnified EM images (Figure 5.6B) indicated the presence of 
autophagosomal structures in 786O-EV cells that are consistent with previous studies 
(Eskelinen, 2008, Klionsky et al., 2012) (Figure 5.6B). The left panel in figure 5.6B highlights 
an early (Figure 5.6B; *) and late autophagosomal structures (Figure 5.6B; #) and right 
panel in figure 5.6B shows an early autophagosome (Figure 5.6B; *), with identifiable 
cytoplasmic structures encapsulated by a double membrane vesicle. Late autophagosomal 
structures are identified as being more electron dense than those earlier in the degradative 
pathway. A number of double membrane autophagosomes can also be observed in the 
non-magnified images in figure 5.6B, which contain clearly visible organelles (Figure 5.6B; 
arrow heads). These data suggest that, re-expression of pVHL in 786O cells affects the 
cellular appearance of markers of macroautophagy. 
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Figure 5.6: pVHL status affects the cellular appearance of markers of autophagy. 
786O-EV and 786O-VHL cells were fixed, sectioned and imaged by electron microscopy 
(EM). Preparation for imaging and microscopy was performed by Mark Turmaine at UCL. 
EM images of (A) 786O-VHL cells and (B) 786O-EV cells show a reduced number of 
autophagosomes in A compared with B. N = nucleus, arrow = early autophagosomes, * = 
autophagosome, # = late autophagosome and + = lysosome. Autophagosomes were 
identified through comparison of images with published literature and in line with 
established opinions on structure identification (Eskelinen, 2008, Klionsky et al., 2012). 
ADDED CELL LABELS on image i.e. 786O-VHL, 786O-EV 
 
Autophagy is a highly evolutionarily conserved process by which a portion of the 
cytoplasm, including organelles such as endoplasmic reticulum (ER) and mitochondria, 
long-lived proteins and pathogens are surrounded non-selectively by a double membrane 
that forms the autophagosome. After membrane elongation and fusion, the contents are 
engulfed and sequestered. Autophagosomes are then directed toward the nucleus and the 
cargo degraded by the lysosome. Physiologically, autophagy occurs continuously at low 
levels. Various signalling events, in response to stress, such as starvation, hypoxia and 
infection can induce autophagy (He and Klionsky, 2009, Mizushima, 2007). 
This complicated sequence of events, commencing with the selection and recognition of 
cargo, to formation and expansion of the autophagosomal membrane and ultimate fusion 
with and degradation by the lysosome is understandably highly regulated and a large 
number of protein mediators are involved. The ATG proteins are the principal controllers of 
the autophagic process and are conserved from yeast to mammals and function in a well-
studied, coordinated  sequence of reactions (He and Klionsky, 2009).  
A method by which autophagy can be measured is through evaluation of the lipidation of 
LC3 protein, of which a number of isoforms exist, the best characterised being LC3B. As 
discussed in the introduction, LC3 is the only identified protein component of the inner 
autophagosome membranes. It is synthesised as a precursor and immediately cleaved in 
the cytoplasm at its C-terminus forming LC3-I. It is then covalently bound to 
phosphatidylethanolamine by the concerted efforts of ATG7 and ATG3 to form LC3-II, 
which allows its targeting to both sides of the autophagosome membrane where it is 
thought to be necessary for the expansion and final fusion of the autophagosome (He and 
Klionsky, 2009, Ravikumar et al., 2010). Autophagosomes then fuse with endosomes and 
finally the lysosome, involving lysosomal-associated membrane protein-2 (LAMP-2) and 
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RAB7. The contents of the autophagosome are degraded by the acid proteases and 
released back into the cytosol to be re-used in bio-synthetic pathways (He and Klionsky, 
2009). 
Despite lipidation of LC3B-I increasing the molecular weight of the protein, the increased 
hydrophobicity of LC3B-II causes the protein to migrate faster by SDS-PAGE, which can be 
readily observed as a band below the un-modified LC3B-I protein (Klionsky et al., 2012). To 
investigate the underlying mechanistic basis of the change in number of autophagosomes 
present after pVHL re-expression, protein from 786O cells was isolated and proteins 
involved in regulating autophagy were detected by western blot analysis. This revealed 
clear differences in the basal levels of lipidated LC3B (LC3B-II) protein (Figure 5.7A).  There 
was lower levels of LC3B-II protein observed in 786O-VHL cells compared with 786O-EV 
cells, however no differences were observed in the levels of a number of other autophagic 
proteins, including beclin, ATG3 and ATG7 (Figure 5.7A) between the two cell lines. The 
LC3B-I to LC3B-II ratio is static, as is the presence of autophagosomes. Therefore, under 
non-stimulated conditions, the decrease in LC3B-II and decreased autophagosome 
identification by EM, observed with pVHL re-expression could suggest a number of 
scenarios. (i) There is a decrease in autophagosome formation, or (ii) increased 
autophagosome turnover, as both scenarios would result in lower protein levels of LC3B-II. 
The activity and protein abundance of LC3B can also be regulated on the transcriptional 
level, hypothesised as a mechanism to replace protein stores during high levels of 
autophagic turnover (Rouschop et al., 2010). LC3B mRNA has been observed to increase 
under periods of ER stress and after activation of the unfolded protein response. It was 
therefore important to measure transcript expression of LC3B-II in the presence and 
absence of pVHL. To assess whether the changes in observed LC3B protein were due to 
alteration in the lipidation of the protein and not due to altered transcript expression, LC3B 
mRNA was analysed using RT-qPCR. Interestingly, there were significantly higher LC3B 
mRNA levels in 786O-VHL cells compared with 786O-EV cells (Figure 5.7B). These data 
suggest that higher levels of LC3B protein observed in the 786O-EV cells compared to the 
786O-VHL cells are likely due to post-translational lipidation and not due to differences in 
LC3B mRNA expression.  
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Figure 5.7: pVHL status affects LC3B protein and mRNA expression. 
(A) Western blot analysis of 786O (786O-VHL (VHL) and 786O-EV (EV)) cells and the 
differential effect on autophagic protein expression. Re-expression of pVHL decreases 
lipidated LC3B under basal conditions, without affecting other autophagic proteins. β-
actin and was used as a protein load control and pVHL to confirm re-expression. (B) 
Graph shows the relative transcript expression of LC3B in 786O (786O-EV (EV, red) and 
786O-VHL (VHL, blue)) cells using RT-qPCR. A significant difference in LC3B expression 
was observed in the 786O-VHL cells compared to the 786O-EV cells (** p<0.01). Data 
analysed using the comparative Ct method after normalisation to a single experimental 
repeat. Values are mean +/- S.E.M (n=4). Data analysed by paired, two-tailed t-test.  
 
Increases in the accumulation of autophagosomes and presence of LC3B-II under non-
stimulated conditions is not representative of autophagic flux, as it could either be 
consequence of increased generation of autophagosomes (increased autophagy) or a block 
in the pathway and inhibition of autophagosomal maturation and/or turnover of LC3B-II 
(decreased autophagy) as discussed (Mizushima et al., 2010). Accumulation of 
autophagosomes may perhaps be due to delayed trafficking to the lysosomes, reduced 
fusion between compartments or impaired lysosomal proteolytic activity.  
In order to examine the effects of pVHL status on autophagy, an autophagic flux assay was 
performed. Hanks balanced salt solution (HBSS) was used to induce autophagy, promoting 
starvation and chloroquine used to block lysosome-mediated proteolysis. Chloroquine 
increases LC3B-II protein, through neutralisation of the lysosomal pH and inhibition of 
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autophagosome degradation, increasing membrane associated LC3B-II. Failure to induce 
LC3B-II in the presence of lysosomal inhibition would suggest a defect or delay earlier in the 
autophagic process, prior lysosomal degradation (Barth et al., 2010). Chloroquine induced 
lipidation of LC3B-I is therefore reflective of intact autophagosome synthesis.  
In the 786O cells, there was an increase in LC3B-II after the addition of chloroquine in both 
the presence and absence of pVHL (Figure 5.8). These data suggest that autophagosome 
synthesis is intact in both the 786O-VHL and 786O-EV cell lines. There remained an 
increased level of LC3B-II in the 786O-EV cells after chloroquine treatment compared with 
the 786O-VHL cells. It is likely that the increase in LC3B-II is occurring alongside 
autophagosome delivery to the lysosome, however LC3B-II synthesis may still be occurring 
in parallel with impaired lysosomal degradation  (Rubinsztein et al., 2009).  
Starvation is a mechanism through which autophagy can be induced. In vitro, the culture of 
cells for a number of hours in HBSS promotes autophagy and LC3B-I lipidation to LC3B-II. 
The addition of HBSS in combination with chloroquine should induce LC3B-II levels to a 
greater extent than that observed with chloroquine alone, indicating increased autophagic 
flux. However HBSS had no effect on promoting autophagy in the 786O cells (Figure 5.8). It 
is possible that the 786O cells are resistant to starvation-induced autophagy, as described 
elsewhere (Mizushima et al., 2010). Stimulation of autophagy is necessary to further 
elucidate effects on stress induced autophagic induction, using an alternative to HBSS to 
induce the pathway.  
These data suggest that autophagosome synthesis is intact in both the 786O-VHL and 
786O-EV cell lines. Interestingly, pVHL has previously been observed to be involved in 
autophagy, through regulating the expression of miR-204, inhibiting autophagy through the 
targeting of LC3B (Mikhaylova et al., 2012).  
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Figure 5.8: Autophagosome synthesis is maintained in the presence and absence of pVHL.  
Autophagic flux assay and western blot analysis of 786O (786O-VHL (VHL) and 786O-EV 
(EV)) cells. Cells were incubated with either HBSS (HB), chloroquine (CHL; 20μM) or 
combination of both for 2 hours to assess autophagic flux. The increase in LC3B-II protein 
is representative of intact autophagosome synthesis in both cell lines. HIF-2α expression 
was assessed as confirmation of cellular phenotype, and α-tubulin was used as a load 
control.  
 
5.8 The effect of pVHL status on selective mitochondrial autophagy  
Autophagy is considered a non-selective process and cytosolic components and organelles 
that reside in the area of autophagosome formation will be engulfed and degraded. This is 
in contrast to cargo-specific autophagy, that occurs under basal conditions to remove 
dysfunctional organelles and proteins (Youle and Narendra, 2011). One selective form of 
autophagy is the targeting and turnover of mitochondria, known as mitophagy (Lemasters, 
2005). Having observed changes in mitochondrial morphology and autophagic parameters 
in the presence and absence of functional pVHL, experiments were undertaken to assess 
any effects of pVHL status on the mitophagic machinery.  
There are a number of proteins whose role extends to mediating mitophagy. p62, also 
called sequestosome 1 (SQSTM1), is not specifically involved in mitophagy alone, however 
provides a molecular binding scaffold which links ubiquitinated substrates on the 
mitochondria to LC3B-II on the autophagosomal membrane (Pankiv, 2007). PINK1 is a 
serine/threonine protein kinase and the full-length protein is extremely difficult to detect 
by SDS-PAGE and western blotting as it is rapidly cleaved and processed under normal 
physiological conditions. Pharmacological uncoupling or alternative means of mitochondrial 
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inner membrane depolarisation stabilises the full-length PINK1 protein, through inhibition 
of the voltage sensitive protease PARL (Deas et al., 2011a). PINK1 accumulates rapidly on 
mitochondrial outer membrane, an event which promotes the PINK1-parkin dependent 
peri-nuclear trafficking of mitochondria (Vives-Bauza, 2010, Imai, 2012). Parkin is an E3-
ubuquitin ligase and associates with mitochondrial outer membrane in response to 
stabilised PINK1. This translocation event promotes ubiquitination of mitochondrial outer 
membrane proteins, their recognition by p62 and autophagic turnover through LC3B-II 
binding and lysosomal degradation (Narendra et al., 2008, Kawajiri, 2010).   
To analyse the expression of mitophagic proteins, 786O-EV and 786O-VHL cell lysates were 
analysed by SDS-PAGE and western blotting. This analysis revealed significant changes in 
parkin and p62 protein expression (Figure 5.9). In 786O-VHL cells, parkin protein was 
increased compared to 786O-EV cells (Figure 5.9A). To investigate whether changes in 
parkin mRNA was affected by pVHL status, mRNA levels from 786O-VHL and 786O-EV cells 
were quantified using RT-qPCR. There was an approximate 70% increase in parkin in 786O-
VHL cells compared with 786O-EV cells (Figure 5.9B). Interestingly, parkin has also been 
shown to affect mitochondrial morphology and turnover of ETC proteins (Poole, 2008, 
Mortiboys et al., 2008, Vincow et al., 2013). In Drosophila, parkin mutation has been 
observed to affect mitochondrial morphology and cristae modelling (Poole, 2008) and in 
parkin mutant human fibroblasts, a more elongated and branched phenotype has also been 
noted (Mortiboys et al., 2008). In addition, parkin has recently been observed to mediate 
the selective turnover of mitochondrial ETC proteins in vivo (Vincow et al., 2013).  
There was also a significant increase in p62 protein expression in 786O-VHL cells compared 
with 786O-EV cells (Figure 5.9C), with no significant change in mRNA (Figure 5.9D), 
suggesting that p62 is modified and/or turned-over at the protein level. Accumulation of 
p62 protein occurs when macroautophagy is inhibited and decreases under conditions of 
increased flux and steady-state levels have been used previously to asses autophagic flux 
(Klionsky, 2010, Klionsky et al., 2012). Steady state assessment of p62 protein levels is 
however questionable given the role of p62 in processes less well understood. The 
decrease in p62 protein in 786O-EV cells may confirm that there is increased autophagic 
flux in these cells compared to those with functional pVHL re-expression. Together these 
data would likely suggest the increase in LC3B-II in 786O-EV cells is due to increased 
macroautophagic flux.  
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Interestingly, p62 functions as a protein adaptor not just for ubiquitinated proteins on the 
mitochondrial outer membrane but for proteins present elsewhere in the cytosol. In 
addition to its role as an adapter that binds ubiquitinated substrates on the outer 
mitochondrial membrane and scaffolding to LC3B-II on the autophagosome membrane, 
p62 is a cargo receptor and also involved in aggregation of unfolded proteins, leading to 
their autophagic turnover (Puissant et al., 2012), suggesting alternative hypotheses for the 
effects of pVHL status on p62 protein abundance.  
Collectively, these data demonstrate that pVHL status affects parkin mRNA and protein 
expression and that wild type pVHL re-expression in 786O cells leads to significantly 
increased parkin levels. Additionally, the significant difference in p62 protein could indicate 
increased autophagic turnover in 786O cells devoid of functional pVHL.  
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Figure 5.9: pVHL status affects parkin and p62 expression. 
(A and C) Western blot analysis of parkin and p62 protein expression in 786O (786O-VHL 
(VHL) and 786O-EV (EV)) cells, demonstrating an increase of both parkin and p62 protein 
in the 786O-VHL cells compared to the 786O-EV cells. β-actin was used as a load control 
and pVHL was assessed to confirm appropriate cellular expression. (B and D) Graphs 
show RT-qPCR analysis of parkin and p62 from cells described in A, demonstrating a 
significant differences in parkin expression and no significant change in p62 mRNA 
expression in the 786O-VHL cells compared with the 786O-EV cells (*** p<0.001 and ns 
p>0.05). Data analysed using the comparative Ct method after normalisation to a single 
experimental repeat. Values are mean +/- S.E.M (n=4). Data analysed by paired, two-
tailed t-test.  
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5.9 Discussion 
In chapter 4, we have previously observed and described several biochemical and cell 
physiological differences in renal carcinoma cells after pVHL re-expression. 786O cells with 
and without functional pVHL protein have been used to explore the relationship between 
pVHL status and mitochondrial function. Here, we explore the relationship of pVHL status 
and mitochondrial morphology, with the aim to link these observations to the pVHL-
dependent mitochondrial phenotype described in chapter 4. In this chapter, we have 
observed alterations in mitochondrial morphology, mitochondrial size and inter-
connectivity to be dependent on pVHL, and have correlated these to a potential 
mechanism through the mitochondrial fusion and fission machinery. Understanding the 
mechanism of morphological plasticity alone is however insufficient. Efforts were therefore 
undertaken to highlight the importance of pVHL-mediated mitochondrial morphological 
alteration from a cellular context and gain insight into a potential molecular mechanism. In 
addition, we identified autophagy as a cellular process through which mitochondria and 
particularly mitochondrial morphology may be linked to pVHL status.  
5.9.1 Re-expression of pVHL alters mitochondrial morphology through affecting shape 
and reducing mitochondrial length 
The most striking phenotype observed throughout this investigation into the mitochondrial 
role of pVHL is the difference in mitochondrial morphology (Figure 5.1). Cells devoid of 
pVHL function have fused, tubular and elongated mitochondria. Conversely, cells re-
expressing wild type VHL have fragmented, round, and distinct mitochondria. These 
morphological differences were clearly visualised by immunofluorescence and electron 
microscopy (Figure 5.1 and Figure 5.2). Analysis of the major regulators of mitochondrial 
dynamics highlighted a global change in the expression both fusion and fission machinery in 
the 786O cells that was pVHL-dependent, with the expression of the mitochondrially 
localised DRP-1 receptor FIS-1 remaining unchanged. Interestingly, FIS-1 is also involved in 
peroxisomal fission and determination of the amount of FIS-1 protein associated with 
mitochondria versus FIS-1 protein associated with peroxisomes might reveal more subtle 
differences with regard to the total FIS-1 protein levels.  How the loss of any single protein 
(DRP-1, MFN1/2 and OPA-1) involved in mitochondrial fusion and fission affects the 
expression of other fusion and fission machinery is an interesting question. The possibility 
that cellular adaptation to loss of pVHL-dependent expression of a single fusion or fission 
protein has downstream compensatory effects on another fusion and fission protein 
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remains unknown. Interestingly loss of DRP-1 has been observed to decrease protein 
expression of MFN-1 and MFN-2 and alter OPA-1 processing (Ishihara et al., 2009, Möpert 
et al., 2009). 
Although there is clearly less total DRP-1 protein in 786O-EV cells compared with 786O-VHL 
cells, the levels of phosphorylated (Ser637) DRP-1 protein are comparatively higher. DRP-1 is 
the principal mediator of mitochondrial outer membrane fission and is regulated through a 
number of complex post-translational modifications, including phosphorylation, 
nitrosylation, SUMOylation and ubiquitination (Otera et al., 2013). DRP-1 is predominantly 
localised to the cytoplasm and recruited to mitochondria by receptor proteins, such as FIS-
1 and MFF (Losón et al., 2013). DRP-1 is a dynamin-related GTPase and contains multiple 
domains including an amino-terminal GTPase domain and a regulatory region that resides 
on the carboxy-terminal end and comprises the GTPase effector domain (GED) (Cribbs and 
Strack, 2007, Hoppins et al., 2007).  
Different cellular protein kinases control the activation state of DRP-1, through 
phosphorylation on a number of sites, including activation of DRP-1 at Ser616 by  protein 
kinase C delta (PKCδ) (Qi et al., 2011), CDK1/cyclin B (Taguchi et al., 2007) or 
Ca2+/calmodulin-dependent protein kinase Iα (CAMK-Iα) (Han et al., 2008), and inactivation 
at Ser637, by protein kinase A (PKA) (Chang and Blackstone, 2007). DRP-1 phosphorylation at 
a third site, Ser693 in cells undergoing apoptosis is mediated through glycogen synthase 
kinase-3β (GSK3β) (Chou et al., 2012). 
Our studies suggest that pVHL status affects the phosphorylation of Ser637. Phosphorylation 
of DRP-1 on Ser637 by protein kinase A (PKA) inhibits its capacity to induce mitochondrial 
fission (Chang and Blackstone, 2007). This post-translational modification inactivates the 
interaction between the GTPase and the GED of DRP-1, inhibits its GTPase activity and 
therefore inhibits mitochondrial fission (Chang and Blackstone, 2007). Additionally, 
increases in cellular cyclic adenine monophosphate (cAMP) have been shown under 
starvation conditions to activate PKA signalling and phosphorylation of DRP-1 Ser637. 
Inhibition of DRP-1 produces a more fused network and mitochondria which are able to 
escape autophagic turnover through mitophagy (Gomes et al., 2011). To date, no 
association exists in the literature as to a relationship between pVHL status and PKA 
signalling. However future work will involve interrogation of this pathway, either through 
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use of assays for cyclic AMP and kinase activity, siRNA mediated approaches or 
pharmacological inhibition of PKA signalling.  
Calcineurin is a serine/threonine protein phosphatase and has been demonstrated to 
dephosphorylate DRP-1 at Ser637 and promote its recruitment to mitochondria and induce 
fission events (Cereghetti et al., 2008). There are no reported links detailing a direct 
relationship between calcineurin and pVHL, nor are there reports of changes in the 
calcineurin activating agents, calcium and calmodulin with relation to pVHL status. 
However, pVHL-mediated DRP-1 Ser637 dephosphorylation through calcineurin signalling 
could just as likely be the mechanism controlling the activation state of DRP-1 in renal 
carcinoma cells. Understanding the relationship pVHL-calcineurin/calcium signalling may 
prove revealing in understanding these DRP-1 modification events. 
Cycling of DRP-1 protein between the mitochondrial membrane and cytosol is determined 
by the rates of phosphorylation and dephosphorylation of DRP-1. This in turn controls the 
extent to which DRP-1-mediated mitochondria fission follows fusion, an event observed to 
occur in vitro in a similar place on the mitochondrion as early as 20 minutes after 
mitochondrial fusion (Twig, 2008, van der Bliek et al., 2013). DRP-1 recruitment to 
mitochondria is important for fission to occur. FIS-1 promotes DRP-1 recruitment and levels 
of FIS-1 at the mitochondrial outer membrane have been demonstrated to regulate 
mitochondrial morphology (Stojanovski et al., 2004). Enhanced binding of DRP-1 to FIS-1 on 
the mitochondrial outer membrane is also observed after DRP-1 phosphorylation at Ser616 
(Han et al., 2008).  
In contrast to FIS-1, where knockdown does not completely abolish DRP-1 mitochondrial 
recruitment, MFF is necessary for DRP-1 mitochondrial localisation and DRP-1-mediated 
mitochondrial division (Otera et al., 2010). Loss of tumour necrosis factor α (TNFα)-
receptor associated protein-1 (TRAP1) (also known as HSP75; heat shock protein 75) has 
been associated with reduced protein expression of DRP-1 and MFF, promoting 
mitochondrial fusion (Takamura et al., 2012). Intriguing, pVHL re-expression in 786O cells 
has been identified as increasing TRAP1 expression by SAGE analysis (Caldwell et al., 2002), 
potentially linking these observations to the pVHL-dependent morphological phenotype 
described in this chapter. Investigation in to how MFF expression is potentially determined 
by pVHL status may help in understanding the increased presence of DRP-1 protein in 
mitochondrial fractions, after pVHL re-expression in renal carcinoma cells. 
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There is clearly more phosphorylated (Ser616) DRP-1 protein in the 786O-VHL cells 
compared with 786O-EV cells; this however may reflect the correlative difference in basal 
levels of total DRP-1 in the respective 786O cell lines. pVHL has been shown to interact 
directly with the delta and zeta isoforms of protein kinase C (PKCδ and PKCζ respectively) 
and sequester each in the cytoplasm (Pal et al., 1997). Cytoplasmic sequestration prevents 
the PKC isoforms from translocating to the plasma membrane and facilitating downstream 
effects on MAPK signalling. It has also been demonstrated that the activating 
phosphorylation at Ser579 on DRP-1 isoform 3 (corresponding to Ser616 on DRP-1 isoform 1 
(Otera et al., 2013)) can be mediated through PKCδ (Qi et al., 2011). This raises the 
possibility that the presence of pVHL in the 786O-VHL renal cells, pVHL binding to PKCδ, 
maintaining its cytosolic localisation, proximity alone may promote association with 
cytosolic DRP-1 and subsequent phosphorylation, promoting fission. Importantly cytosolic 
pVHL-complexed-PKAδ maintains its activity (Pal et al., 1997). It would be interesting to 
explore the possibility of a pVHL-DRP-1-PKCδ complex which may promote mitochondrial 
fission. Inhibition of PKC signalling, using RNA interference or a specific inhibitor of the 
pathways would allow further dissection of the role of protein kinase signalling in the 
phenotype observed in the presence and absence of functional pVHL. pVHL re-expression 
in 786O cells has been demonstrated to decrease cyclin dependent  kinase-1 (CDK-1) 
protein expression (Kim et al., 2011). Therefore, VHL-mediated phosphorylation of DRP-1 at 
Ser616 in this scenario is unlikely due to a CDK1-dependent mechanism.   
Subcellular fractionation was performed to determine the amount of total DRP-1 protein in 
the cytosol versus DRP-1 protein associated with mitochondria. The subcellular localisation 
of endogenous DRP-1 was assessed in the 786O cells, in the presence and absence of 
functional pVHL. This revealed an increase in the DRP-1: VDAC1 ratio in mitochondrial 
fractions in 786O cells re-expressing pVHL compared to 786O cells devoid of pVHL. This 
may suggest more mitochondrially associated DRP-1 protein and provide the mechanism 
mediating the increase in fragmentation observed in cells expressing wild type pVHL. 
However, these data must be carefully interpreted as there is clearly higher total DRP1 
protein level in 786O-VHL cells compared to 786O-EV cells. Thus, accurately determining 
the differences in relative abundance DRP-1 protein at the mitochondria between the two 
cell lines is challenging.  
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Over-expression of wild type DRP-1 tagged to a fluorescent reporter and high resolution 
imaging would allow investigation into the degree of DRP-1 cytosolic versus mitochondrial 
association. Imaging techniques have been utilised to assess DRP-1 mitochondrial 
localisation after cell treatment with 0.001%  digitonin, to rid the cell of the cytosolic pool 
of DRP-1 making the imaging of DRP-1 associated with mitochondria easier to measure and 
more quantifiable (Losón et al., 2013). Interestingly, in lung adenocarcinoma, DRP-1 has 
been observed as nuclear, an event correlating with poor prognosis and mediated through 
interaction with the human homologue of yeast protein Rad23 protein A (Chiang et al., 
2009). Reduced cytosolic DRP-1 in the 786O-EV cells compared with 7860-VHL cells after 
subcellular fractionation may suggest an abundance of protein elsewhere localised in the 
cell, perhaps the nucleus. Further work may involve nuclear isolation and western blot 
analysis or immunofluorescence of endogenous or fluorescently tagged DRP-1 protein to 
determine subcellular localisation.  
The RCC10-pCMV and RCC10-VHL cells exhibit similarities between the respective pVHL 
negative and positive 786O cell lines respectively, in terms of their mitochondrial 
morphology. Given that 786O cells do not express HIF-1α, it would suggest that the pVHL-
mediated mitochondrial morphological phenotype observed is independent of HIF-1α. 
Expression of the R200W pVHL mutant shares a morphological phenotype similar to that 
observed after wild type pVHL re-expression. This is in spite of the differential stabilisation 
of HIF-2α (Figure 4.15), suggesting the abundance of HIF-2α protein present is not affecting 
this process and morphological changes appear HIF-2α independent. Expression of the 
N78S pVHL mutant appears to share morphological characters similar to those of RCC10-
pCMV. Similarities between loss of function pVHL and N78S pVHL mutant expression and 
between wild type and R200W expression may suggest that the correct formation of the 
ECV E3-ligase complex is the factor responsible for the mitochondrial phenotype and not 
HIF-recognition (discussed in chapter 4). Morphological data also correlates with the data 
presented in the previous chapter (chapter 4), where similarities lie in mitochondrial 
protein expression, total ATP and DNA copy number between pCMV-RCC10 and N78S-
RCC10 and between VHL-RCC10 and R200W-RCC10 (Figure 4.16, Figure 4.17 and Figure 
4.18). As outlined in the previous chapter, future work will be aimed at delineating the 
relationship between pVHL mutation, ECV E3-ligase complex formation and mitochondrial 
phenotype. There is limited information available on the residues responsible and/or 
necessary for the recognition of substrates for pVHL beyond HIF-α. Identification of the 
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regions important in the binding to PKCδ may perhaps shed light on a mechanism for pVHL-
dependent effects on mitochondrial morphology. Analysis of the DRP-1 phosphorylation 
states in the RCC10 cells may also confirm the alterations in mitochondrial fission being the 
mechanism regulating mitochondrial morphology in renal carcinoma cells.  
It could be predicted that the increase in oxidative stress in cells with loss of pVHL function 
would affect mitochondrial morphology (Hervouet et al., 2008). Increased oxidative stress 
has been associated with mitochondrial fragmentation, contradictory to the data presented 
here (Wu et al., 2011). However, other reports suggest that through the oxidation of 
glutathione, mitochondrial fusion is stimulated (Shutt et al., 2012). Paradoxical 
observations, as to the role of oxidants in the regulation of mitochondrial morphology 
possibly reflect an early window of mitochondrial protection and resistance to autophagy 
before mitochondria ultimately yield to cellular stress. It is likely in our system that long-
term oxidative stress, experienced in the absence of pVHL is not the cause of the 
mitochondrial morphological changes observed, as 786O-EV cells exhibit a highly fused 
network, more reflective of an acute glutathione response. These observations contribute 
to the evidence that ROS may not be responsible for the observed pVHL-mediated 
mitochondrial phenotype.  
With the data presented here, it is difficult to determine whether re-expression of pVHL is 
mediating mitochondrial fragmentation, or in cells devoid of functional pVHL mitochondria 
become fused. One important aspect of future work will be to determine the universality of 
these pVHL-mediated effects on mitochondrial morphology. Knockdown of pVHL protein 
using siRNA to determine if the morphological observations can be phenocopied in distinct 
cell lines would be useful to determine if pVHL status is a determining factor in maintaining 
morphology outside of a pathological and over-expression system.  
5.9.2 Cell biological function of mitochondrial fusion and fission 
Mitochondrial dynamic proteins work in tandem to promote a balance of fusion and fission 
events and various cellular conditions have been shown to affect these processes. 
Oxidative stress promotes fusion in the early stages (Shutt et al., 2012) followed by 
fragmentation (Wu et al., 2011) and starvation has been observed to promote 
mitochondrial fusion (Rambold et al., 2011, Gomes et al., 2011). Mitochondrial fission is 
thought to allow distribution of mitochondria to daughter cells after cytokinesis, and 
observations have been made linking cell cycle progression to mitochondrial morphology 
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(Margineantu et al., 2002, Taguchi et al., 2007). Alternatively mitochondrial fusion allows 
for the exchange of mitochondrial components and substrates such as ATP and 
mitochondrial DNA, allowing complementation of DNA mutation or repair (Chen and Chan, 
2004). It has been proposed that mitochondrial morphology can also influence 
mitochondrial DNA copy number and the balance of fusion and fission influences a 
nucleoid’s access to proteins required for replication (Bogenhagen et al., 2008). 
Interestingly, cells with reduced mitochondrial fusion or increased mitochondrial 
fragmentation through genetic loss or reduction of OPA-1 or mitofusins have significantly 
reduced mitochondrial DNA content. Loss of fusion machinery also affects the 
mitochondrial capacity to control the distribution of nucleoids and mitochondria have been 
observed that contain no mitochondrial DNA and are respiratory deficient. There is also 
reduced respiratory capacity in mouse embryonic fibroblasts lacking mitofusins and OPA-1 
(Chan, 2012, Chen et al., 2005).  
Cells devoid of functional pVHL have a reduced mitochondrial DNA copy number compared 
to cells stably re-expressing pVHL. Parone et al have observed that knockdown of DRP-1 
promotes mitochondrial and cellular dysfunction, without causing cell death (Parone et al., 
2008). Upon loss of DRP-1, cells exhibit decreased respiration, ATP levels, mitochondrial 
membrane potential and growth rates with parallel increase in ROS and autophagy. 
Immunofluorescence analysis revealed that the increase in LC3 punctae did not co-localise 
with mitochondria, suggesting they were spared. Interestingly the DRP-1 knockdown also 
caused approximately 50% reduction in mitochondrial DNA copy number and reduced 
mitochondrial nucleoid staining (Parone et al., 2008). These observations correlate well 
with the phenotype observed in 786O cells in the absence of pVHL, suggesting that 
potentially re-expression of pVHL and promotion of mitochondrial fission is responsible for 
changes in bioenergetics, mitochondrial DNA maintenance and energy production.  
pVHL protein levels change during the cell cycle and a reduction in both pVHL isoforms 
occurs at late G1 and during mitosis (Liu et al., 2011). It may be worth investigating the role 
of pVHL on mitochondrial morphology during cell cycle progression. Work in our own lab 
(Afshan Ahmed, unpublished) and data in the literature suggests that re-expression of pVHL 
has been shown to reduce the proportion of cells in S-phase (Hughes et al., 2007) and 
increase cells in G1. Cells in G1 have been observed to have more reticular, interconnected 
mitochondria than those in S-phase, which have a greater degree of mitochondrial 
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fragmentation (Margineantu et al., 2002). Mitochondria were shown to hyperfuse at the 
G1-S boundary and this morphology causes a build-up of cyclin E protein, necessary for S-
phase transition (Mitra et al., 2009). The G1-S boundary corresponds with a decrease in 
pVHL protein and our observations that loss of pVHL promotes mitochondrial elongation 
(Liu et al., 2011). It may be worth exploring the relationship between mitochondrial 
morphology and cell cycle in relation to pVHL status. Investigating the levels of cyclin E in 
these cells and tracking morphology throughout the cell cycle, may allow dissection of any 
potential relationship. 
Collectively, observations to date reflect that a balanced fusion and fission of mitochondria 
is necessary for cellular homeostasis and that perturbations in either direction are 
detrimental to the cell. From the data presented here, it is difficult to determine the degree 
to which mitochondria are dynamically regulated. Whether the 786O-EV cells remain fused 
or if they undergo frequent fusion and fission cycles is an important issue. Determination of 
fusion/fission cycling could be accomplished through live cell time-lapse imaging and 
creation of a mixed population of fluorescently labelled mitochondrial using a fusion assay. 
A number of methods have been developed to study the frequency of mitochondrial fusion 
and fission cycles in vitro. The first is to manufacture two parallel cultures of the same cell 
line artificially expressing probes to differentially label mitochondria, achieved through the 
stable expression of mitochondrial targeted fluorescent reporters. These cells can then be 
fused using polyethylene glycol, creating hybrid cells with respect to mitochondrial label 
and can be analysed for merging of colour and mitochondria. Photo-activatable fluorescent 
proteins have also been utilised to selectively label a subset of mitochondria within a cell 
and observe the transfer of this fluorescence to unlabelled mitochondria (Chan, 2012). One 
may hypothesise that cells without pVHL are more static and by not undergoing frequent 
fusion and fission cycles are unable to share proteins necessary for effective functioning 
and mitochondrial DNA maintenance and energy production. 
It is likely that alterations in mitochondrial morphology dictated by the presence of pVHL 
are a consequence of more subtle effects on mitochondrial protein expression. 
Interestingly, a RNA interference screen in Caenorhabditis elegans demonstrated abnormal 
mitochondrial morphology exhibiting either fragmentation or elongation in over 80% of 
cases after mitochondrial gene knockdown (Ichishita et al., 2008). This suggests that a large 
proportion of integral mitochondrial proteins are important in regulating morphology and 
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mitochondrial protein disruption is likely to result in morphological alteration (Ichishita et 
al., 2008). Interestingly, only 25 of these proteins resulted in mitochondrial elongation, 
many involved in metabolism or transport of metabolites.  
5.9.3 Re-expression of pVHL decreases basal autophagy in cells devoid of functional 
pVHL protein 
Autophagy is an adaptive process by which the cell non-selectively degrades and recycles 
cytosolic components. Cellular proteins, organelles and cytoplasm are sequestered, 
delivered to the lysosome and subsequently degradation by acid hydrolyses (He and 
Klionsky, 2009). The engulfment of cellular components is accomplished through formation 
of an isolation membrane of unknown origin. This membrane elongates and encapsulates 
cytosolic material forming a double membrane vesicle, known as the autophagosome, a 
specialised unique organelle responsible for this engulfment of cellular protein and 
organelle recycling (Mizushima, 2007). Three types of autophagy are recognised; 
microautophagy, chaperone-mediated autophagy and macroautophagy. The process of 
macroautophagy is considered the main route of cytoplasm-to-lysosome delivery and 
widely termed “autophagy” (Mizushima, 2005).  
Autophagy consists of a number of distinct phases and involves the orchestrated effort of a 
large number of protein controllers. Autophagy can either be triggered, for the production 
of amino acids under starvation conditions, known as “induced autophagy” or for the 
constitutive turnover of cytosolic components. This constitutive turnover is a quality 
control, homeostatic process involving the removal of damaged/aged organelles and long-
lived proteins, known as “basal autophagy” (Mizushima, 2007). Autophagy is regulated by a 
large number of ATG proteins, which are recruited upon autophagic induction and are 
highly conserved between yeast and mammalian cells (Meléndez and Neufeld, 2008). 
Autophagy can be induced by nutrient starvation, such as amino acid and serum starvation 
in cell culture. The serine/threonine protein kinase mammalian target of rapamycin (mTOR) 
is considered the master regulator of nutrient sensing and signalling in the cell. Many 
signals that affect autophagic flux are mediated through mTOR and inhibitors of this 
pathway such as rapamycin, induce autophagy and are often used experimentally to study 
this pathway (Mizushima, 2007, He and Klionsky, 2009). Many pathways and proteins in 
addition to mTOR have also been shown to affect autophagy, including ROS and calcium 
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signalling, BCL-2 family proteins, AMP activated protein kinase (AMPK) and BNIP3, among 
others (Mizushima, 2007).  
The initial sequence of steps of the process an isolation membrane forms, from an as yet 
unknown origin, elongates to form the pre-autophagosomal structure (PAS) and begins to 
engulf and trap cytosolic components before fusing and forming the double membrane 
vesicle known as the autophagosome (Ravikumar et al., 2010). Autophagosomes then fuse 
with endosomes to form an intermediate know as an amphisome before fusing with the 
lysosome and creating the autophagolysosome. The content of the autophagosome are 
then degraded by the acid proteases within the lysosomal compartment and amino acids 
recycled (Ravikumar et al., 2010).  
Microtubule-associated protein 1 light chain 3 (LC3), is the only identified protein of the 
inner autophagosome membrane. Synthesised as a pre-cursor, it is cleaved at its C-
terminus and forming LC3-I, which resides in the cell cytoplasm. ATG7 and ATG3 are 
involved in the lipidation of LC3-I with PE to form LC3-II, which allows targeting to both 
sides of the membrane of the elongating autophagosome. Membrane associated LC3-II is 
thought to control the membrane size, tethering and hemifusion and thought to be 
necessary for the expansion and final fusion of the autophagosome (He and Klionsky, 2009, 
Ravikumar et al., 2010). LC3-II on the outer autophagosome membrane gets recycled and 
that on the inner membrane degraded after lysosomal fusion. ATG5-ATG12 conjugation is 
also necessary for elongation and maturation of the of the autophagosome (He and 
Klionsky, 2009). Autophagosomes are not static structures and utilise the microtubules to 
traffic to the peri-nuclear region where there is greater abundance of lysosomes and 
disruption of this process will lead to inhibition of autophagy (Ravikumar et al., 2010). 
Autophagosomes will fuse with endosomes and then with lysosomes, which requires 
lysosomal-associated membrane protein-2 (LAMP-2) and RAB7. Autophagosome contents 
are degraded by the acid proteases and released for utilisation in cellular process to 
maintain cellular function in response to the autophagic trigger (He and Klionsky, 2009). 
Here, we found that pVHL status affects the basal levels of lipidated LC3B protein. In the 
absence of any stimuli, stable re-expression of pVHL in 786O cells results in a decrease in 
lipidated LC3B (LC3B-II) under basal conditions compared with 786O cells devoid of 
functional pVHL. As discussed, interpretation of this could go a number of ways. Either 
there is increased autophagosome synthesis, or decreased turnover of autophagosomes, in 
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cells lacking functional pVHL. Newly synthesised LC3B is immediately cleaved to form 
cytosolic LC3-I. Under conditions that promote autophagy, LC3B-I is post-translationally 
modified through the addition of a PE group, by a ubiquitin-like system involving ATG7 and 
ATG3, forming the lipidated form, LC3B-II which becomes associated with the 
autophagosomal membrane. 
Inhibition of the lysosome, achieved after incubation with chloroquine, promotes an 
increase in LC3B-II in both 786O-VHL and 786O-EV cell lines. The addition of chloroquine, 
clamps autophagosome degradation, so is a measure of LC3B-II/autophagosome synthesis 
(Rubinsztein et al., 2009). Independent of pVHL status, the addition of chloroquine 
increases LC3B-II protein levels, therefore loss of pVHL increases LC3B-II levels both in the 
presence and absence of lysosomal blockade. It is likely that the increase in synthesis likely 
occurs alongside delivery to the lysosome, however increased LC3B-II synthesis occurring 
parallel to decreased degradation may also be an explanation (Rubinsztein et al., 2009). 
Therefore, this suggests that in both cell lines, autophagosome synthesis is intact. Further 
analysis is however necessary to determine the extent to which rates of autophagy differ 
dependent on pVHL status. 
Activation of the class III PI3K, VPS34 by the small GTPase RAB5 is required for the initiation 
of a new phagophore membrane and autophagosome (He and Klionsky, 2009, Ravikumar 
et al., 2010). VPS34 is a member of a multi-protein complex which includes beclin among 
others and it is this association which increases the activity of VPS34 (Ravikumar et al., 
2010). Beclin can bind a number of proteins; however its availability to bind VPS34 affects 
autophagosome formation. One of the proteins that binds beclin is BCL-2. This relationship 
negatively regulates autophagy by sequestering beclin away from VPS34 under nutrient 
rich conditions and preventing free beclin inducing autophagy (Pattingre et al., 2005). 
786O-VHL cells express higher levels of BCL-2 and BCL-XL (Schoenfeld et al., 2000b) and 
interestingly both BH3-domain proteins have been observed to bind beclin (Maiuri et al., 
2007). Although our results demonstrate equal amounts of beclin between 786O-VHL and 
786O-EV cells, a hypothesis would be that there is more available beclin in cells without 
functional pVHL, due the reduction in BCL-XL and BCL-2 protein expression. This may 
suggest there is proportionally greater free beclin in the 786O-EV cells, contributing to the 
increase in autophagosomal/autolysosomal structures observed in these cells. Co-
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immunoprecipitation of the beclin-BCL-protein interaction may provide insight into this 
potential mechanism. 
pVHL has recently been observed to play a role in regulating autophagy, through both HIF-α 
dependent and independent mechanisms (Mikhaylova et al., 2012). pVHL has been 
observed to positively regulate miR-204, independent of hypoxia or PHD inhibition 
(Mikhaylova et al., 2012). Treatment of cells with miR-204 significantly reduces the number 
of autophagosomes in pVHL negative cells without effect on those with stable pVHL re-
expression. miR-204 inhibits the formation of autophagosomes, through a direct targeting 
of LC3B. Knockdown of LC3B resulted in significant inhibition of tumour growth in vivo 
suggesting that LC3B-mediated autophagy is necessary for RCC tumour growth. 
Additionally, through inhibition of HIF-2α, pVHL regulates the expression of LC3C, a 
paralogue of LC3B, which functions as a tumour suppressor and loss in vivo results in the 
increased incidence of small tumour growth in kidneys of nude mice. Hence there appears 
to be a distinction between anti-tumourigenic autophagy and pro-tumourigenic autophagy 
with the presence of pVHL promoting the first and suppressing the latter (Mikhaylova et al., 
2012).  
Interestingly, we have identified significant differences in the transcript levels of LC3B in 
the presence and absence of functional pVHL, however it is not currently established 
whether changes in the mRNA expression of autophagic proteins induces or inhibits the 
autophagic process (Klionsky et al., 2012). However, LC3B transcript expression has been 
shown to increase under conditions of ER stress and hypoxia through activation of the 
unfolded protein response (Rouschop et al., 2010). Our results demonstrate a reduced 
LC3B transcript expression in cells lacking functional pVHL. Under conditions of ER stress, it 
is hypothesised that the increase in LC3B expression compensates for the enhanced LC3B 
turnover after prolonged-hypoxia-induced autophagy (Rouschop et al., 2010). On this basis, 
the observed decrease in expression of LC3B mRNA could be an indicator of reduced 
autophagic flux and the cells requiring lower levels of transcript to replace degraded LC3B-
II. However, other indicators suggest the autophagic flux in 786O-EV cells is higher than 
786O-VHL. Based on our data, one could hypothesise that the rate of flux in the 786O-EV 
cells is higher than those with high levels of pVHL re-expressed and a cellular response is to 
stall the process, limiting excessive cellular autophagy, by reducing LC3B transcript 
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expression. Knockdown and over-expression of pVHL in a distinct cell line would be useful 
to test this hypothesis.  
The observed sensitivity of pVHL negative cells to inhibition of autophagy supports the 
notion that they are more dependent on the autophagic process. Linking the altered 
mitochondrial morphology to the decreased autophagic flux after pVHL re-expression, may 
suggest that in the absence of pVHL, the increase in mitochondrial length and network 
elongation is a mechanism through which mitochondria are spared from autophagic 
degradation.  
5.9.4 Assays for monitoring autophagy and future work 
To further characterise the relationship between pVHL and autophagy additional work is 
necessary. Classically electron microscopy is performed after starvation with HBSS and 
addition of chloroquine to investigate the number of autophagosomes and autolysosomes 
observed. This would however require expertise in their identification and has often been 
published incorrectly (Eskelinen, 2008). Autophagosomes are identified as double 
membrane bound organelles or structure containing undigested cytosolic components and 
not fused with a lysosome (Mizushima et al., 2010). Autolysosomes are also difficult to 
identify, as often degradation of cytosolic components deposited from autophagosomes 
has proceeded to a degree that makes organelle and content identification impossible.  
Fluorescence microscopy is a useful tool in studying autophagy. LC3B can be visualised 
using traditional immunofluorescence methods of endogenous protein or by over-
expression of GFP-tagged construct. Punctate distribution would indicate autophagosomal 
formation as LC3B-II associates with both the inner and outer membrane of the 
autophagosomes (Mizushima et al., 2010). Changes in the number of punctae per cell could 
indicate changes in autophagosome number and flux can be determined by combining this 
approach with inhibition of the lysosome. Using the same GFP-LC3 construct, flux related 
changes in total LC3B can be interpreted quantitatively either through flow cytometry or 
qualitatively through SDS-PAGE and western blot. The GFP-LC3 construct is cleaved by the 
lysosomal proteases and results in free GFP which can be identified by GFP-specific 
antibodies by immunoblot (Mizushima et al., 2010).  
The final assay to monitor autophagic flux would be through use of a red fluorescent 
protein (RFP) that is stable and unlike GFP not quenched by the lysosome. The tandem 
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construct would encode RFP-LC3B-GFP and autophagosomes could be tracked as yellow 
signals and autolysosomes as red (Mizushima et al., 2010). Increases in yellow and red 
signals would indicate increases increase in autophagic flux, however if red fails to increase, 
this suggests that there is interference at the terminal end of the process and 
autophagosome-autolysosome maturation (Mizushima et al., 2010).  
The assays detailed above would be necessary first to confirm the increase in autophagy 
observed in the cells devoid of functional pVHL and that the pathway progresses to 
completion. It is also important to investigate the role of pVHL in another cellular context. 
Either through RNA interference and determine change in autophagic flux or over-
expression in combination of autophagic induction and observe protection. Removal of 
mitochondria during periods of starvation is thought to induce a metabolic catastrophe, 
whereby cells resort to cytosolic ATP to maintain membrane potential, ultimately 
promoting bioenergetic crisis and cell death (Gomes et al., 2011). Working from the 
hypothesis that mitochondria elongate in the absence of pVHL to avoid turnover through 
non-selective autophagy, as observed elsewhere under cellular starvation (Gomes et al., 
2011, Rambold et al., 2011), a number of experiments would provide insight in the 
relationship between pVHL status, mitochondrial morphology and autophagy. If this was 
the situation, over-expression of wild type DRP-1 in pVHL deficient cells would be expected 
to precipitate cellular dysfunction, through autophagic mitochondrial degradation and 
reduce viability. Alternatively, rather than promoting fission through DRP-1 over-
expression, inhibiting mitochondrial fusion using RNA interference in cells devoid of 
functional pVHL, to target the mitofusins would precipitate unopposed fission and allow 
determination of cell survival/growth.  
Inhibition of autophagy using 3-methyladenine (3-MA) and determination of mitochondrial 
morphology may provide insight into whether the observed tubular fused network present 
in the cells devoid of functional pVHL protein is a consequence of increased basal 
autophagy and cellular adaptation to stress through maintenance of mitochondrial 
functionality and ATP production. Rapamycin promotes autophagy by inhibition of mTOR. 
Treatment of 786O-VHL cells with rapamycin may provide a correlative link between 
mitochondrial elongation and autophagy in cells devoid of functional pVHL. 
In light of the significant increase in parkin expression in pVHL positive 786O cells, 
mitophagic flux needs to be assessed. Mitophagic flux can be assessed using the same 
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assay as for analysis of autophagy, however FCCP and mitochondrial uncoupling is 
necessary induce the processes in place of HBSS or rapamycin. FCCP depolarises 
mitochondria, inhibits PINK1 cleavage and facilitates parkin recruitment and ubiquitination 
of mitochondrial substrates. It is to ubiquitinated proteins which the p62 adaptor protein 
binds and ultimately facilitates mitochondrial turnover and degradation by the lysosome. 
This assay would reveal an insight in to any effects on mitophagy regulated by pVHL of the 
effects on parkin expression. 
5.9.5 Re-expression of pVHL affects parkin mRNA and protein expression 
Mitochondrial fission is important for promoting clearance of damaged or depolarised 
mitochondria through mitochondrial specific autophagy or mitophagy. Having observed a 
dysfunctional mitochondrial phenotype in the absence of pVHL and the paralleled 
elongated morphology raises questions over mitochondrial quality control and 
maintenance of function. Hence, are dysfunctional mitochondrial avoiding mitophagic 
clearance through morphological changes and down-regulation of quality control proteins?  
Questions remain over the role of pVHL in the regulation of parkin, but the results are 
intriguing and knockdown of VHL in a distinct cell line and consideration of the presence of 
HIF-1α protein are required to understand this relationship further.  
The increase in parkin expression in the 786O cells after pVHL re-expression is large and 
highly significant. Parkin is a RING-in-between-RING (RBR) E3-ubiquitin ligase and exhibits 
low activity in vitro and exists mainly in an auto-ubiquitinated conformation (Trempe et al., 
2013, Chaugule et al., 2011). It is an unusual E3-ligase as it has multiple substrates, can bind 
multiple E2-ubiquitin ligases and has been demonstrated to play a role in multiple cellular 
processes, including mitophagy (Trempe et al., 2013). Why there is a decrease in parkin in 
these cells remains unanswered and is an interesting question. This reduction in parkin 
expression has been observed in a number of cancers, with parkin acting as a putative 
tumour suppressor protein (Veeriah et al., 2010), however not yet identified as being 
rescued through genetic manipulation as observed in this chapter after pVHL re-expression.  
Parkin has also been shown to affect mitochondrial morphology. In Drosophila 
melanogaster the PINK1/parkin pathways has been observed to promote fission and/or 
inhibit mitochondrial fusion (Deng et al., 2008, Poole, 2008) and in rat hippocampal 
neurones, over-expression of parkin and PINK1 has been observed to increase 
mitochondrial number and decrease size, suggesting a role in mediating membrane fission 
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(Yu et al., 2011). In parkin mutant human fibroblasts, an elongated and branched 
morphological phenotype is also observed (Mortiboys et al., 2008). With reference to the 
786O-VHL cells, the increase in parkin expression may be preventing fusion of mitochondria 
or promoting fission as described. Alternatively the decrease in the expression of parkin 
could be an advantage for the cancer cells to avoid autophagy and “hyperfuse” to prevent 
engulfment by the autophagosome, such as what happens under nutrient starvation 
(Rambold et al., 2011, Gomes et al., 2011).  
There are a number of mechanisms though which parkin may affect the fusion and fission 
balance of mitochondria. FIS-1 has been identified as being ubiquitinated and physically 
interacting with parkin (Sarraf et al., 2013) and parkin has been observed to ubiquitinate 
and promote turnover of DRP-1, precipitating mitochondrial fusion (Wang et al., 2011). 
Both mitofusins have been observed to be ubiquitinated by parkin and degraded through a 
mechanism involving the AAA-protease p97 and the proteasome (Tanaka et al., 2010). 
Ubiquitination of mitofusins, prior to their proteasomal turnover, has been suggested to 
interfere with their tethering, a pre-requisite for mitochondrial elongation and interesting 
for the view of the fragmented mitochondria observed in the parkin expressing 786O-VHL 
cells (Ziviani and Whitworth, 2010). Finally, of note is the potential ubiquitination of 
MARCH5 by parkin. MARCH5 has been shown to ubiquitinate DRP-1 and mutant MARCH5 
or knockdown has been observed to induce mitochondrial elongation (Reddy et al., 2011, 
Karbowski et al., 2007). The consequence of the parkin mediated ubiquitination of MARCH5 
is unknown but remains a possibility for an indirect effect on mitochondrial morphology. 
The mitochondrial-depolarisation dependent parkin ubiquitylome has identified a number 
of additional novel and interesting substrates for parkin, including proteins involved in 
mitochondrial function, including; import, metabolism, fission and fusion and trafficking 
(Sarraf et al., 2013). Parkin clearly appears to promote proteasomal turnover of a large 
number of proteins, however on distinct substrates parkin-mediated non-degradative 
ubiquitination may serve in signalling and cellular communication (Sarraf et al., 2013) and 
as such only time will reveal the true diversity and extent as to the role of parkin. 
Expression of wild type parkin into the 786O-EV cells would be evidence of a role for it in 
normal physiology if it were to have any influence on mitochondrial DNA copy number or 
morphology in the 786O cells. In acknowledgment of the decrease in the parkin in the 
786O-EV cells compared to the 786O-VHL cells and its characterised role in mitophagy, it 
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would be useful to look at a time course of chemical uncoupler mediated membrane 
depolarisation and investigate turnover of established parkin substrates and how this 
impacts their clearance by autophagy/mitophagy. Experiments using the FK1 clone of anti-
ubiquitin antibody and subsequent mitochondrial isolation and western blot analysis or 
immunofluorescence using a mitochondrial marker would allow investigation of the 
relative degree of protein ubiquitination in the presence and absence of parkin and pVHL.  
It is however possible to link the observed decrease in parkin expression, mitochondrial 
morphology changes and effects on autophagy observed in the 786O cells in the presence 
and absence of pVHL. A reduction in parkin expression observed, efficiency of 
mitochondrial clearance may be limited. To maintain fidelity, mitochondria may be forced 
to undergo complementation and hence fusion to share components between healthy and 
dysfunctional mitochondria. This would produce a phenotype with elongated 
mitochondria, decreased mitochondrial DNA content and increase in ROS (Youle and van 
der Bliek, 2012).  
Further work, expanding on these observations is necessary. A number of methods to 
monitor mitochondrial autophagy are available. Co-localisation of mitochondria and 
autophagosome can be employed to determine the delivery of mitochondria to the 
lysosomal compartment. Transfection with GFP-LC3 and visualisation of a mitochondrial 
protein, such as translocase of the outer membrane 20 (TOMM20) or VDAC1 and assessing 
co-localisation of the signal will give an indication of the degree of sequestration. 
Alternatively co-localisation of mitochondria with the lysosome could be analysed either in 
fixed cells using markers to each, such LAMP2 for the lysosome. In live cells this can be 
achieved using  MitoTracker® and LysoTracker® dyes, where a merging of colours would 
indicate completion of fusion (Klionsky et al., 2012). EM would facilitate the identification 
of mitochondrial cargo within the autophagosomes and could be combined with lysosomal 
inhibitors to trap the structures. Finally, it may be necessary to induce mitochondrial 
depolarisation to facilitate an increase in mitophagic flux. It must be considered here 
though that this a chemical approach and not a physiological. Together these assays would 
be useful with regard to further delineating the significance of the increased parkin 
expression observed after pVHL re-expression, its role in mitochondrial function and 
ultimately renal disease. 
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Notably, all discussed ubiquitination events occur after mitochondrial depolarisation by 
pharmacological means and results may be not physiologically relevant as activity of parkin, 
at least in vitro without depolarisation is low. There is still much to learn about the 
functional consequence of parkin mediated ubiquitination and it is a rapidly expanding 
field. The observed difference in parkin expression in the 786O cells will undoubtedly have 
functional effect, but more work is necessary to determine what that is and to what cellular 
process they belong. Questions remain about the role of parkin without membrane 
depolarisation. Although it has been observed to have low activity under basal conditions, 
the altered parkin expression may be important in regulating low level ubiquitination 
events in the absence of stress and activation of autophagy. Vincow et al produced a 
brilliant study on the role of the PINK1-parkin pathway in Drosophila melanogaster to 
address the question as to the role of this mitophagic pathway in vivo, using a proteomic 
approach to assess mitochondrial protein turnover in parkin null flies (Vincow et al., 2013). 
They observed that in the absence of parkin, flies demonstrated a slower turnover and 
significantly prolonged half-life of mitochondrial proteins compared to controls, suggestive 
of decreased/impaired basal mitophagy. They performed the same study with atg7 
knockout flies and found that as expected mitochondrial protein turnover showed greater 
dependence on ATG7, as this acts downstream of parkin. However 40 mitochondrial 
proteins, demonstrated greater dependence on parkin, with electron transport chain 
components being over-represented in this group. More interestingly these included 
mitochondrially encoded ETC subunit proteins from all five complexes and a 
disproportionate number of membrane bound proteins. This suggests parkin has a role in 
addition to mitophagy, in the selective turnover of respiratory chain proteins, an effect 
which required PINK1 (Vincow et al., 2013). The authors propose that the selective 
turnover of these proteins may participate in the complex I pathologies observed with 
parkin and PINK1 loss of function studies, through mis-folding (Vincow et al., 2013). Parkin-
dependent selective ETC protein turnover is also interesting from the perspective of the 
786O cells and the lack of parkin the 786O-EV cells as the decreased abundance of ETC 
complex proteins in these cell may be result of mis-folding, due to decreased parkin-
mediated turnover.  
5.9.6 The pVHL-p62 relationship 
Interestingly p62 has been shown as necessary for parkin-induced, peri-nuclear clustering 
of depolarised mitochondria (Okatsu, 2010), but not necessary for mitophagy to occur 
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(Narendra et al., 2010). Hence, p62 is dispensable and not rate-limiting for parkin-induced 
mitophagy, suggesting that there are p62 independent mechanisms that are capable of 
mitochondrial turnover (Narendra et al., 2010). In this chapter, we observed increased 
basal levels of p62 protein and no parallel change in the transcript levels in 786O cells 
stably re-expressing pVHL compared with 786O-EV cells. Similarly to LC3B, p62 has been 
demonstrated to be transcriptionally regulated during autophagy (He and Klionsky, 2009, 
Klionsky et al., 2012). The absence of a transcriptional change suggests the p62 phenotype 
observed is on the level of protein stability or turnover. 
p62 is a ubiquitin scaffold binding protein and binds directly to LC3B  (Bjørkøy et al., 2005). 
p62 is itself turned-over by the autophagic machinery and is proposed to be the 
mechanism through which ubiquitinated proteins are aggregated and targeted to the 
isolation membrane. Therefore p62 serves as the scaffolding protein between ubiquitin and 
LC3B-II on the autophagosome (Bjørkøy et al., 2009). p62 accumulates when autophagy is 
inhibited or there are defects in degradation and decreases under periods of autophagic 
induction. Therefore p62 protein levels are a useful indicator of flux in some scenarios and 
have been used as such in a number of studies (Klionsky et al., 2012). A role for ubiquitin 
and p62 in selective autophagy has been well reviewed elsewhere (Kirkin et al., 2009).  
Western blot analysis of p62 under conditions of induced autophagy often demonstrates a 
reduction in protein levels, as observed in the 786O-EV cells compared with 786O-VHL 
cells, suggesting an increase in autophagic flux in these cells. Interestingly p62 containing 
aggregates are insoluble under certain lysis conditions, including Triton-X (Klionsky et al., 
2012) and likely NP-40, as used throughout these experiments, as both have similar 
detergent properties. Future experiment would involve using NP-40 lysis buffer (as 
described in materials and methods) with the addition 1-2% SDS to analyse the p62 levels 
in the soluble and insoluble fractions in the absence and presence of functional pVHL. This 
would allow interpretation of the extent of p62 oligomerisation and aggresome formation 
(Klionsky et al., 2012). Parkin is required for the initial ubiquitination event that allows p62 
targeting of mitochondria and subsequent clustering (Okatsu, 2010). Therefore 
immunofluorescence of p62 and the identification of aggresomes containing mitochondria, 
would give insight into the consequence of the differential parkin expression between the 
786O cells.  
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5.10 Summary  
The mechanistic basis underlying the changes in pVHL-mediated mitochondrial 
morphology, remain unknown, however we can speculate as to their being a role for basal 
autophagy, DRP-1 and potentially parkin. There is evidence to suggest that mitochondria 
elongate during autophagy, such that they are spared from degradation and able to 
maintain cellular viability. Under starvation, cAMP is increased and activates PKA to 
promote mitochondrial elongation (Gomes et al., 2011). Gomes et al identified that during 
starvation induced autophagy the phosphorylation of DRP-1 at Ser637 promotes 
mitochondrial elongation by negative regulation of fission and maintaining a cytosolic 
localisation for DRP-1  (Gomes et al., 2011). In the 786O-EV cells, in the absence of 
functional pVHL, there is a clear increase in the number of autophagosomes and 
mitochondria appear more elongated compared to 786O cells stably re-expressing wild 
type pVHL. It is tempting to speculate that the increased basal autophagy is promoting 
DRP-1 phosphorylation at Ser637 to maintain cellular integrity and viability.  
Extending the observations of Vincow et al (Vincow et al., 2013), loss of parkin expression 
in cells devoid of functional pVHL may be responsible for the decreased ETC protein 
expression in these cells. Reduced selective turnover of proteins may precipitate 
dysfunctional complexes and mis-folding and bioenergetic deficiency. Fusion of 
dysfunctional mitochondria to allow complementation would link the loss of mitochondrial 
DNA content observed in the absence of pVHL.  
It would be interesting and useful to explore by a proteomic approach pVHL ubiquitination 
or interacting targets, in a similar experiment to Lai et al (Lai et al., 2011) and Sarraf et al 
(Sarraf et al., 2013), to understand the extent of the diversity of pVHL targets and how 
these impact on mitochondrial biology. Targets of pVHL-mediated ubiquitination have 
already been observed to serve as recognition sites for the scaffold protein p62 and be 
targeted to the autophagosome through LC3B binding (Gao et al., 2010). Hence potentially 
pVHL-mediated ubiquitination of substrates, yet to be elucidated may also be regulated 
through this mechanism, linking pVHL status to cellular protein/organelle quality control.  
Important questions remain: 
(i) Does the bioenergetic state of 786O-EV cells dictate mitochondrial shape 
or does mitochondrial morphology dictate bioenergetic state? 
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(ii) Is the mechanism of pVHL-mediated mitochondrial morphological change 
at the level of DRP-1 and/or autophagy and what would be the 
consequences of reversing this? 
(iii) How does the reduction in parkin expression affect mitochondrial turnover, 
morphology and function? 
(iv) What is the relationship between parkin-mediated turnover of 
mitochondria and/or proteins and the biogenesis of new mitochondria? 
(v) Do these observations extend to other forms of renal cell carcinoma and 
distinct cell lines? 
At this stage it is difficult to elucidate cause from effect. Further work with respect to genes 
and proteins regulated by pVHL expression, analysis of downstream effectors and 
potentially consideration of pVHL-regulated microRNAs may provide insight into these 
questions.  
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6.1 Introduction 
HIF-1α and HIF-2α are highly related proteins, share 48% sequence similarity and are both 
induced in response to hypoxia (Tian et al., 1997, Hu et al., 2003). A number of gene sets 
regulated by HIF-1α and HIF-2α are identical; however individually each protein is capable 
of transactivating non-overlapping, distinct gene sets, suggesting diverse cellular 
phenotypes can be regulated by the HIFs. For example, HIF-1α specifically induces a variety 
of proteins involved in the up-regulation of glycolysis and this contributes to the Warburg 
effect in tumours (Hu et al., 2003), while HIF-2α has little role in promoting a glycolytic 
phenotype (Hu et al., 2003). Interestingly, differential binding of transcriptional co-factors 
within the N-terminal transactivation domain of HIF-α is a defining factor in the promotion 
of specific target gene expression thought to be responsible for different gene sets 
activated by either HIF-1α or HIF-2α (Hu et al., 2007).  
The differential effect of HIF-1α and HIF-2α also extends to their role in tumourigenesis. A 
clear distinction can be made as to the role of HIF-α proteins in cancer, particularly with 
respect to renal cell carcinoma (RCC), where HIF-2α appears to function as a tumour 
promoter and HIF-1α a tumour suppressor (Shen and Kaelin Jr, 2013). Loss of HIF-1α is 
commonly observed in clear cell renal carcinoma, which frequently stems from deletion of 
chromosome 14q, on which HIF-1α resides (Shen and Kaelin Jr, 2013). Over-expression of 
HIF-1α in RCC cell lines, that are devoid of HIF-1α, but express HIF-2α, decreases their 
proliferation (Shen and Kaelin Jr, 2013, Raval et al., 2005). Conversely, to date most clear 
cell renal carcinomas analysed, with mutated pVHL express constitutive HIF-2α protein. 
Loss of HIF-2α protein rescues the tumourigenic phenotype in a similar fashion to pVHL re-
expression and causes failure of tumour growth in nude mice (Kondo et al., 2003, Shen and 
Kaelin Jr, 2013). Interestingly however, HIF-2α has been observed as exhibiting tumour 
suppressor activities depending on the tumour context (Acker, 2005). The discrepancies 
between pro- and anti-tumour activities of HIF-2α function are not well understood, but 
the long-standing belief that HIF-1α and HIF-2α proteins exhibit largely overlapping 
functions has been dismissed. It is now clear that their roles, albeit coinciding in some 
instance, are non-redundant, can promote distinct phenotypes and may even have 
opposing roles when expressed in the same cell type (Keith et al., 2012). Interestingly, HIF-
2α protein induction in hypoxia is detected for up to 48 hours, while HIF-1α protein 
declines by 24 hours (Holmquist-Mengelbier, 2006). 
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The HIFs form the crossroads of the adaptive response to hypoxia, allowing the cell to 
survive, proliferate and maintain homeostasis. Importantly, the transcriptional capacity of 
the HIFs has been observed even under ambient oxygen (Huang et al., 2004, Cramer and 
Johnson, 2003). Although the half-life of the alpha subunit is approximately three to five 
minutes, the basal transcriptional role of these factors has been observed as critical and 
necessary in the number of situations. For example, as discussed in chapter 3, HIF is 
important for correct heart function. Mice with cardiac-specific knock out of Hif-1α, using 
cre-lox technology and a myosin light chain promoter exhibited contractile dysfunction, 
due to altered calcium signalling, hypovascularity and changes in energy metabolism 
(Huang et al., 2004). Cramer et al have also observed basal HIF-1α transcription in myeloid 
cells (macrophages and neutrophils) (Cramer et al., 2003). Conditional loss of HIF-1α in the 
myeloid lineage leads to dramatically reduced expression of glycolytic genes and decreased 
cellular ATP pool, affecting myeloid cell activation and bacterial killing. Cramer et al suggest 
that HIF-1α is functioning as a controller of basal metabolism in these cells and has a role in 
mediating inflammatory capacity (Cramer et al., 2003). Together, these observations 
suggest that basal transcription through the HIF pathway is important in both physiology 
and pathophysiology. 
When compared with HIF-1α, the role of HIF-2α has been understudied with respect to its 
role in mitochondrial function and homeostasis. HIF-2α has been shown to regulate 
antioxidant defence and ROS homeostasis through transcriptional regulation of Sod2 in the 
Epas1/Hif-2α-/- mouse, which exhibits increased oxidative stress as well as a reduced 
response to oxidative stress (Scortegagna et al., 2003). Loss of HIF-2α protein also affects 
other mediators of the antioxidant response, such as haem oxygenase and glutathione 
peroxidise among others (Bertout, 2009, Scortegagna et al., 2003). 
To date, only one study investigating the role of global knockout of Epas1/Hif-2α-/- and the 
consequence on mitochondria isolated from hepatocytes has been published (Oktay et al., 
2007). The global knockout of Epas1/Hif-2α-/- mice display a mitochondrial disease-like 
phenotype; have mitochondrial ultra-structural abnormalities and compensatory up-
regulation of succinate dehydrogenase and cytochrome c oxidase. The phenotype of these 
mice closely resembles the phenotype of the Sod2 (Sod2-/-) knockout mice (Oktay et al., 
2007). SOD2 has previously been identified as a HIF-2 transcriptional target and is 
transcriptionally up-regulated by HIF-2α over-expression (Scortegagna et al., 2003). 
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Mitochondria isolated from Epas1/Hif-2α-/- mice exhibited increased oxidative stress, 
reduced respiration, sensitised mPTP opening and reduced activity of mitochondrial 
aconitase and α-ketoglutarate dehydrogenase (αKGDH), while ETC complex activities were 
retained (Oktay et al., 2007). The observed phenotype was a consequence of oxidative 
damage to αKGDH and down-regulation of the HIF-2α target gene, frataxin, a chaperone 
for aconitase. Loss of frataxin promoted oxidative damage to aconitase and highlighted the 
role of HIF-2α basal transcription in healthy physiology under ambient oxygen (Oktay et al., 
2007).  
In this chapter, as in chapters 4 and 5, the 786O cell model was utilised to understand the 
functional consequences of pVHL’s effects on mitochondrial function. Patient derived 786O 
cells exhibit constitutively stabilised HIF-2α due to biallelic inactivation of VHL. The role of 
HIF-2α in the pVHL-dependent alterations in mitochondrial proteins has been addressed in 
chapter 4 and will be further explored in this chapter. Specifically, the role of constitutively 
expressed HIF-2α protein will be addressed with respect to distinct mitochondrial 
parameters after pVHL loss, including effects on bioenergetics, mitochondrial DNA 
maintenance, morphology and autophagy. Additionally the role of basal HIF-2α protein will 
be addressed using RNAi techniques.  
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6.2 Hypothesis 
HIF-2α is important for the maintenance of mitochondrial homeostasis. 
 
 
6.3 Aims 
1. To characterise the role of HIF-2α in pVHL-mediated regulation of mitochondria.  
 
2. To evaluate the effects of HIF-2α silencing on mitochondrial function and 
homeostasis.  
 
3. To investigate the mechanistic basis for the role of HIF-2α in pVHL-dependent and -
independent regulation of mitochondrial function.  
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6.4 The effect of silencing HIF-2α on target gene expression in the 786O 
cell model 
The 786O cell model has proved a useful system for dissecting the role of pVHL in 
regulating mitochondrial function (chapters 4 and 5). Using the 786O cells, the effects of 
both constitutively stabilised HIF-2α, and loss of HIF-2α (using siRNA), can be investigated. 
786O cells lack functional pVHL and HIF-1α protein, allowing specific dissection of the role 
of HIF-2α, without any compensatory or confounding effects of stabilised HIF-1α, providing 
rationale for their use. The evaluation of 786O cells stably re-expressing functional pVHL 
has also provided a platform to understand how pVHL influences mitochondrial function 
(chapters 4 and 5). This chapter aims to investigate the role of HIF-2α in the pVHL-
dependent mitochondrial effects described previously (chapters 4 and 5).  
To confirm the suitability and ease of manipulation of the 786O cell model, HIF-2α was 
silenced in both the 786O-EV and 786O-VHL cell lines and compared to a non-silencing 
control (NSC) siRNA. Protein samples were assessed by SDS-PAGE and western blot analysis 
to confirm HIF-2α knockdown and demonstrate consequential effects on HIF-2α 
downstream targets (GLUT-1). HIF-2α protein could be effectively knocked-down in the 
HIF-2α siRNA targeted cells compared to the NSC siRNA targeted cells (Figure 6.1A). 
Furthermore HIF-2α gene knockdown resulted in a decrease in constitutive GLUT-1 protein 
expression (Figure 6.1A). In parallel, 786O cells targeted with either HIF-2α siRNA or NSC 
siRNA were harvested, RNA was isolated and RT-qPCR performed. The RT-qPCR results 
validate those obtained on protein samples and confirm knockdown of HIF-2α by 70-75% 
compared to that of NSC siRNA control (Figure 6.1B). Interestingly, HIF-2α mRNA was found 
to be higher in the 786O-EV cells compared to the 786O-VHL cells (Figure 6.1B). 
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Figure 6.1: Knockdown of HIF-2α and GLUT-1 in 786O cells. 
(A) Western blot analysis of 786O (786O-EV (EV, red) and 786O-VHL (VHL, blue)) cells 
transfected with either a non-silencing control (NSC, 20nM) siRNA or a siRNA targeted 
toward HIF-2α ((+), 20nM, siRNA-HIF-2α). Western blot shows a significant knockdown of 
HIF-2α protein in the 786O-EV (EV) cells and a correlative reduction in GLUT-1 expression 
in both cell lines (VHL and EV). α-tubulin was used as a load control. (B) Graph shows 
relative expression of the HIF-2α transcript analysed by RT-qPCR from cells described in 
A. siRNA silencing of HIF-2α reduced transcript expression in both the 786O-VHL (* 
p<0.05) and 786O-EV cells (** p<0.01). Data analysed using the comparative Ct method 
after normalisation to a single experimental repeat. Values are mean +/- S.E.M (n=4) and 
data analysed by paired, two-tailed t-test.  
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6.5 The effect of silencing HIF-2α on the expression of a panel of 
mitochondrial proteins 
A previous study, linked to pVHL function (Hervouet et al., 2008), has shown that silencing 
HIF-2α in 786O-EV cells can increase the expression of mitochondrial ETC proteins, 
including COX-IV and core 2 of complex III. Indeed, chapter 4 described the findings that 
key mitochondrial proteins, including COX-IV and mtCO-2 were expressed at higher levels 
in the 786O-VHL cells compared to the 786O-EV cells (chapter 4; Figure 4.2). As an 
extension to the role of HIF-2α in the pVHL-mediated change in ETC protein expression 
(chapter 4; Figure 4.14), HIF-2α was silenced in 786O cells and protein samples subject to 
SDS-PAGE and western blot analysis. There was no effect of HIF-2α silencing on the 
expression of cytochrome c oxidase subunit protein expression (mtCO-2 and COX-IV) as 
reported previously (chapter 4; Figure 4.14). This analysis was expanded to include other 
mitochondrial proteins to investigate whether HIF-2α loss affected non-ETC protein 
expression. No effect on protein expression after HIF-2α silencing was observed for ATPB, 
PHB1 or VDAC1, despite knockdown of HIF-2α protein (Figure 6.2). Together, these data 
suggest that there is no role for HIF-2α in the regulation of expression of a number of 
mitochondrial proteins, however this does not eliminate the possibility there are effects on 
mitochondrial proteins that our analysis has not included.  
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Figure 6.2: Silencing of HIF-2α has no effect on the expression of a panel of mitochondrial 
proteins. 
Western blot analysis of 786O (786O-VHL (VHL) or 786O-EV (EV)) cells each transfected 
with siRNA targeted towards HIF-2α (+, 20nM) or a non-silencing control siRNA (NSC, 
20nM). Knockdown of HIF-2α has no effect on the protein expression of a select panel of 
mitochondrial proteins as indicated. NSC =. α-tubulin was used as a load control.   
 
6.6 The effect of silencing HIF-2α on organelle distribution and 
mitochondrial morphology 
In chapter 5, a pVHL-dependent effect on mitochondrial morphology was observed in the 
786O cells (chapter 5; Figure 5.1). To determine the role of HIF-2α in mediating the pVHL-
dependent morphological change that was observed, HIF-2α was silenced in 786O cells. 
Cells were transfected with HIF-2α siRNA or NSC siRNA control and mitochondria imaged 
after fixation and primary antibody directed towards ATPB, as described previously 
(chapter 5; Figure 5.5). Immunofluorescence analysis showed no difference on the pVHL-
dependent morphological changes observed in either 786O cell line, nor was there any 
global change in mitochondrial morphology after HIF-2α silencing (Figure 6.3A-B).  
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Although the gross morphology appeared not to change after HIF-2α silencing, 
mitochondrial localisation appeared more peri-nuclear in the HIF-2α siRNA transfected cells 
compared with those transfected with NSC siRNA control (Figure 6.3A). This peri-nuclear 
localisation was independent of pVHL status as it was observed in both 786O-VHL (Figure 
6.3A) and 786O-EV cells (Figure 6.3B) 
In order to determine the involvement of the microtubules in the HIF-2α siRNA-mediated 
peri-nuclear mitochondrial clustering, 786O-VHL cells were incubated with the anti-mitotic 
agent, nocodazole for two hours prior to fixation to de-polymerise the microtubules. 
Mitochondria are dependent on microtubules for their trafficking throughout the cell 
(Heggeness et al., 1978) and in the presence of nocodazole, HIF-2α siRNA failed to produce 
a peri-nuclear mitochondrial distribution. These data suggest microtubular involvement in 
this HIF-2α-dependent peri-nuclear mitochondrial process (Figure 6.3C). Staining of α-
tubulin was used as a control on parallel coverslips to confirm the de-polymerisation of 
microtubules, compared to a vehicle treated control (Figure 6.3D). 
Together these data suggest that, loss of HIF-2α by siRNA leads to peri-nuclear localisation 
of mitochondria, which is independent of pVHL status, but dependent on microtubule 
trafficking as indicated by depolymerisation after nocodazole treatment. 
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Figure 6.3: Silencing of HIF-2α leads to a peri-nuclear localisation of mitochondria in 786O 
cells. 
Immunofluorescence staining of (A) 786O-VHL and (B) 786O-EV cells transfected with 
non-silencing control (NSC; 20nM) siRNA or siRNA targeted towards HIF-2α (20nM, 
siRNA-HIF-2α). HIF-2α silencing promotes peri-nuclear clustering of mitochondria. (C) 
Immunofluorescence staining of 786O-VHL cells transfected with NSC siRNA or siRNA 
targeted towards HIF-2α in the presence and absence of nocodazole (10μM) for 2 hours. 
Depolymerisation of the microtubules prevents the peri-nuclear localisation of 
mitochondria induced by siRNA silencing of HIF-2α. Mitochondria were stained using 
primary antibody towards ATPB and Alexa Fluor 568 (red). (D) Treatment with 
nocodazole effectively depolymerises microtubules. α-tubulin antibody was used to 
visualise microtubules (red) and confirm effects of nocodazole treatment. Cells were 
visualised using Nikon Eclipse E600 upright microscope and 40x objective. Images are 
representative of 3 independent experiments.   
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To further explore mitochondrial morphology and organelle subcellular distribution in 
response to HIF-2α knockdown, EM was used. HIF-2α was silenced in both 786O-VHL and 
786O-EV cells and cells were processed for EM.  
Consistent with the peri-nuclear localisation of mitochondria observed by 
immunofluorescence (Figure 6.3), EM analysis demonstrated a similar phenotype (Figure 
6.4; carried out by Mark Turmaine, UCl, UK). However, to our surprise in addition to the re-
distribution of mitochondria most other cellular organelles exhibited a peri-nuclear 
localisation after HIF-2α silencing (Figure 6.4A and B). Large areas of empty cytoplasm in 
cells transfected with HIF-2α siRNA were visible by EM, which was more obvious in the 
786O-EV cells compared to the 786O-VHL cells (Figure 6.4B). 
HIF-2α silencing also appeared to lead to a decrease in mitochondrial length in the 786O-EV 
cells (Figure 6.4B, right panel). Indeed, in the absence of pVHL (786O-EV cells), loss of HIF-
2α decreased mitochondrial length, from 1.67μm to 1.48μm compared to cells expressing 
the NSC siRNA (Figure 6.4C). This phenotype was tending toward the smaller, rounder 
mitochondrial morphological phenotype observed in the 786O-VHL cells (Figure 6.4C 
compare 786O-EV/siRNA-HIF-2α with 786O-VHL/NSC siRNA. Importantly, these data 
suggest that the pVHL-mediated regulation of mitochondrial length in 786O cells is 
dependent on HIF-2α. Also notably, in the presence of re-expressed pVHL, loss of HIF-2α 
significantly increased mitochondrial length from 1.19μm in the NSC siRNA transfected cells 
to 1.6μm in those cells transfected with HIF-2α siRNA (Figure 6.4C) 
These data suggest that there is a pVHL-HIF-2α-dependent mechanism regulating 
mitochondrial length. In the absence of functional pVHL protein, HIF-2α silencing failed to 
increase mitochondrial length, taken together suggesting an important role for HIF-2α in 
regulating the peri-nuclear localisation of organelles and in controlling mitochondrial 
length.  
Interestingly, in 786O-VHL cells after HIF-2α silencing there was also a noticeable increase 
in the number of autophagosomal structures (Figure 6.4A; arrows) compared to the NSC 
siRNA transfected cells. Indeed, the increase in autophagosomes observed, suggests that 
basal HIF-2α protein expression may be involved and important in regulating autophagy.  
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Figure 6.4: Silencing of HIF-2α causes peri-nuclear localisation of organelles and affects 
mitochondrial length in a pVHL-dependent manner. 
786O cells transfected with non-silencing siRNA control (NSC, 20nM) or siRNA targeted 
towards HIF-2α (20nM, siRNA-HIF-2α), were fixed, sectioned and imaged by electron 
microscopy (EM). Preparation for imaging and microscopy was performed by Mark 
Turmaine at UCL. EM images show (A) 786O-VHL cells and (B) 786O-EV cells. Lower panels 
are magnified EM images as indicated. N = nucleus, arrow = autophagosome (C) Graph 
shows quantification of mitochondrial length (µM) in 786O cells in the presence and 
absence of HIF-2α siRNA and pVHL re-expression. Mitochondria were measured using 
Image J software (National Institute of Health, Maryland), after scale bar calibration and 
measured from the most highly curved membrane through the central axis to the 
periphery (*** p<0.001 and * P<0.05). Over 140 mitochondria were scored from single 
independent images of 9-10 cells. Data analysed using unpaired, two-tailed t-test.  
 
6.7 The effect of silencing HIF-2α on autophagic protein expression 
Previous studies have described that peri-nuclear distribution of organelles is associated 
with autophagy (Okatsu, 2010). Autophagosomes are transported along microtubules 
toward the nucleus where they are degraded  by resident lysosomes (Ravikumar et al., 
2010). HIF-2α has been observed previously to suppress autophagy in chondrocytes 
through regulation of mTOR and BCL-XL expression (Bohensky et al., 2009). The 
observations by Bohensky et al suggest that decreased HIF-2α protein expression in 
osteoarthritic tissue is associated with increased autophagy (Bohensky et al., 2009). To 
investigate the role of HIF-2α in the autophagic response in cancer cells, HIF-2α was 
silenced and the expression of a number of autophagic proteins was analysed after SDS-
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PAGE and western blot analysis. No changes were observed in the expression of ATG5 or 
ATG3 and a small decrease in beclin expression after HIF-2α silencing in the 786O-EV cells 
compared with NSC siRNA was observed (Figure 6.5). In both the 786O-VHL and 786O-EV a 
reduction in LC3B-II expression was evident after HIF-2α silencing compared with NSC 
siRNA transfected controls (Figure 6.5A).  
As discussed previously in chapter 5, the LC3B-I to LC3B-II ratio is a static measure of 
autophagosomal membrane, therefore in the absence of autophagic induction, a decrease 
in LC3B-II could suggest a number of possibilities. Either there is decreased 
synthesis/formation of autophagosomes or increased autophagosome turnover, as in both 
scenarios a reduced level of LC3B-II protein would be observed since both situations give 
rise to decreased autophagosomal membrane. While a mechanism for the change in LC3B-I 
to LC3B-II cannot be elucidated from these western data (Figure 6.5), it is clear however 
that loss of HIF-2α, independent of pVHL appears to affects LC3B processing and lipidation. 
In addition to the post-translation lipidation of LC3B, the activity of LC3B can also be 
modulated at the mRNA level (Rouschop et al., 2010). It was therefore important to 
measure transcript expression of LC3B-II in the presence and absence of HIF-2α siRNA. 
Interestingly, no significant difference in LC3B transcript expression after silencing of HIF-
2α compared to the NSC siRNA transfected cells in either the 786O-VHL or 786O-EV cells 
was observed (Figure 6.5B). Therefore indicating, that the change observed in LC3B protein 
is mediated at the post-translational level and independent of pVHL status.  
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Figure 6.5: Silencing of HIF-2α affects post-translational lipidation of LC3B. 
(A) Western blot analysis of 786O cells transfected with non-silencing siRNA control (NSC, 
20nM) or siRNA targeted towards HIF-2α (20nM, siRNA-HIF-2α). Knockdown of HIF-2α in 
each cell line decreases protein expression of LC3B-II without affecting other autophagic 
proteins (as indicated). β-actin was used as a load control (B) Graph shows relative 
expression of the LC3B transcript analysed by RT-qPCR from cells described in A. There 
was no significant difference in the presence of HIF-2α siRNA in each of the cell lines (ns 
p>0.05). Data analysed using the comparative Ct method after normalisation to a single 
experimental repeat. Values are mean +/- S.E.M (n=4) and data analysed by paired, two-
tailed t-test 
 
6.8 The effect of silencing HIF-2α on mitophagy 
Mitochondrial length has been observed to change, under conditions of autophagy and 
additionally during mitochondrial-specific turnover (mitophagy) (Gomes et al., 2011, 
Rambold et al., 2011, Tanaka et al., 2010). Mitophagy can be induced in response to 
mitochondrial dysfunction or damage and has been observed to be deregulated in a 
number of neurological conditions (Youle and van der Bliek, 2012).  
To examine the role of HIF-2α in mitophagy, a number of proteins involved in the 
mitophagic process were investigated. Protein samples obtained after transfection with 
HIF-2α siRNA or NSC siRNA in 786O cells were prepared and subject to SDS-PAGE and 
western blot analysis. Confirming earlier observations (chapter 5; Figure 5.9) there was a 
difference in parkin protein levels between the 786O-VHL and 786O-EV cells (Figure 6.6A). 
Interestingly, after HIF-2α silencing an increase in parkin protein expression in 786O-VHL 
cells was observed (Figure 6.6A). A change in parkin expression was challenging to observe 
in 786O-EV cells since basal parkin protein levels were below levels of detection. Next, RT-
qPCR was employed to deduce whether parkin mRNA levels were also changed. A small but 
reproducible increase in parkin transcript expression was observed in both 786O lines after 
silencing of HIF-2α, albeit not at statistical significance (Figure 6.5B), but potentially 
suggesting that the increase in parkin protein at least in part may be regulated through HIF-
2α-dependent control of parkin gene expression.  
HIF-2α silencing had little effect on the protein expression of the molecular adaptor p62 
(Figure 6.6A). The abundance of p62 protein decreased in the 786O-EV cells compared to 
the 786O-VHL cells, confirming earlier observations (chapter 5; Figure 5.9). p62 protein is 
turned-over under conditions of increased autophagy and can be used marker of 
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autophagic flux, commonly in combination with other strategies (Bjørkøy et al., 2009, 
Klionsky et al., 2012).  
Together, these data suggest that HIF-2α silencing affects the expression of parkin protein 
levels and leads to a small reproducible, but non-statistically significant change in parkin 
mRNA. These effects on parkin are independent of pVHL status. HIF-2α silencing 
interestingly, does not rescue the parkin deficit observed in the 786O-EV cells compared to 
the 786O-VHL cells.   
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Figure 6.6: Silencing of HIF-2α silencing affects parkin protein and mRNA expression. 
(A) Western blot analysis of 786O (786O-VHL (VHL) and 786O-EV (EV)) cells transfected 
with non-silencing siRNA control (NSC, 20nM) or siRNA targeted towards HIF-2α (20nM, 
siRNA-HIF-2α). Knockdown of HIF-2α in each cell line leads to an increase in parkin 
protein expression. There is also a clear reduction in p62 protein levels between the 
786O-VHL and 786O-EV cells as observed previously, however no influence of HIF-2α 
siRNA. β-actin was used as a load control. (B) Graph shows relative expression of the 
parkin transcript analysed by RT-qPCR from cells described in A. There was a small 
increase in parkin expression in both the 786O-VHL and 786O-EV cells in the presence of 
HIF-2α siRNA, however this was not statistically significant (ns p>0.05). Data analysed 
using the comparative Ct method after normalisation to a single experimental repeat. 
Values are mean +/- S.E.M (n=4) and data analysed by paired, two-tailed t-test. 
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To correlate the observed changes in mitochondrial length, organelle subcellular 
distribution and parkin expression after HIF-2α silencing, the rate of HIF-2α-dependent 
mitophagic flux was assessed. 786O cells were transfected with either siRNA targeted 
toward HIF-2α or a NSC siRNA and treated with FCCP, to induce mitochondrial 
depolarisation and/or chloroquine, to inhibit the lysosome for 2 hours prior to analysis. A 
number of observations can be made from the data presented. Firstly and consistent with 
Figure 6.5, HIF-2α silencing led to a decrease in LC3B-II protein levels, compared to NSC 
siRNA control, in both 786O-VHL and 786O-EV cells (Figure 6.7A-B; lanes 1 and 5). The 
addition of chloroquine alone in both NSC and HIF-2α siRNA transfected cells leads to an 
increase LC3B-II protein levels compared to untreated cells, suggesting that HIF-2α is not 
important for LC3B-II/autophagosome membrane synthesis (Figure 6.7A-B; lanes 1 and 3 
vs. 5 and 7). The addition of FCCP alone, which depolarises the mitochondrial inner 
membrane and promotes mitophagy, caused an increase in LC3B-II in both NSC and HIF-2α 
siRNA transfected cells (Figure 6.7A-B; lanes 1 vs. 2 and 5 vs. 6). Most interestingly, when 
autophagic flux was blocked with chloroquine, FCCP treatment increased LC3B-II protein 
levels in NSC transfected control cells, as anticipated (Figure 6.7A-B; lanes 2 vs. 4). 
However, in the presence of HIF-2α siRNA, FCCP treatment was unable to induce LC3B-II 
protein, when autophagosome degradation was blocked by chloroquine (Figure 6.7A-B; 
lanes 2 and 4 vs. 6 and 8). These data collectively suggest that HIF-2α is important for the 
induction of LC3B-II protein levels, specifically when mitophagy is induced and the 
lysosome is blocked, indicating that HIF-2α is regulating the maturation or terminal events 
of the autophagy process (Klionsky et al., 2012, Rubinsztein et al., 2009). Thus, when HIF-2α 
is knocked down, cells fail to increase LC3B protein levels after mitophagic induction with 
lysosomal inhibition which may suggest a block in autophagy/mitophagy at the terminal 
stages and decreased autophagosome degradation.  
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Figure 6.7: Silencing of HIF-2α affects mitophagic flux after pharmacological uncoupling 
with FCCP in 786O cells. 
Western blot analysis of (A) 7860-VHL cells and (B) 786O-EV cells transfected with either 
NSC siRNA (NSC, 20nM) or siRNA towards HIF-2α (HIF-2α-siRNA, 20nM). Cells were 
incubated with FCCP (10μM) and chloroquine (10μM) as indicated (+) for 2 hours and the 
ratio of change in LC3B-II protein was analysed. α-tubulin was used as a load control.  
 
6.9 The effect of silencing HIF-2α on mitochondrial DNA copy number  
Mitochondrial DNA copy number (the number of mitochondrial DNA copies per cell), can 
change either through variations in biosynthesis or mitochondrial turnover (Venegas and 
Halberg, 2012, Clay Montier et al., 2009). To investigate the role of HIF-2α silencing in 786O 
cells on mitochondrial DNA content, mitochondrial DNA copy number was estimated using 
RT-qPCR and estimation of the β2M:ND1 ratio as discussed in chapter 4 (chapter 4; Figure 
4.7) (Venegas and Halberg, 2012).  
HIF-2α silencing revealed a small but reproducible increase in mitochondrial DNA copy 
number compared to NSC siRNA transfected cells, however this increase was not 
statistically significant (Figure 6.8A). Reassuringly, a significant reduction in DNA copy 
number was observed in cells devoid of functional pVHL, validating earlier observations 
(chapter 4; Figure 4.7). HIF-2α silencing, in HCT116 cells revealed a similar increase in 
mitochondrial DNA copy number compared to NSC siRNA control (Figure 6.8B).  
These data suggest that HIF-2α knockdown reproducibly, although non-significantly, leads 
to a small increase in mitochondrial DNA copy number, through a mechanism that is 
independent of pVHL and HIF-1α status. These data also reveal that the reduced 
mitochondrial DNA content observed in the absence of pVHL (786O-EV) compared to those 
cells stably re-expressing pVHL (786O-VHL), described earlier (chapter 4; Figure 4.7), failed 
to be reversed by HIF-2α silencing.  
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Figure 6.8: Silencing of HIF-2α causes a small, reproducible, but non-statistically 
significant increase in mitochondrial DNA copy number. 
Graphs show mitochondrial DNA copy number in (A) 786O (786O-VHL and 786O-EV) and 
(B) HCT116 cells, which was calculated through analysis of expression of the single copy 
nuclear gene β2M and mitochondrial ND1 by RT-qPCR in cells transfected with either 
non-silencing control (NSC, 20nM) siRNA or siRNA towards HIF-2α (20nM, siRNA-HIF-2α). 
Ct values were calculated for each cell line and the ratio calculated as described in 
(Venegas and Halberg, 2012). Values are mean +/- S.E.M (n=5) and data analysed by 
paired, two-tailed t-test (ns P>0.05). 
 
6.10 The effect of silencing HIF-2α on mitochondrial bioenergetics 
Epas1/Hif-2α loss has detrimental effects on mitochondrial function and adversely effects 
metabolism (Oktay et al., 2007). Oktay et al observed that knockout of Epas1/Hif-2α in 
mice decreases OCR and ETC activity in isolated mitochondria from hepatocytes, giving rise 
to a phenotype similar to that of the Sod2-/- mouse (Oktay et al., 2007). To investigate the 
role of transient HIF-2α loss on OCR, HIF-2α was silenced in 786O cells and effects on 
respiratory rate analysed using the Oroboros O2K. In the presence of HIF-2α siRNA, 
independent of pVHL expression, there was a significant increase in routine OCR compared 
with the NSC siRNA transfected cells (Figure 6.9A). Significant increases were also observed 
in leak respiration and maximum respiratory capacity (Figure 6.9B and C). A representative 
trace for 786O-VHL (Figure 6.9E) and 786O-EV cells is included (Figure 6.9F). Note, HIF-2α 
silencing was confirmed by RT-qPCR and found to be reduced by approximately 60% 
compared to control (Figure 6.9D).    
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These data suggest that in contrast to HIF-2α knockout, where respiratory capacity is 
diminished (Oktay et al., 2007), transient HIF-2α silencing increases mitochondrial 
respiration and ETC capacity. Notably, there was a highly significant increase in OCR in 
786O-VHL cells compared to 786O-EV cells, confirming previous observations (chapter 4; 
Figure 4.3). These data also reveal that the reduced OCR observed in the absence of pVHL 
(786O-EV) compared to those cells stably re-expressing pVHL (786O-VHL), described earlier 
(chapter 4; Figure 4.3), failed to be reversed by HIF-2α silencing. 
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Figure 6.9: Silencing of HIF-2α increase OCR in 786O cells. 
786O (786O-VHL (VHL) and 786O-EV (EV)) cells transfected with non-silencing siRNA 
control (NSC, 20nM) or siRNA targeted towards HIF-2α (20nM, siRNA-HIF-2α) were 
analysed using the Oroboros O2K. Graphs show (A) routine respiration, (B) leak 
respiration and (C) maximum respiratory rate, corrected for cell number and non-
mitochondrial respiration. (A-C) HIF-2α silencing significantly increased routine 
respiration and bioenergetic parameters. Values are mean +/- S.E.M (n=4). Data analysed 
using paired, two-tailed t-test (** P<0.01 and * p<0.05). (D) Graph shows relative 
expression of HIF-2α transcript analysed by RT-qPCR from cells described in A-C. HIF-2α 
was reduced by 60% in cells transfected with HIF-2α siRNA compared to NSC siRNA (* 
p<0.05). Data analysed using the comparative Ct method after normalisation to a single 
experimental repeat. Values are mean +/- S.E.M (n=4) and data analysed by paired, two-
tailed t-test. (E-F) Representative graphs showing OCR (pmol.s-1.106 cells) measured over 
time (minutes) for 786O cells described in A-C using the Oroboros O2K.  
 
Calculation of the bioenergetic flux ratios, described previously (chapter 4; Figure 4.3), 
allows more subtle changes in respiration to be investigated. Calculation and analysis of the 
leak and net-routine control ratios identified that there are no significant change in flux 
ratio in the presence after HIF-2α silencing compared to NSC siRNA control (Figure 6.10). 
These data indicate that: (i) there is no alteration in how close routine respiration operates 
in relation to maximum respiratory capacity after transient loss of HIF-2α protein, as 
indicated by the routine control ratio (R/E); (ii) there is no influence of HIF-2α status on the 
degree of uncoupling within the ETC, as indicated by the fact there was no change 
observed in the in the leak control ratio; (iii) HIF-2α status does not affect the proportion of 
the maximum capacity utilised to drive ATP synthesis, as indicated by the fact there was no 
change in net-routine control ratio (Figure 6.10).  
These data also reveal that the effect on flux ratios observed in the absence of pVHL (786O-
EV) compared to those cells stably re-expressing pVHL (786O-VHL), described earlier 
(chapter 4; Figure 4.3), failed to be revered by HIF-2α silencing.  
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Figure 6.10: Bioenergetic flux ratios are unaffected by HIF-2α silencing in 786O cells. 
Flux ratios were calculated as previously described from the data presented in Figure 6.9. 
There was no significant difference in routine control ratio (R/E), nor where there 
significant differences observed in leak control ratio (L/E) or net routine control ratio (ns 
p>0.05). Values are mean +/- S.E.M (n=4) and data analysed using paired, two-tailed t-
test.  
 
Oxygen consumption analysis performed in 786O cells was repeated using the HCT116 cell 
line to determine how the bioenergetic phenotype associated with HIF-2α silencing 
reproduced across cell lines. HIF-2α was silenced in HCT116 cells and OCR analysed using 
the Oroboros O2K. Analysis of routine respiration revealed that transient silencing of HIF-
2α led to an increase in OCR (Figure 6.11A), consistent with previous observations in the 
786O cells (Figure 6.9A). HIF-2α silencing also caused a significant increase in maximum 
respiratory capacity (Figure 6.11C), confirming data observed with the 786O cells (Figure 
6.9C). A representative trace is shown below (Figure 6.11E). RT-qPCR analysis of samples 
confirmed HIF-2α silencing of approximately 80% in these experiments (Figure 6.11D).  
Taken together, these data confirm that transient HIF-2α silencing leads to an increase in 
routine respiration and associated bioenergetic parameters, a phenotype that can be 
paralleled across cell lines. Transient knockdown of HIF-2α increases routine OCR, 
independently of pVHL or HIF-1α expression, and importantly leads to a corresponding 
increase in maximum respiratory flux, indicative of minimal mitochondrial toxicity after HIF-
2α silencing.   
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Figure 6.11: Silencing of HIF-2α increases OCR in HCT116 cells. 
Bioenergetic analysis of HCT116 cells transfected with either NSC siRNA or siRNA targeted 
toward HIF-2α (siRNA-HIF-2α, 20nM) analysed using the Oroboros O2K. Graphs show (A) 
routine respiration, (B) leak respiration and (C) maximum respiratory rate, corrected for 
cell number and non-mitochondrial respiration. (A-C) HIF-2α silencing significantly 
increased routine respiration and bioenergetic parameters. Values are mean +/- S.E.M 
(n=3). Data analysed using paired, two-tailed t-test (** P<0.01 and ns p>0.05). (D) Graph 
shows relative expression of HIF-2α transcript analysed by RT-qPCR from cells described 
in A-C. HIF-2α was reduced by 80% in cells transfected with HIF-2α siRNA compared to 
NSC siRNA (* p<0.05). Data analysed using the comparative Ct method after 
normalisation to a single experimental repeat. Values are mean +/- S.E.M (n=3) and data 
analysed by paired, two-tailed t-test. (E) Representative graphs showing OCR (pmol.s-
1.106 cells) measured over time (minutes) for cells described in A-C using the Oroboros 
O2K. 
 
6.11 Discussion 
Metabolism has to be tightly regulated in hypoxia and a number of genes are involved in 
allowing cells to continue to produce ATP and adapt to periods of low oxygen. The HIFs are 
key mediators of metabolic control in hypoxia. HIF-1α is responsible for the down-
regulation of oxidative metabolism and diversion of substrates away from mitochondria to 
promote glycolysis (Semenza, 2007b). Unlike HIF-1α, HIF-2α is not thought to be involved in 
up-regulating glycolysis in hypoxia and appears more involved in the transactivation of 
genes that regulate redox state and cellular anti-oxidant capacity (SOD2), tumourigenesis 
and pro-survival factors (cyclin D1, VEGF and TGF-α) (Hu et al., 2003).  
The HIF proteins are highly regulated, such that under ambient oxygen, HIF-1α protein 
levels remain low, with a half-life of less than five minutes (Berra et al., 2001). Despite tight 
regulation in normoxia limiting the transcriptional activity of the HIFs, HIF-dependent gene 
transcription, albeit low, occurs under ambient oxygen. Indeed, how the HIFs and their 
basal gene expression influence cell fate has previously been explored (Huang et al., 2004, 
Cai et al., 2008, Cramer and Johnson, 2003, Oktay et al., 2007). Interestingly, the basal gene 
expression of HIF-1α has been identified as vital for cardiac function (Huang et al., 2004), 
ischaemic preconditioning (Cai et al., 2008) and inflammation (Cramer et al., 2003). 
However, how the basal gene expression of the HIF proteins influences cellular 
homeostasis through regulation of mitochondrial function remains to be fully understood.  
In comparison to HIF-1α, the role of HIF-2α in the regulation of mitochondrial function has 
been has been scarcely investigated. To date, there is one study in mice with global 
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Epas1/Hif-2α knockout and investigation into the chronic loss of Epas1/Hif-2α in liver 
mitochondria (Oktay et al., 2007). Oktay et al described livers of mice lacking Epas1/Hif-2α 
to exhibit a phenotype similar to that of the Sod2-/- mouse (Oktay et al., 2007). The 
Epas1/Hif-2α-/- mouse had previously allowed Scortegagna et al to identify the role for HIF-
2α in the regulation of anti-oxidant homeostasis and the identification of SOD2 as a HIF-2α 
target gene (Scortegagna et al., 2003). SOD2 encodes manganese superoxide dismutase 
(MnSOD) which converts superoxide to hydrogen peroxide (H2O2). Investigation into the 
effects of Epas1/Hif-2α deficiency on mitochondrial homeostasis identified increased 
oxidative stress and superoxide levels, consistent with the loss of Sod2 mRNA and protein 
expression which correlated with increased sensitivity to calcium induced mPTP opening 
(Oktay et al., 2007). Epas1/Hif-2α-/- mitochondria also demonstrated impaired respiratory 
coupling and as such, respiratory control ratio (RCR) was reduced by 25% for complex I-
linked respiration. There was no impairment of ETC complex activities, consistent with TCA 
cycle dysfunction. The comparison of Epas1/Hif-2α-/- and Sod2-/- phenotypes was suggestive 
that there were distinct SOD2-independent mechanisms contributing to Epas1/Hif-2α-/- 
mitochondrial phenotype.  
The activity of αKGDH and mitochondrial aconitase were both significantly decreased after 
Epas1/Hif-2α knockout, with no correlative decrease in protein levels. Frataxin was 
identified as a novel Hif-2α target gene, down-regulated in the Epas1/Hif-2α null liver 
mitochondria.  Frataxin protects iron-sulphur clusters from disassembly or inactivation and 
dysfunction, in combination with increased oxidative stress lead to the observed 
mitochondrial dysfunction (Oktay et al., 2007).  
In this chapter, we aimed to investigate the effects of transient HIF-2α silencing on 
mitochondrial homeostasis, explore the role of HIF-2α in the pVHL-mediated effects on 
mitochondrial function and morphology described in chapters 4 and 5, and delineate 
and/or propose a potential mechanism for the observed effects. 
6.11.1 Silencing of HIF-2α causes microtubule-dependent peri-nuclear mitochondrial 
clustering 
HIF-2α silencing clearly affected the subcellular localisation of mitochondria in 786O cells. 
Mitochondria appeared to be peri-nuclearly localised upon HIF-2α knockdown, a 
phenotype which could be reversed through de-polymerisation the microtubules. Peri-
nuclear clustering of mitochondria has been observed in a number of studies (DeWitt et al., 
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2006, Yu et al., 2010, Hashiatni et al., 2010, Al-Mehdi et al., 2012). Al-Mehdi et al 
demonstrated that under hypoxia, peri-nuclear mitochondria are observed in pulmonary 
artery endothelial cells (Al-Mehdi et al., 2012). Al-Mehdi et al also demonstrated that the 
retrograde mitochondrial movement observed was also dependent on the microtubules 
and the motor protein dynein. Peri-nuclear mitochondrial clustering was accompanied by 
an accumulation of ROS in the nucleus, promoting oxidative modifications on the VEGF 
promoter, increasing gene expression. VEGF gene transcription was reduced when 
mitochondrial clustering was disrupted, suggesting that ROS-dependent modifications are 
important for HIF-dependent gene transcription (Al-Mehdi et al., 2012). Additionally peri-
nuclear mitochondria have been hypothesised to function as sensors of intracellular 
metabolites (Hashiatni et al., 2010), observed in the periods preceding apoptosis (DeWitt et 
al., 2006) and in oocyte maturation (Yu et al., 2010).  
Interestingly, the peri-nuclear distribution of mitochondria observed upon HIF-2α 
knockdown was reversed with nocodazole. Nocodazole depolymerises the microtubules 
and prevents microtubule-dependent vesicular transport throughout the cell. The reversal 
of peri-nuclear mitochondrial clustering by nocodazole treatment, suggests that the 
microtubules play a role in this peri-nuclear localisation process. Microtubules are also 
important for movement of a number of organelles and whether distinct organelles alter 
their subcellular localisation in a HIF-2α-dependent manner is an interesting question. EM 
images suggest that this may be the case, particularly evident in the 7860-EV cells, which 
are devoid of functional pVHL. In cells transfected with siRNA targeted towards HIF-2α, 
large vacant areas of cytoplasm are evident, which are not as obvious in the 786O-VHL 
cells. Differences in global cell shape between the pVHL positive and negative cells make 
mitochondrial distribution within the cell difficult to interpret from the EM images. The 
pVHL positive (786O-VHL) cells are less elongated and more rounded than the pVHL 
negative (786O-EV) cells. Thus the distance from the nucleus to cell membrane in the 
786O-VHL cells compared with the 786O-EV cells is not as great, and any peri-nuclear 
organelle localisation is therefore less obvious by EM. The gross peri-nuclear distribution of 
organelles observed by EM would need to be confirmed by immunostaining using markers 
for a number of organelles or using organelle-specific tracking dyes. In addition to 
nocodazole treatment, knockout of dynein would allow confirmation of the microtubule-
dependence of the peri-nuclear mitochondrial localisation and it would be important to 
Chapter 6: The role of HIF-2α in the regulation of mitochondrial function and turnover 
Page | 275  
 
establish a high-throughput imaging platform and analysis algorithms in order to get better 
quantification of organelle movement with respect to cell size and shape.  
During mitophagy, mitochondria also become clustered around the nucleus (Okatsu, 2010). 
Peri-nuclear aggregation of mitochondria in response to FCCP-mediated mitochondrial 
depolarisation has been shown to be dependent on p62, however not essential for 
mitochondrial degradation (Okatsu, 2010). Interestingly, parkin mutations have been 
shown to affect the mitophagic process at distinct stages and “mitoaggresomes” identified 
that require dynein motors and microtubules for their peri-nuclear localisation (Lee et al., 
2010b). Although all parkin mutants in the study by Lee et al were defective at clearing 
mitochondria, mutations in the ubiquitin E3-ligase domain of parkin, still associated with 
depolarised mitochondria after FCCP treatment and caused peri-nuclear aggregates of 
mitochondria. Peri-nuclear mitochondrial clustering was reversed by nocodazole-induced 
microtubule depolymerisation and loss of parkin-dependent ubiquitination failed to recruit 
p62 and histone deacetylase 6 (HDAC6) (Lee et al., 2010b). Our data however raises the 
intriguing possibility that HIF-2α is involved in the final clearance step of mitochondria 
between their nuclear transport and lysosomal degradation. Additionally, as demonstrated 
in the previous chapter (chapter 5;  
Figure 5.9) there appear to be clear changes in the expression of parkin in the presence and 
absence of pVHL in the 786O cells, which has been discussed with respect to possible 
effects on mitochondrial morphology observed in the 786O cells (chapter 5). Based on 
these observations we decided to investigate the role of HIF-2α and pVHL in regulation of 
autophagy and mitophagy.  
6.11.2 The effects of HIF-2α on mitochondrial morphology and autophagy 
A number of interesting observations have emerged from the EM studies in relation to HIF-
2α and pVHL status. As described and discussed in chapter 5, mitochondrial length was 
greater in 786O-EV cells compared to 786O-VHL cells, indicating a role for pVHL in 
regulating mitochondrial morphology. Smaller mitochondria may be more susceptible to 
removal through non-selective autophagy and more likely to be engulfed by an 
autophagosome, in a process based on proximity and size. Mitochondrial fusion and fission 
cycles may therefore be important in regulating mitochondria turnover by autophagy 
(Twig, 2008). Fission is required for mitophagy to occur and can be suppressed through 
introduction of a dominant negative form of DRP-1 (Twig, 2008, Youle and van der Bliek, 
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2012). Interestingly, silencing the constitutively stable and active HIF-2α in the 786O-EV 
cells in part reverses the increase in mitochondrial length observed in 786O-EV cells 
compared to the 786O-VHL. The change in mitochondrial length may suggest both pVHL 
and HIF-2α-dependent mechanisms function in parallel. One notable observation is the 
significant increase in mitochondrial length observed after HIF-2α silencing in the presence 
of pVHL, indicating that basal HIF-2α regulates mitochondrial length in the presence of 
pVHL.  
As discussed in the chapter 5, pVHL status affects the number of autophagosomes 
observed within the cell and is associated with altered in mitochondrial length. In a similar 
observation, HIF-2α silencing in cells expressing functional pVHL increases the number of 
autophagosomes observed in the cell, therefore mitochondrial length may increase as a 
mechanism to avoid autophagic removal, as suggested elsewhere (Gomes et al., 2011, 
Rambold et al., 2011). It would be necessary to determine the effects HIF-2α silencing on 
the mitochondrial fusion and fission apparatus. Assessment of the fusion and fission 
machinery may reveal insights into the apparent pVHL-dependent effects on mitochondrial 
length. The phosphorylation status of DRP-1 would be of great interest, as would 
determination of the DRP-1 protein abundance localised at the mitochondria in the 
presence and absence of HIF-2α siRNA.  
Behensky et al investigated the role of HIF-2α in autophagy in chondrocytes and observed 
that when HIF-2α was silenced there was an increase in LC3 punctae by 
immunofluorescence, evidence of autophagic induction (Bohensky et al., 2009). An 
increase in lysotracker activity and examination of electron micrographs suggested an 
increase number of autophagosomes present in the HIF-2α silenced cells compared to 
control (Bohensky et al., 2009). A reduced binding of beclin and BCL-2 was also observed, 
suggesting greater amounts of free beclin. The role of HIF-2α in autophagy has also been 
investigated in the context of hepatocellular carcinoma in a tumour spheroid model 
(Menrad et al., 2010). Menrad et al observed that after HIF-2α silencing there was a 
compensatory up-regulation of HIF-1α-dependent BNIP3 expression, autophagy and an 
increase in pro-survival BCL-XL (Menrad et al., 2010).  
To investigate the role of HIF-2α further and relate observations to pVHL status, 
independent of the influence of HIF-1α, autophagic flux assays were performed in 786O 
cells. Under basal conditions, loss of HIF-2α protein reduced LC3B-II protein levels. The 
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addition of chloroquine alone in the presence and absence of HIF-2α siRNA also caused an 
increase in LC3B-II in both the 786O-VHL and 786O-EV cells, suggesting LC3B-II is being 
synthesised effectively in the absence of HIF-2α. In the presence of FCCP, we observed an 
increase in LC3B-II protein in both HIF-2α knockdown and control cells, suggesting 
mitophagic induction is unaffected by HIF-2α silencing. To investigate LC3B-II turnover, cells 
were treated with both chloroquine, to inhibit the lysosome and FCCP to induce mitophagy.  
Analysis revealed a smaller increase in LC3B-II relative to FCCP alone, in cells with HIF-2α 
knocked down compared to NSC siRNA control, suggesting reduced turnover or 
degradation of LC3B-II. The failure to increase LC3B protein levels after mitophagic 
induction by FCCP in the context of lysosomal inhibition may suggest a block in 
autophagy/mitophagy at the terminal stages and decreased autophagosome degradation 
(Klionsky et al., 2012, Rubinsztein et al., 2009). These observations indicate that transient 
loss of HIF-2α in the presence of pVHL may affect autophagosome maturation or 
degradation. Therefore our observations suggest that silencing HIF-2α has little effect on 
autophagosome formation the 786O renal cells demonstrated through the increase in LC3B 
after chloroquine and FCCP in isolation. HIF-2α silencing may however affect 
autophagosome degradation (Rubinsztein et al., 2009). A schematic representation of our 
proposed hypothetical model is included below (Figure 6.12). 
A follow-up experiment would involve using a second activator of autophagy and 
mitophagy. Rapamycin could be used to inhibit mTOR and combination of antimycin A and 
oligomycin to depolarise mitochondria promoting their removal. Use of these activators 
would allow interpretation of whether just mitochondrial removal is affected or the more 
encompassing process of macroautophagy. Rapamycin induces autophagy by removing the 
negative pressure of mTOR on autophagic axis.  
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Figure 6.12: Diagrammatic representation of the potential effects HIF-2α silencing on 
autophagy. 
In the presence of chloroquine alone both control cells and cells treated with HIF-2α 
siRNA increase LC3B-II levels as degradation is blocked and basal synthesis remains 
functional. In the presence of FCCP, autophagic induction causes an increase in LC3B-II 
levels in both control and HIF-2α silenced cells. Treatment with chloroquine and FCCP 
reveals a functional system in the control cells, as there is a further increase in LC3B-II 
after FCCP induction and lysosomal inhibition by chloroquine. This suggests that the 
FCCP-mediated induction is going to completion. The lack of an increase in LC3B-II by 
FCCP in the presence of chloroquine in the HIF-2α silenced cells indicates a stalling in the 
pathway, resulting in the pathway not going to completion. 
 
EM revealed insights into the relationship of pVHL and HIF-2α in the regulation of 
autophagosome formation. Loss of HIF-2α, in the presence of pVHL increased the number 
of autophagosomes observed, suggesting that autophagosome formation is intact; 
however maturation and turnover cannot be assessed using this assay. The increase in 
autophagosomes in the 786O-VHL cells may however correlate with the data from the flux 
assay and suggest reduced autophagosome turnover. EM would need to be undertaken in 
the presence of inducers and inhibitors of the autophagic pathway, to confirm the 
autophagy is progressing to completion. Immunogold labelling of the autophagosomal 
structures and lysosomes would be required to confirm identify of these organelles. 
Although expert advice has been sought confirming their identification, this alternative 
approach remains necessary. Visualisation of lysosomal proteins, such as LAMP-2 would 
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allow identification of lysosomes and LC3B, the autophagosomes and allow confident 
identification of the two organelles. The EM phenotype observed is  similar to that of the 
HDAC6 knockout (Lee et al., 2010a). The images from EM revealed an increase in the 
number of multilamellar bodes in the presence of HIF-2α siRNA compared to NSC siRNA 
control. Loss of HDAC6 causes failure of autophagosome fusion to the lysosome and results 
in accumulation of autophagosomes.  
With respect to the data presented in this chapter, it is difficult to conclude if HIF-2α 
dependency for autophagosome maturation or degradation is limited to the removal of 
mitochondria or a more global macroautophagic dysfunction. To investigate this in 786O 
cells, an alternative to HBSS would need to be sought in order to induce macroautophagy 
and determine the effects in the presence and absence of HIF-2α protein. If this were to be 
a dysfunction in the terminal stages of autophagosome removal, one would hypothesise 
that the effects of HIF-2α is likely to affect global autophagy, as the two processes share a 
common terminal pathway of autophagosome turnover. Additionally, observations from 
EM reveal a global localisation of cytoplasmic components toward the nucleus after HIF-2α 
silencing. Nuclear organelle distribution again suggests that autophagy is affected on a 
macro scale. A number of assays could be performed to investigate whether this holds true 
and have been discussed in the previous chapter, including LC3-GFP, LC3-lysosome fusion 
assays and use of inhibitors and activators of the pathway. Experiments using rapamycin 
and FCCP individually and the addition of chloroquine, after HIF-2α silencing and imaging 
using EM may reveal the likely mechanism and would allow identification of precise part of 
the autophagic pathway that is disrupted after HIF-2α loss.  
6.11.3 Potential role for HIF-2α in mitophagy  
The selective degradation of mitochondria by autophagy is known as mitophagy. 
Autophagosome formation, elongation and degradation are performed by the same 
molecular players as for non-selective autophagy, described previously. Under physiological 
basal conditions mitochondria are cleared when damaged, dysfunctional or mature and a 
number of proteins orchestrate this selective turnover, including parkin, PINK1 and p62. 
Maintenance of a healthy mitochondrial population is essential for cell health and viability. 
Mitochondria are a significant source of ROS, therefore susceptible to oxidative damage 
and themselves mediators of apoptosis. Therefore, damage to mitochondria impacts on the 
global cellular health. Nutrient starvation can also stimulate mitophagy, which 
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experimentally can be visualised using GFP-LC3 and analysing mitochondrial co-localisation 
(Ravikumar et al., 2010). Finally, the mitochondrial permeability transition pore has also 
been implicated in mitophagy. This non-selective conductance pore allows solutes to 
transverse the mitochondrial membrane with a mass up to approximately 1500 Daltons 
and contributes to mitochondrial depolarisation (Lemasters et al., 2002, Kim et al., 2007).  
In vitro, loss of mitochondrial inner membrane potential is used to trigger the mitophagic 
process. Constitutive expression of full length PINK1 protein is kept low by after import into 
the mitochondrial IMS and processing by the protease PARL (Deas et al., 2011a). Loss of 
mitochondrial inner membrane potential, through pharmacological uncoupling, prevents 
the processing of PINK1 and facilitates its accumulation on the outer mitochondrial 
membrane. The kinase activity of PINK1 recruits the E3-ligase parkin specifically to 
depolarised/damaged mitochondria. At mitochondria the E3-ligase activity of parkin 
increases (Matsuda, 2010) and parkin then ubiquitinates target proteins, predominantly 
Lys63-linked polyubiquitin on outer membrane proteins, tagging them for removal (Youle 
and Narendra, 2011, Youle and van der Bliek, 2012, Narendra, 2010, Vives-Bauza, 2010), 
through either autophagy or the ubiquitin proteasome system. Transient knockdown of 
HIF-2α has a small effect on parkin expression. We observed a small reproducible increase 
in protein and mRNA expression after HIF-2α silencing, the importance of which remains to 
be fully elucidated. The localisation of endogenous parkin and if and how its translocation 
to mitochondria is affected by HIF-2α silencing would be the next question to address.  
To date, there are no reports of HIF-2α playing a role in the regulation of mitophagy. From 
the data presented in this chapter (Figure 6.7), it appears that in response to FCCP there is 
reduced mitophagic flux, likely due to decreased autophagosome clearance when HIF-2α is 
silenced. FCCP-meditated mitochondrial depolarisation is of course an extremely non-
physiological model as doses required are in excess of those necessary to depolarise the 
membrane and induce maximum respiratory rate (Klionsky et al., 2012), but useful as a tool 
to determine a possible role for a protein in the pathway. A number of further experiments 
would need to be performed to understand the HIF-2α-mitophagy relationship.  
Interestingly, reduction of HIF-2α protein has been observed to increase BNIP3 expression 
(Raval et al., 2005), the homologue of NIX and over-expression of BNIP3 has been observed 
to induce autophagy and the co-localisation of mitochondria with autophagosomes. BNIP3 
over-expression also increased parkin translocation and parkin-positive mitochondria 
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association with the autophagosomes, an effect reversed in the absence of BAK and BAX. 
BNIP3 has been also observed to interact directly with LC3B (Hanna et al., 2012). 
Interestingly, there appears to be an inverse relationship between HIF-2α status and BNIP3 
expression. BNIP3 has been observed to be positively regulated by HIF-1α and responsible 
for increased mitophagy in hypoxia (Zhang et al., 2008). However stabilisation of HIF-2α in 
cells devoid of HIF-1α, or over-expression of HIF-2α causes decreased BNIP3 transcription 
(Raval et al., 2005). BNIP3 has been observed to augment autophagy through disruption of 
the beclin-BCL-2 complex, freeing beclin and accelerating the pathway. This process has 
also been observed to require DRP-1-mediated mitochondrial fission and parkin 
recruitment (Youngil et al., 2011). BNIP3 is involved in the recruitment of DRP-1 to 
mitochondria, and over-expression increases DRP-1 association with mitochondria, induces 
mitochondrial fragmentation and triggers parkin recruitment (Youngil et al., 2011). These 
observations suggest that in the absence of HIF-2α, BNIP3 levels may increase, recruiting 
DRP-1 to mitochondria and inducing mitochondrial fragmentation and turnover through 
parkin-mediated mitophagy. Mitochondrial isolation and immunoblotting for 
mitochondrially associated BNIP3, DRP-1 and parkin may reveal this mechanism. This 
mechanism could explain the smaller mitochondria observed after HIF-2α silencing in cells 
devoid of functional pVHL. It does not however explain the phenotype when HIF-2α is 
silenced in the presence of pVHL. 
The accumulation of PINK1 on the mitochondrial outer membrane is necessary for parkin 
recruitment after pharmacological uncoupling (Matsuda, 2010, Narendra, 2010). 
Investigation into how loss of functional pVHL and HIF-2α silencing affects the association 
of stabilisation of PINK1 and recruitment process would be interesting to determine. Early 
indications suggest that in response to FCCP, PINK1 stabilisation is not affected by HIF-2α 
silencing. However further work is necessary to determine localisation and details in to the 
kinetics of PINK1 depolarisation-dependent stabilisation. Immunofluorescence of p62 in 
the presence and absence of pVHL and HIF-2α siRNA would allow identification of 
aggresomes of mitochondria and again give insight into the effect of the differential parkin 
expression between the 786O cells as parkin is required for the initial ubiquitination event 
that allows p62 targeting of mitochondria their clustering.   
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6.11.4 HIF-2α silencing affects mitochondrial bioenergetics   
In response to HIF-2α silencing, in both HCT116 colon carcinoma and 786O renal carcinoma 
cells, basal respiration increased, demonstrated through an increase in OCR using the 
Oroboros O2K. There was also a significant increase in maximum respiratory rate after HIF-
2α silencing in both cell lines. The increased OCR was both independent of pVHL status and 
any compensatory effects of HIF-2α silencing on HIF-1α activity. Increased OCR and 
maximum respiratory rate could be consequence of a number of factors. The increased 
OCR may suggest that there are more respiratory substrates feeding the electron transport 
chain; there is an increase in mitochondrial ETC components, greater amounts of 
mitochondria per cell or an increase in ATP demand. Bioenergetic flux ratios also suggest 
that minimal difference after HIF-2α loss on energetic status, including the degree of ETC 
uncoupling.  
In contrast to the negative regulation on c-MYC activity by HIF-1α, HIF-2α promotes c-MYC 
transcriptional activity and cell cycle progression (Gordan et al., 2007, Gordan, 2008). HIF-
1α-dependent transactivation of MXI-1 and inhibition of c-MYC inhibits mitochondrial 
biogenesis (Zhang, 2007). Therefore one may predict that loss of HIF-2α in our system may 
negatively affect the transcriptional capacity of c-MYC, disrupting the MYC-MAX 
transcriptional complex (Gordan et al., 2007) and promote mitochondrial biogenesis. As 
discussed, activation of c-MYC has been shown to influence mitochondrial biogenesis 
through increasing mitochondria mass, mitochondrial DNA content and oxygen 
consumption rate (Li et al., 2005). These studies however do not correlate with what we 
observe, as transient HIF-2α silencing had little effect in mitochondrial mass (not shown), 
slightly increased mitochondrial DNA content and increased oxygen consumption rate. 
Therefore basal effects of HIF-2α on the regulation of c-MYC are either below the limits of 
detection or absent under ambient oxygen. Additionally, there was no effect on the 
transcription of PGC-1β, a c-MYC target involved in mitochondrial biogenesis, and notably 
in the absence of HIF-2α there are no changes observed in the expression of mitochondrial 
ETC proteins, contradictory to published observations (Hervouet et al., 2008).  
Bertout et al demonstrated that HIF-2α negatively regulates p53 stabilisation and 
knockdown of HIF-2α promotes p53 stabilisation, phosphorylation and transcriptional 
activity on a select number of genes, through effects on ROS and alterations to the cellular 
redox state (Bertout, 2009). Shortly after this study was published, Roberts et al also 
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demonstrated in 786O-EV cells, the stabilisation and accumulation of HIF-2α, suppressed 
p53 activity through promoting the p53-HDM2 interaction. Loss of HIF-2α by RNA 
interference, or re-expression of pVHL, restores p53 activity by relieving this negative 
regulation (Roberts, 2009). p53 has also been observed to affect mitochondrial respiration 
through the transcriptional up-regulation of SCO2, an assembly factor for cytochrome c 
oxidase (Matoba et al., 2006). In light of this evidence, the role of p53 in the HIF-2α-
dependent change in OCR was tested. In the presence of HIF-2α siRNA, OCR still increased 
in the absence of p53 compared to NSC control siRNA, suggesting the increase in OCR 
observed after HIF-2α silencing was independent of any HIF-2α-mediated effect on p53 
(data not shown). Transcript levels of the p53 target gene, SCO2 were also measured in 
these cells after silencing of HIF-2α and there was no significant difference (data not 
shown). The p53 independence of the HIF-2α-dependendent change in OCR suggests that, 
the silencing of HIF-2α and its effect on cellular OCR was independent of p53 stability and 
gene transcription, at least with respect to SCO2. p53 transcriptional targets have however 
been demonstrated to be cell type, context and post-translational modification dependent 
(Bertout, 2009).  
Future experiments with respect to the role of HIF-2α in regulating mitochondrial 
respiration would be to silence HIF-1β in the 786O cells, which lack HIF-1α to determine if 
the role of HIF-2α is transcriptional and binding of the alpha and beta subunits is necessary. 
Alternatively, mitochondrial effects mediated by loss of HIF-2α may be due to the direct 
role of HIF-2α on a yet undefined process. Dissection of the ETC using ETC complex-linked 
substrates and respirometry in isolated mitochondria or permeabilised cells would allow 
determination of the direct role of HIF-2α on these processes. Spectrophotometric ETC 
complex assays or BN-PAGE and in-gel activity assays would confirm complex assembly and 
activity would continue to lay a foundation on which to build a conclusion as to the role of 
HIF-2α in mitochondrial bioenergetics.  
6.11.5 The role of HIF-2α in regulating mitochondrial DNA copy number 
Finally, mitochondrial DNA copy number has been shown to decrease with increased 
mitophagic flux (Klionsky et al., 2012). Interestingly, there is a slight, but reproducible 
increase in mitochondrial DNA copy number in all cell lines examined after HIF-2α silencing, 
however this does not reach significance, but may be suggestive of a decrease in 
mitophagic flux after HIF-2α silencing. An interesting series of experiment would be to 
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measure mitochondrial DNA copy number in cells treated with inhibitor(s) of autophagy, 
such as chloroquine and determine any change in the presence and absence of HIF-2α 
protein and the relationship with pVHL. Analysis of mitochondrial DNA content would also 
give a quantitative idea on mitophagic flux and could be combined with inducers of 
mitophagy to manipulate the process and determine how HIF-2α gene manipulation affects 
mitophagy under extreme conditions.  
 
6.12 Summary 
It is clear more work needs to be done to uncover the role of HIF-2α in the regulation of 
autophagy and cellular quality control. From the experiments presented here, HIF-2α 
appears necessary for the terminal maturation and/or clearance of autophagosomes, while 
autophagosome synthesis is maintained. HIF-2α also appears to differentially regulate 
mitochondrial length. Most importantly, pVHL-dependent regulation of mitochondrial 
length was found to be HIF-2α dependent.  
Further experiments are necessary to determine whether the use of FCCP to induce 
mitophagic flux and the failure to increase LC3B-II in the presence of chloroquine, 
compared to FCCP treatment alone is specific to mitochondrial selective autophagy or 
extends to macroautophagy. Identification as to the role of HIF-2α in global autophagy can 
be achieved through use of alternative inducer(s) of autophagy. Alternatively, a distinct cell 
line could be starved in the presence of HIF-2α silencing and effects investigated after 
incubation with HBSS. The experiments outlined here are clearly among the most pressing 
to confirm or dismiss a role of basal HIF-2α in autophagy.   
In this chapter, we have identified a potentially separable HIF-independent role for pVHL in 
mitochondrial function. Silencing of HIF-2α does not significantly affect the pVHL-
dependent alterations in mitochondrial function, described in chapters 4 and 5, however 
does affect mitochondrial length. 
The increase in basal OCR observed after HIF-2α silencing also remains unexplained. 
Whether the increase is related to the decreased in mitochondrial turnover or increased 
ATP demand after HIF-2α silencing remains unknown. However, increased OCR may be 
interpreted as a short-term adaptive response to decreased turnover of defective 
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mitochondria, whereby cells are respiring more to produce the same amount of energy, 
ATP.  
From the work presented in this chapter a number of questions remain to be answered: 
(i) What are the mechanisms underlying the change in autophagosome 
maturation and/or turnover after HIF-2α silencing?  
 
(ii) Under basal conditions, how does the HIF-2α-dependent inhibition of terminal 
autophagosome clearance affect mitochondrial function? 
 
(iii) How is the autophagic targeting of mitochondria regulated by HIF-2α? 
 
(iv) Are HIF-2α-dependent mitochondrial morphology/localisation and bioenergetic 
changes associated with autophagy/mitophagy? 
 
(v) What is the role of pVHL in regulating mitochondrial length and 
autophagy/mitophagy after transient loss of HIF-2α? 
 
Data presented in this chapter are novel, and provide a platform on which to build further 
investigation with respect to both HIF-2α and pVHL in regulating autophagy/mitophagy and 
mitochondrial function. Significant work is necessary to confirm and further these 
observations, and ultimately to translate these findings as to their importance in disease.  
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7.1 General background and summary 
7.1.1 HIF and the hypoxic response 
Cells are adapted to utilise oxygen to survive and it is necessary to maintain oxidative 
metabolism. Under oxygen limiting conditions, it is necessary for cells to sense and adapt to 
an environment of altered oxygenation. It is this role which the HIF/oxygen-sensing 
pathway plays. Oxygen, as a substrate for the PHD proteins keeps the HIF-α subunits tightly 
controlled under normal ambient conditions. When oxygen is limiting (hypoxia) PHDs are 
inhibited, limiting HIF-α turnover by pVHL and ultimately leading to HIF-α stabilisation, 
subsequent nuclear translocation and dimerisation with the HIF-1β subunit. HIF-dependent 
transactivation of target genes functions to maintain cellular homeostasis, allowing cell 
survival, demonstrating the physiological importance of this pathway. 
Although physiologically necessary, the HIF/hypoxic response can become deregulated. The 
solid tumour micro-environment is a heterogeneous mass of cells that often becomes 
hypoxic towards its core. Under these conditions a robust hypoxic response is induced, 
promoting tumour growth and survival. Loss of the VHL tumour suppressor also promotes 
unopposed HIF-α stabilisation and associated pathology.  
7.1.2 The HIF-mitochondria relationship 
A well-established relationship between HIF and mitochondria exists. Metabolic adaptation 
to hypoxia involves HIF-dependent gene transactivation, regulating the balance of glycolytic 
and oxidative metabolism (Fukuda et al., 2007, Papandreou et al., 2006, Luo et al., 2011). 
Mitochondrial electron transport is also necessary for the hypoxic stabilisation of HIF-α. In 
this thesis, we investigated the relationship between the oxygen-sensing pathway and 
mitochondrial function, and have begun to delineate a more direct link between HIF-α and 
mitochondria. Additionally, we have begun to understand the HIF-2α/mitochondrial 
relationship and how HIF-2α specifically may act in cellular and mitochondrial quality 
control. 
7.1.3 Clinical significance of pVHL 
pVHL is the recognition component of the ECV E3-ligase responsible for the normoxic 
regulation of the HIF-α subunit, tags HIF-α for proteasomal degradation upon hydroxy-
proline ubiquitination (Maxwell et al., 1999, Jaakkola et al., 2001). Study into the role of 
pVHL has contributed much towards our understanding of the cellular and physiological 
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response to hypoxia and mechanisms through which cells sense and react to altered 
oxygenation. Germline inactivation of VHL is a key event in the development of tumours 
characteristic of VHL disease and in the development of sporadic clear cell renal cell 
carcinomas. Here, we have established a novel role of pVHL distinct from that of HIF-α 
regulation. pVHL affects global mitochondrial properties after re-expression in renal cancer 
cells and positively modulates mitochondrial function.  
 
7.2 Summary of key findings 
In chapter 3, we first confirmed the HL-1 cell line as a suitable model for measuring and 
investigating the hypoxic response and HIF stabilisation in vitro. This validates previous 
observations (Nguyen and Claycomb, 1999) and identified a cardiomyocyte model for 
establishing a basis on which to further study the mitochondrial relationship with HIF-1α. 
We went on to identify several members of the oxygen-sensing machinery to be associated 
with mitochondria. We observed HIF-1α, HIF-1β, PHD2 and PHD3 in purified mitochondrial 
fractions from both cells and tissue. Interestingly, a hydroxylated HIF-1α species was also 
observed in mitochondrial preparations. Identification of HIF-1α protein at the 
mitochondria opens a number of exploratory avenues and the potential to uncover novel 
roles for HIF-1α protein outside that of nuclear transcriptional control.  
Further to these observations, identification of the rapid accumulation of HIF-1α protein 
associated with mitochondria led to use of the PHD inhibitor DMOG, to investigate the 
early, transcriptional independent functions of HIF-1α. Investigations were extended to 
explore the HIF-1α independent roles of the PHD proteins. Although evidence suggests that 
the gene expression profile in MCF-7 cells after DMOG treatment correlates well with that 
of the hypoxic response (Elvidge et al., 2006), we have identified dissimilarities in the 
transcriptional independent, metabolic effects of DMOG compared with alternative PHD 
inhibitors  suggesting off-target effects of DMOG.  
A number of observations have identified a role for pVHL in the regulation of mitochondrial 
function in renal cells and in clear cell renal carcinoma (Shiao et al., 2000, Hervouet et al., 
2005, Hervouet et al., 2008). In this thesis, we extended the studies of Hervouet et al to 
investigate the role of wild type and mutant pVHL re-expression in a defective pVHL renal 
carcinoma cell background. Interestingly, correlations can be made regarding pVHL 
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mutation and the mitochondrial phenotype observed. In this thesis, we have identified a 
role for pVHL in the regulation of mitochondrial protein expression, mitochondrial DNA 
maintenance and respiration, independent of HIF-α, but dependent on specific amino acid 
residues within the pVHL protein. We have also identified a role for pVHL in affecting 
mitochondrial mass or lipid content and pVHL-dependent effects on mitochondrial 
ribosomal protein expression. These data potentially link mitochondrial translation to the 
VHL-dependent mitochondrial ETC protein expression patterns observed in the 786O and 
RCC10 cells. Experiments using pVHL mutant protein expression suggest a phenotype 
dependent on pVHL protein stability and potentially a role for the ECV E3-ligase complex, 
linking pVHL-dependent mitochondrial phenotype toward a role for protein ubiquitination 
and potential turnover.  
We have observed pVHL to affect mitochondrial morphology and mitochondrial length 
when re-expressed in 786O and RCC10 cells. Re-expression of pVHL decreases 
mitochondrial length by approximately 25% in 786O cells and produces a phenotype of less 
connected, rounder mitochondria compared with cells devoid of pVHL function. These 
observations were paralleled by pVHL-dependent expression of mitochondrial fusion and 
fission machinery. pVHL re-expression globally up-regulates MFN-1, MFN-2, OPA-1 and 
DRP-1. In the absence of pVHL an increase in phosphorylation of Ser637 on DRP-1, inhibiting 
fission, without affecting the ratio of total DRP-1 to that phosphorylated at Ser616, suggests 
a potential mechanism for the morphological change. pVHL re-expression is associated with 
an increased DRP-1: VDAC1 ratio present in mitochondrial fractions. Potentially, 
morphological alteration is a phenotype dependent on pVHL-mediated changes in 
macroautophagy, after an increased number of autophagosomes can be observed in the 
absence of pVHL in renal carcinoma cells and correlates with a mitochondrial sparing 
phenotype observed elsewhere (Rambold et al., 2011, Gomes et al., 2011).  
Aiming to determine a relationship between the observed pVHL-dependent mitochondrial 
phenotype and HIF-2α, we identified these observations to being independent of HIF-2α 
status and in parallel identified a novel role for HIF-2α protein itself in mediating peri-
nuclear organelle distribution, number of autophagosomes and FCCP-mediated mitophagy. 
An interesting HIF-2α-dependent effect on mitochondrial length was also observed in the 
786O cells, a phenotype that appears to be determined by pVHL status.  
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7.3 Future studies 
7.3.1 Investigate the direct effect of the HIF-1 complex on mitochondria 
Data presented in this thesis suggests the potential for the localisation of the HIF-1 complex 
with mitochondria. Both HIF-1α and HIF-1β subunits have been identified in mitochondrial 
preparations from tissue and cells. Further work to investigate the sub-mitochondrial 
topology of HIF-1α and HIF-1β proteins and subsequently their function is necessary.  In 
this thesis, mitochondrial localisation of the HIF proteins has been identified only through 
the isolation and preparation of purified mitochondria from cells and tissues. In order to 
expand these findings and to further understand the role of HIFs in directly regulating 
mitochondrial function, the subcellular localisation of the HIFs must be confirmed through 
additional, complementary approaches. 
An increasing number of nuclear transcription factors have been identified in mitochondria 
(Gough et al., 2009, Marchenko et al., 2000, Psarra et al., 2005). Findings from this thesis 
suggest we may be able to add the HIF-1 complex to this select list of highly specialised 
proteins. Understanding the mitochondrial topology of the HIF-1 complex would aid in 
dissecting the role of the HIFs in directly regulating mitochondrial function. Identification of 
any potential mitochondrial nucleoid association of the HIF-1 complex, in line with its 
recognised role as a transcription factor, and investigations into the role of the HIFs in 
mitochondrial DNA maintenance and gene expression may be promising for further study. 
Investigations into the regulation of mitochondrial DNA, in the presence and absence of 
HIF-1α and the influence of hypoxia, may allow identification of novel mitochondrial gene 
regulation and mitochondrial adaptation to hypoxia. 
Investigations into transcriptional independent roles of HIF-1α have identified the 
mitochondrial disulphide relay protein CHCHD4/MIA40 as a new regulator of the hypoxic 
response (Yang et al., 2012). Unpublished work from our laboratory indicate the possibility 
that HIF-1α binds CHCHD4 and regulates the electron transferring capacity of the DRS and 
consequently capacity of the mitochondrial ETC. This would suggest that HIF-1α may be 
present within the IMS, and/or affects CHCHD4/MIA40 import function.  
Finally, having identified an association between HIF-1α and mitochondria, it is conceivable 
that the same relationship may exist between HIF-2α and mitochondria. Future work may 
concentrate on first identifying if HIF-2α protein can be detected with mitochondria and 
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follow-up with same confirmatory studies, including sub-mitochondrial topology and 
immunogold labelled protein, as detailed previously with relation to HIF-1α. Finally, 
targeting HIF-1α and/or HIF-2α to mitochondria may reveal a more subtle role for the 
complex.  
7.3.2 Identify a role for the PHD proteins in mitochondrial regulation of HIF-α or distinct 
mitochondrial hydroxylation targets 
Recently, the PHD proteins have emerged as an increasingly promiscuous class of enzymes. 
Initially, characterised in the negative regulation of the HIF-α subunit, the PHD proteins are 
ever more being recognised to bind, hydroxylate and mediate turnover of a large number 
of distinct proteins, involved in a diverse array of cellular functions (Xie et al., 2009, 
Hiwatashi et al., 2011, Kuznetsova et al., 2003). 
As eluded to previously, with respect to mitochondrial localisation of HIF-1α, in situ 
confirmation of mitochondrial association/localisation of the PHD proteins is necessary. 
Having provided initial evidence supporting mitochondrial association of the PHD proteins 
and their emerging HIF-α independent function, proteomic analysis of PHD targets within 
mitochondria would provide a mechanism through which novel mitochondrial 
hydroxylation targets may be identified. Database search has already identified LXXLAP 
consensus hydroxylation sites in a number of mitochondrial proteins, including ATP5A and 
OPA-1.  
7.3.3 Further explore the relationship between pVHL and mitochondria in 786O cells 
There exists a multifaceted, as yet non-delineated relationship between pVHL and 
mitochondria. pVHL functions as the substrate recognition component of a multifunctional 
E3-ligase complex (Iwai et al., 1999, Kibel et al., 1995), best characterised for the normoxic 
proteasomal turnover of HIF-α subunits (Maxwell et al., 1999). However, pVHL is 
increasingly being recognised to have important HIF-α independent functions 
(Mukhopadhyay et al., 1997, Pal et al., 1997). How these HIF-α-independent roles of pVHL 
extend to regulating mitochondrial function and their importance in the tumour suppressor 
function of pVHL remains unknown. Investigation into the mitochondrial regulatory role of 
the ECV E3-ligase complex and the requirement for complex assembly and function is 
necessary to separate any potential independent roles of pVHL protein alone in controlling 
mitochondrial function. Mitochondrial effects of genetic manipulation of other ECV E3-
Chapter 7: Summary and conclusions 
Page | 292  
 
ligase complex components and determination of whether this would phenocopy the pVHL 
null phenotype would establish grounds on which to build a hypothesis.  
Identification of mitochondrial substrates of pVHL or more likely cytoplasmic proteins that 
regulate mitochondrial function, whose fate is determined by the ECV E3-ligase complex 
would go somewhere to understanding the mitochondrial phenotype. Evidence suggests 
that pVHL may affect mitochondrial protein translation. We have identified a number of 
mitochondrial ribosomal protein subunits that are differentially expressed in the presence 
and absence of pVHL in 786O cells. Investigation into mitochondrial ribosome assembly and 
protein expression may begin to unravel a complex relationship and could be extended to 
understand any relationship between pVHL and mitochondrial translation using in vitro 
translation assays.  
There is a clear relationship between pVHL status and mitochondrial DNA copy number 
established in this thesis. Further investigations into the mechanism behind this alteration 
may reveal novel targets for pVHL regulation. Understanding the cause versus effect 
relationship relating to mitochondrial morphology, bioenergetics and mitochondrial DNA 
maintenance is necessary to determine the focus for further mechanistic study.  
To date, proteomic investigation of the pVHL interactome suggests few targets that may be 
responsible for mediating such a phenotype. Investigation into mitochondrial complex 
assembly in the presence and absence of pVHL may allow correlation to be established 
between the decrease in subunit protein expression and complex abundance and activity 
observed after loss of pVHL. These investigations could be extended to investigate 
mitochondrial super complex assembly and the impact of pVHL-dependent changes in 
mitochondrial lipid content.  
7.3.4 Investigate the cellular consequences of reversing mitochondrial morphology 
observed in the presence and absence of pVHL 
Prominent pVHL-dependent morphological alterations have been identified that are unable 
to be corrected after HIF-2α silencing in pVHL defective cells. Mitochondrial morphology 
has been observed to protect mitochondria from non-selective autophagic turnover, 
maintaining energy biosynthesis and cell survival (Gomes et al., 2011, Rambold et al., 
2011). Understanding how reversal of the pVHL-dependent mitochondrial morphological 
phenotype affects cell viability and function would allow dissection of the significance of 
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this effect. Understanding the mechanism behind the pVHL-dependent morphological 
alterations would also be valuable. Investigation into the classical regulation of DRP-1 
phosphorylation states would prove a starting point to begin to untangle the likely 
signalling involved.  Investigation into how the dynamics of fusion and fission change after 
pVHL re-expression will be necessary to determine whether we are observing a phenotype 
of reduced fusion or increased fission.  
7.3.5 Investigate the pVHL-parkin relationship, understand the regulation and cellular 
consequence 
We have identified a strong correlation between pVHL status and parkin expression. 
Investigation is necessary to determine how the pVHL-parkin relationship observed in 786O 
cells extends across cell lines and once a positive correlation is established, investigation 
into the role of pVHL in parkin-mediated function could be investigated. In cells lacking 
pVHL there is a striking deficiency in parkin expression compared to those cells with pVHL 
re-expressed. Understanding the signalling involved in this transcriptional response would 
first be important to establish the likely scenarios under which these proteins and pathway 
cross-talk in vivo. Investigation into the cellular effects of parkin re-expression in a pVHL 
defective background may provide insight into the influence of this protein on the observed 
pVHL-dependent mitochondrial phenotype in 786O cells.  
7.3.6 Understand how the pVHL relationship with mitochondria extends across cell 
lines and tissues.  
Most importantly however, is to determine how the pVHL-dependent mitochondrial 
phenotype extends across cell lines. Characterisation of pVHL loss of function would be 
necessary to determine the extent to which pVHL controls mitochondrial function. Access 
to a conditional VHL-/- mouse, would allow identification of how a mitochondrial phenotype 
observed in VHL defective renal cell carcinoma, compared to that after stable re-expression 
extends in vivo and in different tissues. With respect to the role of pVHL in the apparent 
positive regulation of parkin expression and identification of parkin as a tumour suppressor 
protein, at least in hepatocellular carcinoma (Fujiwara et al., 2008) may indicate a role for 
pVHL in expression of this protein in tissues other than the kidney.  
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7.3.7 Investigate the role of HIF-2α in renal cells and pVHL-dependent and independent 
regulation of autophagy and mitochondrial selective turnover 
The observations presented in this thesis regarding the role of HIF-2α in autophagy are 
clearly in their infancy and considerable amounts of further work are required to 
investigate this phenotype further. Studies of autophagic flux, the identification of 
autophagosome structures and investigation into any mechanism and impact on cellular 
function need to be established. The pVHL-HIF-2α dependent changes in mitochondrial 
length are also an interesting observation and further investigation into mitochondrial and 
protein turnover through autophagy may reveal some additional insights.  
 
7.4 Limitations of the current study 
As in any study, it is important to understand where limitations lie in data obtained and 
how these limitations impact on interpretation of results. Firstly, with respect to the 
hypothesis that DMOG has off-target affects that influence metabolism, although highly 
revealing, the metabolomic data is limited only to cell treatment with DMOG and no data 
has been obtained with the second PHD inhibitor. The lack of metabolomic analysis on 
PHD-I restricts comprehensive conclusions. Although a second PHD inhibitor does not 
phenocopy the effects of DMOG on mitochondrial function, it would be necessary to 
compare and contrast metabolite profiles to determine whether the TCA cycle interference 
hypothesis of DMOG remains valid.  
As mentioned in chapter 3, there are inherent problems associated with subcellular 
fractionation and determining cellular topology of proteins. The chance of protein and 
organelle contamination through subcellular fractionation techniques need to be 
considered, and in situ localisation studies addressed in parallel, would add real value to 
the work presented in this thesis. 
The pVHL positive and negative 786O cell model has been utilised throughout this thesis. 
The 786O cell model has many advantages, such as the defining expression of only HIF-2α 
and not HIF-1α. Additionally, the loss of pVHL and stable re-expression allows the genetic 
fault to be corrected and the role of this single protein change to be examined in matched 
cell lines. However stable re-expression of pVHL produces supra-physiological levels of the 
protein that one may associate with protein over-expression. In light of pVHL protein over-
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expression, investigation into loss of pVHL, through silencing or knockout would useful in 
delineating a phenotype associated with over-expression to that of physiological function 
of pVHL. Finally, with respect to the observations involving HIF-2α, use of a second, 
validated siRNA is essential to confirm that we are observing a target-specific phenotype.  
 
7.5 Final conclusions 
7.5.1 Chapter 3 
We have investigated a direct relationship between protein members of the oxygen-
sensing pathway and mitochondria. We have identified a potential mitochondrial 
association between HIF and the PHD proteins and have begun to hypothesise novel routes 
through which the HIF-1 complex and the PHD proteins may directly regulate mitochondrial 
function and homeostasis.  
In chapter 3, we have also established potential off-target effects of DMOG on metabolism, 
potentially through effects on the TCA cycle. As a well utilised method for pharmacological 
activation of the HIF/hypoxic response in normoxia, observations stemming from this thesis 
suggest that metabolic phenotypes identified using this compound in future, must be 
carefully interpreted before conclusions made. As analysis of metabolite profile in cells 
treated with DMOG suggests that it may affect several metabolic pathways and affect 
substrate supply to the ETC. Therefore, in any future studies, comparison must be made 
between DMOG and those with a more selective inhibitor and/or compound with 
alternative mechanism of action.  
Therefore from chapter 3 we can conclude: 
 HIF-1α and HIF-1β associate with mitochondria in cells and tissue 
 PHD2 and PHD3 proteins associate with mitochondria 
 DMOG treatment causes rapid mitochondrial and metabolic alterations, that 
cannot be reproduced with a second inhibitor of the PHD protein 
7.5.2 Chapter 4 
We have extended published observations (Hervouet et al., 2005, Hervouet et al., 2008) 
regarding the re-expression of pVHL in renal cell carcinoma and its effects on mitochondrial 
phenotype. In chapter 4, we have identified that this relationship is likely independent of 
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HIF-2α and potentially reliant on the capacity of the ECV E3-ligase complex. pVHL re-
expression increases mitochondrial respiration, mitochondrial DNA content and has 
differential effects on the protein expression of a number of mitochondrially and nuclear 
encoded ETC subunits. Analysis of ETC subunit gene expression also suggests mitochondrial 
protein translational effects, potentially through pVHL-dependent regulation of 
mitochondrial ribosomal protein expression.  
Therefore from chapter 4 we can conclude: 
 pVHL status affects mitochondrial function in renal carcinoma cells 
 The pVHL-dependent mitochondrial phenotype is primarily independent of HIF-α 
7.5.3 Chapter 5 
Here we have established a role in the regulation of mitochondrial morphology after re-
expression of pVHL in renal cell carcinoma. Approaches to understand a mechanism behind 
these observations led to the identification of increased inhibitory phosphorylation events 
on DRP-1 in the 786O-EV cells. In the absence of pVHL a decrease in DRP-1, MFN-1 and 
MFN-2 and OPA-1 expression was also identified.  A correlation between the re-expression 
of pVHL and presence of autophagosomes was also noted, confirming established links 
between pVHL and macroautophagy. A positive regulatory role of pVHL re-expression on 
parkin was also identified, potentially linking pVHL and/or renal cell carcinoma to 
alterations in mitochondrial turnover.  
Therefore from chapter 5 we can conclude: 
 pVHL status affect mitochondrial morphology and the expression and post-
translational modification of mitochondrial fusion and fission proteins 
 pVHL status affects markers of autophagy  
 A relationship exists between pVHL status and parkin expression 
7.5.4 Chapter 6 
Here we have identified that loss of HIF-2α, is associated with peri-nuclear distribution of 
mitochondria. This nuclear re-distribution likely extends to distinct cytoplasmic organelles, 
a phenotype which may be associated with altered autophagic flux. Loss of HIF-2α also 
appears to affect mitochondrial respiration independently of pVHL status and has a small 
influence on mitochondrial DNA copy number, a phenotype evident across cell lines. 
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Interestingly, we have also identified a HIF-2α-dependent role in regulating mitochondrial 
length in 786O cells, a phenotype that is dependent on pVHL status.  
Therefore from chapter 6 we can conclude: 
 Loss of HIF-2α affects mitochondrial distribution and function 
 Loss of HIF-2α may influence mitochondrial turnover and autophagy 
 
7.6 Final thoughts 
Throughout this thesis, we have aimed to identify novel regulatory mechanisms of the 
oxygen-sensing machinery on mitochondrial function. There is much still to learn and 
discover regarding the function of HIF and the PHD proteins, their coordination, regulation, 
localisation, relationship and mechanistic activity in influencing the mitochondrial 
phenotype. Additionally, we have established many pVHL-dependent effects on 
mitochondrial function using a wild type genetic gene re-expression in a renal carcinoma 
matched cell system. It is our hope that the findings presented in this thesis will lead to the 
identification of novel molecular mechanisms that regulate cellular health and 
homeostasis, and help us further understand specific disease pathologies that involve 
deregulation of the oxygen-sensing pathway.   
 
 
  
Bibliography 
Page | 298  
 
 
 
 
 
Bibliography 
 
Bibliography 
Page | 299  
 
ACKER, T. 2005. Genetic evidence for a tumor suppressor role of HIF-2α. Cancer 
Cell, 8, 131-141. 
ACTON, B. M., JURISICOVA, A., JURISICA, I. & CASPER, R. F. 2004. Alterations in 
mitochondrial membrane potential during preimplantation stages of mouse 
and human embryo development. Molecular Human Reproduction, 10, 23-
32. 
ADDABBO, F., MONTAGNANI, M. & GOLIGORSKY, M. S. 2009. Mitochondria and 
reactive oxygen species. Hypertension, 53, 885-92. 
AGANI, F. H., PICHIULE, P., CARLOS CHAVEZ, J. & LAMANNA, J. C. 2002. Inhibitors of 
mitochondrial complex I attenuate the accumulation of hypoxia-inducible 
factor-1 during hypoxia in Hep3B cells. Comp Biochem Physiol A Mol Integr 
Physiol, 132, 107-9. 
AGANI, F. H., PICHIULE, P., CHAVEZ, J. C. & LAMANNA, J. C. 2000. The role of 
mitochondria in the regulation of hypoxia-inducible factor 1 expression 
during hypoxia. J Biol Chem, 275, 35863-7. 
AL-MEHDI, A.-B., PASTUKH, V. M., SWIGER, B. M., REED, D. J., PATEL, M. R., 
BARDWELL, G. C., PASTUKH, V. V., ALEXEYEV, M. F. & GILLESPIE, M. N. 2012. 
Perinuclear Mitochondrial Clustering Creates an Oxidant-Rich Nuclear 
Domain Required for Hypoxia-Induced Transcription. Sci. Signal., 5, ra47-. 
ALAM, H., WECK, J., MAIZELS, E., PARK, Y., LEE, E. J., ASHCROFT, M. & HUNZICKER-
DUNN, M. 2009. Role of the phosphatidylinositol-3-kinase and extracellular 
regulated kinase pathways in the induction of hypoxia-inducible factor (HIF)-
1 activity and the HIF-1 target vascular endothelial growth factor in ovarian 
granulosa cells in response to follicle-stimulating hormone. Endocrinology, 
150, 915-928. 
ALLEN, S., BALABANIDOU, V., SIDERIS, D. P., LISOWSKY, T. & TOKATLIDIS, K. 2005. 
Erv1 mediates the Mia40-dependent protein import pathway and provides a 
functional link to the respiratory chain by shuttling electrons to cytochrome 
c. J.Mol.Biol., 353, 937-944. 
ANDERSON, K., NORDQUIST, K. A., GAO, X., HICKS, K. C., ZHAI, B., GYGI, S. P. & 
PATEL, T. B. 2011. Regulation of Cellular Levels of Sprouty2 Protein by Prolyl 
Hydroxylase Domain and von Hippel-Lindau Proteins. Journal of Biological 
Chemistry, 286, 42027-42036. 
APPELHOFF, R. J., TIAN, Y. M., RAVAL, R. R., TURLEY, H., HARRIS, A. L., PUGH, C. W., 
RATCLIFFE, P. J. & GLEADLE, J. M. 2004. Differential function of the prolyl 
hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible 
factor. J Biol Chem, 279, 38458-65. 
APRELIKOVA, O., CHANDRAMOULI, G. V. R., WOOD, M., VASSELLI, J. R., RISS, J., 
MARANCHIE, J. K., LINEHAN, W. M. & BARRETT, J. C. 2004. Regulation of HIF 
prolyl hydroxylases by hypoxia-inducible factors. Journal of Cellular 
Biochemistry, 92, 491-501. 
Bibliography 
Page | 300  
 
ARAGONES, J., FRAISL, P., BAES, M. & CARMELIET, P. 2009. Oxygen sensors at the 
crossroad of metabolism. Cell Metab., 9, 11-22. 
ARAGONES, J., SCHNEIDER, M., VAN GEYTE, K., FRAISL, P., DRESSELAERS, T., 
MAZZONE, M., DIRKX, R., ZACCHIGNA, S., LEMIEUX, H., JEOUNG, N. H., 
LAMBRECHTS, D., BISHOP, T., LAFUSTE, P., DIEZ-JUAN, A., HARTEN, S. K., 
VAN NOTEN, P., DE BOCK, K., WILLAM, C., TJWA, M., GROSFELD, A., NAVET, 
R., MOONS, L., VANDENDRIESSCHE, T., DEROOSE, C., WIJEYEKOON, B., 
NUYTS, J., JORDAN, B., SILASI-MANSAT, R., LUPU, F., DEWERCHIN, M., PUGH, 
C., SALMON, P., MORTELMANS, L., GALLEZ, B., GORUS, F., BUYSE, J., SLUSE, 
F., HARRIS, R. A., GNAIGER, E., HESPEL, P., VAN HECKE, P., SCHUIT, F., VAN 
VELDHOVEN, P., RATCLIFFE, P., BAES, M., MAXWELL, P. & CARMELIET, P. 
2008. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia 
tolerance by reprogramming basal metabolism. Nat Genet, 40, 170-80. 
ARANY, Z., HUANG, L. E., ECKNER, R., BHATTACHARYA, S., JIANG, C., GOLDBERG, M. 
A., BUNN, H. F. & LIVINGSTON, D. M. 1996. An essential role for p300/CBP in 
the cellular response to hypoxia. Proc Natl Acad Sci U S A, 93, 12969-73. 
ARLT, H., STEGLICH, G., PERRYMAN, R., GUIARD, B., NEUPERT, W. & LANGER, T. 
1998. The formation of respiratory chain complexes in mitochondria is 
under the proteolytic control of the m-AAA protease. EMBO Journal, 17, 
4837-4847. 
ARSTALL, M. A., ZHAO, Y. Z., HORNBERGER, L., KENNEDY, S. P., BUCHHOLZ, R. A., 
OSATHANONDH, R. & KELLY, R. A. 1998. Human ventricular myocytes in vitro 
exhibit both early and delayed preconditioning responses to simulated 
ischemia. J Mol Cell Cardiol, 30, 1019-25. 
BAE, S. H., JEONG, J. W., PARK, J. A., KIM, S. H., BAE, M. K., CHOI, S. J. & KIM, K. W. 
2004. Sumoylation increases HIF-1alpha stability and its transcriptional 
activity. Biochem Biophys Res Commun, 324, 394-400. 
BALLINGER, S. W. 2005. Mitochondrial dysfunction in cardiovascular disease. Free 
Radical Biology and Medicine, 38, 1278-1295. 
BANGIYEVA, V., ROSENBLOOM, A., ALEXANDER, A., ISANOVA, B., POPKO, T. & 
SCHOENFELD, A. 2009. Differences in regulation of tight junctions and cell 
morphology between VHL mutations from disease subtypes. BMC Cancer, 9, 
229. 
BARDOS, J. I. & ASHCROFT, M. 2005. Negative and positive regulation of HIF-1: a 
complex network. Biochim Biophys Acta, 1755, 107-20. 
BARDOS, J. I., CHAU, N. M. & ASHCROFT, M. 2004. Growth factor-mediated 
induction of HDM2 positively regulates hypoxia-inducible factor 1alpha 
expression. Mol Cell Biol, 24, 2905-14. 
BARRY, R. E. 2004. Functional analysis of the von Hippel-Lindau tumour suppressor 
and its role in tumourigenesis. DPhil, Universitat Basel. 
Bibliography 
Page | 301  
 
BARTEL, D. P. 2004. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. 
Cell, 116, 281-297. 
BARTH, S., EDLICH, F., BERCHNER-PFANNSCHMIDT, U., GNEUSS, S., JAHREIS, G., 
HASGALL, P. A., FANDREY, J., WENGER, R. H. & CAMENISCH, G. 2009. 
Hypoxia-inducible factor prolyl-4-hydroxylase PHD2 protein abundance 
depends on integral membrane anchoring of FKBP38. J Biol Chem, 284, 
23046-58. 
BARTH, S., GLICK, D. & MACLEOD, K. F. 2010. Autophagy: assays and artifacts. The 
Journal of Pathology, 221, 117-124. 
BEESON, C. C., BEESON, G. C. & SCHNELLMANN, R. G. 2010. A high-throughput 
respirometric assay for mitochondrial biogenesis and toxicity. Analytical 
Biochemistry, 404, 75-81. 
BELL, E. L., EMERLING, B. M. & CHANDEL, N. S. 2005. Mitochondrial regulation of 
oxygen sensing. Mitochondrion, 5, 322-332. 
BELL, E. L., KLIMOVA, T. A., EISENBART, J., MORAES, C. T., MURPHY, M. P., 
BUDINGER, G. R. & CHANDEL, N. S. 2007. The Qo site of the mitochondrial 
complex III is required for the transduction of hypoxic signaling via reactive 
oxygen species production. J Cell Biol, 177, 1029-36. 
BERRA, E., BENIZRI, E., GINOUVES, A., VOLMAT, V., ROUX, D. & POUYSSEGUR, J. 
2003. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-
state levels of HIF-1alpha in normoxia. Embo J, 22, 4082-90. 
BERRA, E., ROUX, D., RICHARD, D. E. & POUYSSEGUR, J. 2001. Hypoxia-inducible 
factor-1 alpha (HIF-1 alpha) escapes O(2)-driven proteasomal degradation 
irrespective of its subcellular localization: nucleus or cytoplasm. EMBO Rep, 
2, 615-20. 
BERTA, M. A., MAZURE, N., HATTAB, M., POUYSSEGUR, J. & BRAHIMI-HORN, M. C. 
2007. SUMOylation of hypoxia-inducible factor-1alpha reduces its 
transcriptional activity. Biochem Biophys Res Commun, 360, 646-52. 
BERTOUT, J. A. 2009. HIF2α inhibition promotes p53 pathway activity, tumor cell 
death, and radiation responses. Proc. Natl Acad. Sci. USA, 106, 14391-14396. 
BHANDARY, B., MARAHATTA, A., KIM, H.-R. & CHAE, H.-J. 2012. Mitochondria in 
relation to cancer metastasis. Journal of Bioenergetics and Biomembranes, 
44, 623-627. 
BIEN, M., LONGEN, S., WAGENER, N., CHWALLA, I., HERRMANN, J. M. & RIEMER, J. 
2010. Mitochondrial disulfide bond formation is driven by intersubunit 
electron transfer in Erv1 and proofread by glutathione. Mol.Cell, 37, 516-
528. 
BIHLMAIER, K., MESECKE, N., TERZIYSKA, N., BIEN, M., HELL, K. & HERRMANN, J. M. 
2007. The disulfide relay system of mitochondria is connected to the 
respiratory chain. J.Cell Biol., 179, 389-395. 
Bibliography 
Page | 302  
 
BISWAS, S., TROY, H., LEEK, R., CHUNG, Y. L., LI, J. L., RAVAL, R. R., TURLEY, H., 
GATTER, K., PEZZELLA, F., GRIFFITHS, J. R., STUBBS, M. & HARRIS, A. L. 2010. 
Effects of HIF-1alpha and HIF2alpha on Growth and Metabolism of Clear-Cell 
Renal Cell Carcinoma 786-0 Xenografts. J Oncol, 2010, 757908. 
BJØRKØY, G., LAMARK, T., BRECH, A., OUTZEN, H., PERANDER, M., ØVERVATN, A., 
STENMARK, H. & JOHANSEN, T. 2005. p62/SQSTM1 forms protein 
aggregates degraded by autophagy and has a protective effect on 
huntingtin-induced cell death. The Journal of Cell Biology, 171, 603-614. 
BJØRKØY, G., LAMARK, T., PANKIV, S., ØVERVATN, A., BRECH, A. & JOHANSEN, T. 
2009. Chapter 12 Monitoring Autophagic Degradation of p62/SQSTM1. In: 
DANIEL, J. K. (ed.) Methods in Enzymology. Academic Press. 
BOGENHAGEN, D. F., ROUSSEAU, D. & BURKE, S. 2008. The Layered Structure of 
Human Mitochondrial DNA Nucleoids. Journal of Biological Chemistry, 283, 
3665-3675. 
BOHENSKY, J., TERKHORN, S. P., FREEMAN, T. A., ADAMS, C. S., GARCIA, J. A., 
SHAPIRO, I. M. & SRINIVAS, V. 2009. Regulation of autophagy in human and 
murine cartilage: Hypoxia-inducible factor 2 suppresses chondrocyte 
autophagy. Arthritis & Rheumatism, 60, 1406-1415. 
BOLLI, R., SHINMURA, K., TANG, X. L., KODANI, E., XUAN, Y. T., GUO, Y. & DAWN, B. 
2002. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a 
cardioprotective protein that alleviates ischemia/reperfusion injury and 
mediates the late phase of preconditioning. Cardiovasc Res, 55, 506-19. 
BOND, J., GALE, D. P., CONNOR, T., ADAMS, S., DE BOER, J., GASCOYNE, D. M., 
WILLIAMS, O., MAXWELL, P. H. & ANCLIFF, P. J. 2011. Dysregulation of the 
HIF pathway due to VHL mutation causing severe erythrocytosis and 
pulmonary arterial hypertension. Blood, 117, 3699-3701. 
BOULAHBEL, H., DURAN, R. V. & GOTTLIEB, E. 2009. Prolyl hydroxylases as 
regulators of cell metabolism. Biochem Soc Trans, 37, 291-4. 
BRAHIMI-HORN, C., MAZURE, N. & POUYSSEGUR, J. 2005. Signalling via the hypoxia-
inducible factor-1alpha requires multiple posttranslational modifications. 
Cell Signal, 17, 1-9. 
BRAND, M. D. & ESTEVES, T. C. 2005. Physiological functions of the mitochondrial 
uncoupling proteins UCP2 and UCP3. Cell Metabolism, 2, 85-93. 
BRAND, M. D. & NICHOLLS, D. G. 2011. Assessing mitochondrial dysfunction in cells. 
Biochem J, 435, 297-312. 
BRAUNWALD, E. & KLONER, R. A. 1985. Myocardial reperfusion: a double-edged 
sword? J Clin Invest, 76, 1713-9. 
BRISTON, T., YANG, J. & ASHCROFT, M. 2011. HIF-1alpha localization with 
mitochondria: a new role for an old favorite? Cell Cycle, 10, 4170-1. 
Bibliography 
Page | 303  
 
BROWN, S. T. & NURSE, C. A. 2008. Induction of HIF-2alpha is dependent on 
mitochondrial O2 consumption in an O2-sensitive adrenomedullary 
chromaffin cell line. Am J Physiol Cell Physiol, 294, C1305-12. 
BRUCE ALBERTS, A. J., JULIAN LEWIS, MARTIN RAFF, KEITH ROBERTS, AND PETER 
WALTER 2002. Molecular Biology of the Cell, New York: Garland Science. 
BRUNELLE, J. K., BELL, E. L., QUESADA, N. M., VERCAUTEREN, K., TIRANTI, V., 
ZEVIANI, M., SCARPULLA, R. C. & CHANDEL, N. S. 2005. Oxygen sensing 
requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab, 
1, 409-14. 
BUNZ, F., DUTRIAUX, A., LENGAUER, C., WALDMAN, T., ZHOU, S., BROWN, J. P., 
SEDIVY, J. M., KINZLER, K. W. & VOGELSTEIN, B. 1998. Requirement for p53 
and p21 to Sustain G2 Arrest After DNA Damage Science 282 1497-1501  
CADENAS, S., ARAGONES, J. & LANDAZURI, M. O. 2010. Mitochondrial 
reprogramming through cardiac oxygen sensors in ischemic heart disease. 
Cardiovasc Res, 88, 219-28. 
CAI, Z., ZHONG, H., BOSCH-MARCE, M., FOX-TALBOT, K., WANG, L., WEI, C., TRUSH, 
M. A. & SEMENZA, G. L. 2008. Complete loss of ischaemic preconditioning-
induced cardioprotection in mice with partial deficiency of HIF-1 alpha. 
Cardiovasc Res, 77, 463-70. 
CALDWELL, M. C., HOUGH, C., FURER, S., LINEHAN, W. M., MORIN, P. J. & GOROSPE, 
M. 2002. Serial analysis of gene expression in renal carcinoma cells reveals 
VHL-dependent sensitivity to TNFalpha cytotoxicity. Oncogene, 21, 929-36. 
CAMPBELL, C. T., KOLESAR, J. E. & KAUFMAN, B. A. 2012. Mitochondrial 
transcription factor A regulates mitochondrial transcription initiation, DNA 
packaging, and genome copy number. Biochimica et Biophysica Acta (BBA) - 
Gene Regulatory Mechanisms, 1819, 921-929. 
CAMPS, C., BUFFA, F. M., COLELLA, S., MOORE, J., SOTIRIOU, C., SHELDON, H., 
HARRIS, A. L., GLEADLE, J. M. & RAGOUSSIS, J. 2008. hsa-miR-210 Is Induced 
by Hypoxia and Is an Independent Prognostic Factor in Breast Cancer. 
Clinical Cancer Research, 14, 1340-1348. 
CARDACI, S. & CIRIOLO, M. R. 2012. TCA Cycle Defects and Cancer: When 
Metabolism Tunes Redox State. International Journal of Cell Biology, 2012, 
9. 
CARROLL, V. A. & ASHCROFT, M. 2006. Role of hypoxia-inducible factor (HIF)-1alpha 
versus HIF-2alpha in the regulation of HIF target genes in response to 
hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: 
implications for targeting the HIF pathway. Cancer Res, 66, 6264-70. 
CARROLL, V. A. & ASHCROFT, M. 2008. Regulation of angiogenic factors by HDM2 in 
renal cell carcinoma. Cancer Research.68(2):545-52,. 
Bibliography 
Page | 304  
 
CAVALLI, L., VARELLA-GARCIA, M. & LIANG, B. 1997. Diminished tumorigenic 
phenotype after depletion of mitochondrial DNA. Cell Growth Differ, 8, 
1189-1198. 
CEREGHETTI, G. M., STANGHERLIN, A., DE BRITO, O. M., CHANG, C. R., BLACKSTONE, 
C., BERNARDI, P. & SCORRANO, L. 2008. Dephosphorylation by calcineurin 
regulates translocation of Drp1 to mitochondria. Proceedings of the National 
Academy of Sciences, 105, 15803-15808. 
CHACINSKA, A., PFANNSCHMIDT, S., WIEDEMANN, N., KOZJAK, V., SANJUAN 
SZKLARZ, L. K., SCHULZE-SPECKING, A., TRUSCOTT, K. N., GUIARD, B., 
MEISINGER, C. & PFANNER, N. 2004. Essential role of Mia40 in import and 
assembly of mitochondrial intermembrane space proteins. Embo J, 23, 
3735-3746. 
CHAMPAGNE, E., MARTINEZ, L. O., COLLET, X. & BARBARAS, R. 2006. Ecto-F1Fo ATP 
synthase/F1 ATPase: metabolic and immunological functions. Curr Opin 
Lipidol, 17, 279-84. 
CHAN, D. C. 2012. Fusion and Fission: Interlinked Processes Critical for 
Mitochondrial Health. Annu Rev Genet, 46, 265-287. 
CHAN, S. Y., ZHANG, Y.-Y., HEMANN, C., MAHONEY, C. E., ZWEIER, J. L. & LOSCALZO, 
J. 2009. MicroRNA-210 Controls Mitochondrial Metabolism during Hypoxia 
by Repressing the Iron-Sulfur Cluster Assembly Proteins ISCU1/2. Cell 
Metabolism, 10, 273-284. 
CHANDEL, N. S., MALTEPE, E., GOLDWASSER, E., MATHIEU, C. E., SIMON, M. C. & 
SCHUMACKER, P. T. 1998. Mitochondrial reactive oxygen species trigger 
hypoxia-induced transcription. Proc Natl Acad Sci U S A, 95, 11715-20. 
CHANDEL, N. S., MCCLINTOCK, D. S., FELICIANO, C. E., WOOD, T. M., MELENDEZ, J. 
A., RODRIGUEZ, A. M. & SCHUMACKER, P. T. 2000. Reactive oxygen species 
generated at mitochondrial complex III stabilize hypoxia-inducible factor-
1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem, 275, 25130-
8. 
CHANDEL, N. S. & SCHUMACKER, P. T. 1999. Cells depleted of mitochondrial DNA 
(rho0) yield insight into physiological mechanisms. FEBS Lett, 454, 173-6. 
CHANDRA, D. & SINGH, K. K. 2011. Genetic insights into OXPHOS defect and its role 
in cancer. Biochimica et Biophysica Acta (BBA) - Bioenergetics, 1807, 620-
625. 
CHANG, C.-R. & BLACKSTONE, C. 2007. Cyclic AMP-dependent Protein Kinase 
Phosphorylation of Drp1 Regulates Its GTPase Activity and Mitochondrial 
Morphology. Journal of Biological Chemistry, 282, 21583-21587. 
CHAUGULE, V. K., BURCHELL, L., BARBER, K. R., SIDHU, A., LESLIE, S. J., SHAW, G. S. 
& WALDEN, H. 2011. Autoregulation of Parkin activity through its ubiquitin-
like domain. Embo J, 30, 2853-2867. 
Bibliography 
Page | 305  
 
CHEN, E. I., HEWEL, J., KRUEGER, J. S., TIRABY, C., WEBER, M. R., KRALLI, A., BECKER, 
K., YATES, J. R. & FELDING-HABERMANN, B. 2007. Adaptation of Energy 
Metabolism in Breast Cancer Brain Metastases. Cancer Research, 67, 1472-
1486. 
CHEN, H. & CHAN, D. C. 2004. Mitochondrial Dynamics in Mammals. In: GERALD, P. 
S. (ed.) Current Topics in Developmental Biology. Academic Press. 
CHEN, H., CHOMYN, A. & CHAN, D. C. 2005. Disruption of fusion results in 
mitochondrial heterogeneity and dysfunction. J Biol Chem, 280, 26185-
26192. 
CHEN, H., VERMULST, M., WANG, Y. E., CHOMYN, A., PROLLA, T. A., MCCAFFERY, J. 
M. & CHAN, D. C. 2010. Mitochondrial Fusion Is Required for mtDNA 
Stability in Skeletal Muscle and Tolerance of mtDNA Mutations. Cell, 141, 
280-289. 
CHIANG, Y.-Y., CHEN, S.-L., HSIAO, Y.-T., HUANG, C.-H., LIN, T.-Y., CHIANG, I. P., HSU, 
W.-H. & CHOW, K.-C. 2009. Nuclear expression of dynamin-related protein 1 
in lung adenocarcinomas. Mod Pathol, 22, 1139-1150. 
CHICCO, A. J. & SPARAGNA, G. C. 2007. Role of cardiolipin alterations in 
mitochondrial dysfunction and disease. American Journal of Physiology - Cell 
Physiology, 292, C33-C44. 
CHO, H., AHN, D. R., PARK, H. & YANG, E. G. 2007. Modulation of p300 binding by 
posttranslational modifications of the C-terminal activation domain of 
hypoxia-inducible factor-1alpha. FEBS Lett, 581, 1542-8. 
CHOU, C.-H., LIN, C.-C., YANG, M.-C., WEI, C.-C., LIAO, H.-D., LIN, R.-C., TU, W.-Y., 
KAO, T.-C., HSU, C.-M., CHENG, J.-T., CHOU, A.-K., LEE, C.-I., LOH, J.-K., 
HOWNG, S.-L. & HONG, Y.-R. 2012. GSK3beta-Mediated Drp1 
Phosphorylation Induced Elongated Mitochondrial Morphology against 
Oxidative Stress. PLoS One, 7, e49112. 
CHRISTIAN, B. E. & SPREMULLI, L. L. 2012. Mechanism of protein biosynthesis in 
mammalian mitochondria. Biochim Biophys Acta, 1819, 1035-54. 
CHUA, Y. L., DUFOUR, E., DASSA, E. P., RUSTIN, P., JACOBS, H. T., TAYLOR, C. T. & 
HAGEN, T. 2010. Stabilization of HIF-1alpha protein in hypoxia occurs 
independently of mitochondrial reactive oxygen species production. J Biol 
Chem, 285, 31277-84. 
CHUN, Y. S., KIM, M. S. & PARK, J. W. 2002. Oxygen-dependent and -independent 
regulation of HIF-1alpha. J Korean Med Sci, 17, 581-8. 
CLARK, I. E. 2006. Drosophila pink1 is required for mitochondrial function and 
interacts genetically with parkin. Nature, 441, 1162-1166. 
CLAY MONTIER, L. L., DENG, J. J. & BAI, Y. 2009. Number matters: control of 
mammalian mitochondrial DNA copy number. J Genet Genomics, 36, 125-31. 
Bibliography 
Page | 306  
 
CLAYCOMB, W. C., LANSON, N. A., JR., STALLWORTH, B. S., EGELAND, D. B., 
DELCARPIO, J. B., BAHINSKI, A. & IZZO, N. J., JR. 1998. HL-1 cells: a cardiac 
muscle cell line that contracts and retains phenotypic characteristics of the 
adult cardiomyocyte. Proc Natl Acad Sci U S A, 95, 2979-84. 
COLLA, S., TAGLIAFERRI, S., MORANDI, F., LUNGHI, P., DONOFRIO, G., MARTORANA, 
D., MANCINI, C., LAZZARETTI, M., MAZZERA, L., RAVANETTI, L., BONOMINI, 
S., FERRARI, L., MIRANDA, C., LADETTO, M., NERI, T. M., NERI, A., GRECO, A., 
MANGONI, M., BONATI, A., RIZZOLI, V. & GIULIANI, N. 2007. The new tumor-
suppressor gene inhibitor of growth family member 4 (ING4) regulates the 
production of proangiogenic molecules by myeloma cells and suppresses 
hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in 
myeloma-induced angiogenesis. Blood, 110, 4464-75. 
CONCHELLO, J.-A. & LICHTMAN, J. W. 2005. Optical sectioning microscopy. Nat 
Meth, 2, 920-931. 
CORMIER-REGARD, S., NGUYEN, S. V. & CLAYCOMB, W. C. 1998. Adrenomedullin 
gene expression is developmentally regulated and induced by hypoxia in rat 
ventricular cardiac myocytes. J Biol Chem, 273, 17787-92. 
CRAMER, T. & JOHNSON, R. S. 2003. A novel role for the hypoxia inducible 
transcription factor HIF-1alpha: critical regulation of inflammatory cell 
function. Cell Cycle, 2, 192-3. 
CRAMER, T., YAMANISHI, Y., CLAUSEN, B. E., FÖRSTER, I., PAWLINSKI, R., 
MACKMAN, N., HAASE, V. H., JAENISCH, R., CORR, M., NIZET, V., FIRESTEIN, 
G. S., GERBER, H.-P., FERRARA, N. & JOHNSON, R. S. 2003. HIF-1α Is Essential 
for Myeloid Cell-Mediated Inflammation. Cell, 112, 645-657. 
CRAVEN, R. A., HANRAHAN, S., TOTTY, N., HARNDEN, P., STANLEY, A. J., MAHER, E. 
R., HARRIS, A. L., TRIMBLE, W. S., SELBY, P. J. & BANKS, R. E. 2006. Proteomic 
identification of a role for the von Hippel Lindau tumour suppressor in 
changes in the expression of mitochondrial proteins and septin 2 in renal 
cell carcinoma. PROTEOMICS, 6, 3880-3893. 
CRIBBS, J. T. & STRACK, S. 2007. Reversible phosphorylation of Drp1 by cyclic AMP-
dependent protein kinase and calcineurin regulates mitochondrial fission 
and cell death. EMBO Rep, 8, 939-944. 
CUMMINS, E. P., BERRA, E., COMERFORD, K. M., GINOUVES, A., FITZGERALD, K. T., 
SEEBALLUCK, F., GODSON, C., NIELSEN, J. E., MOYNAGH, P., POUYSSEGUR, J. 
& TAYLOR, C. T. 2006. Prolyl hydroxylase-1 negatively regulates IkappaB 
kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl 
Acad Sci U S A, 103, 18154-9. 
DABIR, D. V., LEVERICH, E. P., KIM, S. K., TSAI, F. D., HIRASAWA, M., KNAFF, D. B. & 
KOEHLER, C. M. 2007. A role for cytochrome c and cytochrome c peroxidase 
in electron shuttling from Erv1. Embo J, 26, 4801-11. 
Bibliography 
Page | 307  
 
DATE, T., MOCHIZUKI, S., BELANGER, A. J., YAMAKAWA, M., LUO, Z., VINCENT, K. A., 
CHENG, S. H., GREGORY, R. J. & JIANG, C. 2005. Expression of constitutively 
stable hybrid hypoxia-inducible factor-1alpha protects cultured rat 
cardiomyocytes against simulated ischemia-reperfusion injury. Am J Physiol 
Cell Physiol, 288, C314-20. 
DAVIDOWITZ, E. J., SCHOENFELD, A. R. & BURK, R. D. 2001. VHL Induces Renal Cell 
Differentiation and Growth Arrest through Integration of Cell-Cell and Cell-
Extracellular Matrix Signaling. Molecular and Cellular Biology, 21, 865-874. 
DAVIS, M. A. 2002. Apoptosis Methods in Pharmacology and Toxicology: 
Approaches to Measurement and Quantification, Humana Press 
Incorporated. 
DAWN, B. & BOLLI, R. 2005. HO-1 induction by HIF-1: a new mechanism for delayed 
cardioprotection? Am J Physiol Heart Circ Physiol, 289, H522-4. 
DE VRIES, R. L. A. & PRZEDBORSKI, S. 2013. Mitophagy and Parkinson's disease: Be 
eaten to stay healthy. Molecular and Cellular Neuroscience, 55, 37-43. 
DEAS, E., PLUN-FAVREAU, H., GANDHI, S., DESMOND, H., KJAER, S., LOH, S. H. Y., 
RENTON, A. E. M., HARVEY, R. J., WHITWORTH, A. J., MARTINS, L. M., 
ABRAMOV, A. Y. & WOOD, N. W. 2011a. PINK1 cleavage at position A103 by 
the mitochondrial protease PARL. Human Molecular Genetics, 20, 867-879. 
DEAS, E., WOOD, N. W. & PLUN-FAVREAU, H. 2011b. Mitophagy and Parkinson's 
disease: The PINK1–parkin link. Biochimica et Biophysica Acta (BBA) - 
Molecular Cell Research, 1813, 623-633. 
DEHAAN, C., HABIBI-NAZHAD, B., YAN, E., SALLOUM, N., PARLIAMENT, M. & 
ALLALUNIS-TURNER, J. 2004. Mutation in mitochondrial complex I ND6 
subunit is associated with defective response to hypoxia in human glioma 
cells. Mol Cancer, 3, 19. 
DELCARPIO, J. B., LANSON, N. A., JR., FIELD, L. J. & CLAYCOMB, W. C. 1991. 
Morphological characterization of cardiomyocytes isolated from a 
transplantable cardiac tumor derived from transgenic mouse atria (AT-1 
cells). Circ Res, 69, 1591-600. 
DENG, H., DODSON, M. W., HUANG, H. & GUO, M. 2008. The Parkinson's disease 
genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion 
in Drosophila. Proc. Natl Acad. Sci. USA, 105, 14503-14508. 
DEWITT, D. A., HURD, J. A., FOX, N., TOWNSEND, B. E., GRIFFIOEN, K. J. S., GHRIBI, 
O. & SAVORY, J. 2006. Peri-nuclear clustering of mitochondria is triggered 
during aluminum maltolate induced apoptosis. Journal of Alzheimer's 
Disease, 9, 195-205. 
DI LISA, F. & BERNARDI, P. 2006. Mitochondria and ischemia-reperfusion injury of 
the heart: fixing a hole. Cardiovasc Res, 70, 191-9. 
Bibliography 
Page | 308  
 
DING, W. X. 2010. Nix is critical to two distinct phases of mitophagy, reactive 
oxygen species-mediated autophagy induction and Parkin-ubiquitin-p62- 
mediated mitochondrial priming. J. Biol. Chem., 285, 27879-27890. 
DOEGE, K., HEINE, S., JENSEN, I., JELKMANN, W. & METZEN, E. 2005. Inhibition of 
mitochondrial respiration elevates oxygen concentration but leaves 
regulation of hypoxia-inducible factor (HIF) intact. Blood, 106, 2311-7. 
DOWNEY, J. M., DAVIS, A. M. & COHEN, M. V. 2007. Signaling pathways in ischemic 
preconditioning. Heart Fail Rev, 12, 181-8. 
DURANTEAU, J., CHANDEL, N. S., KULISZ, A., SHAO, Z. & SCHUMACKER, P. T. 1998. 
Intracellular signaling by reactive oxygen species during hypoxia in 
cardiomyocytes. J Biol Chem, 273, 11619-24. 
EBERT, B. L., FIRTH, J. D. & RATCLIFFE, P. J. 1995. Hypoxia and mitochondrial 
inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting 
sequences. J Biol Chem, 270, 29083-9. 
ECKLE, T., KOHLER, D., LEHMANN, R., EL KASMI, K. & ELTZSCHIG, H. K. 2008. 
Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm 
for ischemic preconditioning. Circulation, 118, 166-75. 
EIMRE, M., PAJU, K., PELLOUX, S., BERAUD, N., ROOSIMAA, M., KADAJA, L., GRUNO, 
M., PEET, N., ORLOVA, E., REMMELKOOR, R., PIIRSOO, A., SAKS, V. & SEPPET, 
E. 2008. Distinct organization of energy metabolism in HL-1 cardiac cell line 
and cardiomyocytes. Biochimica et Biophysica Acta (BBA) - Bioenergetics, 
1777, 514-524. 
EKSTRAND, M. I., FALKENBERG, M., RANTANEN, A., PARK, C. B., GASPARI, M., 
HULTENBY, K., RUSTIN, P., GUSTAFSSON, C. M. & LARSSON, N.-G. 2004. 
Mitochondrial transcription factor A regulates mtDNA copy number in 
mammals. Human Molecular Genetics, 13, 935-944. 
ELVIDGE, G. P., GLENNY, L., APPELHOFF, R. J., RATCLIFFE, P. J., RAGOUSSIS, J. & 
GLEADLE, J. M. 2006. Concordant regulation of gene expression by hypoxia 
and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-
1alpha, HIF-2alpha, and other pathways. J Biol Chem, 281, 15215-26. 
EMA, M., TAYA, S., YOKOTANI, N., SOGAWA, K., MATSUDA, Y. & FUJII-KURIYAMA, Y. 
1997. A novel bHLH-PAS factor with close sequence similarity to hypoxia-
inducible factor 1alpha regulates the VEGF expression and is potentially 
involved in lung and vascular development. Proc Natl Acad Sci U S A, 94, 
4273-8. 
EMERLING, B. M., PLATANIAS, L. C., BLACK, E., NEBREDA, A. R., DAVIS, R. J. & 
CHANDEL, N. S. 2005. Mitochondrial reactive oxygen species activation of 
p38 mitogen-activated protein kinase is required for hypoxia signaling. Mol 
Cell Biol, 25, 4853-62. 
Bibliography 
Page | 309  
 
ESKELINEN, E.-L. 2008. To be or not to be? Examples of incorrect identification of 
autophagic compartments in conventional transmission electron microscopy 
of mammalian cells. Autophagy, 4, 257-260. 
FALKENBERG, M., LARSSON, N. G. & GUSTAFSSON, C. M. 2007. DNA replication and 
transcription in mammalian mitochondria. Annu Rev Biochem, 76, 679-99. 
FELDSER, D., AGANI, F., IYER, N. V., PAK, B., FERREIRA, G. & SEMENZA, G. L. 1999. 
Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-
like growth factor 2. Cancer Res, 59, 3915-8. 
FERNANDEZ-MARCOS, P. J. & AUWERX, J. 2011. Regulation of PGC-1α, a nodal 
regulator of mitochondrial biogenesis. The American Journal of Clinical 
Nutrition, 93, 884S-890S. 
FERNÁNDEZ-VIZARRA, E., TIRANTI, V. & ZEVIANI, M. 2009. Assembly of the oxidative 
phosphorylation system in humans: What we have learned by studying its 
defects. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 
1793, 200-211. 
FERRICK, D. A., NEILSON, A. & BEESON, C. 2008. Advances in measuring cellular 
bioenergetics using extracellular flux. Drug Discovery Today, 13, 268-274. 
FIRTH, J. D., EBERT, B. L. & RATCLIFFE, P. J. 1995. Hypoxic regulation of lactate 
dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP 
response elements. J Biol Chem, 270, 21021-7. 
FORMAN, J. R., WORTH, C. L., BICKERTON, G. R. J., EISEN, T. G. & BLUNDELL, T. L. 
2009. Structural bioinformatics mutation analysis reveals genotype–
phenotype correlations in von Hippel-Lindau disease and suggests molecular 
mechanisms of tumorigenesis. Proteins: Structure, Function, and 
Bioinformatics, 77, 84-96. 
FRANK, S., GAUME, B., BERGMANN-LEITNER, E. S., LEITNER, W. W., ROBERT, E. G., 
CATEZ, F., SMITH, C. L. & YOULE, R. J. 2001. The Role of Dynamin-Related 
Protein 1, a Mediator of Mitochondrial Fission, in Apoptosis. Developmental 
Cell, 1, 515-525. 
FREY, P. A. 1996. The Leloir pathway: a mechanistic imperative for three enzymes to 
change the stereochemical configuration of a single carbon in galactose. The 
FASEB Journal, 10, 461-70. 
FUJIWARA, M., MARUSAWA, H., WANG, H. Q., IWAI, A., IKEUCHI, K., IMAI, Y., 
KATAOKA, A., NUKINA, N., TAKAHASHI, R. & CHIBA, T. 2008. Parkin as a 
tumor suppressor gene for hepatocellular carcinoma. Oncogene, 27, 6002-
6011. 
FUKUDA, R., HIROTA, K., FAN, F., JUNG, Y. D., ELLIS, L. M. & SEMENZA, G. L. 2002. 
Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated 
vascular endothelial growth factor expression, which is dependent on MAP 
kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol 
Chem, 277, 38205-11. 
Bibliography 
Page | 310  
 
FUKUDA, R., ZHANG, H., KIM, J.-W., SHIMODA, L., DANG, C. V. & SEMENZA, G. L. 
2007. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of 
respiration in hypoxic cells. Cell, 129, 111-122. 
GALLOWAY, C. A., LEE, H. & YOON, Y. 2012. Mitochondrial morphology—emerging 
role in bioenergetics. Free Radical Biology and Medicine, 53, 2218-2228. 
GALMICHE, L., SERRE, V., BEINAT, M., ASSOULINE, Z., LEBRE, A.-S., CHRETIEN, D., 
NIETSCHKE, P., BENES, V., BODDAERT, N., SIDI, D., BRUNELLE, F., RIO, M., 
MUNNICH, A. & RÖTIG, A. 2011. Exome sequencing identifies MRPL3 
mutation in mitochondrial cardiomyopathy. Human Mutation, 32, 1225-
1231. 
GAO, C., CAO, W., BAO, L., ZUO, W., XIE, G., CAI, T., FU, W., ZHANG, J., WU, W., 
ZHANG, X. & CHEN, Y.-G. 2010. Autophagy negatively regulates Wnt 
signalling by promoting Dishevelled degradation. Nat Cell Biol, 12, 781-790. 
GARCIA FERNANDEZ, M. I., CECCARELLI, D. & MUSCATELLO, U. 2004. Use of the 
fluorescent dye 10-N-nonyl acridine orange in quantitative and location 
assays of cardiolipin: a study on different experimental models. Analytical 
Biochemistry, 328, 174-180. 
GEGG, M. E. 2010. Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-
dependent manner upon induction of mitophagy. Hum. Mol. Genet., 19, 
4861-4870. 
GEISLER, S. 2010. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and 
p62/SQSTM1. Nature Cell Biol., 12, 119-131. 
GERALD, D., BERRA, E., FRAPART, Y. M., CHAN, D. A., GIACCIA, A. J., MANSUY, D., 
POUYSSEGUR, J., YANIV, M. & MECHTA-GRIGORIOU, F. 2004. JunD reduces 
tumor angiogenesis by protecting cells from oxidative stress. Cell, 118, 781-
94. 
GNARRA, J. R., TORY, K., WENG, Y., SCHMIDT, L., WEI, M. H., LI, H., LATIF, F., LIU, S., 
CHEN, F., DUH, F. M. & ET AL. 1994. Mutations of the VHL tumour 
suppressor gene in renal carcinoma. Nat Genet, 7, 85-90. 
GOH, J., ENNS, L., FATEMIE, S., HOPKINS, H., MORTON, J., PETTAN-BREWER, C. & 
LADIGES, W. 2011. Mitochondrial targeted catalase suppresses invasive 
breast cancer in mice. BMC Cancer, 11, 191. 
GOHIL, V. M., SHETH, S. A., NILSSON, R., WOJTOVICH, A. P., LEE, J. H., PEROCCHI, F., 
CHEN, W., CLISH, C. B., AYATA, C., BROOKES, P. S. & MOOTHA, V. K. 2010. 
Nutrient-sensitized screening for drugs that shift energy metabolism from 
mitochondrial respiration to glycolysis. Nat Biotech, 28, 249-255. 
GOMES, L. C., BENEDETTO, G. D. & SCORRANO, L. 2011. During autophagy 
mitochondria elongate, are spared from degradation and sustain cell 
viability. Nat Cell Biol, 13, 589-598. 
GONG, Y. & AGANI, F. H. 2005. Oligomycin inhibits HIF-1alpha expression in hypoxic 
tumor cells. Am J Physiol Cell Physiol, 288, 1023-1029. 
Bibliography 
Page | 311  
 
GONZALVEZ, F., D'AURELIO, M., BOUTANT, M., MOUSTAPHA, A., PUECH, J.-P., 
LANDES, T., ARNAUNÉ-PELLOQUIN, L., VIAL, G., TALEUX, N., SLOMIANNY, C., 
WANDERS, R. J., HOUTKOOPER, R. H., BELLENGUER, P., MØLLER, I. M., 
GOTTLIEB, E., VAZ, F. M., MANFREDI, G. & PETIT, P. X. 2013. Barth 
syndrome: Cellular compensation of mitochondrial dysfunction and 
apoptosis inhibition due to changes in cardiolipin remodeling linked to 
tafazzin (TAZ) gene mutation. Biochimica et Biophysica Acta (BBA) - 
Molecular Basis of Disease, 1832, 1194-1206. 
GORDAN, J. D. 2008. HIF-α effects on c-Myc distinguish two subtypes of sporadic 
VHL-deficient clear cell renal carcinoma. Cancer Cell, 14, 435-446. 
GORDAN, J. D., BERTOUT, J. A., HU, C.-J., DIEHL, J. A. & SIMON, M. C. 2007. HIF-2α 
Promotes Hypoxic Cell Proliferation by Enhancing c-Myc Transcriptional 
Activity. Cancer Cell, 11, 335-347. 
GOSWAMI, S. K., MAULIK, N. & DAS, D. K. 2007. Ischemia-reperfusion and 
cardioprotection: a delicate balance between reactive oxygen species 
generation and redox homeostasis. Ann Med, 39, 275-89. 
GOUGH, D. J., CORLETT, A., SCHLESSINGER, K., WEGRZYN, J., LARNER, A. C. & LEVY, 
D. E. 2009. Mitochondrial STAT3 supports Ras-dependent oncogenic 
transformation. Science, 324, 1713-6. 
GU, Y. Z., MORAN, S. M., HOGENESCH, J. B., WARTMAN, L. & BRADFIELD, C. A. 1998. 
Molecular characterization and chromosomal localization of a third alpha-
class hypoxia inducible factor subunit, HIF3alpha. Gene Expr, 7, 205-13. 
GUO, S., OLM-SHIPMAN, A., WALTERS, A., URCIUOLI, W. R., DEVITO, S., NADTOCHIY, 
S. M., WOJTOVICH, A. P. & BROOKES, P. S. 2012. A Cell-Based Phenotypic 
Assay to Identify Cardioprotective Agents. Circulation Research, 110, 948-
957. 
GUO, Y., JONES, W. K., XUAN, Y. T., TANG, X. L., BAO, W., WU, W. J., HAN, H., 
LAUBACH, V. E., PING, P., YANG, Z., QIU, Y. & BOLLI, R. 1999. The late phase 
of ischemic preconditioning is abrogated by targeted disruption of the 
inducible NO synthase gene. Proc Natl Acad Sci U S A, 96, 11507-12. 
GUZY, R. D., HOYOS, B., ROBIN, E., CHEN, H., LIU, L., MANSFIELD, K. D., SIMON, M. 
C., HAMMERLING, U. & SCHUMACKER, P. T. 2005. Mitochondrial complex III 
is required for hypoxia-induced ROS production and cellular oxygen sensing. 
Cell Metab., 1, 401-408. 
GUZY, R. D. & SCHUMACKER, P. T. 2006. Oxygen sensing by mitochondria at 
complex III: the paradox of increased reactive oxygen species during 
hypoxia. Exp.Physiol, 91, 807-819. 
HACKER, K. E., LEE, C. M. & RATHMELL, W. K. 2008. VHL Type 2B Mutations Retain 
VBC Complex Form and Function. PLoS One, 3, e3801. 
Bibliography 
Page | 312  
 
HAGEN, T., TAYLOR, C. T., LAM, F. & MONCADA, S. 2003. Redistribution of 
intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science, 
302, 1975-8. 
HALESTRAP, A. P., CLARKE, S. J. & KHALIULIN, I. 2007. The role of mitochondria in 
protection of the heart by preconditioning. Biochim Biophys Acta, 1767, 
1007-31. 
HAN, X.-J., LU, Y.-F., LI, S.-A., KAITSUKA, T., SATO, Y., TOMIZAWA, K., NAIRN, A. C., 
TAKEI, K., MATSUI, H. & MATSUSHITA, M. 2008. CaM kinase Iα–induced 
phosphorylation of Drp1 regulates mitochondrial morphology. The Journal 
of Cell Biology, 182, 573-585. 
HANNA, R. A., QUINSAY, M. N., OROGO, A. M., GIANG, K., RIKKA, S. & GUSTAFSSON, 
A. B. 2012. Microtubule-Associated Protein 1 Light Chain 3 (LC3) Interacts 
with Bnip3 to Selectively Remove Endoplasmic Reticulum and Mitochondria 
via Autophagy. Journal of Biological Chemistry. 
HARA, S., HAMADA, J., KOBAYASHI, C., KONDO, Y. & IMURA, N. 2001. Expression 
and characterization of hypoxia-inducible factor (HIF)-3alpha in human 
kidney: suppression of HIF-mediated gene expression by HIF-3alpha. 
Biochem Biophys Res Commun, 287, 808-13. 
HARTEN, S. K., ASHCROFT, M. & MAXWELL, P. H. 2010. Prolyl hydroxylase domain 
inhibitors: a route to HIF activation and neuroprotection. Antioxid Redox 
Signal, 12, 459-80. 
HARTEN, S. K., ESTEBAN, M. A. & MAXWELL, P. H. 2009. Identification of novel VHL 
regulated genes by transcriptomic analysis of RCC10 renal carcinoma cells. 
Adv Enzyme Regul, 49, 43-52. 
HASHIATNI, H., LANG, R. J. & SUZUKI, H. 2010. Role of perinuclear mitochondria in 
the spatiotemporal dynamics of spontaneous Ca2+ waves in interstitial cells 
of Cajal-like cells of the rabbit urethra. British Journal of Pharmacology, 161, 
680-694. 
HATCH, G. M. 2004. Cell biology of cardiac mitochondrial phospholipids. 
Biochemistry and Cell Biology, 82, 99-112. 
HAUSENLOY, D. J. & YELLON, D. M. 2007. Preconditioning and postconditioning: 
united at reperfusion. Pharmacol Ther, 116, 173-91. 
HE, C. & KLIONSKY, D. J. 2009. Regulation Mechanisms and Signaling Pathways of 
Autophagy. Annu Rev Genet, 43, 67-93. 
HEGGENESS, M. H., SIMON, M. & SINGER, S. J. 1978. Association of mitochondria 
with microtubules in cultured cells. Proceedings of the National Academy of 
Sciences, 75, 3863-3866. 
HEINEMAN, F. W. & BALABAN, R. S. 1990. Control of mitochondrial respiration in 
the heart in vivo. Annu Rev Physiol, 52, 523-42. 
Bibliography 
Page | 313  
 
HELTON, R., CUI, J., SCHEEL, J. R., ELLISON, J. A., AMES, C., GIBSON, C., BLOUW, B., 
OUYANG, L., DRAGATSIS, I., ZEITLIN, S., JOHNSON, R. S., LIPTON, S. A. & 
BARLOW, C. 2005. Brain-specific knock-out of hypoxia-inducible factor-
1alpha reduces rather than increases hypoxic-ischemic damage. J Neurosci, 
25, 4099-107. 
HERVOUET, E., CIZKOVA, A., DEMONT, J., VOJTISKOVA, A., PECINA, P., FRANSSEN-
VAN HAL, N. L., KEIJER, J., SIMONNET, H., IVANEK, R., KMOCH, S., GODINOT, 
C. & HOUSTEK, J. 2008. HIF and reactive oxygen species regulate oxidative 
phosphorylation in cancer. Carcinogenesis, 29, 1528-37. 
HERVOUET, E., DEMONT, J., PECINA, P., VOJTISKOVA, A., HOUSTEK, J., SIMONNET, 
H. & GODINOT, C. 2005. A new role for the von Hippel-Lindau tumor 
suppressor protein: stimulation of mitochondrial oxidative phosphorylation 
complex biogenesis. Carcinogenesis, 26, 531-9. 
HICKEY, M. M., LAM, J. C., BEZMAN, N. A., RATHMELL, W. K. & SIMON, M. C. 2007. 
von Hippel–Lindau mutation in mice recapitulates Chuvash polycythemia via 
hypoxia-inducible factor-2α signaling and splenic erythropoiesis. The Journal 
of Clinical Investigation, 117, 3879-3889. 
HIWATASHI, Y., KANNO, K., TAKASAKI, C., GORYO, K., SATO, T., TORII, S., SOGAWA, 
K. & YASUMOTO, K.-I. 2011. PHD1 interacts with ATF4 and negatively 
regulates its transcriptional activity without prolyl hydroxylation. 
Experimental Cell Research, 317, 2789-2799. 
HOFMANN, S., ROTHBAUER, U., MUHLENBEIN, N., BAIKER, K., HELL, K. & BAUER, M. 
F. 2005. Functional and mutational characterization of human MIA40 acting 
during import into the mitochondrial intermembrane space. J.Mol.Biol., 353, 
517-528. 
HOLMES, J. L. & POLLENZ, R. S. 1997. Determination of Aryl Hydrocarbon Receptor 
Nuclear Translocator Protein Concentration and Subcellular Localization in 
Hepatic and Nonhepatic Cell Culture Lines: Development of Quantitative 
Western Blotting Protocols for Calculation of Aryl Hydrocarbon Receptor 
and Aryl Hydrocarbon Receptor Nuclear Translocator Protein in Total Cell 
Lysates. Molecular Pharmacology, 52, 202-211. 
HOLMQUIST-MENGELBIER, L. 2006. Recruitment of HIF-1α and HIF-2α to common 
target genes is differentially regulated in neuroblastoma: HIF-2α promotes 
an aggressive phenotype. Cancer Cell, 10, 413-423. 
HOPFER, U., HOPFER, H., JABLONSKI, K., STAHL, R. A. & WOLF, G. 2006. The novel 
WD-repeat protein Morg1 acts as a molecular scaffold for hypoxia-inducible 
factor prolyl hydroxylase 3 (PHD3). J Biol Chem, 281, 8645-55. 
HOPPINS, S., LACKNER, L. & NUNNARI, J. 2007. The machines that divide and fuse 
mitochondria. Annu Rev Biochem, 76, 751-780. 
Bibliography 
Page | 314  
 
HU, C. J., SATAUR, A., WANG, L., CHEN, H. & SIMON, M. C. 2007. The N-terminal 
transactivation domain confers target gene specificity of hypoxia-inducible 
factors HIF-1α and HIF-2α. Mol. Biol. Cell, 18, 4528-4542. 
HU, C. J., WANG, L. Y., CHODOSH, L. A., KEITH, B. & SIMON, M. C. 2003. Differential 
roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in 
hypoxic gene regulation. Mol Cell Biol, 23, 9361-74. 
HUANG, L. E., WILLMORE, W. G., GU, J., GOLDBERG, M. A. & BUNN, H. F. 1999. 
Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and 
nitric oxide. Implications for oxygen sensing and signaling. J Biol Chem, 274, 
9038-44. 
HUANG, M., CHAN, D. A., JIA, F., XIE, X., LI, Z., HOYT, G., ROBBINS, R. C., CHEN, X., 
GIACCIA, A. J. & WU, J. C. 2008. Short hairpin RNA interference therapy for 
ischemic heart disease. Circulation, 118, S226-33. 
HUANG, Y., HICKEY, R. P., YEH, J. L., LIU, D., DADAK, A., YOUNG, L. H., JOHNSON, R. 
S. & GIORDANO, F. J. 2004. Cardiac myocyte-specific HIF-1alpha deletion 
alters vascularization, energy availability, calcium flux, and contractility in 
the normoxic heart. Faseb J, 18, 1138-40. 
HUDSON, C. C., LIU, M., CHIANG, G. G., OTTERNESS, D. M., LOOMIS, D. C., KAPER, F., 
GIACCIA, A. J. & ABRAHAM, R. T. 2002. Regulation of hypoxia-inducible 
factor 1alpha expression and function by the mammalian target of 
rapamycin. Mol Cell Biol, 22, 7004-14. 
HUGHES, M., KAPLLANI, E., ALEXANDER, A., BURK, R. & SCHOENFELD, A. 2007. HIF-
2alpha downregulation in the absence of functional VHL is not sufficient for 
renal cell differentiation. Cancer Cell International, 7, 13. 
HYVARINEN, J., HASSINEN, I. E., SORMUNEN, R., MAKI, J. M., KIVIRIKKO, K. I., 
KOIVUNEN, P. & MYLLYHARJU, J. 2010. Hearts of hypoxia-inducible factor 
prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute 
ischemia-reperfusion injury. J.Biol.Chem., 285, 13646-13657. 
ICHISHITA, R., TANAKA, K., SUGIURA, Y., SAYANO, T., MIHARA, K. & OKA, T. 2008. An 
RNAi Screen for Mitochondrial Proteins Required to Maintain the 
Morphology of the Organelle in Caenorhabditis elegans. Journal of 
Biochemistry, 143, 449-454. 
ILIOPOULOS, O., KIBEL, A., GRAY, S. & KAELIN, W. G. 1995. Tumour suppression by 
the human von Hippel-Lindau gene product. Nat Med, 1, 822-826. 
IMAI, Y. 2012. Mitochondrial Regulation by PINK1-Parkin Signaling. ISRN Cell 
Biology, 2012, 15. 
ISHIHARA, N., NOMURA, M., JOFUKU, A., KATO, H., SUZUKI, S. O., MASUDA, K., 
OTERA, H., NAKANISHI, Y., NONAKA, I., GOTO, Y.-I., TAGUCHI, N., 
MORINAGA, H., MAEDA, M., TAKAYANAGI, R., YOKOTA, S. & MIHARA, K. 
2009. Mitochondrial fission factor Drp1 is essential for embryonic 
development and synapse formation in mice. Nat Cell Biol, 11, 958-966. 
Bibliography 
Page | 315  
 
ISHIKAWA, K., TAKENAGA, K., AKIMOTO, M., KOSHIKAWA, N., YAMAGUCHI, A., 
IMANISHI, H., NAKADA, K., HONMA, Y. & HAYASHI, J. 2008. ROS-generating 
mitochondrial DNA mutations can regulate tumor cell metastasis. Science, 
320, 661-4. 
IWAI, K., YAMANAKA, K., KAMURA, T., MINATO, N., CONAWAY, R. C., CONAWAY, J. 
W., KLAUSNER, R. D. & PAUSE, A. 1999. Identification of the von Hippel–
Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase 
complex. Proceedings of the National Academy of Sciences, 96, 12436-
12441. 
IYER, N. V., KOTCH, L. E., AGANI, F., LEUNG, S. W., LAUGHNER, E., WENGER, R. H., 
GASSMANN, M., GEARHART, J. D., LAWLER, A. M., YU, A. Y. & SEMENZA, G. 
L. 1998. Cellular and developmental control of O2 homeostasis by hypoxia-
inducible factor 1 alpha. Genes Dev, 12, 149-62. 
JAAKKOLA, P., MOLE, D. R., TIAN, Y. M., WILSON, M. I., GIELBERT, J., GASKELL, S. J., 
KRIEGSHEIM, A., HEBESTREIT, H. F., MUKHERJI, M., SCHOFIELD, C. J., 
MAXWELL, P. H., PUGH, C. W. & RATCLIFFE, P. J. 2001. Targeting of HIF-
alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated 
prolyl hydroxylation. Science, 292, 468-72. 
JACOBSON, J., DUCHEN, M. R. & HEALES, S. J. R. 2002. Intracellular distribution of 
the fluorescent dye nonyl acridine orange responds to the mitochondrial 
membrane potential: implications for assays of cardiolipin and 
mitochondrial mass. Journal of Neurochemistry, 82, 224-233. 
JAFRI, M. S., DUDYCHA, S. J. & O'ROURKE, B. 2001. Cardiac energy metabolism: 
models of cellular respiration. Annu Rev Biomed Eng, 3, 57-81. 
JEREMY M BERG, J. L. T. A. L. S. 2002. Biochemistry, New York, WH Freeman. 
JIANG, B. H., RUE, E., WANG, G. L., ROE, R. & SEMENZA, G. L. 1996a. Dimerization, 
DNA binding, and transactivation properties of hypoxia-inducible factor 1. J 
Biol Chem, 271, 17771-8. 
JIANG, B. H., SEMENZA, G. L., BAUER, C. & MARTI, H. H. 1996b. Hypoxia-inducible 
factor 1 levels vary exponentially over a physiologically relevant range of O2 
tension. Am J Physiol, 271, C1172-80. 
JIANG, Y., ZHANG, W., KONDO, K., KLCO, J. M., ST. MARTIN, T. B., DUFAULT, M. R., 
MADDEN, S. L., KAELIN, W. G. & NACHT, M. 2003. Gene Expression Profiling 
in a Renal Cell Carcinoma Cell Line: Dissecting VHL and Hypoxia-Dependent 
Pathways. Molecular Cancer Research, 1, 453-462. 
JIN, F., BROCKMEIER, U., OTTERBACH, F. & METZEN, E. 2012. New Insight into the 
SDF-1/CXCR4 Axis in a Breast Carcinoma Model: Hypoxia-Induced 
Endothelial SDF-1 and Tumor Cell CXCR4 Are Required for Tumor Cell 
Intravasation. Molecular Cancer Research, 10, 1021-1031. 
JOUAVILLE, L. S., PINTON, P., BASTIANUTTO, C., RUTTER, G. A. & RIZZUTO, R. 1999. 
Regulation of mitochondrial ATP synthesis by calcium: Evidence for a long-
Bibliography 
Page | 316  
 
term metabolic priming. Proceedings of the National Academy of Sciences, 
96, 13807-13812. 
KAELIN, W. G. 2002. Molecular basis of the VHL hereditary cancer syndrome. Nat 
Rev Cancer, 2, 673-682. 
KAELIN, W. G. 2008. The von Hippel-Lindau tumour suppressor protein: O2 sensing 
and cancer. Nature Rev. Cancer, 8, 865-873. 
KAGEYAMA, Y., KOSHIJI, M., TO, K. K., TIAN, Y. M., RATCLIFFE, P. J. & HUANG, L. E. 
2004. Leu-574 of human HIF-1alpha is a molecular determinant of prolyl 
hydroxylation. Faseb J, 18, 1028-30. 
KALLIO, P. J., PONGRATZ, I., GRADIN, K., MCGUIRE, J. & POELLINGER, L. 1997. 
Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation 
and conformational change by recruitment of the Arnt transcription factor. 
Proc Natl Acad Sci U S A, 94, 5667-72. 
KARBOWSKI, M., NEUTZNER, A. & YOULE, R. J. 2007. The mitochondrial E3 ubiquitin 
ligase MARCH5 is required for Drp1 dependent mitochondrial division. The 
Journal of Cell Biology, 178, 71-84. 
KAWAJIRI, S. 2010. PINK1 is recruited to mitochondria with parkin and associates 
with LC3 in mitophagy. FEBS Lett., 584, 1073-1079. 
KEITH, B., JOHNSON, R. S. & SIMON, M. C. 2012. HIF1α and HIF2α: sibling rivalry in 
hypoxic tumour growth and progression. Nat Rev Cancer, 12, 9-22. 
KHAN, M. N., BHATTACHARYYA, T., ANDRIKOPOULOS, P., ESTEBAN, M. A., BAROD, 
R., CONNOR, T., ASHCROFT, M., MAXWELL, P. H. & KIRIAKIDIS, S. 2011. 
Factor inhibiting HIF (FIH-1) promotes renal cancer cell survival by protecting 
cells from HIF-1alpha-mediated apoptosis. Br J Cancer, 104, 1151-9. 
KHAN, Z., MICHALOPOULOS, G. K. & STOLZ, D. B. 2006. Peroxisomal localization of 
hypoxia-inducible factors and hypoxia-inducible factor regulatory 
hydroxylases in primary rat hepatocytes exposed to hypoxia-reoxygenation. 
Am J Pathol, 169, 1251-69. 
KIBEL, A., ILIOPOULOS, O., DECAPRIO, J. A. & KAELIN, W. G., JR. 1995. Binding of the 
von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science, 
269, 1444-6. 
KIDO, M., DU, L., SULLIVAN, C. C., LI, X., DEUTSCH, R., JAMIESON, S. W. & 
THISTLETHWAITE, P. A. 2005. Hypoxia-inducible factor 1-alpha reduces 
infarction and attenuates progression of cardiac dysfunction after 
myocardial infarction in the mouse. J Am Coll Cardiol, 46, 2116-24. 
KIM, I., RODRIGUEZ-ENRIQUEZ, S. & LEMASTERS, J. J. 2007. Selective degradation of 
mitochondria by mitophagy. Arch. Biochem. Biophys., 462, 245-253. 
KIM, J.-H., KONONENKO, A., ERLIANDRI, I., KIM, T.-A., NAKANO, M., IIDA, Y., 
BARRETT, J. C., OSHIMURA, M., MASUMOTO, H., EARNSHAW, W. C., 
LARIONOV, V. & KOUPRINA, N. 2011. Human artificial chromosome (HAC) 
Bibliography 
Page | 317  
 
vector with a conditional centromere for correction of genetic deficiencies 
in human cells. Proceedings of the National Academy of Sciences, 108, 
20048-20053. 
KIM, J.-W., TCHERNYSHYOV, I., SEMENZA, G. L. & DANG, C. V. 2006. HIF-1-mediated 
expression of pyruvate dehydrogenase kinase: a metabolic switch required 
for cellular adaptation to hypoxia. Cell Metab, 3, 177-185. 
KIRKIN, V., MCEWAN, D. G., NOVAK, I. & DIKIC, I. 2009. A Role for Ubiquitin in 
Selective Autophagy. Mol Cell, 34, 259-269. 
KLIONSKY, D. J. 2010. A comprehensive glossary of autophagy-related molecules 
and processes. Autophagy, 6, 438-448. 
KLIONSKY, D. J., ABDALLA, F. C., ABELIOVICH, H., ABRAHAM, R. T., ACEVEDO-
AROZENA, A., ADELI, K., AGHOLME, L., AGNELLO, M., AGOSTINIS, P., 
AGUIRRE-GHISO, J. A., AHN, H. J., AIT-MOHAMED, O., AIT-SI-ALI, S., 
AKEMATSU, T., AKIRA, S., AL-YOUNES, H. M., AL-ZEER, M. A., ALBERT, M. L., 
ALBIN, R. L., ALEGRE-ABARRATEGUI, J., ALEO, M. F., ALIREZAEI, M., 
ALMASAN, A., ALMONTE-BECERRIL, M., AMANO, A., AMARAVADI, R. K., 
AMARNATH, S., AMER, A. O., ANDRIEU-ABADIE, N., ANANTHARAM, V., ANN, 
D. K., ANOOPKUMAR-DUKIE, S., AOKI, H., APOSTOLOVA, N., ARANCIA, G., 
ARIS, J. P., ASANUMA, K., ASARE, N. Y. O., ASHIDA, H., ASKANAS, V., ASKEW, 
D. S., AUBERGER, P., BABA, M., BACKUES, S. K., BAEHRECKE, E. H., BAHR, B. 
A., BAI, X.-Y., BAILLY, Y., BAIOCCHI, R., BALDINI, G., BALDUINI, W., BALLABIO, 
A., BAMBER, B. A., BAMPTON, E. T. W., JUHÁSZ, G., BARTHOLOMEW, C. R., 
BASSHAM, D. C., BAST, R. C., BATOKO, H., BAY, B.-H., BEAU, I., BÉCHET, D. 
M., BEGLEY, T. J., BEHL, C., BEHRENDS, C., BEKRI, S., BELLAIRE, B., BENDALL, 
L. J., BENETTI, L., BERLIOCCHI, L., BERNARDI, H., BERNASSOLA, F., BESTEIRO, 
S., BHATIA-KIŠŠOVÁ, I., BI, X., BIARD-PIECHACZYK, M., BLUM, J. S., BOISE, L. 
H., BONALDO, P., BOONE, D. L., BORNHAUSER, B. C., BORTOLUCI, K. R., 
BOSSIS, I., BOST, F., BOURQUIN, J.-P., BOYA, P., BOYER-GUITTAUT, M., 
BOZHKOV, P. V., BRADY, N. R., BRANCOLINI, C., BRECH, A., BRENMAN, J. E., 
BRENNAND, A., BRESNICK, E. H., BREST, P., BRIDGES, D., BRISTOL, M. L., 
BROOKES, P. S., BROWN, E. J., BRUMELL, J. H., et al. 2012. Guidelines for the 
use and interpretation of assays for monitoring autophagy. Autophagy, 8, 
445-544. 
KLUZA, J., CORAZAO-ROZAS, P., TOUIL, Y., JENDOUBI, M., MAIRE, C., GUERRESCHI, 
P., JONNEAUX, A., BALLOT, C., BALAYSSAC, S., VALABLE, S., CORROYER-
DULMONT, A., BERNAUDIN, M., MALET-MARTINO, M., DE LASSALLE, E. M., 
MABOUDOU, P., FORMSTECHER, P., POLAKOWSKA, R., MORTIER, L. & 
MARCHETTI, P. 2012. Inactivation of the HIF-1α/PDK3 Signaling Axis Drives 
Melanoma toward Mitochondrial Oxidative Metabolism and Potentiates the 
Therapeutic Activity of Pro-Oxidants. Cancer Research, 72, 5035-5047. 
KOC, E. C., RANASINGHE, A., BURKHART, W., BLACKBURN, K., KOC, H., MOSELEY, A. 
& SPREMULLI, L. L. 2001. A new face on apoptosis: death-associated protein 
Bibliography 
Page | 318  
 
3 and PDCD9 are mitochondrial ribosomal proteins. FEBS Letters, 492, 166-
170. 
KODITZ, J., NESPER, J., WOTTAWA, M., STIEHL, D. P., CAMENISCH, G., FRANKE, C., 
MYLLYHARJU, J., WENGER, R. H. & KATSCHINSKI, D. M. 2007. Oxygen-
dependent ATF-4 stability is mediated by the PHD3 oxygen sensor. Blood, 
110, 3610-7. 
KOEHLER, C. M. & TIENSON, H. L. 2009. Redox regulation of protein folding in the 
mitochondrial intermembrane space. Biochim.Biophys.Acta, 1793, 139-145. 
KOH, M. Y. & POWIS, G. 2009. HAF : the new player in oxygen-independent HIF-
1alpha degradation. Cell Cycle, 8, 1359-66. 
KOIVUNEN, P., HIRSILA, M., REMES, A. M., HASSINEN, I. E., KIVIRIKKO, K. I. & 
MYLLYHARJU, J. 2007a. Inhibition of hypoxia-inducible factor (HIF) 
hydroxylases by citric acid cycle intermediates: possible links between cell 
metabolism and stabilization of HIF. J Biol Chem, 282, 4524-4532. 
KOIVUNEN, P., TIAINEN, P., HYVARINEN, J., WILLIAMS, K. E., SORMUNEN, R., KLAUS, 
S. J., KIVIRIKKO, K. I. & MYLLYHARJU, J. 2007b. An endoplasmic reticulum 
transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on 
hypoxia-inducible factor alpha. J Biol Chem, 282, 30544-52. 
KONDO, K., KIM, W. Y., LECHPAMMER, M. & KAELIN, W. G. 2003. Inhibition of HIF2α 
is sufficient to suppress pVHL-defective tumor growth. PLoS Biol., 1, e83. 
KULAWIEC, M., OWENS, K. M. & SINGH, K. K. 2009. Cancer cell mitochondria confer 
apoptosis resistance and promote metastasis. Cancer Biology & Therapy, 8, 
1378-1385. 
KULSHRESHTHA, R., FERRACIN, M., WOJCIK, S. E., GARZON, R., ALDER, H., AGOSTO-
PEREZ, F. J., DAVULURI, R., LIU, C.-G., CROCE, C. M., NEGRINI, M., CALIN, G. 
A. & IVAN, M. 2007. A MicroRNA Signature of Hypoxia. Molecular and 
Cellular Biology, 27, 1859-1867. 
KUZNETSOVA, A. V., MELLER, J., SCHNELL, P. O., NASH, J. A., IGNACAK, M. L., 
SANCHEZ, Y., CONAWAY, J. W., CONAWAY, R. C. & CZYZYK-KRZESKA, M. F. 
2003. von Hippel-Lindau protein binds hyperphosphorylated large subunit of 
RNA polymerase II through a proline hydroxylation motif and targets it for 
ubiquitination. Proc Natl Acad Sci U S A, 100, 2706-11. 
LAI, Y., SONG, M., HAKALA, K., WEINTRAUB, S. T. & SHIIO, Y. 2011. Proteomic 
Dissection of the von Hippel–Lindau (VHL) Interactome. Journal of Proteome 
Research, 10, 5175-5182. 
LANCASTER, D. E., MCDONOUGH, M. A. & SCHOFIELD, C. J. 2004a. Factor inhibiting 
hypoxia-inducible factor (FIH) and other asparaginyl hydroxylases. Biochem 
Soc Trans, 32, 943-5. 
LANCASTER, D. E., MCNEILL, L. A., MCDONOUGH, M. A., APLIN, R. T., HEWITSON, K. 
S., PUGH, C. W., RATCLIFFE, P. J. & SCHOFIELD, C. J. 2004b. Disruption of 
Bibliography 
Page | 319  
 
dimerization and substrate phosphorylation inhibit factor inhibiting hypoxia-
inducible factor (FIH) activity. Biochem J, 383, 429-37. 
LANDO, D., PEET, D. J., WHELAN, D. A., GORMAN, J. J. & WHITELAW, M. L. 2002. 
Asparagine hydroxylation of the HIF transactivation domain a hypoxic 
switch. Science, 295, 858-61. 
LAUGHNER, E., TAGHAVI, P., CHILES, K., MAHON, P. C. & SEMENZA, G. L. 2001. HER2 
(neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-
1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial 
growth factor expression. Mol Cell Biol, 21, 3995-4004. 
LEE, J.-Y., KOGA, H., KAWAGUCHI, Y., TANG, W., WONG, E., GAO, Y.-S., PANDEY, U. 
B., KAUSHIK, S., TRESSE, E., LU, J., TAYLOR, J. P., CUERVO, A. M. & YAO, T.-P. 
2010a. HDAC6 controls autophagosome maturation essential for ubiquitin-
selective quality-control autophagy. Embo J, 29, 969-980. 
LEE, J. W., BAE, S. H., JEONG, J. W., KIM, S. H. & KIM, K. W. 2004. Hypoxia-inducible 
factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol 
Med, 36, 1-12. 
LEE, J. Y., NAGANO, Y., TAYLOR, J. P., LIM, K. L. & YAO, T. P. 2010b. Disease-causing 
mutations in Parkin impair mitochondrial ubiquitination, aggregation, and 
HDAC6-dependent mitophagy. J. Cell Biol., 189, 671-679. 
LEE, S., CHEN, D. Y., HUMPHREY, J. S., GNARRA, J. R., LINEHAN, W. M. & KLAUSNER, 
R. D. 1996. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor 
suppressor gene product is determined by cell density. Proceedings of the 
National Academy of Sciences, 93, 1770-1775. 
LEE, S., NAKAMURA, E., YANG, H., WEI, W., LINGGI, M. S., SAJAN, M. P., FARESE, R. 
V., FREEMAN, R. S., CARTER, B. D., KAELIN, W. G., JR. & SCHLISIO, S. 2005. 
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial 
pheochromocytoma genes: developmental culling and cancer. Cancer Cell, 
8, 155-67. 
LEE, S. H., WOLF, P. L., ESCUDERO, R., DEUTSCH, R., JAMIESON, S. W. & 
THISTLETHWAITE, P. A. 2000. Early expression of angiogenesis factors in 
acute myocardial ischemia and infarction. N Engl J Med, 342, 626-33. 
LEGROS, F., LOMBÈS, A., FRACHON, P. & ROJO, M. 2002. Mitochondrial fusion in 
human cells is efficient, requires the inner membrane potential, and is 
mediated by mitofusins. Molecular Biology of the Cell, 13, 4343-4354. 
LEIGH-BROWN, S., ENRIQUEZ, J. & ODOM, D. 2010. Nuclear transcription factors in 
mammalian mitochondria. Genome Biology, 11, 215. 
LEMASTERS, J., CALDWELL-KENKEL, J., GAO, W., NIEMINEN, A., HERMAN, B. & 
THURMAN, R. 1992. Hypoxic, ischemic and reperfusion injury in the liver. 
Pathophysiology of Reperfusion Injury Boca Raton, FL: CRC. 
Bibliography 
Page | 320  
 
LEMASTERS, J. J. 2005. Selective mitochondrial autophagy, or mitophagy, as a 
targeted defense against oxidative stress, mitochondrial dysfunction, and 
aging. Rejuvenation Res, 8, 3-5. 
LEMASTERS, J. J., QIAN, T., HE, L., KIM, J. S., ELMORE, S. P., CASCIO, W. E. & 
BRENNER, D. A. 2002. Role of mitochondrial inner membrane 
permeabilization in necrotic cell death, apoptosis, and autophagy. Antioxid 
Redox Signal, 4, 769-81. 
LEVRAUT, J., IWASE, H., SHAO, Z.-H., VANDEN HOEK, T. L. & SCHUMACKER, P. T. 
2003a. Cell death during ischemia: relationship to mitochondrial 
depolarization and ROS generation. Am J Physiol Heart Circ Physiol, 284, 
549-558. 
LEVRAUT, J., IWASE, H., SHAO, Z. H., VANDEN HOEK, T. L. & SCHUMACKER, P. T. 
2003b. Cell death during ischemia: relationship to mitochondrial 
depolarization and ROS generation. Am J Physiol Heart Circ Physiol, 284, 
H549-58. 
LEWIS, M. D. & ROBERTS, B. J. 2003. Role of the C-terminal [alpha]-helical domain 
of the von Hippel-Lindau protein in its E3 ubiquitin ligase activity. Oncogene, 
23, 2315-2323. 
LEYSSENS, A., NOWICKY, A. V., PATTERSON, L., CROMPTON, M. & DUCHEN, M. R. 
1996. The relationship between mitochondrial state, ATP hydrolysis, [Mg2+]i 
and [Ca2+]i studied in isolated rat cardiomyocytes. The Journal of 
Physiology, 496, 111-128. 
LI, C. & JACKSON, R. M. 2002. Reactive species mechanisms of cellular hypoxia-
reoxygenation injury. Am J Physiol Cell Physiol, 282, C227-41. 
LI, F., WANG, Y., ZELLER, K. I., POTTER, J. J., WONSEY, D. R., O'DONNELL, K. A., KIM, 
J.-W., YUSTEIN, J. T., LEE, L. A. & DANG, C. V. 2005. Myc Stimulates Nuclearly 
Encoded Mitochondrial Genes and Mitochondrial Biogenesis. Molecular and 
Cellular Biology, 25, 6225-6234. 
LI, K., LI, Y., SHELTON, J. M., RICHARDSON, J. A., SPENCER, E., CHEN, Z. J., WANG, X. 
& WILLIAMS, R. S. 2000. Cytochrome c deficiency causes embryonic lethality 
and attenuates stress-induced apoptosis. Cell, 101, 389-99. 
LI, M. & KIM, W. Y. 2011. Two sides to every story: the HIF-dependent and HIF-
independent functions of pVHL. J Cell Mol Med, 15, 187-195. 
LICHTMAN, J. W. & CONCHELLO, J.-A. 2005. Fluorescence microscopy. Nat Meth, 2, 
910-919. 
LIEB, M. E., MENZIES, K., MOSCHELLA, M. C., NI, R. & TAUBMAN, M. B. 2002. 
Mammalian EGLN genes have distinct patterns of mRNA expression and 
regulation. Biochem Cell Biol, 80, 421-6. 
LIESA, M., PALACÍN, M. & ZORZANO, A. 2009. Mitochondrial Dynamics in 
Mammalian Health and Disease. Physiological Reviews, 89, 799-845. 
Bibliography 
Page | 321  
 
LIN, C.-S., LEE, H.-T., LEE, S.-Y., SHEN, Y.-A., WANG, L.-S., CHEN, Y.-J. & WEI, Y.-H. 
2012. High Mitochondrial DNA Copy Number and Bioenergetic Function Are 
Associated with Tumor Invasion of Esophageal Squamous Cell Carcinoma 
Cell Lines. International Journal of Molecular Sciences, 13, 11228-11246. 
LIN, X., DAVID, C. A., DONNELLY, J. B., MICHAELIDES, M., CHANDEL, N. S., HUANG, 
X., WARRIOR, U., WEINBERG, F., TORMOS, K. V., FESIK, S. W. & SHEN, Y. 
2008. A chemical genomics screen highlights the essential role of 
mitochondria in HIF-1 regulation. Proc Natl Acad Sci U S A, 105, 174-179. 
LIPSCOMB, E. A., SARMIERE, P. D. & FREEMAN, R. S. 2001. SM-20 is a novel 
mitochondrial protein that causes caspase-dependent cell death in nerve 
growth factor-dependent neurons. J Biol Chem, 276, 5085-92. 
LIU, W., XIN, H., ECKERT, D. T., BROWN, J. A. & GNARRA, J. R. 2011. Hypoxia and cell 
cycle regulation of the von Hippel-Lindau tumor suppressor. Oncogene, 30, 
21-31. 
LIU, Y., HUO, Z., YAN, B., LIN, X., ZHOU, Z.-N., LIANG, X., ZHU, W., LIANG, D., LI, L., 
LIU, Y., ZHAO, H., SUN, Y. & CHEN, Y.-H. 2010. Prolyl hydroxylase 3 interacts 
with Bcl-2 to regulate doxorubicin-induced apoptosis in H9c2 cells. 
Biochemical and Biophysical Research Communications, 401, 231-237. 
LOOR, G. & SCHUMACKER, P. T. 2008. Role of hypoxia-inducible factor in cell 
survival during myocardial ischemia-reperfusion. Cell Death.Differ., 15, 686-
690. 
LOSÓN, O. C., SONG, Z., CHEN, H. & CHAN, D. C. 2013. Fis1, Mff, MiD49, and MiD51 
mediate Drp1 recruitment in mitochondrial fission. Molecular Biology of the 
Cell, 24, 659-667. 
LUO, W., HU, H., CHANG, R., ZHONG, J., KNABEL, M., O'MEALLY, R., COLE, 
ROBERT N., PANDEY, A. & SEMENZA, GREGG L. 2011. Pyruvate Kinase M2 Is 
a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1. Cell, 145, 
732-744. 
LUO, W. & SEMENZA, G. L. 2011. Pyruvate kinase M2 regulates glucose metabolism 
by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. 
Oncotarget, 2, 551-6. 
MAHON, P. C., HIROTA, K. & SEMENZA, G. L. 2001. FIH-1: a novel protein that 
interacts with HIF-1alpha and VHL to mediate repression of HIF-1 
transcriptional activity. Genes Dev, 15, 2675-86. 
MAIURI, M. C., LE TOUMELIN, G., CRIOLLO, A., RAIN, J.-C., GAUTIER, F., JUIN, P., 
TASDEMIR, E., PIERRON, G., TROULINAKI, K., TAVERNARAKIS, N., HICKMAN, 
J. A., GENESTE, O. & KROEMER, G. 2007. Functional and physical interaction 
between Bcl-XL and a BH3-like domain in Beclin-1. Embo J, 26, 2527-2539. 
MAKINO, Y., CAO, R., SVENSSON, K., BERTILSSON, G., ASMAN, M., TANAKA, H., CAO, 
Y., BERKENSTAM, A. & POELLINGER, L. 2001. Inhibitory PAS domain protein 
Bibliography 
Page | 322  
 
is a negative regulator of hypoxia-inducible gene expression. Nature, 414, 
550-4. 
MAKINO, Y., KANOPKA, A., WILSON, W. J., TANAKA, H. & POELLINGER, L. 2002. 
Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant 
of the hypoxia-inducible factor-3alpha locus. J Biol Chem, 277, 32405-8. 
MAMBO, E., CHATTERJEE, A., XING, M., TALLINI, G., HAUGEN, B. R., YEUNG, S.-C. J., 
SUKUMAR, S. & SIDRANSKY, D. 2005. Tumor-specific changes in mtDNA 
content in human cancer. International Journal of Cancer, 116, 920-924. 
MANSFIELD, K. D., GUZY, R. D., PAN, Y., YOUNG, R. M., CASH, T. P., SCHUMACKER, P. 
T. & SIMON, M. C. 2005. Mitochondrial dysfunction resulting from loss of 
cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha 
activation. Cell Metab., 1, 393-399. 
MARCHENKO, N. D., ZAIKA, A. & MOLL, U. M. 2000. Death signal-induced 
localization of p53 protein to mitochondria. A potential role in apoptotic 
signaling. J Biol Chem, 275, 16202-12. 
MARGINEANTU, D. H., GREGORY COX, W., SUNDELL, L., SHERWOOD, S. W., 
BEECHEM, J. M. & CAPALDI, R. A. 2002. Cell cycle dependent morphology 
changes and associated mitochondrial DNA redistribution in mitochondria of 
human cell lines. Mitochondrion, 1, 425-35. 
MARTINEZ-OUTSCHOORN, U. E., BALLIET, R. M., RIVADENEIRA, D., CHIAVARINA, B., 
PAVLIDES, S., WANG, C., WHITAKER-MENEZES, D., DAUMER, K., LIN, Z., 
WITKIEWICZ, A., FLOMENBERG, N., HOWELL, A., PESTELL, R., KNUDSEN, E., 
SOTGIA, F. & LISANTI, M. P. 2010a. Oxidative stress in cancer associated 
fibroblasts drives tumor-stroma co-evolution: A new paradigm for 
understanding tumor metabolism, the field effect and genomic instability in 
cancer cells. Cell Cycle, 9, 3276-3296. 
MARTINEZ-OUTSCHOORN, U. E., TRIMMER, C., LIN, Z., WHITAKER-MENEZES, D., 
CHIAVARINA, B., ZHOU, J., WANG, C., PAVLIDES, S., MARTINEZ-CANTARIN, 
M. P., CAPOZZA, F., WITKIEWICZ, A. K., FLOMENBERG, N., HOWELL, A., 
PESTELL, R. G., CARO, J., LISANTI, M. P. & SOTGIA, F. 2010b. Autophagy in 
cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, 
HIF1 induction and NF&kappa;B activation in the tumor stromal 
microenvironment. Cell Cycle, 9, 3515-3533. 
MASSON, N., WILLAM, C., MAXWELL, P. H., PUGH, C. W. & RATCLIFFE, P. J. 2001. 
Independent function of two destruction domains in hypoxia-inducible 
factor-alpha chains activated by prolyl hydroxylation. Embo J, 20, 5197-206. 
MATEO, J., GARCIA-LECEA, M., CADENAS, S., HERNANDEZ, C. & MONCADA, S. 2003. 
Regulation of hypoxia-inducible factor-1alpha by nitric oxide through 
mitochondria-dependent and -independent pathways. Biochem J, 376, 537-
44. 
Bibliography 
Page | 323  
 
MATOBA, S., KANG, J.-G., PATINO, W. D., WRAGG, A., BOEHM, M., GAVRILOVA, O., 
HURLEY, P. J., BUNZ, F. & HWANG, P. M. 2006. p53 Regulates Mitochondrial 
Respiration. Science, 312, 1650-1653. 
MATSUDA, N. 2010. PINK1 stabilized by mitochondrial depolarization recruits Parkin 
to damaged mitochondria and activates latent Parkin for mitophagy. J. Cell 
Biol., 189, 211-221. 
MAXWELL, P. H. 2005. Hypoxia-inducible factor as a physiological regulator. Exp 
Physiol, 90, 791-7. 
MAXWELL, P. H., PUGH, C. W. & RATCLIFFE, P. J. 1993. Inducible operation of the 
erythropoietin 3' enhancer in multiple cell lines: evidence for a widespread 
oxygen-sensing mechanism. Proc Natl Acad Sci U S A, 90, 2423-7. 
MAXWELL, P. H., WIESENER, M. S., CHANG, G. W., CLIFFORD, S. C., VAUX, E. C., 
COCKMAN, M. E., WYKOFF, C. C., PUGH, C. W., MAHER, E. R. & RATCLIFFE, P. 
J. 1999. The tumour suppressor protein VHL targets hypoxia-inducible 
factors for oxygen-dependent proteolysis. Nature, 399, 271-5. 
MCNEILL, L. A., HEWITSON, K. S., CLARIDGE, T. D., SEIBEL, J. F., HORSFALL, L. E. & 
SCHOFIELD, C. J. 2002. Hypoxia-inducible factor asparaginyl hydroxylase 
(FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. 
Biochem J, 367, 571-5. 
MEEUSEN, S., DEVAY, R., BLOCK, J., CASSIDY-STONE, A., WAYSON, S., MCCAFFERY, J. 
M. & NUNNARI, J. 2006. Mitochondrial Inner-Membrane Fusion and Crista 
Maintenance Requires the Dynamin-Related GTPase Mgm1. Cell, 127, 383-
395. 
MELÉNDEZ, A. & NEUFELD, T. P. 2008. The cell biology of autophagy in metazoans: a 
developing story. Development, 135, 2347-2360. 
MENRAD, H., WERNO, C., SCHMID, T., COPANAKI, E., DELLER, T., DEHNE, N. & 
BRÜNE, B. 2010. Roles of hypoxia-inducible factor-1α (HIF-1α) versus HIF-2α 
in the survival of hepatocellular tumor spheroids. Hepatology, 51, 2183-
2192. 
MESECKE, N., TERZIYSKA, N., KOZANY, C., BAUMANN, F., NEUPERT, W., HELL, K. & 
HERRMANN, J. M. 2005. A disulfide relay system in the intermembrane 
space of mitochondria that mediates protein import. Cell, 121, 1059-1069. 
METZEN, E., BERCHNER-PFANNSCHMIDT, U., STENGEL, P., MARXSEN, J. H., STOLZE, 
I., KLINGER, M., HUANG, W. Q., WOTZLAW, C., HELLWIG-BURGEL, T., 
JELKMANN, W., ACKER, H. & FANDREY, J. 2003. Intracellular localisation of 
human HIF-1 alpha hydroxylases: implications for oxygen sensing. J Cell Sci, 
116, 1319-26. 
METZEN, E., STIEHL, D. P., DOEGE, K., MARXSEN, J. H., HELLWIG-BURGEL, T. & 
JELKMANN, W. 2005. Regulation of the prolyl hydroxylase domain protein 2 
(phd2/egln-1) gene: identification of a functional hypoxia-responsive 
element. Biochem J, 387, 711-7. 
Bibliography 
Page | 324  
 
MIKHAYLOVA, O., IGNACAK, M. L., BARANKIEWICZ, T. J., HARBAUGH, S. V., YI, Y., 
MAXWELL, P. H., SCHNEIDER, M., VAN GEYTE, K., CARMELIET, P., REVELO, M. 
P., WYDER, M., GREIS, K. D., MELLER, J. & CZYZYK-KRZESKA, M. F. 2008. The 
von Hippel-Lindau tumor suppressor protein and Egl-9-Type proline 
hydroxylases regulate the large subunit of RNA polymerase II in response to 
oxidative stress. Mol Cell Biol, 28, 2701-17. 
MIKHAYLOVA, O., STRATTON, Y., HALL, D., KELLNER, E., EHMER, B., DREW, 
ANGELA F., GALLO, CATHERINE A., PLAS, DAVID R., BIESIADA, J., MELLER, J. & 
CZYZYK-KRZESKA, MARIA F. 2012. VHL-Regulated MiR-204 Suppresses 
Tumor Growth through Inhibition of LC3B-Mediated Autophagy in Renal 
Clear Cell Carcinoma. Cancer Cell, 21, 532-546. 
MINAMISHIMA, Y. A., MOSLEHI, J., BARDEESY, N., CULLEN, D., BRONSON, R. T. & 
KAELIN, W. G., JR. 2008. Somatic inactivation of the PHD2 prolyl hydroxylase 
causes polycythemia and congestive heart failure. Blood, 111, 3236-44. 
MINET, E., MOTTET, D., MICHEL, G., ROLAND, I., RAES, M., REMACLE, J. & MICHIELS, 
C. 1999. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 
interaction. FEBS Lett, 460, 251-6. 
MISRA, M. K., SARWAT, M., BHAKUNI, P., TUTEJA, R. & TUTEJA, N. 2009. Oxidative 
stress and ischemic myocardial syndromes. Med Sci Monit, 15, RA209-219. 
MITRA, K., WUNDER, C., ROYSAM, B., LIN, G. & LIPPINCOTT-SCHWARTZ, J. 2009. A 
hyperfused mitochondrial state achieved at G1–S regulates cyclin E buildup 
and entry into S phase. Proceedings of the National Academy of Sciences, 
106, 11960-11965. 
MIZUSHIMA, N. 2005. The pleiotropic role of autophagy: from protein metabolism 
to bactericide. Cell Death Differ, 12, 1535-1541. 
MIZUSHIMA, N. 2007. Autophagy: process and function. Genes & Development, 21, 
2861-2873. 
MIZUSHIMA, N., YOSHIMORI, T. & LEVINE, B. 2010. Methods in Mammalian 
Autophagy Research. Cell, 140, 313-326. 
MOLE, D. R., BLANCHER, C., COPLEY, R. R., POLLARD, P. J., GLEADLE, J. M., 
RAGOUSSIS, J. & RATCLIFFE, P. J. 2009. Genome-wide association of hypoxia-
inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression 
profiling of hypoxia-inducible transcripts. J Biol Chem, 284, 16767-75. 
MOLE, D. R., SCHLEMMINGER, I., MCNEILL, L. A., HEWITSON, K. S., PUGH, C. W., 
RATCLIFFE, P. J. & SCHOFIELD, C. J. 2003. 2-oxoglutarate analogue inhibitors 
of HIF prolyl hydroxylase. Bioorg Med Chem Lett, 13, 2677-80. 
MONGE, C., BERAUD, N., TEPP, K., PELLOUX, S., CHAHBOUN, S., KAAMBRE, T., 
KADAJA, L., ROOSIMAA, M., PIIRSOO, A., TOURNEUR, Y., KUZNETSOV, A. V., 
SAKS, V. & SEPPET, E. 2009. Comparative analysis of the bioenergetics of 
adult cardiomyocytes and nonbeating HL-1 cells: respiratory chain activities, 
glycolytic enzyme profiles, and metabolic fluxesThis article is one of a 
Bibliography 
Page | 325  
 
selection of papers from the NATO Advanced Research Workshop on 
Translational Knowledge for Heart Health (published in part 2 of a 2-part 
Special Issue). Canadian Journal of Physiology and Pharmacology, 87, 318-
326. 
MÖPERT, K., HAJEK, P., FRANK, S., CHEN, C., KAUFMANN, J. & SANTEL, A. 2009. Loss 
of Drp1 function alters OPA1 processing and changes mitochondrial 
membrane organization. Experimental Cell Research, 315, 2165-2180. 
MORTIBOYS, H., THOMAS, K. J., KOOPMAN, W. J., KLAFFKE, S., ABOU-SLEIMAN, P., 
OLPIN, S., WOOD, N. W., WILLEMS, P. H., SMEITINK, J. A., COOKSON, M. R. & 
BANDMANN, O. 2008. Mitochondrial function and morphology are impaired 
in parkin-mutant fibroblasts. Ann Neurol, 64, 555-65. 
MUKHOPADHYAY, D., KNEBELMANN, B., COHEN, H. T., ANANTH, S. & SUKHATME, V. 
P. 1997. The von Hippel-Lindau tumor suppressor gene product interacts 
with Sp1 to repress vascular endothelial growth factor promoter activity. 
Molecular and Cellular Biology, 17, 5629-39. 
MULLER, F. L., LIU, Y. & VAN REMMEN, H. 2004. Complex III releases superoxide to 
both sides of the inner mitochondrial membrane. J Biol Chem, 279, 49064-
73. 
MURRY, C. E., JENNINGS, R. B. & REIMER, K. A. 1986. Preconditioning with ischemia: 
a delay of lethal cell injury in ischemic myocardium. Circulation, 74, 1124-36. 
MYLONIS, I., CHACHAMI, G., SAMIOTAKI, M., PANAYOTOU, G., PARASKEVA, E., 
KALOUSI, A., GEORGATSOU, E., BONANOU, S. & SIMOS, G. 2006. 
Identification of MAPK phosphorylation sites and their role in the 
localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem, 281, 
33095-106. 
NADANACIVA, S., RANA, P., BEESON, G., CHEN, D., FERRICK, D., BEESON, C. & WILL, 
Y. 2012. Assessment of drug-induced mitochondrial dysfunction via altered 
cellular respiration and acidification measured in a 96-well platform. Journal 
of Bioenergetics and Biomembranes, 44, 421-437. 
NAKAYAMA, K., FREW, I. J., HAGENSEN, M., SKALS, M., HABELHAH, H., BHOUMIK, 
A., KADOYA, T., ERDJUMENT-BROMAGE, H., TEMPST, P., FRAPPELL, P. B., 
BOWTELL, D. D. & RONAI, Z. E. 2004. Siah2 Regulates Stability of Prolyl-
Hydroxylases, Controls HIF1α Abundance, and Modulates Physiological 
Responses to Hypoxia. Cell, 117, 941-952. 
NAOE, M., OHWA, Y., ISHIKAWA, D., OHSHIMA, C., NISHIKAWA, S., YAMAMOTO, H. 
& ENDO, T. 2004. Identification of Tim40 that mediates protein sorting to 
the mitochondrial intermembrane space. J Biol Chem, 279, 47815-21. 
NARENDRA, D., KANE, L., HAUSER, D., FEARNLEY, I. & YOULE, R. 2010. p62/SQSTM1 
is required for Parkin-induced mitochondrial clustering but not mitophagy; 
VDAC1 is dispensible for both. Autophagy, 6, 1090-1106. 
Bibliography 
Page | 326  
 
NARENDRA, D., TANAKA, A., SUEN, D. F. & YOULE, R. J. 2008. Parkin is recruited 
selectively to impaired mitochondria and promotes their autophagy. J. Cell 
Biol., 183, 795-803. 
NARENDRA, D. P. 2010. PINK1 is selectively stabilized on impaired mitochondria to 
activate Parkin. PLoS Biol., 8, e1000298. 
NEELY, J. R. & MORGAN, H. E. 1974. Relationship between carbohydrate and lipid 
metabolism and the energy balance of heart muscle. Annu Rev Physiol, 36, 
413-59. 
NEELY, J. R., ROVETTO, M. J. & ORAM, J. F. 1972. Myocardial utilization of 
carbohydrate and lipids. Prog Cardiovasc Dis, 15, 289-329. 
NEUSPIEL, M., ZUNINO, R., GANGARAJU, S., RIPPSTEIN, P. & MCBRIDE, H. 2005. 
Activated Mitofusin 2 Signals Mitochondrial Fusion, Interferes with Bax 
Activation, and Reduces Susceptibility to Radical Induced Depolarization. 
Journal of Biological Chemistry, 280, 25060-25070. 
NGUYEN, S. V. & CLAYCOMB, W. C. 1999. Hypoxia regulates the expression of the 
adrenomedullin and HIF-1 genes in cultured HL-1 cardiomyocytes. Biochem 
Biophys Res Commun, 265, 382-6. 
NOLDEN, M., EHSES, S., KOPPEN, M., BERNACCHIA, A., RUGARLI, E. I. & LANGER, T. 
2005. The m-AAA Protease Defective in Hereditary Spastic Paraplegia 
Controls Ribosome Assembly in Mitochondria. Cell, 123, 277-289. 
O'BRIEN, T. W. 2003. Properties of Human Mitochondrial Ribosomes. IUBMB Life, 
55, 505-513. 
OCKAILI, R., NATARAJAN, R., SALLOUM, F., FISHER, B. J., JONES, D., FOWLER, A. A., 
3RD & KUKREJA, R. C. 2005. HIF-1 activation attenuates postischemic 
myocardial injury: role for heme oxygenase-1 in modulating microvascular 
chemokine generation. Am J Physiol Heart Circ Physiol, 289, H542-8. 
OEHME, F., ELLINGHAUS, P., KOLKHOF, P., SMITH, T. J., RAMAKRISHNAN, S., 
HUTTER, J., SCHRAMM, M. & FLAMME, I. 2002. Overexpression of PH-4, a 
novel putative proline 4-hydroxylase, modulates activity of hypoxia-
inducible transcription factors. Biochem Biophys Res Commun, 296, 343-9. 
OHH, M., PARK, C. W., IVAN, M., HOFFMAN, M. A., KIM, T. Y., HUANG, L. E., 
PAVLETICH, N., CHAU, V. & KAELIN, W. G. 2000. Ubiquitination of hypoxia-
inducible factor requires direct binding to the beta-domain of the von 
Hippel-Lindau protein. Nat Cell Biol, 2, 423-7. 
OHTSUKA, T., NISHIJIMA, M., SUZUKI, K. & AKAMATSU, Y. 1993. Mitochondrial 
dysfunction of a cultured Chinese hamster ovary cell mutant deficient in 
cardiolipin. Journal of Biological Chemistry, 268, 22914-9. 
OKATSU, K. 2010. p62/SQSTM1 cooperates with Parkin for perinuclear clustering of 
depolarized mitochondria. Genes Cells, 15, 887-900. 
Bibliography 
Page | 327  
 
OKTAY, Y., DIOUM, E., MATSUZAKI, S., DING, K., YAN, L. J., HALLER, R. G., SZWEDA, 
L. I. & GARCIA, J. A. 2007. Hypoxia-inducible factor 2alpha regulates 
expression of the mitochondrial aconitase chaperone protein frataxin. J Biol 
Chem, 282, 11750-6. 
OSTRANDER, D. B., ZHANG, M., MILEYKOVSKAYA, E., RHO, M. & DOWHAN, W. 2001. 
Lack of Mitochondrial Anionic Phospholipids Causes an Inhibition of 
Translation of Protein Components of the Electron Transport Chain: A YEAST 
GENETIC MODEL SYSTEM FOR THE STUDY OF ANIONIC PHOSPHOLIPID 
FUNCTION IN MITOCHONDRIA. Journal of Biological Chemistry, 276, 25262-
25272. 
OTERA, H., ISHIHARA, N. & MIHARA, K. 2013. New insights into the function and 
regulation of mitochondrial fission. Biochim Biophys Acta, 1833, 1256-68. 
OTERA, H., WANG, C., CLELAND, M. M., SETOGUCHI, K., YOKOTA, S., YOULE, R. J. & 
MIHARA, K. 2010. Mff is an essential factor for mitochondrial recruitment of 
Drp1 during mitochondrial fission in mammalian cells. The Journal of Cell 
Biology, 191, 1141-1158. 
PADDOCK, S. W. 2005. Microscopy. In: KEITH WILSON, J. W. (ed.) Principles and 
Techniques of Biochemistry and Molecular Biology. 6 ed. New York, USA: 
Cambridge University Press. 
PAGLIARINI, D. J., CALVO, S. E., CHANG, B., SHETH, S. A., VAFAI, S. B., ONG, S.-E., 
WALFORD, G. A., SUGIANA, C., BONEH, A., CHEN, W. K., HILL, D. E., VIDAL, 
M., EVANS, J. G., THORBURN, D. R., CARR, S. A. & MOOTHA, V. K. 2008. A 
Mitochondrial Protein Compendium Elucidates Complex I Disease Biology. 
Cell, 134, 112-123. 
PAL, S., CLAFFEY, K. P., DVORAK, H. F. & MUKHOPADHYAY, D. 1997. The von Hippel-
Lindau gene product inhibits vascular permeability factor/vascular 
endothelial growth factor expression in renal cell carcinoma by blocking 
protein kinase C pathways. J Biol Chem, 272, 27509-12. 
PAN, Y., MANSFIELD, K. D., BERTOZZI, C. C., RUDENKO, V., CHAN, D. A., GIACCIA, A. 
J. & SIMON, M. C. 2007. Multiple factors affecting cellular redox status and 
energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase 
activity in vivo and in vitro. Mol Cell Biol, 27, 912-925. 
PANKIV, S. 2007. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation 
of ubiquitinated protein aggregates by autophagy. J. Biol. Chem., 282, 
24131-24145. 
PAPANDREOU, I., CAIRNS, R. A., FONTANA, L., LIM, A. L. & DENKO, N. C. 2006. HIF-1 
mediates adaptation to hypoxia by actively downregulating mitochondrial 
oxygen consumption. Cell Metab., 3, 187-197. 
PARK, J. 2006. Mitochondrial dysfunction in Drosophila PINK1 mutants is 
complemented by parkin. Nature, 441, 1157-1161. 
Bibliography 
Page | 328  
 
PARK, S. K., DADAK, A. M., HAASE, V. H., FONTANA, L., GIACCIA, A. J. & JOHNSON, R. 
S. 2003. Hypoxia-induced gene expression occurs solely through the action 
of hypoxia-inducible factor 1alpha (HIF-1alpha): role of cytoplasmic trapping 
of HIF-2alpha. Mol Cell Biol, 23, 4959-71. 
PARONE, P. A., DA CRUZ, S., TONDERA, D., MATTENBERGER, Y., JAMES, D. I., 
MAECHLER, P., BARJA, F. & MARTINOU, J.-C. 2008. Preventing mitochondrial 
fission impairs mitochondrial function and leads to loss of mitochondrial 
DNA. PLoS One, 3. 
PATTEN, D. A., LAFLEUR, V. N., ROBITAILLE, G. A., CHAN, D. A., GIACCIA, A. J. & 
RICHARD, D. E. 2010. Hypoxia-inducible Factor-1 Activation in Nonhypoxic 
Conditions: The Essential Role of Mitochondrial-derived Reactive Oxygen 
Species. Mol Biol Cell, 21, 3247-57. 
PATTINGRE, S., TASSA, A., QU, X., GARUTI, R., LIANG, X. H., MIZUSHIMA, N., 
PACKER, M., SCHNEIDER, M. D. & LEVINE, B. 2005. Bcl-2 Antiapoptotic 
Proteins Inhibit Beclin 1-Dependent Autophagy. Cell, 122, 927-939. 
PENG, J., ZHANG, L., DRYSDALE, L. & FONG, G. H. 2000. The transcription factor 
EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular 
remodeling. Proc Natl Acad Sci U S A, 97, 8386-91. 
PESCADOR, N., CUEVAS, Y., NARANJO, S., ALCAIDE, M., VILLAR, D., LANDAZURI, M. 
O. & DEL PESO, L. 2005. Identification of a functional hypoxia-responsive 
element that regulates the expression of the egl nine homologue 3 
(egln3/phd3) gene. Biochem J, 390, 189-97. 
PESTA, D. & GNAIGER, E. 2012. High-Resolution Respirometry: OXPHOS Protocols 
for Human Cells and Permeabilized Fibers from Small Biopsies of Human 
Muscle. In: PALMEIRA, C. M. & MORENO, A. J. (eds.) Mitochondrial 
Bioenergetics. Humana Press. 
PI, Y., GOLDENTHAL, M. J. & MARIN-GARCIA, J. 2007. Mitochondrial involvement in 
IGF-1 induced protection of cardiomyocytes against hypoxia/reoxygenation 
injury. Mol Cell Biochem, 301, 181-9. 
POLLENZ, R. S., SATTLER, C. A. & POLAND, A. 1994. The aryl hydrocarbon receptor 
and aryl hydrocarbon receptor nuclear translocator protein show distinct 
subcellular localizations in Hepa 1c1c7 cells by immunofluorescence 
microscopy. Molecular Pharmacology, 45, 428-438. 
POOLE, A. C. 2008. The PINK1/Parkin pathway regulates mitochondrial morphology. 
Proc. Natl Acad. Sci. USA, 105, 1638-1643. 
POON, E., HARRIS, A. L. & ASHCROFT, M. 2009. Targeting the hypoxia-inducible 
factor (HIF) pathway in cancer. Expert Rev Mol Med, 11, e26. 
POYTON, R. O., CASTELLO, P. R., BALL, K. A., WOO, D. K. & PAN, N. 2009. 
Mitochondria and hypoxic signaling: a new view. Ann N Y Acad Sci, 1177, 48-
56. 
Bibliography 
Page | 329  
 
PSARRA, A. M. & SEKERIS, C. E. 2009. Glucocorticoid receptors and other nuclear 
transcription factors in mitochondria and possible functions. Biochim 
Biophys Acta, 1787, 431-6. 
PSARRA, A. M., SOLAKIDI, S., TROUGAKOS, I. P., MARGARITIS, L. H., SPYROU, G. & 
SEKERIS, C. E. 2005. Glucocorticoid receptor isoforms in human 
hepatocarcinoma HepG2 and SaOS-2 osteosarcoma cells: presence of 
glucocorticoid receptor alpha in mitochondria and of glucocorticoid receptor 
beta in nucleoli. Int J Biochem Cell Biol, 37, 2544-58. 
PUISSANT, A., FENOUILLE, N. & AUBERGER, P. 2012. When autophagy meets cancer 
through p62/SQSTM1. Am J Cancer Res, 2, 397-413. 
QI, X., DISATNIK, M. H., SHEN, N., SOBEL, R. A. & MOCHLY-ROSEN, D. 2011. Aberrant 
mitochondrial fission in neurons induced by protein kinase C{delta} under 
oxidative stress conditions in vivo. Mol Biol Cell, 22, 256-65. 
RAMBOLD, A. S., KOSTELECKY, B., ELIA, N. & LIPPINCOTT-SCHWARTZ, J. 2011. 
Tubular network formation protects mitochondria from autophagosomal 
degradation during nutrient starvation. Proc Natl Acad Sci U S A, 108, 10190-
5. 
RANE, S., HE, M., SAYED, D., VASHISTHA, H., MALHOTRA, A., SADOSHIMA, J., 
VATNER, D. E., VATNER, S. F. & ABDELLATIF, M. 2009. Downregulation of 
miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and 
recapitulates hypoxia preconditioning in cardiac myocytes. Circ.Res., 104, 
879-886. 
RANTANEN, K., PURSIHEIMO, J.-P., HÖGEL, H., MIIKKULAINEN, P., SUNDSTRÖM, J. & 
JAAKKOLA, P. M. 2013. p62/SQSTM1 regulates cellular oxygen sensing by 
attenuating PHD3 activity through aggregate sequestration and enhanced 
degradation. Journal of Cell Science, 126, 1144-1154. 
RAVAL, R. R., LAU, K. W., TRAN, M. G. B., SOWTER, H. M., MANDRIOTA, S. J., LI, J.-L., 
PUGH, C. W., MAXWELL, P. H., HARRIS, A. L. & RATCLIFFE, P. J. 2005. 
Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von 
Hippel-Lindau-Associated Renal Cell Carcinoma. Molecular and Cellular 
Biology, 25, 5675-5686. 
RAVIKUMAR, B., SARKAR, S., DAVIES, J. E., FUTTER, M., GARCIA-ARENCIBIA, M., 
GREEN-THOMPSON, Z. W., JIMENEZ-SANCHEZ, M., KOROLCHUK, V. I., 
LICHTENBERG, M., LUO, S., MASSEY, D. C. O., MENZIES, F. M., MOREAU, K., 
NARAYANAN, U., RENNA, M., SIDDIQI, F. H., UNDERWOOD, B. R., WINSLOW, 
A. R. & RUBINSZTEIN, D. C. 2010. Regulation of Mammalian Autophagy in 
Physiology and Pathophysiology. Physiological Reviews, 90, 1383-1435. 
RECHSTEINER, M. P., VON TEICHMAN, A., NOWICKA, A., SULSER, T., SCHRAML, P. & 
MOCH, H. 2011. VHL Gene Mutations and Their Effects on Hypoxia Inducible 
Factor HIFα: Identification of Potential Driver and Passenger Mutations. 
Cancer Research, 71, 5500-5511. 
Bibliography 
Page | 330  
 
REDDY, P. H., REDDY, T. P., MANCZAK, M., CALKINS, M. J., SHIRENDEB, U. & MAO, P. 
2011. Dynamin-related protein 1 and mitochondrial fragmentation in 
neurodegenerative diseases. Brain Res Rev, 67, 103-18. 
RICHARD, D. E., BERRA, E. & POUYSSEGUR, J. 2000. Nonhypoxic pathway mediates 
the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle 
cells. J Biol Chem, 275, 26765-71. 
ROBERTS, A. M. 2009. Suppression of hypoxia-inducible factor 2α restores p53 
activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. 
Cancer Res., 69, 9056-9064. 
ROBIN, E., GUZY, R. D., LOOR, G., IWASE, H., WAYPA, G. B., MARKS, J. D., HOEK, T. L. 
& SCHUMACKER, P. T. 2007. Oxidant stress during simulated ischemia 
primes cardiomyocytes for cell death during reperfusion. J Biol Chem, 282, 
19133-43. 
ROHRBACH, S., SIMM, A., PREGLA, R., FRANKE, C. & KATSCHINSKI, D. R. M. 2005. 
Age-dependent increase of prolyl-4-hydroxylase domain (PHD) 3 expression 
in human and mouse heart. Biogerontology. Springer Netherlands. 
ROSE, N. R., MCDONOUGH, M. A., KING, O. N., KAWAMURA, A. & SCHOFIELD, C. J. 
2011. Inhibition of 2-oxoglutarate dependent oxygenases. Chem Soc Rev, 40, 
4364-97. 
RÖTIG, A. 2011. Human diseases with impaired mitochondrial protein synthesis. 
Biochimica et Biophysica Acta (BBA) - Bioenergetics, 1807, 1198-1205. 
ROUSCHOP, K. M. A., VAN DEN BEUCKEN, T., DUBOIS, L., NIESSEN, H., BUSSINK, J., 
SAVELKOULS, K., KEULERS, T., MUJCIC, H., LANDUYT, W., VONCKEN, J. W., 
LAMBIN, P., VAN DER KOGEL, A. J., KORITZINSKY, M. & WOUTERS, B. G. 
2010. The unfolded protein response protects human tumor cells during 
hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. 
The Journal of Clinical Investigation, 120, 127-141. 
RUBINSZTEIN, D. C., CUERVO, A. M., RAVIKUMAR, B., SARKAR, S., KOROLCHUK, V. I., 
KAUSHIK, S. & KLIONSKY, D. J. 2009. In search of an “autophagomometer”. 
Autophagy, 5, 585-589. 
SALCEDA, S. & CARO, J. 1997. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein 
is rapidly degraded by the ubiquitin-proteasome system under normoxic 
conditions. Its stabilization by hypoxia depends on redox-induced changes. J 
Biol Chem, 272, 22642-7. 
SARRAF, S. A., RAMAN, M., GUARANI-PEREIRA, V., SOWA, M. E., HUTTLIN, E. L., 
GYGI, S. P. & HARPER, J. W. 2013. Landscape of the PARKIN-dependent 
ubiquitylome in response to mitochondrial depolarization. Nature, 496, 372-
376. 
SARTO, C., MAROCCHI, A., SANCHEZ, J. C., GIANNONE, D., FRUTIGER, S., GOLAZ, O., 
WILKINS, M. R., DORO, G., CAPPELLANO, F., HUGHES, G., HOCHSTRASSER, D. 
Bibliography 
Page | 331  
 
F. & MOCARELLI, P. 1997. Renal cell carcinoma and normal kidney protein 
expression. Electrophoresis, 18, 599-604. 
SATO, M., SAKOTA, M. & NAKAYAMA, K. 2010. Human PRP19 interacts with prolyl-
hydroxylase PHD3 and inhibits cell death in hypoxia. Experimental Cell 
Research, 316, 2871-2882. 
SCARPULLA, R. C. 2008. Nuclear control of respiratory chain expression by nuclear 
respiratory factors and PGC-1-related coactivator. Ann N Y Acad Sci, 1147, 
321-34. 
SCHMITTGEN, T. D. & LIVAK, K. J. 2008. Analyzing real-time PCR data by the 
comparative CT method. Nat. Protocols, 3, 1101-1108. 
SCHOENFELD, A. R., DAVIDOWITZ, E. J. & BURK, R. D. 2000a. Elongin BC complex 
prevents degradation of von Hippel-Lindau tumor suppressor gene products. 
Proceedings of the National Academy of Sciences, 97, 8507-8512. 
SCHOENFELD, A. R., PARRIS, T., EISENBERGER, A., DAVIDOWITZ, E. J., DE LEON, M., 
TALASAZAN, F., DEVARAJAN, P. & BURK, R. D. 2000b. The von Hippel-Lindau 
tumor suppressor gene protects cells from UV-mediated apoptosis. 
Oncogene, 19, 5851-7. 
SCHROEDL, C., MCCLINTOCK, D. S., BUDINGER, G. R. & CHANDEL, N. S. 2002. 
Hypoxic but not anoxic stabilization of HIF-1alpha requires mitochondrial 
reactive oxygen species. Am J Physiol Lung Cell Mol Physiol, 283, L922-31. 
SCORTEGAGNA, M., DING, K., OKTAY, Y., GAUR, A., THURMOND, F., YAN, L. J., 
MARCK, B. T., MATSUMOTO, A. M., SHELTON, J. M., RICHARDSON, J. A., 
BENNETT, M. J. & GARCIA, J. A. 2003. Multiple organ pathology, metabolic 
abnormalities and impaired homeostasis of reactive oxygen species in 
Epas1-/- mice. Nat Genet, 35, 331-40. 
SELVANAYAGAM, P. & RAJARAMAN, S. 1996. Detection of mitochondrial genome 
depletion by a novel cDNA in renal cell carcinoma. Laboratory investigation; 
a journal of technical methods and pathology, 74, 592-599. 
SEMENZA, G. 2007a. HIF-1 mediates the Warburg effect in clear cell renal 
carcinoma. Journal of Bioenergetics and Biomembranes, 39, 231-234. 
SEMENZA, G. L. 2003. Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 3, 721-32. 
SEMENZA, G. L. 2004. Hydroxylation of HIF-1: oxygen sensing at the molecular level. 
Physiology (Bethesda), 19, 176-82. 
SEMENZA, G. L. 2007b. Oxygen-dependent regulation of mitochondrial respiration 
by hypoxia-inducible factor 1. Biochem.J., 405, 1-9. 
SEMENZA, G. L., AGANI, F., BOOTH, G., FORSYTHE, J., IYER, N., JIANG, B. H., LEUNG, 
S., ROE, R., WIENER, C. & YU, A. 1997. Structural and functional analysis of 
hypoxia-inducible factor 1. Kidney Int, 51, 553-5. 
SEMENZA, G. L., NEJFELT, M. K., CHI, S. M. & ANTONARAKIS, S. E. 1991 Hypoxia-
inducible nuclear factors bind to an enhancer element located 3' to the 
Bibliography 
Page | 332  
 
human erythropoietin gene Proceedings of the National Academy of 
Sciences of the United States of America 88 5680-5684  
SEMENZA, G. L. & WANG, G. L. 1992. A nuclear factor induced by hypoxia via de 
novo protein synthesis binds to the human erythropoietin gene enhancer at 
a site required for transcriptional activation. Mol. Cell. Biol., 12, 5447-5454. 
SEN BANERJEE, S., THIRUNAVUKKARASU, M., TIPU RISHI, M., SANCHEZ, J. A., 
MAULIK, N. & MAULIK, G. 2012. HIF-prolyl hydroxylases and cardiovascular 
diseases. Toxicol Mech Methods, 22, 347-58. 
SHEN, C. & KAELIN JR, W. G. 2013. The VHL/HIF axis in clear cell renal carcinoma. 
Seminars in Cancer Biology, 23, 18-25. 
SHIAO, Y. H., RESAU, J. H., NAGASHIMA, K., ANDERSON, L. M. & RAMAKRISHNA, G. 
2000. The von Hippel-Lindau tumor suppressor targets to mitochondria. 
Cancer Res, 60, 2816-9. 
SHIMODA, L. A., FALLON, M., PISARCIK, S., WANG, J. & SEMENZA, G. L. 2006. HIF-1 
regulates hypoxic induction of NHE1 expression and alkalinization of 
intracellular pH in pulmonary arterial myocytes. American Journal of 
Physiology - Lung Cellular and Molecular Physiology, 291, L941-L949. 
SHMUELI, M. D., SCHNAIDER, L., ROSENBLUM, D., HERZOG, G., GAZIT, E. & SEGAL, 
D. 2013. Structural Insights into the Folding Defects of Oncogenic pVHL Lead 
to Correction of Its Function In Vitro. PLoS One, 8, e66333. 
SHOHET, R. V. & GARCIA, J. A. 2007. Keeping the engine primed: HIF factors as key 
regulators of cardiac metabolism and angiogenesis during ischemia. 
J.Mol.Med., 85, 1309-1315. 
SHUTT, T., GEOFFRION, M., MILNE, R. & MCBRIDE, H. M. 2012. The intracellular 
redox state is a core determinant of mitochondrial fusion. EMBO Rep, 13, 
909-915. 
SIMONNET, H., ALAZARD, N., PFEIFFER, K., GALLOU, C., BÉROUD, C., DEMONT, J., 
BOUVIER, R., SCHÄGGER, H. & GODINOT, C. 2002. Low mitochondrial 
respiratory chain content correlates with tumor aggressiveness in renal cell 
carcinoma. Carcinogenesis, 23, 759-768. 
SMIRNOVA, E., GRIPARIC, L., SHURLAND, D.-L. & VAN DER BLIEK, A. M. 2001. 
Dynamin-related Protein Drp1 Is Required for Mitochondrial Division in 
Mammalian Cells. Molecular Biology of the Cell, 12, 2245-2256. 
SMIRNOVA, N. A., RAKHMAN, I., MOROZ, N., BASSO, M., PAYAPPILLY, J., KAZAKOV, 
S., HERNANDEZ-GUZMAN, F., GAISINA, I. N., KOZIKOWSKI, A. P., RATAN, R. R. 
& GAZARYAN, I. G. 2010. Utilization of an in vivo reporter for high 
throughput identification of branched small molecule regulators of hypoxic 
adaptation. Chem Biol, 17, 380-91. 
SMITS, P., SMEITINK, J. & VAN DEN HEUVEL, L. 2010. Mitochondrial translation and 
beyond: processes implicated in combined oxidative phosphorylation 
deficiencies. J Biomed Biotechnol, 2010, 737385. 
Bibliography 
Page | 333  
 
SOLAINI, G., BARACCA, A., LENAZ, G. & SGARBI, G. 2010. Hypoxia and mitochondrial 
oxidative metabolism. Biochim.Biophys.Acta, 1797, 1171-1177. 
SOLAINI, G. & HARRIS, D. A. 2005. Biochemical dysfunction in heart mitochondria 
exposed to ischaemia and reperfusion. Biochem J, 390, 377-394. 
SOTGIA, F., WHITAKER-MENEZES, D., MARTINEZ-OUTSCHOORN, U. E., 
FLOMENBERG, N., BIRBE, R., WITKIEWICZ, A. K., HOWELL, A., PHILP, N. J., 
PESTELL, R. G. & LISANTI, M. P. 2012. Mitochondrial metabolism in cancer 
metastasis: Visualizing tumor cell mitochondria and the “reverse Warburg 
effect” in positive lymph node tissue. Cell Cycle, 11, 1445-1454. 
SRIDHARAN, V., GUICHARD, J., BAILEY, R. M., KASIGANESAN, H., BEESON, C. & 
WRIGHT, G. L. 2007. The prolyl hydroxylase oxygen-sensing pathway is 
cytoprotective and allows maintenance of mitochondrial membrane 
potential during metabolic inhibition. Am J Physiol Cell Physiol, 292, C719-
28. 
SRIDHARAN, V., GUICHARD, J., LI, C. Y., MUISE-HELMERICKS, R., BEESON, C. C. & 
WRIGHT, G. L. 2008. O(2)-sensing signal cascade: clamping of O(2) 
respiration, reduced ATP utilization, and inducible fumarate respiration. Am 
J Physiol Cell Physiol, 295, C29-37. 
SRINIVAS, V., LESHCHINSKY, I., SANG, N., KING, M. P., MINCHENKO, A. & CARO, J. 
2001. Oxygen sensing and HIF-1 activation does not require an active 
mitochondrial respiratory chain electron-transfer pathway. J Biol Chem, 276, 
21995-21998. 
ST-PIERRE, J., BUCKINGHAM, J. A., ROEBUCK, S. J. & BRAND, M. D. 2002. Topology 
of superoxide production from different sites in the mitochondrial electron 
transport chain. J Biol Chem, 277, 44784-90. 
STEBBINS, C. E., KAELIN, W. G. & PAVLETICH, N. P. 1999. Structure of the VHL-
ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor 
Function. Science, 284, 455-461. 
STOJANOVSKI, D., KOUTSOPOULOS, O. S., OKAMOTO, K. & RYAN, M. T. 2004. Levels 
of human Fis1 at the mitochondrial outer membrane regulate mitochondrial 
morphology. Journal of Cell Science, 117, 1201-1210. 
SU, X. & DOWHAN, W. 2006. Translational Regulation of Nuclear Gene COX4 
Expression by Mitochondrial Content of Phosphatidylglycerol and Cardiolipin 
in Saccharomyces cerevisiae. Molecular and Cellular Biology, 26, 743-753. 
SULEIMAN, M. S., SINGH, R. J. & STEWART, C. E. 2007. Apoptosis and the cardiac 
action of insulin-like growth factor I. Pharmacol Ther, 114, 278-94. 
SUN, J. & TRUMPOWER, B. L. 2003. Superoxide anion generation by the cytochrome 
bc1 complex. Arch Biochem Biophys, 419, 198-206. 
SYNNESTVEDT, K., FURUTA, G. T., COMERFORD, K. M., LOUIS, N., KARHAUSEN, J., 
ELTZSCHIG, H. K., HANSEN, K. R., THOMPSON, L. F. & COLGAN, S. P. 2002. 
Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 
Bibliography 
Page | 334  
 
mediates permeability changes in intestinal epithelia. J Clin Invest, 110, 993-
1002. 
TAGUCHI, N., ISHIHARA, N., JOFUKU, A., OKA, T. & MIHARA, K. 2007. Mitotic 
phosphorylation of dynamin-related GTPase Drp1 participates in 
mitochondrial fission. J Biol Chem, 282, 11521-11529. 
TAKAMURA, H., KOYAMA, Y., MATSUZAKI, S., YAMADA, K., HATTORI, T., MIYATA, S., 
TAKEMOTO, K., TOHYAMA, M. & KATAYAMA, T. 2012. TRAP1 Controls 
Mitochondrial Fusion/Fission Balance through Drp1 and Mff Expression. 
PLoS One, 7, e51912. 
TAKEDA, K., HO, V. C., TAKEDA, H., DUAN, L. J., NAGY, A. & FONG, G. H. 2006. 
Placental but not heart defects are associated with elevated hypoxia-
inducible factor alpha levels in mice lacking prolyl hydroxylase domain 
protein 2. Mol Cell Biol, 26, 8336-46. 
TANAKA, A., CLELAND, M. M., XU, S., NARENDRA, D. P., SUEN, D.-F., KARBOWSKI, 
M. & YOULE, R. J. 2010. Proteasome and p97 mediate mitophagy and 
degradation of mitofusins induced by Parkin. The Journal of Cell Biology, 
191, 1367-1380. 
TAYLOR, C. T. 2008. Mitochondria and cellular oxygen sensing in the HIF pathway. 
Biochem.J., 409, 19-26. 
TAYLOR, C. T. & POUYSSEGUR, J. 2007. Oxygen, hypoxia, and stress. Ann N Y Acad 
Sci, 1113, 87-94. 
TAZUKE, S. I., MAZURE, N. M., SUGAWARA, J., CARLAND, G., FAESSEN, G. H., SUEN, 
L. F., IRWIN, J. C., POWELL, D. R., GIACCIA, A. J. & GIUDICE, L. C. 1998. 
Hypoxia stimulates insulin-like growth factor binding protein 1 (IGFBP-1) 
gene expression in HepG2 cells: a possible model for IGFBP-1 expression in 
fetal hypoxia. Proc Natl Acad Sci U S A, 95, 10188-93. 
TELLO, D., BALSA, E., ACOSTA-IBORRA, B., FUERTES-YEBRA, E., ELORZA, A., 
ORDÓÑEZ, Á., CORRAL-ESCARIZ, M., SORO, I., LÓPEZ-BERNARDO, E., 
PERALES-CLEMENTE, E., MARTÍNEZ-RUIZ, A., ENRÍQUEZ, JOSÉ A., 
ARAGONÉS, J., CADENAS, S. & LANDÁZURI, MANUEL O. 2011. Induction of 
the Mitochondrial NDUFA4L2 Protein by HIF-1α Decreases Oxygen 
Consumption by Inhibiting Complex I Activity. Cell Metabolism, 14, 768-779. 
TIAN, H., HAMMER, R. E., MATSUMOTO, A. M., RUSSELL, D. W. & MCKNIGHT, S. L. 
1998. The hypoxia-responsive transcription factor EPAS1 is essential for 
catecholamine homeostasis and protection against heart failure during 
embryonic development. Genes Dev., 12, 3320-3324. 
TIAN, H., MCKNIGHT, S. L. & RUSSELL, D. W. 1997. Endothelial PAS domain protein 1 
(EPAS1), a transcription factor selectively expressed in endothelial cells. 
Genes Dev, 11, 72-82. 
TOKATLIDIS, K. 2005. A disulfide relay system in mitochondria. Cell, 121, 965-967. 
Bibliography 
Page | 335  
 
TORMOS, K. V. & CHANDEL, N. S. 2010. Inter-connection between mitochondria and 
HIFs. J Cell Mol Med, 14, 795-804. 
TREMPE, J.-F., SAUVÉ, V., GRENIER, K., SEIRAFI, M., TANG, M. Y., MÉNADE, M., AL-
ABDUL-WAHID, S., KRETT, J., WONG, K., KOZLOV, G., NAGAR, B., FON, E. A. & 
GEHRING, K. 2013. Structure of Parkin Reveals Mechanisms for Ubiquitin 
Ligase Activation. Science, 340, 1451-1455. 
TWIG, G. 2008. Fission and selective fusion govern mitochondrial segregation and 
elimination by autophagy. EMBO J., 27, 433-446. 
ULLAH, M. S., DAVIES, A. J. & HALESTRAP, A. P. 2006. The Plasma Membrane 
Lactate Transporter MCT4, but Not MCT1, Is Up-regulated by Hypoxia 
through a HIF-1α-dependent Mechanism. Journal of Biological Chemistry, 
281, 9030-9037. 
VAN DER BLIEK, A. M., SHEN, Q. & KAWAJIRI, S. 2013. Mechanisms of Mitochondrial 
Fission and Fusion. Cold Spring Harbor Perspectives in Biology, 5. 
VARDATSIKOS, G., SAHU, A. & SRIVASTAVA, A. K. 2009. The insulin-like growth 
factor family: molecular mechanisms, redox regulation, and clinical 
implications. Antioxid Redox Signal, 11, 1165-90. 
VAUX, E. C., METZEN, E., YEATES, K. M. & RATCLIFFE, P. J. 2001. Regulation of 
hypoxia-inducible factor is preserved in the absence of a functioning 
mitochondrial respiratory chain. Blood, 98, 296-302. 
VEERIAH, S., TAYLOR, B. S., MENG, S., FANG, F., YILMAZ, E., VIVANCO, I., 
JANAKIRAMAN, M., SCHULTZ, N., HANRAHAN, A. J., PAO, W., LADANYI, M., 
SANDER, C., HEGUY, A., HOLLAND, E. C., PATY, P. B., MISCHEL, P. S., LIAU, L., 
CLOUGHESY, T. F., MELLINGHOFF, I. K., SOLIT, D. B. & CHAN, T. A. 2010. 
Somatic mutations of the Parkinson's disease-associated gene PARK2 in 
glioblastoma and other human malignancies. Nat Genet, 42, 77-82. 
VENEGAS, V. & HALBERG, M. 2012. Measurement of Mitochondrial DNA Copy 
Number. In: WONG, P. D. L.-J. C. (ed.) Mitochondrial Disorders. Humana 
Press. 
VENTURA-CLAPIER, R., GARNIER, A. & VEKSLER, V. 2008. Transcriptional control of 
mitochondrial biogenesis: the central role of PGC-1α. Cardiovascular 
Research. 
VIDONI, S., ZANNA, C., RUGOLO, M., SARZI, E. & LENAERS, G. 2013. Why 
mitochondria must fuse to maintain their genome integrity. Antioxid Redox 
Signal, 19, 379-88. 
VINCOW, E. S., MERRIHEW, G., THOMAS, R. E., SHULMAN, N. J., BEYER, R. P., 
MACCOSS, M. J. & PALLANCK, L. J. 2013. The PINK1-Parkin pathway 
promotes both mitophagy and selective respiratory chain turnover in vivo. 
Proc Natl Acad Sci U S A, 110, 6400-5. 
VIVES-BAUZA, C. 2010. PINK1-dependent recruitment of Parkin to mitochondria in 
mitophagy. Proc. Natl Acad. Sci. USA, 107, 378-383. 
Bibliography 
Page | 336  
 
VIVES-BAUZA, C. & PRZEDBORSKI, S. 2011. Mitophagy: the latest problem for 
Parkinson's disease. Trends in Molecular Medicine, 17, 158-165. 
VON BALLMOOS, C., WIEDENMANN, A. & DIMROTH, P. 2009. Essentials for ATP 
synthesis by F1F0 ATP synthases. Annu Rev Biochem, 78, 649-72. 
WALLACE, D. C. 2012. Mitochondria and cancer. Nat Rev Cancer, 12, 685-698. 
WANG, G. L., JIANG, B. H., RUE, E. A. & SEMENZA, G. L. 1995. Hypoxia-inducible 
factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 
tension. Proceedings of the National Academy of Sciences of the United 
States of America, 92, 5510-5514. 
WANG, G. L. & SEMENZA, G. L. 1993. Characterization of hypoxia-inducible factor 1 
and regulation of DNA binding activity by hypoxia. J Biol Chem, 268, 21513-
8. 
WANG, G. L. & SEMENZA, G. L. 1995. Purification and characterization of hypoxia-
inducible factor 1. J Biol Chem, 270, 1230-7. 
WANG, H., SONG, P., DU, L., TIAN, W., YUE, W., LIU, M., LI, D., WANG, B., ZHU, Y., 
CAO, C., ZHOU, J. & CHEN, Q. 2011. Parkin Ubiquitinates Drp1 for 
Proteasome-dependent Degradation: IMPLICATION OF DYSREGULATED 
MITOCHONDRIAL DYNAMICS IN PARKINSON DISEASE. Journal of Biological 
Chemistry, 286, 11649-11658. 
WARBURG, O. 1956. On the origin of cancer cells. Science, 123, 309-14. 
WARD, J. B. J., LAWLER, K., AMU, S., TAYLOR, C. T., FALLON, P. G. & KEELY, S. J. 
2011. Hydroxylase inhibition attenuates colonic epithelial secretory function 
and ameliorates experimental diarrhea. The FASEB Journal, 25, 535-543. 
WEBB, J. D., COLEMAN, M. L. & PUGH, C. W. 2009. Hypoxia, hypoxia-inducible 
factors (HIF), HIF hydroxylases and oxygen sensing. Cell Mol Life Sci, 66, 
3539-54. 
WEIDEMANN, A. & JOHNSON, R. S. 2008. Biology of HIF-1alpha. Cell Death Differ, 
15, 621-7. 
WEINBERG, F., HAMANAKA, R., WHEATON, W. W., WEINBERG, S., JOSEPH, J., 
LOPEZ, M., KALYANARAMAN, B., MUTLU, G. M., BUDINGER, G. R. S. & 
CHANDEL, N. S. 2010. Mitochondrial metabolism and ROS generation are 
essential for Kras-mediated tumorigenicity. Proceedings of the National 
Academy of Sciences. 
WENGER, R. H. 2002. Cellular adaptation to hypoxia: O2-sensing protein 
hydroxylases, hypoxia-inducible transcription factors, and O2-regulated 
gene expression. Faseb J, 16, 1151-62. 
WHEATON, W. W. & CHANDEL, N. S. 2011. Hypoxia. 2. Hypoxia regulates cellular 
metabolism. Am J Physiol Cell Physiol, 300, C385-93. 
WHITE, S. M., CONSTANTIN, P. E. & CLAYCOMB, W. C. 2004. Cardiac physiology at 
the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac 
Bibliography 
Page | 337  
 
muscle cell structure and function. Am J Physiol Heart Circ Physiol, 286, 
H823-9. 
WITTIG, I. & SCHÄGGER, H. 2009. Supramolecular organization of ATP synthase and 
respiratory chain in mitochondrial membranes. Biochimica et Biophysica 
Acta (BBA) - Bioenergetics, 1787, 672-680. 
WU, S., ZHOU, F., ZHANG, Z. & XING, D. 2011. Mitochondrial oxidative stress causes 
mitochondrial fragmentation via differential modulation of mitochondrial 
fission-fusion proteins. FEBS J, 278, 941-54. 
XIE, L., PI, X., MISHRA, A., FONG, G., PENG, J. & PATTERSON, C. 2012. PHD3-
dependent hydroxylation of HCLK2 promotes the DNA damage response. 
The Journal of Clinical Investigation, 122, 2827-2836. 
XIE, L., XIAO, K., WHALEN, E. J., FORRESTER, M. T., FREEMAN, R. S., FONG, G., GYGI, 
S. P., LEFKOWITZ, R. J. & STAMLER, J. S. 2009. Oxygen-regulated beta(2)-
adrenergic receptor hydroxylation by EGLN3 and ubiquitylation by pVHL. Sci 
Signal, 2, ra33. 
YAN, B., JIAO, S., ZHANG, H.-S., LV, D.-D., XUE, J., FAN, L., WU, G.-H. & FANG, J. 
2011. Prolyl hydroxylase domain protein 3 targets Pax2 for destruction. 
Biochemical and Biophysical Research Communications, 409, 315-320. 
YANG, J., STAPLES, O., THOMAS, L. W., BRISTON, T., ROBSON, M., POON, E., 
SIMOES, M. L., EL-EMIR, E., BUFFA, F. M., AHMED, A., ANNEAR, N. P., 
SHUKLA, D., PEDLEY, B. R., MAXWELL, P. H., HARRIS, A. L. & ASHCROFT, M. 
2012. Human CHCHD4 mitochondrial proteins regulate cellular oxygen 
consumption rate and metabolism and provide a critical role in hypoxia 
signaling and tumor progression. J Clin Invest, 122, 600-11. 
YAO, Z., JONES, A. W. E., FASSONE, E., SWEENEY, M. G., LEBIEDZINSKA, M., SUSKI, J. 
M., WIECKOWSKI, M. R., TAJEDDINE, N., HARGREAVES, I. P., YASUKAWA, T., 
TUFO, G., BRENNER, C., KROEMER, G., RAHMAN, S. & SZABADKAI, G. 2013. 
PGC-1[beta] mediates adaptive chemoresistance associated with 
mitochondrial DNA mutations. Oncogene, 32, 2592-2600. 
YASINSKA, I. M. & SUMBAYEV, V. V. 2003. S-nitrosation of Cys-800 of HIF-1alpha 
protein activates its interaction with p300 and stimulates its transcriptional 
activity. FEBS Lett, 549, 105-9. 
YOON, Y., PITTS, K. R. & MCNIVEN, M. A. 2001. Mammalian Dynamin-like Protein 
DLP1 Tubulates Membranes. Molecular Biology of the Cell, 12, 2894-2905. 
YOULE, R. J. & NARENDRA, D. P. 2011. Mechanisms of mitophagy. Nat Rev Mol Cell 
Biol, 12, 9-14. 
YOULE, R. J. & VAN DER BLIEK, A. M. 2012. Mitochondrial Fission, Fusion, and 
Stress. Science, 337, 1062-1065. 
YOUNGIL, L., HWA-YOUN, L., RITA, A. H. & ÅSA, B. G. 2011. Mitochondrial 
autophagy by Bnip3 involves Drp1-mediated mitochondrial fission and 
Bibliography 
Page | 338  
 
recruitment of Parkin in cardiac myocytes. American Journal of Physiology - 
Heart and Circulatory Physiology, 301, H1924-H1931. 
YU, W., SUN, Y., GUO, S. & LU, B. 2011. The PINK1/Parkin pathway regulates 
mitochondrial dynamics and function in mammalian hippocampal and 
dopaminergic neurons. Human Molecular Genetics, 20, 3227-3240. 
YU, Y., DUMOLLARD, R., ROSSBACH, A., LAI, F. A. & SWANN, K. 2010. Redistribution 
of mitochondria leads to bursts of ATP production during spontaneous 
mouse oocyte maturation. Journal of Cellular Physiology, 224, 672-680. 
ZELZER, E., LEVY, Y., KAHANA, C., SHILO, B. Z., RUBINSTEIN, M. & COHEN, B. 1998. 
Insulin induces transcription of target genes through the hypoxia-inducible 
factor HIF-1alpha/ARNT. Embo J, 17, 5085-94. 
ZHANG, H. 2007. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in 
VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer 
Cell, 11, 407-420. 
ZHANG, H., BOSCH-MARCE, M., SHIMODA, L. A., TAN, Y. S., BAEK, J. H., WESLEY, J. 
B., GONZALEZ, F. J. & SEMENZA, G. L. 2008. Mitochondrial autophagy is an 
HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem, 283, 
10892-10903. 
ZHAO, J., ZHANG, J., YU, M., XIE, Y., HUANG, Y., WOLFF, D. W., ABEL, P. W. & TU, Y. 
2012. Mitochondrial dynamics regulates migration and invasion of breast 
cancer cells. Oncogene, 32, 4814-24. 
ZIELLO, J. E., JOVIN, I. S. & HUANG, Y. 2007. Hypoxia-Inducible Factor (HIF)-1 
regulatory pathway and its potential for therapeutic intervention in 
malignancy and ischemia. Yale J Biol Med, 80, 51-60. 
ZIVIANI, E. & WHITWORTH, A. J. 2010. How could Parkin-mediated ubiquitination of 
mitofusin promote mitophagy? Autophagy, 6, 660-662. 
 
 
Appendix 
Page | 339  
 
 
 
 
 
Appendix 
  
Appendix 
Page | 340  
 
Chapter 3: Full analysis of cellular metabolites 
 
 
Appendix 
Page | 341  
 
Chapter 3: Full analysis of media metabolites 
 
 
 
